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Abstract 
 
Muscular Dystrophy (MD) is a progressive muscle wasting disease which currently has 
no cure, and is caused by the mutation of the dystrophin gene. A multitude of 
approaches for the improvement of the muscular pathology caused by this condition 
are being investigated, one of which is gene therapy. This approach is used to deliver 
vectors containing therapeutic transgenes such as dystrophin to target muscle cells. 
One method of gene delivery utilises viral vectors, and although this has resulted in 
systemic delivery and efficient transgene expression, there are many safety 
implications which have led to the development of non-viral approaches, such as the 
direct delivery of naked plasmid DNA. However, the shortcomings of these vectors 
include an inability to replicate within host cells, resulting in the loss of vector as cells 
replicate, and the silencing of transgene expression. In an effort to overcome such 
limitations, a novel system called the ‘pEPI vector’ has been developed. Here, the 
inclusion of the β-IFN scaffold/matrix-attachment region (S/MAR) element into the 
open reading frame of an actively transcribed transgene has been found to lead to 
sustained, long term transgene expression, and to allow the episomal propagation and 
maintenance of the vector in dividing cells over many generations. The aim of this 
thesis was to investigate the potential of this vector for use as a gene therapy vector in 
muscle cells in order to treat MD. 
In this study, the long-term expression of the eGFP reporter transgene inserted into 
the pEPI vector was evaluated, and the pEPI vector’s episomal/integrant status was 
investigated, in C2C12 murine myoblasts, HeLa, and HepG2 cell lines. 60 days after 
transfection the vector was found not to have integrated into the host genomes of any 
of the cell lines. Transgene expression had declined to nearly undetectable levels in 
fast-replicating C2C12 and HeLa cells, but was at high levels in the relatively slow-
dividing HepG2 cells. An attempt to improve long term transgene expression in C2C12 
cells by changing the promoter from CMV to CAGG still led to low transgene 
expression after 60 days.  
To address this issue, this study focused on the development of a novel approach to 
ameliorate long-term transgene expression, based upon the origin of replication and 
nuclear matrix attachment properties of the S/MAR element, as well as the results 
obtained from testing the vector in the HeLa and HepG2 cells. It involved the arrest of 
C2C12 cells in the G0/G1 phase of the cell cycle post transfection with the pEPI vector 
in order to allow these fast-dividing cells an extended period of time to epigenetically 
mark pEPI prior to selection. The findings indicated that this novel method of pEPI 
vector establishment was superior to that which utilises selection alone. However, in 
spite of the improvement in long-term episomal transgene expression observed using 
this novel method of establishment of the pEPI vector, transgene expression levels 
were still relatively low after 35 days of cell proliferation, which led to the conclusion 
that further development of this vector is essential in order for it to be able to elicit a 
significant restoration of muscle function in MD patients.  
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Additionally, two other S/MAR vectors were tested in C2C12 cells. One vector 
contained the ‘mini-S/MAR’, a shorter version of the β-IFN S/MAR, and the other 
contained a novel S/MAR derived from the c-myc proto-oncogene. Transgene 
expression by either vector was nearly undetectable after several weeks of 
proliferation, and both were found to integrate into the C2C12 host genome, leading 
to the conclusion that not all S/MAR elements inserted within a plasmid vector can 
lead to long-term transgene expression, nor confer protection from vector integration. 
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Glossary of Abbreviations 
 
2’OMe 2’-O-Methoxyethyl 
AAV Adeno-Associated Virus 
Ac Acetylation 
ADP Adenosine Diphosphate 
ATF Activating Transcription Factor  
ATP Adenosine Triphosphate 
BrdU Bromodeoxyuridine 
BUR Base-Unpairing Region 
CAF-1 Chaperone Chromatin Assembly 
Factor 
CAGG CMV enhancer/chicken β-actin 
fusion promoter 
CaM Calmodulin 
CBP CREB Binding Protein 
cc coiled coil 
CMV Cytomegalovirus 
c-myc c-myelocytomatosis oncogene 
CREB cAMP-Response Element-Binding 
CUE Core-Unparining Element 
DAPC Dystrophin Associated Protein 
Complex 
DMD Duchenne Muscular Dystrophy 
DNA Deoxyribonucleic Acid 
EF-1 α Elongation Factor-1 α 
FACS Fluorescent Activated Cell Sorting 
FCS Foetal Calf Serum 
FISH Fluorescent In-Situ Hybridisation 
G0 Growth phase 0/quiescence 
G1/2 Growth phase 1/2 
HAT Histone Acetyltransferase 
HDAC Histone Deacetylase 
HMG High Mobility Group 
Kb Kilobase 
LNA Locked Nucleic Acids 
M Mitosis 
MBD1 Methyl CpG-Binding protein 
MBF-1 Multiprotein Bridging Factor 1 
MCM Minichromosome Maintenance
 proteins 
MD Muscular dystrophy 
Me Methylation 
Myf-5 Myogenic Factor 5 
MyoD Myoblast Determination Protein 
NFκB Nuclear Factor Kappa B 
nNOS neuronal Nitric Oxide Synthase 
NuMA Nuclear Mitottic Apparatus protein 
ORC Origin Recognition Complex 
Ori Origin ofreplication 
P Phosphorylation 
PCNA Proliferating Cell Nuclear Antigen 
PCR Polymerase Chain Reaction 
pDNA plasmid DNA 
PMO Phosphorodiamidate Morpholino 
PNA Pepetide Nucleic Acids  
Pre-RC Pre-Recognition Complex 
rAAV recombinant Adeno-Associated 
Virus 
RNA Ribonucleic Acid 
S Synthesis phase 
S/MAR Scaffold/Matrix Attachment Region 
SAF Scaffold Attachment Factor 
SATB1 Special AT-rich Binding Protein 
SDF-1 Stromal Cell-Derived Factor-1 
SIN Self-Inactivating  
SP Side Population 
TLR9 Toll-Like Receptor 9 
TNF-α Tumor Necrosis Factor α
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Chapter 1: Introduction 
 
 
1.1 Muscular Dystrophy 
 
Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic disease whereby 
the dystrophin gene is mutated. This disease can also occur as a result of spontaneous 
mutations seen in 1/10000 gametes (Nowak and Davies, 2004). There are over 40 
types of muscular dystrophy (Muir and Chamberlain, 2009) that occur as a result of 
different mutations occurring in dystrophin or other associated proteins (Blake et al., 
2002), which include Duchenne, Becker, Limb- girdle, Congenital, and Oculopharyngeal 
muscular dystrophies, amongst others (Trollet et al., 2009). An estimated 60% of these 
mutations are a result of large insertions or deletions, and 40% from point mutations 
(Hoffman and Dressman, 2001). Dystrophin is a subsarcolemmal protein found in 
muscle that is required for the dystrophin-glycoprotein transmembrane complex, 
essential for the prevention of exercise-induced muscle damage (Nowak and Davies, 
2004). The more severely the protein is mutated, the more susceptible the 
sarcolemma is to damage, of which repeated cycles of damage/regeneration leads to 
tissue necrosis and myofibre replacement with fat and connective tissue (Grounds and 
Davies, 2007) (Figure 1.1). The severity of this type of muscular dystrophy is due to 
mutations which lead to out of frame transcription resulting in a dystrophin protein 
that is non-functional. 
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(A) 
 
(B) 
 
       (Seidman, RJ, 2006) 
Figure 1.1 Adapted from Seidman, RJ, 2006. Hematoxylin and eosin (H&E) staining of frozen cross-
section of normal muscle (A) indicating similar sized fibres (pink), with thin endomysial connective tissue 
between the fibres (white), and the nuclei present at the peripheries (purple). Image (B) shows H&E 
staining of a frozen cross-section muscle from a patient with muscular dystrophy and indicates an 
increase in fibre size variability, atrophied rounded fibres, and an increase in the amount of endomysial 
connective tissue between and around the fibres denoting fibrosis. 
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This disease affects 1/3500 young boys and eventually claims their lives due to cardiac 
or respiratory failure (Grounds and Davies, 2007). At birth these boys appear normal, 
however abnormally high levels of the enzyme creatine kinase can be detected in the 
bloodsteam, indicating muscle damage (Blake et al., 2002). The first symptons are 
usually evident between the ages of 2 and 5 (Dubowitz et al., 1978; De Matteis and 
Morrow, 2000), which include a ‘waddling gait’, pseudohypertrophy of the calf 
muscles, Gower’s sign where the use of the arms is required to stand up from a lying 
position, and a general weakness in the limbs (Sakuta, 2009). Dystrophin has also been 
seen to be expressed in the brain. While its mutation can lead to abnormal brain 
function in some patients (Blake and Kroger, 2000; Mehler, 2000), other patients have 
been found to be of normal, or above normal, intelligence. By their early teenage years 
the boys are wheelchair-bound, and most die by their early 20s.  
In the case of Becker’s muscular dystrophy, a mutation occurs without disrupting the 
reading frame, where a semi-functional truncated protein is created. The disease is far 
less severe or debilitating than Duchenne’s (Nowak and Davies, 2004), and a later 
onset of pathology is observed in addition to longer survival time (Blake et al., 2002). 
Over 90% of those affected are still alive by their early 20s, and many can live to 
remain mobile until an old age (reviewed in Blake et al., 2002). 
To fully understand the disease in order to amerliorate pathologies and find 
treatments, it is essential to study the molecular mechanisms behind muscle function, 
in addition to genetic mutations which lead to impaired function thus leading to the 
onset of muscular dystrophy. 
 
1.2 Skeletal Muscle Function 
 
1.2.1 General Muscle Structure 
 
Healthy muscle is composed of fascicles, which are each composed of bundles of 
fibres. Each fibre is enveloped in a membrane called the sarcolemma, is 
multinucleated, and is formed by the fusion of many myoblasts with one another. 
These nuclei are found directly beneath the sarcolemma. Within the cytoplasm of 
these fibres is a high concentration of mitochondria, present in order to supply energy, 
and myofibrils, which contain the contractile components of muscle. Each myofibril is 
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surrounded by a membrane called the sarcoplasmic reticulum, and the components 
that make up each myofibril are thick filaments composed of myosin, and thin 
filaments made of actin. In skeletal muscle, these filaments run parallel to the long axis 
of the fibre and are found in repeating units along each myofibril called sarcomeres 
(Germann and Stanfield, 2001).  
Myosin is a molecule of two subunits, each with a long tail and a globular head, both 
intertwined with one another.  It has an actin-binding site located on the globular 
head, in addition to an ATPase site. Thick filaments are composed of many of these 
myosin filaments that are bound at the tail end, with the head ends jutting out in 
opposite directions, arranged in a staggered pattern (Germann and Stanfield, 2001).   
Actin is made up of monomeric globular protein arranged as two helical polymer 
strands. On each monomer is a myosin-binding site. In close proximity to the actin and 
within the thin filaments are two other proteins essential for muscle contraction: 
tropomyosin and troponin. Tropomyosin is a long protein that extends over a number 
of actin molecules and blocks their myosin-binding sites. Troponin is composed of 
three proteins, each with a specific function. The first is bound to actin, the second to 
tropomyosin, and the third contains a calcium binding site. When calcium binds at this 
site, troponin undergoes a conformational change which allows it to move the 
tropomyosin from its resting position to expose the myosin binding sites on the actin 
(Germann and Stanfield, 2001). 
Contraction occurs through an interplay between all of these proteins following an 
influx of calcium into the cytosol. Muscle receives an impulse, or an action potential, 
from nerves at the neuromuscular junction. This impulse is in the form of the chemical 
acetylcholine released from the motor neuron. Receptors at the motor end plate 
region of the sarcolemma bind the chemical, which in turn depolarises the membrane. 
This depolarisation triggers a release of calcium ions from the sarcoplasmic reticulum 
where they are stored, through voltage-gated channels, and into the cytosol. When 
calcium enters it binds to others channels triggering the release of more calcium ions. 
This increase in calcium concentration leads to the binding of calcium to troponin, 
which moves tropomyosin, allowing actin and myosin to bind. They bind and allow 
muscle contraction by what is called a ‘crossbridge cycle’(Germann and Stanfield, 
2001). 
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An influx of calcium leads troponin to displace tropomyosin and expose actin’s myosin-
binding sites.  ATP bound to the ATPase site on the myosin head is hydrolysed into ADP 
and Pi where the energy released leads to a myosin conformational change, allowing it 
to bind to actin. The Pi  is then released which makes myosin revert back to its previous 
conformation, pulling the thin filament along with it and releasing the ADP. This pulling 
action between actin and myosin in every sarcomere along the fibres causes a 
contraction. Finally, ATP binds to the ATPase site on the myosin head and triggers 
another conformational change which leads to the detachment of myosin from the 
actin.  
Once the calcium levels are high they bind to sites on the SR channels to which they 
have a lower affinity to than those sites that lead the channels to open. This closes the 
gates and the calcium is then actively transported back out of the cytosol. The 
decrease in calcium leads it to dissociate from troponin where the myosin-binding sites 
on actin are once again blocked (Germann and Stanfield, 2001). 
 
1.2.2 The Role of Dystrophin Protein In Skeletal Muscle Function 
 
There are many other proteins that are involved in skeletal muscle contraction besides 
actin and myosin that perform crucial structural and/or signalling roles. Dystrophin is 
one such protein, which interacts with a series of proteins that form a complex and are 
collectively named the Dystrophin-Associated Protein Complex (DAPC).  Dystrophin is 
bound to the actin-based cytoskeleton within the muscle fibre, then spans the 
membrane and binds the sarcolemma via the DAPC complex. The dystrophin gene is 
the largest gene in the genome, composed of approximately 2.5Mb, or 79 exons, and 
has a molecular weight of 427 kDa (Blake et al., 2002). Its expression is controlled by 
three different promoters, each named according to the location in which it is active: B 
promoter expresses mostly in the brain (Barnea et al., 1990; Chelly et al., 1990; 
Gorecki et al., 1992), P promoter in Purkinje cell and skeletal muscle (Gorecki et al., 
1992; Holder et al., 1996), and M promoter in skeletal and cardiac muscle (Barnea et 
al., 1990; Chelly et al., 1990). The dystrophin gene also has four internal promoters 
that initiate the expression of several  isoforms of the protein by unique exon splicing 
mechanisms that leave the protein truncated at the COOH terminal (Blake et al., 2002). 
Again, the promoters’ names are based on their locations of expression: R promoter 
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expresses in the retina, B3 expresses in brain-3 cells, S in the Schwann cells, and G 
expresses generally in several tissue types (Figure 1.2). More alternative splicing also 
occurs in these truncated versions at the 3’ ends of the transcripts (Bies et al., 1992; 
Feener et al., 1989). Although it is unclear what the functions are of these isoforms it is 
believed they may bind to dystrophin-like complexes found outside muscle tissue, or 
that they may regulate the binding of dystrophin to its associated protein complex. In 
skeletal muscle, the dystrophin protein resulting from the translation of the full length 
transcript is 427kDa and is a cytoskeletal protein that has a structural function in 
muscle contraction (Blake et al., 2002). It is composed of four different regions (Acsadi 
et al., 1991) which are: the NH2 terminal, the central rod domain, the cysteine-rich 
domain, and the COOH-terminal domain (Figure 1.2). As a member of the β-spectrin/α-
actinin family (Koenig et al., 1988), dystrophin can bind actin at its NH2 terminal. After 
this structure lies the central rod domain which is composed of a series of 24 spectrin-
like repeats. Spectrin repeats are structures of three-helix bundles assembled as 
antiparallel dimers that allow it to interact with many different proteins (Djinovic-
Carugo et al, 2002). These α-helical coiled coil repeats make up most of the protein 
and give it flexibility and a rod shape similar to that of β-spectrin (Koenig and Kunkel, 
1990). There are four proline-rich regions within the rod domain that act as hinges. The 
fourth hinge is located at the end of the last spectrin-like repeat, after which the WW 
domain can be found. This domain binds to proline-rich ligands (Macias et al., 1996) 
and it is believed to interact with the cytoplasmic region of a protein called β-
dystroglycan which is very proline rich. The third domain which is the cysteine-rich 
domain has two types of motifs that define its function, which is believed namely to be 
its binding to the protein calmodulin and allowing its interaction with other protein 
members associated with dystrophin. The first is an EF-hand motif, which is where two 
helices E and F are bound by a loop that can directly bind intracellular calcium (Koenig 
et al., 1988). The second is a ZZ domain composed of a calcium-dependent zinc finger 
motif that binds to the protein calmodulin (Anderson et al., 1996). Calmodulin (CaM) is 
an important calcium-binding protein that mediates calcium binding for proteins that 
are unable to do so themselves and is involved in muscle contraction. Once bound to 
calcium it changes its conformation and binds to other proteins in order to elicit a 
specific response (www.ebi.ac.uk). The fourth and final domain of dystrophin, the 
COOH terminus,  is believed to be made of α-helical coiled coils such as those found in 
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the rod domain (Blake et al., 1995), each composed of a ‘conserved repeating heptad’ 
called the CC (coiled coil) domain. This is a region that can bind to other proteins such 
as dystrobrevin, and is thought to mediate interaction between members of the DAPC 
and syntrophin (Blake et al., 1995; Sadoulet-Puccio et al., 1997). 
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(Davies et al, 2002) 
 
Figure 1.2  Adapted from Davies et al, 2002. The dystrophin gene is the largest gene in the genome, 
composed of approximately 2.5Mb, or 79 exons, and has a molecular weight of 427 kDa. Its expression is 
controlled by three different promoters, each named according to the location in which it is active and 
the protein molecular weight (kDa): Dp427(B) promoter expresses mostly in the brain, Dp427(P) 
promoter in Purkinje cell and skeletal muscle, and Dp427(M) promoter in skeletal and cardiac muscle, as 
indicated in the top image of the figure above.The dystrophin gene also has four internal promoters that 
initiate the expression of several isoforms of the protein by unique exon splicing mechanisms that leave 
the protein truncated at the COOH terminal. Again, the promoters’ names are based on their locations 
of expression and protein molecular weight (kDa): Dp260(R) promoter expresses in the retina, 
Dp140(B3) expresses in brain-3 cells, Dp116(S) in the Schwann cells, and Dp71(G) expresses generally in 
several tissue types. More alternative splicing also occurs in these truncated versions at the 3’ ends of 
the transcripts 
The lower figure indicates the structure of the dystrophin protein which includes the actin-binding 
domain at the NH2 terminal (in green), the rod domain composed of 24 spectrin-like repeats giving the 
protein its rod shape and flexibility (in yellow), the four proline-rich hinges (1-4 in red), the WW domain 
(purple) which binds proline-rich ligands such as the cytoplasmic region of β-dystroglycan (DG), the 
cysteine-rich (CYS) domain (in dark blue) composed of an EF-hand motif (EF) that can bind intracellular 
calcium, and a calcium-dependent zinc finger motif (ZZ) that binds to the protein calmodulin , and the 
COOH terminus (CT) (light blue), made of α-helical coiled coils (CC), binds dystrobrevin (DFB), and may 
mediate interaction between members of the DAPC and syntrophin (SYN). 
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1.2.3 The Role of Dystrophin-Associated Protein Complex (DAPC) In Skeletal 
Muscle Function 
 
The DAPC complex shows the interrelated nature of protein-protein interaction in 
muscle contraction. It is a complex that allows dystrophin to connect the inside of a 
myofibre to the outside. Yoshida et al found that the complex can be separated into 
three entities: the dystroglycan complex, the sarcoglycan-sarcospan complex, and the 
cytoplasmic dystrophin-containing complex (Yoshida et al., 1994) (Figure 1.3).  
The dystroglycan complex is believed to be involved in organising the extracellular 
matrix (McDearmon et al., 1998; Pall et al., 1996). It is composed of several 
dystroglycan isoforms that are produced by the action of a protease (Ibraghimov-
Beskrovnaya et al., 1993), which are different molecular weights in different tissues. In 
muscle the α-dystroglycan protein is found in the extracellular matrix and is believed 
to bind β-dystroglycan (Figure 1.3), which is a transmembrane protein with its COOH 
terminus located within the cytoplasm. This terminus is proline-rich and is the region 
that binds to the cysteine-rich region of dystrophin (James et al., 2000) at the WW 
domain and the EF hands region (Huang et al., 2000). β-dystroglycan is also capable of 
binding another transmembrane protein whose function it is to recruit signalling 
molecules and is called Caveolin-3 (Sotgia et al., 2000). Like dystrophin it has a WW 
domain with which it competes with dystrophin at the COOH terminal of β-
dystroglycan. β-dystroglycan also binds other proteins such as laminins, agrins, and 
perlecan (Hohenester et al., 1999).  
The sarcoglycan-sarcospan complex anchors the dystroglycan complex (Figure 1.3) and 
is essential for its stability within the sarcolemma (Blake et al., 2002) and may also 
mediate signalling functions. The complex is made up of α, β, γ, and δ- sarcoglycans 
which are all transmembrane glycoproteins, as well as the protein sarcospan (Crosbie 
et al., 1997; Lim and Campbell, 1998). α-sarcoglycan is found only in skeletal muscle 
and is a Type I membrane protein which is a transmembrane protein whose COOH 
terminus is located in the cytoplasmic side. ε-sarcoglycan is the same as α-sarcoglycan 
and replaces it in smooth muscle (Barresi et al., 2000; Roberds et al., 1993; Straub et 
al., 1999). β, γ, and δ- sarcoglycans are found in skeletal, smooth, and cardiac muscle 
and are Type II membrane proteins (Barresi et al., 2000; Roberds et al., 1993; Straub et 
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al., 1999), which are transmembrane proteins whose COOH terminals are in the 
extracellular matrix rather than the cytoplasm. It has been shown by Chan et al that β, 
γ, and δ- sarcoglycans are closely associated and that δ- sarcoglycan binds dystroglycan 
(Chan et al., 1998). γ and δ- sarcoglycan are believed to be paralogs and have been 
found to interact with a protein that is involved in transducing signals as well as 
reorganising actin filaments, called filmin-2 (Thompson et al., 2000). This interaction is 
evidence that the DAPC has a role in signalling functions within muscle (reviewed in 
Blake et al., 2002). 
The cytoplasmic dystrophin-containing complex is composed of the syntrophins and 
the dystrobrevins (Figure 1.3). The syntrophin family is composed of α, β1, β2, γ1, and γ2 
–sarcoglycan (Adams et al., 1993; Bradley et al., 1972; Piluso et al., 2000). They all have 
a similar structure in that they have one split Pleckstrin Homology (PH) domain, one 
intact one, and one PSD95/DLG/ZO-1 (PDZ) domain. PH domains are defined by their 
affinity to ligand binding due to their electrostatic ‘pocket’ and their hydrophobic core 
that provides stability (www.ebi.ac.uk). PDZ domains are protein binding domains that 
can bind peptide sequences or COOH terminal sequences (www.ebi.ac.uk). The PH and 
PDZ domains in syntrophins allow them to bind to dystrophin as well as dystrobrevin at 
a similar location in both proteins, which is the first coiled coil in the COOH termini. 
There are two syntrophin binding sites in dystrophin and two in dystrobrevin (Newey 
et al., 2000), meaning four syntrophin molecules are bound to the DPC at once (Newey 
et al., 2000). 
The other protein family dystrobrevin is believed to have a role in intracellular 
signalling (reviewed in Blake et al., 2002). The family is composed of at least five 
different isoforms (Blake et al., 1996; Sadoulet-Puccio et al., 1996), with the gene for 
α-dystrobrevin located in a different location to the β-dystrobrevin gene. The genes 
have different promoters for expression in different locations for each of the various 
isoforms (reviewed in (Blake et al., 2002). These proteins can be found at the 
neuromuscular junction and at the sarcolemma (Wagner, 2008) where they are 
believed to bind to dystrophin directly and to the sarcoglycan complex (Yoshida et al., 
2000) which keeps them anchored to the DAPC (Figure 1.3). They also bind to three 
other proteins: dysbindin (Benson et al., 2001), syncoilin (Newey et al., 2001), and 
desmuslin (Mizuno et al., 2001). From their interaction with the predicted 
intermediate filament proteins syncoilin and desmuslin (Mizuno et al., 2001; Newey et 
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al., 2001) it is thought that the DAPC is linked to the cytoskeletal network within 
muscle (reviewed in Blake et al., 2002). The role of dysbindin has not been elucidated 
yet, and no protein binding domains have been found, therefore it is theorised that it 
is a protein that recruits other proteins to the DAPC (reviewed in Blake et al., 2002). 
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(Davies et al, 2002) 
Figure 1.3 Adapted from Davies et al (2002). The DAPC is a complex that allows dystrophin to connect 
the inside of a myofibre to the outside. The complex can be separated into three entities: the 
dystroglycan complex, the sarcoglycan-sarcospan complex, and the cytoplasmic dystrophin-containing 
complex. The dystroglycan complex is composed of several dystroglycan isoforms and organises the 
extracellular matrix. The α-dystroglycan (αDG, in blue in the figure above) protein is found in the 
extracellular matrix and is believed to bind β-dystroglycan (βDG, in teal), which is a transmembrane 
protein with its COOH terminus located within the cytoplasm, bound to dystrophin (also in teal). β-
dystroglycan is also capable of binding another transmembrane protein, Caveolin-3, and other proteins 
such as laminins, agrins, and perlecan. The sarcoglycan-sarcospan complex (in yellow) anchors the 
dystroglycan complex and is essential for its stability within the sarcolemma. The complex is made up of 
α, β, γ, and δ- sarcoglycans which are all transmembrane glycoproteins, as well as the protein sarcospan 
(SS). β, γ, and δ- sarcoglycans are closely associated and δ- sarcoglycan binds dystroglycan. The 
cytoplasmic dystrophin-containing complex is composed of the syntrophins (syn, in green) and the 
dystrobrevins (DB, in pink). The syntrophin family is composed of α, β1, β2, γ1, and γ2 –sarcoglycan. The 
PH and PDZ domains in syntrophins allow them to bind to dystrophin as well as dystrobrevin. 
Dystrobrevin is believed to have a role in intracellular signalling, and at least five different isoforms exist. 
These proteins can be found at the neuromuscular junction and at the sarcolemma where they bind to 
dystrophin directly and to the sarcoglycan complex, which keeps them anchored to the DAPC.  
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1.2.4 Utrophin Protein in Skeletal Muscle 
 
Utrophin is a protein that has been found to be a paralog of dystrophin, and also plays 
a role in muscle function. The full length transcript encodes a 395kDa protein and its 
structure is believed to be similar to that of dystrophin (Tinsley et al., 1992). Its exons 
are also spread out over a large area of the genome (Pearce et al., 1993), and it is also 
controlled by several different promoters (Burton et al., 1999; Dennis et al., 1996) 
leading to the creation of several isoforms (Pearce et al., 1993) altered at the COOH 
terminus as a result of variable splicing (Blake et al., 1995; Lumeng et al., 1999; Wilson 
et al., 1999). Its structure at the COOH terminus suggests that it can bind to protein 
members of the DAPC such as β-dystroglycan (Matsumura et al., 1992), α-
dystrobrevin-1 (Peters et al., 1998), the syntrophin proteins (Peters et al., 1998; 
Kramarcy et al., 1994), and also has an affinity for a section of the sarcoglycan complex 
(Matsumura et al., 1992).  The NH2 terminus has been found to contain an actin 
binding site similar to that in dystrophin (Tinsley et al., 1992; Winder et al., 1995) and 
can bind F-actin (Winder et al., 1995) which is the filamentous protein composing thin 
filaments in muscle, and β-actin (Moores and Kendrick-Jones, 2000; Morris et al., 1999; 
Winder et al., 1995) which is a cytoskeletal protein. Utrophin has been found in many 
different tissue types (reviewed in Blake et al., 2002) and in adult skeletal tissue it is 
mostly found in the vascular structures and associated with nerves (Khurana et al., 
1991; Vater et al., 1998) and localised in the myotendinous and neuromuscular 
junctions (Nguyen et al., 1991; Ohlendieck et al., 1991). It is only found in the 
sarcolemma during embryonal development or after muscular injury and regeneration 
(Chelly et al., 1990; Gramolini et al., 1999) where the levels of utrophin are higher than 
in normal healthy muscle.  
 
1.2.5 Therapeutic Approaches to Muscular Dystrophy 
 
It is clear that there are many different proteins involved in the correct function of 
muscular contraction, and that their roles are highly interrelated. Therefore, it can be 
seen that a mutation in a gene encoding one of these factors can have a knock-on 
effect on the function of other related factors, thus affecting muscle performance, and 
leading, in the case of dystrophin mutations, to the onset of muscular dystrophy. 
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The treatment of muscular dystrophy is a challenging one where several factors must 
be considered. There are several different approaches to the treatment of the 
muscular dystrophies that have emerged such as gene therapy or cell therapy which 
have promising potential. The cell therapy approach includes the delivery or 
engraftment of allogeneic or treated autologous myogenic precursors with the ability 
to fuse with myofibres and generate new ones. The viral gene therapy approach 
utilises a virus such as Adeno-Associated Virus (AAV) or Lentivirus to deliver DNA to the 
muscle fibres where the therapeutic protein is subsequently expressed. The non-viral 
gene therapy approach involves the delivery of naked plasmid DNA, or the systematic 
delivery of oligonucleotides resulting in exon skipping, leading to in-frame, albeit 
truncated, transcript expression of the mutated gene. In order to describe the cell 
therapy treatments that have thus far been developed for muscular dystrophy, muscle 
stem cells, which are used for muscle cell therapy, will first be described. Following 
this, the general principles of viral and non-viral gene therapy will be covered, before 
reviewing the gene therapy approaches taken in the development of treatments for 
muscular dystrophy. 
 
1.3 Muscle Stem Cells  
 
1.3.1 Satellite Cells 
 
Muscle fibres are post-mitotic tissue and therefore are unable to replicate. However, 
when injury occurs a mechanism must exist where the damaged tissue can be repaired 
or necrotic tissue can be replaced with healthy new fibres. These fibres are created by 
the fusion of myoblasts which are believed to originate from a precursor stem cell 
called the satellite cell. These cells are located in ‘niches’ just underneath the basal 
lamina of muscle fibres. They are classified as stem cells due to their ability to divide 
and give rise to differentiated cells as well as new satellite cells (Collins et al., 2005). 
After division, they can re-enter their state of quiescence until recruited once more. 
Collins et al locally irradiated muscle in mice and grafted a single fibre estimated to 
have 7 satellite cells (Collins et al., 2005). It was found that these cells were able to 
generate new muscle fibres and satellite cells as the number of new ones exceeded 
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the number originally transplanted. Blaveri et al and Heslop et al found that these 
precursor cells are even capable of occupying the satellite cell ‘niche’ (Blaveri et al., 
1999; Heslop et al., 2001). It was proposed by Yablonka-Reuveni and Rivera that these 
satellite cells, once activated, commit to the myogenic lineage, and are replenished 
from another source (Yablonka-Reuveni and Rivera, 1994; Blaveri et al., 1999; Heslop 
et al., 2001). Several different sources have been proposed, such as endothelial-
associated cells by (De Angelis et al., 1999), interstitial cells (Tamaki et al., 2002; 
Polesskaya et al., 2003; Kuang et al., 2006), or side population (SP) cells (Gussoni et al., 
1999; Asakura et al., 2002). Primary cells isolated from the endothelium as well as cells 
isolated from vasculature such as mesoangioblasts were able to create myogenic 
progeny (Graves et al., 2000; Cusella De Angelis et al., 2003). Satellite cells and primary 
endothelial cells even have markers in common such as CD34 (De Angelis et al., 1999; 
Beauchamp et al., 2000) indicating the possibility of a common precursor cell (Kardon 
et al., 2002). SP cells are derived from bone marrow and can differentiate into the 
hemopoietic or myogenic lineage, and can even occupy the satellite cell niche on 
myofibres (Gussoni et al., 1999; Asakura et al., 2002).  
Other stem cells may be able to contribute to muscle fibre growth or regeneration. A 
study by Sherwood et al indicated that some precursor cells that are able to create 
myogenic progeny are also able to occupy the satellite cell niche (Sherwood et al., 
2004). However, the niche is unable to direct these cells to behave as satellite cells, 
nor to have the same characteristics (Sherwood et al., 2004). They are able to have 
myogenic precursors and fuse with myofibres as is the case with cells from bone 
marrow (LaBarge and Blau, 2002; Dreyfus et al., 2004), and do not have to go through 
a satellite cell step in order to do so (Grounds et al., 2002). But, they are unable to 
repopulate muscle tissue to any significant degree, even when the tissue is sustaining 
continuous damage as was observed in dystrophic mice (Ferrari et al., 2001). The 
contribution by these circulating precursor cells is low, and most of muscle fibre is 
generated from satellite cells (Zammit et al., 2002; Collins et al., 2005), which is 
evident through studies by Wakeford et al and Heslop et al where regeneration was 
found to be insignificant by these cells after muscle was irradiated and satellite cells 
destroyed (Wakeford et al., 1991; Heslop et al., 2000). 
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1.3.2 Satellite Cell Identifiable Markers and Transcription Factors During 
Quiescence, Activation, and Differentiation 
 
Studies have uncovered several markers by which satellite cells can be identified or 
isolated. These include Pax7 (Seale et al., 2000), M-cadherin (Irintchev et al.,1994), 
saliomucin CD34 (Beauchamp et al., 2000), Myf5 (Tajbakhsh et al., 1997; Beauchamp 
et al.,2000; Shefer et al.,2006), lysenin which binds to sphingomyelin found on the cell 
membrane (Nagata et al.,2006), and caveolin I (Volonte et al.,2005) (Figure 1.4). 
Markers such as CD34 are not exclusive to satellite cells but are useful as markers 
when identifying satellite cells on isolated myofibres (reviewed in Zammit, et al.,2006)  
(Figure 1.5). 
MyoD, Myf-5, and myogenin, amongst others, are transcription factors which are 
important regulators that activate the transcription of genes required for myogenesis 
to occur in muscle (Weintraub, 1993). Throughout quiescence, MyoD protein 
expression is downregulated whereas Myf-5 and all the markers mentioned above are 
expressed (Yoshida et al., 1998; Kitzmann et al.,1998).  
The expression of certain genes in satellite cells during quiescence changes once these 
cells are activated (Figure 1.4). It is believed that activated satellite cells divide 
asymmetrically (Zammit et al., 2004) where the fate of each cell diverges. Before the 
cell divides, Pax7 and MyoD are co-expressed. One of the daughter cells suppresses 
MyoD, expresses Pax7, and goes into quiescence (Zammit et al., 2004) (Figure 1.5). The 
Notch signalling pathway also exerts a form of control where it directs the satellite cell 
to stop cycling (Conboy et al., 2002). Shinin et al found that when satellite cells divide 
asymmetrically Numb, a Notch inhibitor, segregates into the cells that will keep cycling 
(Shinin et al., 2006).  
In those cells that have been activated, MyoD expression is rapidly upregulated 
(Fuchtbauer and Westphal, 1992; Grounds et al., 1992; Yablonka-Reuveni and Rivera, 
1994) and the expression of Myf-5 decreases as the cells re-enter the cell cycle 
(Yoshida et al., 1998; Kitzmann et al., 1998). There is a change in the CD34 isoform 
expressed, and sphingomyelin amounts decrease (Nagata et al., 2006). After 24hrs in 
cell culture, the cells are then able to co-express MyoD and Myf-5. More genes that 
are characteristic of proliferating cells begin to be expressed such as PCNA 
(proliferating cell nuclear antigen) found in cells at the DNA synthesis, or S phase, stage 
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of the cell cycle. Other regulatory and structural genes expressed in myocytes are also 
switched on. Upon differentiation, the cells express myogenin, leading to the fusion of 
myoblasts to create myofibres (Andres and Walsh, 1996). 
Immunostaining experiments by Kitzman et al revealed that the ratio of expression of 
MyoD and Myf-5 is highly affected, and is in fact regulated, by the cell cycle (Kitzmann 
et al., 1998). MyoD expression varies in proliferating myoblasts but is found to be 
evenly high in myotubes (Tapscott et al., 1988). MyoD expression peaks twice in the 
cell cycle, once in the middle of G1 phase and again at the end of G2. Myf-5 shows the 
opposite to MyoD, where it is maintained mostly in G0, S, mitosis, and G2 phases, 
where MyoD expression is minimal. 
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(Zammit et al, 2006) 
 
 
 
Figure 1.4  Adapted from Zammit et al, 2006. This diagram represents myogenesis from satellite cell 
activation, through to proliferation, commitment, and finally fusion into myotubes and the formation of 
myofibres. It also indicates the markers that can be used to identify the cells at each stage, and the 
duration of which they are expressed. 
 
 
 
 
 
(Yablonka-Reuveni et al, 2006)  
 
Figure 1.5 Adapted from Yablonka-Reuveni et al, 2006. Image of muscle satellite cell stained for 
quiescent satellite cell markers Pax7 and CD34, located on a muscle fibre. 
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1.3.3 The C2C12 Cell Line As  A Model For Quiescent Satellite Cells, 
Proliferating Myoblasts, And Myofibres 
 
The C2C12 murine muscle cell line has been used in many studies as a model for 
muscle cells. An important feature which makes this cell line an excellent model is that 
some of the cells can be induced into quiescence, where they express many of the 
same markers as those which quiescent satellite cells express, such as Myf5 and CD34. 
The induction of C2C12 cells has been conducted by Kitzman et al by two different 
methods (Kitzmann et al., 1998). 
The first method by which quiescent myoblasts were generated was to differentiate a 
culture for 3 days using low-serum medium. This resulted in a culture containing 
approximatly 60-70% of fused, differentiated myoblasts, now called myotubes, and 30-
40% of myoblasts which had ceased to proliferate, but had not differentiated. These 
are called reserve cells. These quiescent cells could be separated from the myotubes 
and isolated by trypsinising with a low percentage of trypsin (Kitzmann et al.,1998). 
Myotubes are more sensitive to such treatment and detach from the dish first, leaving 
the undifferentiated quiescent myoblasts attached to the dish. These quiescent cells 
were found in both C2C12 differentiated cultures and in isolated primary mouse 
myoblasts put into culture. They could be made to re-enter the cell cycle by the 
addition of proliferation medium. The second method involved the use of low serum 
methionine depleted medium to induce myoblasts artificially into a reversible state of 
G0/G1 quiescence. Methionine is an amino acid that is vital for the growth of a cell, 
but not necessary for it to stay alive (Nadal-Ginard, 1978).  
These quiescent cells, as well as reserve cells, were found to express the same factors 
and regulators during quiescence, proliferation, and differentiation, and were able to 
differentiate into myotubes just as myoblasts derived from adult skeletal muscle 
differentiate into myofibres (Yoshida et al., 1998; Kitzmann et al., 1998). An analysis of 
C2C12 cells’ MyoD, Myf-5, and myogenin markers showed the same pattern of 
expression during quiescence, proliferation, and differentiation (Yoshida et al., 1998; 
Kitzmann et al., 1998; Andres and Walsh, 1996) where in G0 the cells expressed Myf-5 
but not MyoD. In mid-G1 phase, the cells expressed MyoD and were able to 
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differentiate. During proliferation, MyoD and Myf-5 were co-expressed during S and 
G2 phases. Furthermore, upon differentiation, myogenin was found to be expressed. 
1.4 Muscular Dystrophy Treatment Using Cell Therapy 
 
Cell therapy involves the transplantation of stem cells into the body, derived from one 
of two ways: the first is from allogeneic precursor cells which requires 
immunosuppression of the patient and also runs the risk of graft rejection, and the 
second is the extraction of autologous precursors, their modification ex vivo, followed 
by their re-transplantation.  
Stem cells derived from blood vessels are called mesoangioblasts and have been found 
to have the ability to migrate to damaged tissue and repopulate cells more efficiently 
than other types of stem cells (Sampaolesi et al., 2006). Galvez et al found that stem 
cells migrate to a specific location within the body based upon cytokines circulating in 
the target tissue as well as receptors expressed on the surface of the stem cells and 
endothelial cells which allow adhesion of the cells and their transmigration into muscle 
tissue (Galvez et al., 2006). In their study, Galvez et al pre-treated wild type 
mesoangioblast stem cells with cytokines Stromal cell-Derived Factor 1 (SDF-1) and 
Tumor Necrosis Factor α (TNF- α), which led to the expression of L-selectin and α4 
integrin proteins (Galvez et al., 2006). These proteins, not normally expressed on  
mesoangioblast cell surfaces, dimerised with integrins already being expressed on 
these cells such as β1, β7, αL, and αm, which in turn allowed 15 times more 
endothelial adhesion and hence transmigration in vitro and over 5 times more in vivo, 
without affecting myogenic differentiation. Where a mere 10% of intraarterially 
injected untreated non- SDF-1/TNFα expressing mesoangioblasts managed to 
transmigrate to damaged muscule tissue in the control experiment, with the rest being 
presumably trapped in filter organs such as the liver or the lungs, an impressive 50% 
were now reaching targeted downstream muscle. This was confirmed by the detection 
of modified mesoangioblasts using immunohistochemistry within muscle fibers, which 
were also found as satellite cells. 
Though this experiment shows that mesoangioblasts have enormous potential, there 
are of course a few parameters that need further investigation. For example, the 
excess of the cells injected that are trapped by filter organs, such as the lungs, may 
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have some negative effects on the organism that may as yet have not been detected, 
or may not manifest in mice but may become apparent in humans. Furthermore, 
mesoangioblasts don’t have an infinite ability to divide and self-renew, which could be 
limiting in that dystrophic phenotypes may be reversed or prevented until these cells 
have exhausted their replicative potential and then another injection may be required. 
And in that light, Goetz et al had found that age was a significant factor in 
transmigration efficiency, due to altered microcirculation, as is disease progression, 
due to much of the muscle having been replaced by fat, leading to the absence of key 
cytokine excretion from damaged muscle tissue essential for mesoangioblast 
recruitment (Goetze et al., 2005). However, despite these potentially limiting factors, 
mesoangioblasts appear to offer the best alternative to viral vectors in terms of their 
safety, and can compete with their ability to significantly restore muscle integrity and 
function to muscle tissue throughout the body.   
The second method using genetically modified autologous precursors does not run the 
risk of graft rejection and can be conducted without immunosuppression of the 
patient. However, there still remains the challenge of collecting enough precursor cells 
from patients at more progressive stages of the disease, transforming the cells ex vivo, 
and efficiently engrafting the cells back into the host after expansion (Skuk and 
Tremblay, 2003).  
 
1.5 Gene Therapy 
 
Gene therapy is defined as the delivery of a therapeutic gene into a cell in order to 
treat a disease. There are two main systems used for the delivery of such a gene: viral 
and non-viral. Viruses have been the prime candidates to be used as vectors as they 
exhibit high rates of transduction and offer general rather than localized delivery of 
the expressing transgene. Additionally, retroviruses such as MLV and lentiviruses are 
able to give sustained expression of the transgene by integrating their DNA into the 
host’s genome (Schroder et al.,2002; Wu et al.,2003). Unfortunately, however, there 
are safety implications associated with the use of viruses which have not been so far 
surpassed thus limiting their potential as suitable candidates for gene therapy. For 
example, it has been found that retoviruses and lentiviruses preferentially integrate 
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their DNA into regions of their host’s DNA that are actively being transcribed (Schroder 
et al.,2002; Wu et al., 2003). Also, viral proteins expressed that are essential for the 
propagation of virus and/or the replication of their DNA can be immunogenic and 
cytotoxic to the host, thus leading to inflammatory responses (Glover et al., 2005). 
Additionally, viral proteins are also capable of disrupting normal gene expression 
either by activating oncogenes or disrupting the expression of tumour suppressor 
genes (Glover et al., 2005), thus leading to cancer. As a result, some of the focus has 
been shifted to the development of non-viral vector alternatives.Non-viral vectors 
have several advantages over viruses, such as a lower ability for insertional 
mutagenesis. Another advantage is that they do not directly induce host aquired 
inflammatory responses (Glover et al., 2005), however they have been found to be 
able to stimulate the innate immune response which could, in itself, lead to an 
inflammatory reaction. There have been several types of non-viral approaches, such as 
Yeast Artificial Chromosomes (YACs), which helped define the requirements for the 
creation of a replicating chromosome which include a centromere, telomeres at both 
ends, and origins of replication (Murray and Szostak, 1983). YACs led to the 
development of Human Artificial Chromosomes (HACs) but have unfortunately not 
been very popular as vectors due to their large size, thus leading to inefficient in vivo 
delivery. Furthermore, instability as a result of concatamer formations and unforeseen 
recombination events leading to variation in sizes make it even less of a candidate. 
Another alternative is to send plasmid DNA into cells, as plasmids are smaller in size 
and are more stable. Plasmid DNA can be delivered to cells as naked DNA, or with the 
use of a carrier such as cationic lipids, polymers, or pepetides. The benefits to using 
naked plasmid DNA include the fact it allows a large capacity for transgene size which 
is not limited as is the case with packaging DNA into viral vectors (Gill et al., 2009). 
Furthermore, plasmid DNA can be constructed and produced cheaply and with relative 
ease in large amounts to a quality standard sufficient for in vivo delivery. This means 
that it does not contain bacterial contaminants such as DNA, RNA, endotoxins, or other 
bacterial proteins that could trigger an immunogenic reaction, and that the majority of 
the pDNA is supercoiled, a form that allows higher transfection efficiency into target 
cells (Gill et al., 2009).  pDNA used in gene therapy is made of two components. The 
first is the expression cassette which includes the promoter, transgene, and 
polyadenylation signal. The second is the segment that contains the elements required 
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for its propagation and production in bacteria which includes a bacterial origin of 
replication and an antibiotic resistance marker. 
Transgene expression resulting from the delivery of plasmid DNA does not always 
reach the threshold required for a significant functional improvement of a disease, 
thus efforts are being directed towards the improvement of pDNA delivery to, and 
expression in, target cells. When pDNA is sent into target tissue it must first be able to 
escape its delivery vehicle or carrier, if used, and then avoid cellular endosomes or 
cytosolic nucleases that degrade DNA before reaching the nucleus (Gill et al., 2009). A 
major drawback to using plasmid DNA is that its expression is often lost with time in 
dividing cells as it cannot replicate with the host DNA. Plasmids contain antibiotic 
resistance markers in order to maintain the plasmid within the host cell by using an 
initial period of selection for establishment. However, when selection is removed, the 
episome is gradually lost at a rate of 4% per cell generation (Glover et al., 2005). If the 
plasmid is delivered to non-dividing cells where it can remain episomal within the 
nucleus expression can still often be silenced with time for several different reasons, 
and this varies according to the target cell type (Gill et al., 2009).  
Often when persistent expression of a pDNA transgene is observed it is due to an 
integration event occurring as a result of the use of an initial period of selection or due 
to highly recombinogenic sequences present within the plasmid. Integration of DNA 
into the host genome is unsafe as has already been mentioned. Attempts have been 
made at directing DNA integration into ‘safe sites’ (Glover et al., 2005) by 
recombination (Kapsa et al., 2001) but the frequency of such an event is too low and 
thus cannot be used for therapeutic purposes. Several Site-Specific Recombinases 
(SSRs) have been identified that can direct integration to a specific site within the 
genome. These act very efficiently, however further studies are still required in order 
to be certain that integration occurs strictly and solely at identified and known safe 
sites (Glover et al., 2005). 
There are many factors that can influence the expression of a pDNA transgene and its 
persistence over time. Daughter cells of actively dividing cells do not merely inherit 
DNA but also inherit the markings placed upon the DNA, such as histones and sites of 
methylation. Indeed there is no doubt that foreign DNA introduced into cells is also 
subject to such markings that will also be passed down to their progeny. The study of 
such markings is termed ‘epigenetics’ and is essential in the study of cells’ mechanisms 
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of expression and/or silencing and the passing down of plasmid DNA down the 
generations. 
1.6 Muscular Dystrophy Treatment  
 
1.6.1 Viral Approaches for Gene Delivery  
 
Recombinant Adeno-Associated Virus (rAAV) is a viral vector that carries single 
stranded DNA and the wild type requires a helper virus in order to replicate (Atchison 
et al., 1965). It has been engineered to be able to replicate on its own (rAAV) and is 
able to infect both dividing and post-mitotic cells (Podsakoff et al., 1994) which allows 
it to target a wide variety of tissues. Its DNA does not integrate into the host genome 
but has been found to persist episomally (Duan, 1998; Schnepp et al., 2009) unless 
high doses of the virus are administered where integration has been shown to occur 
(Chamberlain et al., 2004; Inagaki et al., 2007). Disadvantages of using this vector 
include the packaging capacity which is approximately 5kb, and the fact that the 
episomes delivered are eventually lost with cell division in mitotic tissue (Muir and 
Chamberlain, 2009). In treating Duchenne muscular dystrophy where a correct form of 
the dystrophin gene is required the rAAV vector system would be unsuitable due to 
packaging issues. However, several methods have been devised to circumvent this 
issue. Mini- and micro-dystrophins have been engineered which yield truncated yet 
functional forms of the dystrophin protein and are within the carrying capacity of AAV. 
However, the problem with using truncated versions of the original protein is shown 
by several studies where dystophin’s function of localising the signalling molecule 
nitric oxide’s precursor nNOS (neuronal nitric oxide synthase) is lost (Thomas et al., 
1998; Kobayashi et al., 2008). This molecule is important for supplying blood to active 
muscles and vasodilation (Thomas et al., 1998; Kobayashi et al., 2008). 
Another way the rAAV packaging problem was resolved was by the use of a ‘split-
vector’ approach where the full length cDNA of the dystrophin gene is carried by two 
AAV vectors. This then involves trans-splicing, recombination, or the use of overlapping 
sequences in order to combine the transcripts into one, thus yielding a full length 
dystrophin transcript that can be expressed. The trans-splicing method is a 
discontinuous group II intron trans-splicing method that occurs in mammalian cells and 
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is used to join two coding sequences together. It requires the insertion of a splice 
donor sequence at the tail end of the first transcript carrying the 5’ end of the 
sequence, derived from a natural dystrophin intron. A splice acceptor sequence from 
the same intron is inserted at the start of the 3’ transcript (La et al.,. 2005). The 
sequences are then spliced together within the cell creating a full length transcript 
yielding the dystrophin protein. When recombination is the method to be employed, 
the transcripts contain fragments that overlap and undergo homologous 
recombination within the cell.  
Lentiviral vectors, like AAV, can infect a wide range of tissues that are mitotic or post-
mitotic, but it has a greater carrying capacity than rAAV vectors (approximately 9kb) 
(Muir and Chamberlain, 2009). However, it integrates its DNA into the host genome 
(Muir and Chamberlain, 2009). Although integration could provide longer lasting 
expression, there is the risk of insertional mutagenesis in addition to the hazard of viral 
promoters and enhancers activating proto-oncogenes, and conversely disruption of 
gene expression that may inactivate a tumour suppressor gene locus (Hacein-Bey-
Abina et al., 2003; Ciuffi et al., 2006; Beard et al., 2007). A safer lentiviral vector has 
been referred to as SIN (self-inactivating) vectors that do not contain any of these 
promoters or enhancers and has been used to deliver minidystrophin to muscle (Li et 
al., 2005). 
Although viral gene transfer methods may result in greater gene expression and more 
systemic delivery, the use of non-viral vectors has many benefits such as the reduced 
risk of insertional mutagenesis (Glover et al., 2005), and a carrying capacity for 
transgenes which is not limited by a packaging capacity. There are several different 
approaches that are included as non-viral gene therapy methods. These include 
oligonucleotide-mediated exon skipping, oligonucleotide-mediated genome repair, cell 
therapy, and naked plasmid DNA (pDNA) delivery amongst others (reviewed in Trollet 
et al., 2009; Muir and Chamberlain, 2009) 
 
1.6.2 Muscular Dystrophy Treatment Using Non-Viral Gene Transfer 
 
An estimated 10-15% of cases of Duchenne muscular dystrophy are caused by 
nonsense mutations where a base pair is altered leading to a frameshit mutation, a 
premature stop codon, or an inappropriately placed splice site that results in a non-
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functional protein (Trollet et al., 2009). The exon skipping approach aims to target such 
mutations by allowing the transcription machinery to effectively ‘skip’ the exon where 
the mutation is located and continue reading the rest of the gene in-frame. This results 
in a truncated yet still functional dystrophin protein, thus alleviating the severe 
symptoms of Duchenne and changing it to the milder form of Becker’s. 
Antisense Oligonuceotide-Induced exon skipping is an RNA-based approach where an 
oligonucleotide complementary to the exon targeted is designed which then modifies 
the pre-mRNA splicing leading to the restoration of the reading frame (Trollet et al., 
2009). The oligonucleotides must be designed specifically for each exon that is to be 
skipped. The skipping can occur either by physically blocking the enhancer sequences 
at a specific location, or by altering the secondary structure of the pre-mRNA in order 
to prevent splicing, thus ‘skipping’ the targeted exon (Trollet et al., 2009) by the 
removal of the mutated exon together with its flanking introns (Muir and Chamberlain, 
2009). The stronger the binding of the oligo and the more easily accessible it is to the 
target sequence, the more effective exon skipping will be (Popplewell et al.,2009; 
Wilton and Fletcher, 2007). 
There are several different chemistries of oligonucleotides that have been designed for 
exon skipping. These include Peptide Nucleic Acids (PNAs), Locked Nucleic Acids 
(LNAs), 2’-O-Methoxyethyl (2’OMe), and Phosphorodiamidate Morpholinos (PMOs) 
(Trollet,C. 2009). In terms of safety the PMOs and 2’OMe chemistries have proven the 
safest (van Deutekom et al., 2007). PMOs, also called morpholinos, have a similar 
chemistry to 2’OMe, except that the ribose rings were replaced with morpholino rings 
thus replacing the phosphodiester bonds with phosphorodiamidate (reviewed in (Muir 
and Chamberlain, 2009). This gives the PMOs a better ability to resist nuclease 
degradation within a cell, and they have proven to be the most efficient at maintaining 
skipping that is both reliable and persistent (Trollet et al., 2009). This was shown in 
studies utilising in the mdx mouse model (Alter et al., 2006) and human muscle 
explants (McClorey et al., 2006). It was also taken into clinical trials (Kinali et al., 2009). 
2’OMe was also in clinical trial (Arechavala-Gomeza et al., 2007) showing that there 
were also no apparent adverse effects resulting from this treatment (van Deutekom et 
al., 2007). Another advantage of using PMOs is that their delivery to target cells can be 
further improved by their conjugation to cell-penetrating peptides (Fletcher et al., 
2007).  
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The drawback with exon skipping, however, is the requirement for repeated 
oligonucleotide administration due to their short half-life (Vacek et al., 2003). The 
major risk with this method is non-specific binding of the oligo which may cause 
unknown adverse effects (Trollet et al., 2009). Even if the non-specific binding is very 
low, administration of high doses of oligos in order to reach an acceptable therapeutic 
index would magnify such harmful effects (Muir and Chamberlain, 2009). Furthermore, 
the cost of creating these oligos is high (Muir and Chamberlain, 2009). 
Another non-viral method involves the delivery of naked DNA such as a plasmid 
containing the correct form of the gene. There are several methods that have been 
devised for the delivery of naked plasmid DNA into muscle tissue in vivo. Although 
these methods are less efficient than the use of viral vectors, there is no doubt that 
some of them are safer for use in gene therapy (Gao et al., 2007). One is the direct 
injection of the plasmid DNA however the DNA does not enter the cells easily and with 
great efficiency, and it may be degraded by intra-/extra-cellular nucleases before 
reaching the target nucleus. A second method is the use of a gene gun. This involves 
coating gold particles with pDNA and penetrating cells of a tissue with them thus 
releasing the DNA into these cells. A third and popular method is electroporation, 
where the pDNA is injected into the tissue first before electrodes are inserted and 
moves the DNA along an electric field through the cell membrane which is reversibly 
permeabilised and into the cell. Vilquin et al (Vilquin et al., 2001) found that both 
healthy and dystrophic mouse muscles were transfected with the same efficiency 
indicating that fibrosis does not interfere with the efficiency of electroporation-
mediated gene transfer. Therefore this method could be useful and applicable to gene 
therapy of muscular dystrophy. However, several issues are posed by the use of this 
method. The first is that the expression in the study by Vilquin et al was mostly found 
near the sites of injection and was not spread out over the whole muscle area (Vilquin 
et al., 2001). It is further limited in that it cannot be applied to deep seated tissue 
within the body without surgery being required, nor for large areas of tissue (Gao et 
al., 2007). Furthermore, it has safety implications in that it could considerably damage 
the muscle. A fourth method involves the use of ultrasound where it creates 
temporary holes within the cell membrane through which the DNA can diffuse into the 
cell, however this method has a low efficiency and needs improvement. A fifth method 
is the hydrodynamic injection via the tail vein of mice where a temporary overflow of 
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fluid within the mouse’s system results in a overflow within the liver thus efficiently 
deliver the DNA into the liver. This method is the most efficient non-viral method, 
however it may be more complicated to apply to humans. Chemical methods have also 
been used to deliver pDNA to target cells where particles are taken up by the cells by 
methods such as endocytosis or phagocytosis into the cytoplasm, and then find their 
way to the nucleus. The most used chemical method is the complexing of pDNA with 
cationic lipids to form lipoplexes. The benefit of using this method is that the pDNA is 
protected until it is released into the cell. However, these lipoplexes can be toxic to 
some cells according to the cell type (Gao et al., 2007). 
A limiting factor to the use of plamid DNA is that plasmids contain antibiotic resistance 
markers used to maintain the plasmid within the host cell by using an initial period of 
selection for establishment. When selection is removed, the episome is gradually lost 
at a rate of 4% per cell generation (Glover et al., 2005) and if expression is maintained 
it is due to an integration event occurring.  
Furthermore, these plasmids do not replicate within their host genomes. A study by 
Vilquin et al confirmed this (Vilquin et al., 2001). They attempted the use of notexin, a 
snake venom that destroys muscle fibres, after transduction with the pDNA carrying 
the β-Gal reporter gene in healthy mice, and then assessed the expression after the 
muscles had regenerated. It was found that the β-Gal reporter protein could hardly be 
detected. This indicated that the plasmid did not transduce muscle satellite cells 
efficiently, and if it did then the plasmid was unable to replicate with the cell divisions 
and the plasmid was subsequently diluted out and lost. 
Considering the safety implications involved with the use of viral vectors, non-viral 
vectors have been utilised and manipulated in many studies in an effort to improve the 
levels and duration of transgene expression. In order to develop these vectors, it is 
necessary to understand the epigenetic factors that led these vectors to be less than 
ideal to begin with. Therefore, a description of epigenetics, the mechanisms of DNA 
marking, and gene silencing will be discussed, before reviewing the improvements that 
have been made to conventional non-viral vectors to circumvent their shortcomings 
thus far, and how this can be applied to the development of a novel therapeutic 
approach to the treatment of muscular dystrophy. 
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1.7 Epigenetics 
 
‘Epigenetics’ is defined as “the study of heritable changes in gene function that occur 
without alterations to the DNA sequence” (Probst et al., 2009). Epigenetic marks are 
things that can define the reading of DNA by the cell and can be passed down to 
daughter cells. Epigenetic markers are both stable and flexible modifications to DNA 
and include the methylation of cytosine residues, the packaging of DNA with histones, 
of which there can exist several variants, the modification of these histones, such as 
acetylation, the binding of non-histone proteins to DNA or to histones/modified 
histones, higher-order chromatin organisation, and positional information. All of these 
marks contribute to and influence the way in which DNA is accessed and therefore 
read and transcribed (Probst et al., 2009). Certain modifications are short term and can 
occur as a result of a signal due to specific stimuli, whereas others play a role in cellular 
memory and remain longer-term (Turner, 2002).  
 
1.7.1 Histones 
 
Histone packaging of DNA is an important function of the cell and is crucial in DNA 
organisation. DNA is organised by wrapping around a histone octamer that is 
composed of an H3-H4 tetramer and capped by two H2A-H2B dimers. Histone H1 is a 
linker histone, and all together this forms a nucleosome. The modifications that can 
occur to histones include methylation (Me), acetylation (Ac), and phosphorylation (P). 
The acetylation of histones is conducted by histone acetyltransferase enzymes (HATs) 
and involves the neutralising of the histone tail’s positive charge leading the histone to 
have less affinity to the negatively charged DNA (Grant, 2001). Acetylated histones are 
found with DNA that is transcriptionally active such as euchromatin. Deacetylated 
histones are found to be associated with inactive DNA such as heterochromatin, and 
are deacetylated by histone deacetylases (HDACs). Phosphorylated histones are also 
those associated with transcriptionally active DNA and, as with histone acetylation, 
also have their tail charge neutralised, and here it is by the addition of a negatively 
charged phosphate group (Grant, 2001). It is believed that histone phosphorylation 
may actually lead to transcriptional activation, possibly by stimulating the activity of 
HATs on the same histone tail leading to acetylation as well. These marks create a 
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‘histone code’ which can be read alone, in combination if several marks exist, or in 
addition to marks present on other histones nearby.  
In addition to histone markings, the variant of histone present can relate information. 
Different variants can lead to variable levels of nucleosomal stability which can 
determine regions of higher or lower degrees of transcriptional activity.  
Groth et al suggest that there may be a mechanism by which the cell re-uses and re-
incorporates parental histones and newly created ones (Groth et al., 2007). Histone 
chaperones would be the factors that carry out functions such as tethering histones 
and assembling or disassembling nucleosomes. One such factor is the chaperone 
chromatin assembly factor (CAF1) that associates with H3.1 and H4 in addition to 
PCNA and histone deacetylases or Lys methyltransferases (Shibahara and Stillman, 
1999). Another such factor, also an H3-H4 chaperone, is ASF1 which can also interact 
with CAF1 and donates newly made histones during replication. Newly made H4 
histones do carry acetylation marks (Loyol et al., 2006) that are subsequently removed.  
There are two ways in which these marks are inherited after the passing of a 
replication fork where such marks are inevitably displaced. One is to inherit histone 
variants outside of S phase where the inheritance is not coupled to DNA replication. 
These are histone variants such as H3.3 or CenH3 (CENP-A in humans) that bind to the 
centromeres of chromosomes (Loyola and Almouzni, 2007; Henikoff et al., 2004). H3.3 
is found to associate with transcriptionally active DNA and can mark it as such. These 
histones have many active histone markers (Loyola et al., 2006; McKittrick et al., 2004) 
and also make the nucleosomes in which they are contained less stable than those that 
may have the variant H3.1 incorporated (Jin and Felsenfeld, 2007). The degree of 
instability varies according to other additional factors which include the amount and 
type of modification status of the nucleosome itself (Loyola et al., 2006), or the 
possible incorporation of other variants (Henikoff, 2008). For example, histone H3 
variant is defined as a replicative histone and is expressed and incorporated during 
DNA replication (for example, H3.1 and H3.2), whereas a replacement variant is 
expressed throughout the cell cycle and is incorporated in a DNA synthesis-
independent manner (for example, H3.3m and the centromere-specific histone H3 
variant CenH3) (Grant, 2001). This means that when DNA is not being replicated in the 
S phase, the exchange of replicative histone variants such as H3.1 and H4 is very low, 
whereas that for H2A and H2B can easily occur (Kimura and Cook, 2001). This could 
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point to the histone variants H3.1 and H4 to be the ones most liable to transfer 
information which can be considered heritable.  
The second way in which marks are inherited is by being coupled with replication. 
After a replication fork passes histones are displaced and there is no template from 
which the nucleosomes can be reassembled. There are three possible scenarios by 
which parental histones are re-incorporated into replicating DNA after displacement. 
The first is considered random, where the marked H3 and H4 histones are depositied 
randomly and the corresponding gaps where histones are missing are subsequently 
filled by new H3-H4 dimers. The second proposal is a semi-conservative one, where 
the parental dimers are distributed evenly between the daughter strands and new 
ones are placed to complete the nucleosome structures. The final theory is an 
asymmetric distribution where all the parental histones are transferred to one 
daughter strand and newly synthesised ones are placed in the other strand based on 
possible cross-talk between the two strands. It is quite possible that all three proposals 
could be occurring as well.  
It is also a possibility that new histones could inherit their marks from older 
neighbouring ones. It has been found that PCNA and CAF1 are able to stay on 
replicated DNA for an amount of time sufficient enough to allow them to modify the 
new chromatin such as by removing the acetylation markers present on newly 
synthesised histones (Sporbert et al., 2002; Taddei et al., 1999; Loyola et al., 2006). It is 
also possible that regions which are highly methylated are able to guide histone 
modifications via the machinery that maintains these methylation marks that may act 
as a guide. Sarraf and Stancheva (Sarraf and Stancheva, 2004) found that methyl CpG-
binding protein (MBD1) is capable of forming a complex with Lys methyltransferase 
(SETDB1) and Reese et al found that this complex is able to associate with CAF1 during 
replication (Reese et al., 2003). Furthermore, Fuks et al found an association between 
DNMT1 and HDAC1 (Fuks et al., 2000) and with HDAC2 (Rountree et al., 2000). This 
indicates that a connection may indeed exist between DNA modifications via marks 
and the placement of histones.  
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1.7.2 Plasmid DNA And Epigenetics 
 
The aim of a study conducted by Riu et al was to determine whether histones associate 
with pDNA, and if they are at least in part responsible for silencing if it occurs (Riu et 
al., 2007). Riu et al confirmed that plasmid DNA is epigenetically altered within cells 
(Riu et al., 2007). In the study by Riu et al, mouse livers were transfected with 
minicircle, or the minicircle parental plasmid, using RSV or EF1-α promoters to control 
transgene expression. It was found that the minicircle produced expression that was 
100 times that of the parental plasmid and was persistent whereas the parental 
plasmid was silenced over the period of several weeks (Riu et al., 2007). This was not 
due to any difference in plasmid copy number within the livers as this was tested and 
the numbers were found to be similar. Antibodies were used against certain modified 
histones and chromatin immunoprecipitation (ChIP) analysis was performed. The 
results indicated that the minicircle had histones associated with it whose 
modifications were those found to be associated with euchromatin. This shows that 
pDNA does undergo chromatinisation within cells and that the sustained expression 
observed can be attributed to the association of euchromatin-associated modifications 
of the histones associated. The analysis was conducted at several time points. On day 1 
no differences were observed between the two indicating that chromatinisation had 
not yet fully occurred, or that the DNA had not yet reached the correct nuclear 
compartment. Similar results were observed by day 7. At day 35 however, it was 
shown that the parental samples contained 2-5 fold more heterochromatin markers 
than the minicircle samples, indicating transcriptional repression. These markers 
included di- and tri-methylation of lysine 9 on histone 3 (H3K9me2 and H3K9me3), di- 
and tri-methylation of lysine 20 on histone 4 (H4K20me2 and H4K20me3), histone 
deacetylase 2 (HDAC2), HP1α, and H3K9 methylase SUV39H1. Low levels of these 
markers were found within the minicircle lysates, however the authors attributed this 
to a low level of contaminating parental plasmid within the minicircle precipitation 
solution. In the minicircle lysates, 2-6 fold more euchromatin markers were present 
than in the parental plasmid lysates, which indicated transcriptional activation. These 
included the acetylation of histones 3 and 4 (H3Ac and H4Ac), the di- and tri-
methylation of lysine 4 in histone 3 (H3K4me2 and H3K4me3), the di-methylation of 
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lysine 79 in histone 3 (HeK79me2), the acetylation of lysine 9 in histone 3 (H3K9Ac), 
and the phosphorylation of serine 10 on histone 3 (H3S10P). This indicates that 
chromatin in an open configuration can lead to long term transgene expression.  
These results were obtained when the RSV and the EF1-α promoters were used. 
Interestingly, when a third promoter was tested, the UbC promoter, sustained 
transgene expression resulted from both the minicircle and the parental plasmid, 
without silencing. Both plasmids showed high levels of serum hAAT, which was the 
transgene being expressed, over the period of 35 days. ChIP analysis at day 35 
indicated that both types of lysates had low amounts of heterochromatin-associated 
markers and large amounts of euchromatin markers in both the promoter and cDNA 
regions. This indicates that sustained long term expression is a result of an open and 
active state of DNA that has been marked with euchromatin-associated markers. 
 
1.7.3 Methylation 
 
Silencing of DNA occurs by histone modifications and changes in chromatin structure, 
both of which are easily reversible (Shi et al., 2004), in addition to methylation, which 
is a more permanent modification. DNA methylation is the alteration of the cytosine 
residue by the covalent addition of a methyl group by methyltransferases with S-
adenosyl-methionine as the methyl donor (Miranda and Jones, 2007). Methylation of 
CpG residues takes place in mammalian cells and is usually a marking of 
heterochromatin (Miranda and Jones, 2007). Methylation as a silencing mechanism 
may have evolved due to the foreign elements present within the human genome such 
as transposons and parasitic elements which are potentially dangerous if not silenced 
(Kochanek et al., 1995; Robertson and Wolffe, 2000). Furthermore, methylation is 
important for other heritable epigenetic markings such as X-chromosome inactivation 
and imprinting. X-chromosome inactivation occurs during embryogenesis is where one 
allele is methylated and silenced leading to expression resulting only from the other 
allele (Chang et al., 2006). Imprinting is also important in order to control which 
parental allele will be expressed. DNA methylation also occurs in somatic cells during 
differentiation where certain genes are silenced thus allowing the cell to progress 
down a particular lineage (Webe et al., 2007).  
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Methylated DNA recruits methyl-binding proteins (MBPs) to the methylation sites. 
There are five members in this protein family, all of which contain a homologous 
domain that binds methylated CpGs (Sansom et al., 2007). They are called MBD1-3, 
MeCP2, and Kaiso. These proteins can bind to histone deacetylases and repressors that 
make the chromatin inactive by changing its structure (Harikrishnan et al., 2005). De 
novo methylation occurs by DNA methyltransferases recognising chromatin structures 
within the genome. Euchromatin is DNA that is actively transcribed and is defined by 
the di- and tri-methylation of histone H3 at its lysine 4 site, and the acetylation of the 
histones H3 and H4 that are bound to the DNA. Kouzarides states that this is a flexible 
and reversible state of DNA (Kouzarides, 2007). Heterochromatin is DNA that is 
silenced and compacted and is characterised by the trimethylation of histone H3 at the 
lysine 27 or the lysine 9 site, or the methylation of histone H4 on lysine 20. These 
histone modifications in heterochromatin may possibly be targets for 
methyltransferases.  
Methylation can lead to silencing by two proposed theories. The first is that the methyl 
groups bound block the binding of transcription factors to the DNA. Comb and 
Goodman (Comb and Goodman, 1990) found that many transcription factors bind to 
sequences that contain CGs and therefore methylation could be interfering with the 
binding. The second proposed theory was that methylation alters the structure of the 
chromatin by affecting histone modifications and therefore the structure of the 
nucleosomes. This in turn could block the binding of transcription factors by 
disallowing activation markings to occur or to be propagated. When methylation 
occurs in promoters gene expression is silenced and the genes cannot be reactivated, 
even when the silencing histone markers are removed (McGarvey et al., 2007).  
The lack of methylation markers on CpG motifs of foreign DNA can also trigger an 
immune response. Cells have an innate immune response against forgein DNA 
(Vilaysane and Muruve, 2009). Toll-like receptor 9 (TLR9) is a protein that is bound to 
the membranes of endosomes and acts as a DNA sensor (Vilaysane and Muruve, 2009). 
Hemmi et al showed that TLR9 was able to recognise foreign unmethylated bacterial 
DNA but not its own self-DNA (Hemmi et al., 2000). TLRs are able to activate the 
transcription of cytokines that initiate an inflammatory response.  
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1.8 Improving Plasmid Transgene Expression 
 
One approach involved the development of a novel kind of plasmid called the 
‘minicircle’, which is as a conventional plasmid but does not contain an antibiotic 
resistance gene nor any bacterial sequences but solely the gene transcriptional unit 
(Chen et al., 2003). Its creation is based upon the recombination of a parent plasmid 
yielding the minicircle and a ‘maxicircle’ which is then digested and degraded leaving 
only the minicircle. Its benefits include the circumvention of the safety issues that 
come with the use of a conventional plasmid in addition to better transfection 
efficiency as a result of its smaller size and a smaller likelihood of silencing from CpG 
methylation. Minicircles are also relatively easy to produce. Chen et al developed a 
new plasmid vector devoid of bacterial backbone based upon the Streptomyces 
temperate phage integrase ØC31 –mediated site-specific intramolecular 
recombination technology (Chen et al., 2003). The parent plasmid undergoes 
recombination at two specifically inserted sites resulting in a minicircle containing the 
transcription unit, and a maxicircle containing the bacterial backbone. The principle is 
based on the destruction of the maxicircle and parent plasmid after recombination has 
taken place by the insertion of the endonuclease I-SceI gene and I-SceI recognition 
sequences outside the minicircle unit in order to linearize maxicircle and parent 
plasmid, which would eventually be digested by exonucleases within the cell, leaving 
the minicircle intact. Chen et al conducted a study which compared the human FIX 
expressing minicircle to the unrecombined plasmid in mice (Chen et al., 2003). The 
mice infused with the minicircle had high levels of human FIX in their serum initially, 
which then stablilized to a concentration of 12µg/ml, being over two fold normal 
levels, which remained constant for the 7 weeks that were the length of the 
experiment. The mice infused with the unrecombined plasmid showed high expression 
at first and then dropped more than 45 times the initial amount within three weeks 
and continued to decrease thereafter. When tested with another expression cassette 
using human AAT, minicircle transgenes gave a 560 fold higher level of expression than 
that of the unrecombined parent plasmid transgene. This study shows that the 
minicircle can provide high levels of transgene expression and persist within mouse 
liver. However, it is unable to be replicated in dividing tissue and would best be 
employed in post-mitotic tissue.  
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The second approach was to change the promoter. Many studies have utilised 
ubiquitous promoters, often of viral origin, such as the cytomegalovirus (CMV) 
promoter, which drive high levels of transgene expression in a wide variety of cell 
types. However, expression is often short-lived and is shut down after a period of time. 
The use of non-viral ubiquitous promoters can circumvent such issues (Gill et al., 
2009). In a study by Pringle et al for example, the use of the human polyubiquitin C 
(UbC) promoter drove the long term expression of the transgene when delivered as 
naked plasmid DNA to mouse lungs by electroporation (Pringle et al., 2007).  
Fusion promoters have also been tested with promising results, such as the CMV 
enhancer/chicken β-actin (CAGG) fusion promoter in the liver that allowed sustained 
long-term expression (Pringle et al., 2007). Several studies have compared the CMV 
and CAGG promoters in plasmid constructs and found the resulting expression to be 
superior when driven by the CAGG promoter. One such study was conducted by Niwa 
et al where it was tested in several cell lines and was found to have superior 
expression over the CMV promoter construct (Niwa et al.,1991). A second study by 
Garg et al used the CAGG promoter to drive the expression of the influenza-
hemagglutinin (HA) gene, to be used as a DNA vaccine against influenza (Garg et al., 
2004). The expression of this construct was compared with one driven by the CMV 
promoter in mice. It was found that there was a significantly higher immune response 
from the vaccine with the CAGG construct than the CMV one, leading to the conclusion 
that its expression better than that of the CMV. Another study by Alexopoulou et al 
used vectors expressing eGFP driven by CAGG that were stably transfected in 
undifferentiated and differentiated murine embryonic stem cells (CCE cell line) 
(Alexopoulou et al., 2008). This vector was directly compared to one driven by the 
CMV promoter, and one by the chicken β-actin promoter. Under the CAGG promoter it 
was found that 50% of the stable transfectants of undifferentiated and differentiated 
cells were positive. Under the CMV promoter it was found that less than 50% of cells 
were eGFP positive and this declined further in differentiated cells. The same was seen 
under the chicken β-actin promoter, leading to the conclusion that the CAGG promoter 
drove higher expression than the other two promoters tested in these cells. Yet 
another study, by Ngyen et al aimed to compare four promoters driving the luciferase 
transgene in Hek 293 cells and in mouse liver by hydrodynamic injection through the 
tail vein (Nguyen et al., 2008). These promoters were CMV, CAGG, EF1α (elongation 
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factor-1 α), and PGK (phosphoglycerokinase). It was found that the CAGG promoter 
produced the highest levels of transgene expression both in vitro and in vivo when 
assessed 24hours post transfection. 
Tissue-specific promoters are also useful tools for driving expression as, although they 
may not lead to initial expression levels as high as promoters of viral origins, they can 
allow for more specific expression in target cells, leading to increased safety. They may 
also lead to more sustained, long-term gene expression as was observed in the study 
by Argyros et al in comparing the AAT liver-specific promoter to CMV, where the 
expression resulting from AAT was slightly higher than that of CMV 6 months post 
transgene delivery (Argyros et al., 2008). 
A third approach to improve expression was to reduce or eliminate CpG sequences 
from the pDNA that can be methylated. In a study by Hyde et al the aim was to 
improve the expression of a plasmid carrying the Cftr transgene complexed with 
cationic lipids to the lungs of cystic fibrosis mouse model by aerosolization (Hyde et al., 
2008). The CMV promoter was used to drive expression, which lasted approximately 2 
weeks before being silenced. The promoter was then changed to UbC, and a small 
increase in the duration of the expression was observed. The aim was then to 
determine whether the CpG motifs within the plasmid sequence were the cause of the 
silencing observed. It was found that even a single CpG sequence was enough to 
trigger an immune response within these animals leading to silencing, and that the 
eradication of these motifs resulted in continuous long term transgene expression free 
from an immune response, and the level was adequate enough to functionally improve 
the condition of cystic fibrosis (Hyde et al., 2008). 
A fourth approach to improve transgene expression and its duration was to include a 
Scaffold/Matrix Attachment Region (S/MAR) element within the open reading frame of 
the transgene in the plasmid. The inclusion of this element has led, in some cases, to 
prolonged expression without being subject to silencing, in addition to preventing 
integration and thus maintaining the plasmid in an episomal state in actively dividing 
cells (Jenke et al., 2004). Such a vector appears to be a promising gene therapy vector 
as it overcomes the integration issues that hold back other potential vectors whilst at 
the same time offering stable, long-term transgene expression. A plasmid containing 
an S/MAR element has not, as yet, been tested in muscle cells. Considering the 
properties the S/MAR element can potentially confer to its plasmid, this could be a 
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useful vector in the treatment of muscular dystrophy if it can be directed to and 
successfully transfected into muscle satellite cells.  
In order to understand the mechanism by which S/MAR elements can confer such 
properties to a plasmid, it is important first to evaluate what S/MARs are, what defines 
them, and what their natural functions and characteristics have been shown to be. 
 
1.9 Scaffold/Matrix Attachment Region (S/MAR) Elements, DNA 
Organisation, and The Nuclear Matrix 
 
Scaffold or matrix attachment regions (S/MARs) are DNA sequences that are 
considered to be chromatin domain borders (Bode et al., 2003). S/MAR elements are 
interspersed throughout the genome and are typically found at intervals of between 5-
200kb (Bode et al., 2003). S/MARs do not have a consensus sequence, but all are AT-
rich and have an unusual inclination for strand separation, which occurs most easily at 
the site of a core-unpairing element (CUE), where the DNA destabilizes the most, and 
strand separation spreads out from there throughout the base-unpairing regions 
(BURs) (Bode et al., 2006). It is believed that the 25 million nucleosomes in mammalian 
cells are arranged by S/MARs into around 60,000 chromatin loops (Heng et al., 2004) 
(Figure 1.6). These loops are dynamic, as the S/MARs move along the matrix, attaching 
as needed (Heng et al., 2004). 
Eukaryotic chromosomes have a quarternary structure with many levels of packaging. 
DNA associates with histones that are compacted into structures called nucleosomes, 
which then fold into chromatin fibers. Chromatin is organized into independent loops 
of DNA called replicons (Heng et al., 2004). These loops are anchored at the S/MAR 
sites via proteins to the nuclear matrix (Bickmore and Oghene, 1996) (Figure 1.6) which 
is made up of protein, RNA (Bode et al., 2003), and nuclear lamina (Wan et al., 1999). 
Several proteins that enable the S/MAR-matrix association have been identified and 
are involved in nuclear architecture. These include two isoforms of the scaffold 
attachment factor A (SAF-A), two isoforms of SAF-B, and the factor E1B-AP5 (Kipp et 
al., 2000). Kipp et al found that these proteins bind S/MARs via a SAF-Box which is a 
domain that has been evolutionarily conserved (Kipp et al., 2000). This domain does 
not recognise specific sequences, considering S/MARs do not contain consensus 
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sequences, however the interactions occur as a result of the S/MARs’ structural 
features and possibly a series of sequence motifs common to these elements (Kipp et 
al., 2000). 
The loops created as a result of S/MAR-matrix association are important structures for 
packaging of DNA, DNA replication, and transcription (Bode et al., 2003). It is believed 
that the matrix plays two important roles in DNA replication. Firstly, it acts as a support 
for the replication machinery; and secondly the key proteins required for replication 
are associated there, with Hozak et al establishing that the replication machinery is, in 
fact, attached to the nuclear matrix (Hozak et al., 1993). In addition, Pardoll et al 
proved that newly synthesized DNA moves away from the loop bases, suggesting that 
DNA replication occurs at the bases of the loops by DNA polymerase complexes 
attached to the nuclear matrix (Pardoll et al., 1980). 
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(Brown, 2002) 
 
 
Figure 1.6 Adapted from Brown, 2002. The figure shows DNA organisation within the nucleus as 
packaged by histones, and indicates loops of DNA attached to the nuclear scaffold/matrix via AT-rich 
regions of the genome, known as scaffold/matix attachment regions (S/MARs). 
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1.9.1 DNA Replication Initiation Complex And The Binding of Associated 
Proteins To S/MAR Elements 
 
DNA replication is associated with the nuclear matrix and it was found that the origin 
of replication binds to the matrix just before S phase of the cell cycle (Cook, 1999). 
S/MARs have been found to be located close to origins of replication where they 
arbitrate function (Bode et al., 2003) or even act as origins of replication themselves 
(Jenke et al., 2002). Their AT tracts are highly important for this function as origin 
recognition complexes (ORCs) preferentially bind to AT rich sequences and do not 
discriminate between AT-rich tracts and natural Ori sites (Abdurashidova et al., 2003). 
Replication initiation begins with the initiation complex assembling at origins of 
replication. Cells have a mechanism to regulate genomic replication by limiting it to a 
once-per-cycle event. The origin recognition complex, which makes up the pre-
replication complex, recognizes and binds an origin of replication at early G1 phase. 
Other proteins are then able to bind such as Cdc6, Cdt1, and MCM2-MCM7 
(MiniChromosome Maintenance) proteins. As the cell cycle progresses to S phase 
protein kinases are activated which lead to the pre-replication complexes to becoming 
initiation complexes (Bell and Dutta, 2002; Blow and Hodgson, 2002). Once replication 
is initiated the pre-replication complex loses the associated Mcm proteins and partly 
dissociates (Schaarschmidt et al., 2002) which then leads to the complex’s dissociation 
from the DNA (Tye, 1999). It has been postulated that replication origins are not 
determined by DNA sequence as much as by epigenetic factors such as the binding of 
specific factors its position within chromatin of a specific conformation (Mechali, 
2001). Studies using BrdU indicated that the episomes replicate in a once-per-cycle 
manner just as genomic DNA (Price et al., 2003). Price et al blocked the cells at the 
G1/S-phase checkpoint and, using BrdU again, determined that the time the episome is 
replicated is at early S phase (Price et al., 2003). Regions containing S/MARs are 
considered to be areas that have open DNA conformations around active genes and 
may be replicated earlier (Gilbert, 2001; Lin et al., 2003). Using ChIP it was determined 
that Orc2p and Mcm3p are able to associate with the S/MAR. Price et al believe that 
they were able to determine a very loosely defined 36bp consensus sequence which 
may be contained in every origin of replication where the ORC binds (Price et al., 
2003). If 3 mismatches are allowed on this sequence, it can be found to occur 6 times 
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within the S/MAR sequence. Schaarschmidt et al also believe that the pre-RC 
components bind to the S/MAR at more than one site and are thought to be functional 
as they also dissociate partially in S phase as they would when bound to genomic DNA 
(Schaarschmidt et al., 2004). 
 Other proteins that have been found to have an affinity for S/MARs which 
demonstrate the involvement of some S/MAR elements in DNA replication are 
Topoisomerase II, nucleolin, and NuMA. Adachi et al found that S/MARs have 
Topoisomerase II cleavage sequences within them (Adachi et al., 1989). 
Topoisomerase II is an enzyme capable of relaxing supercoiled DNA and unknotting 
DNA by introducing double-stranded breaks and then re-linking them back again. 
These enzymes are found on the nuclear matrix during metaphase (Adachi et al., 1989) 
and are important in resolving replication. In addition, nucleolin, a protein that is 
highly abundant in the nuclei of actively dividing cells, also binds S/MARs at the minor 
groove of AT rich tracts (Dickinson and Kohwi-Shigematsu, 1995). Finally, Luderus et al 
found that the structurally related protein NuMA which has an important role during 
mitosis (Compton and Cleveland, 1993) also specifically binds to S/MARs (Luderus et 
al., 1994).  
 
1.9.2 The Role of S/MARs In Transcription And Its Related Factors 
 
S/MARs have also been found to exert an effect on gene transcription (Bode et al., 
2006). For instance, they can act as insulators for genes from positive/negative effects 
from the surrounding genome (Goetze et al., 2005). For example, an enhancer in one 
domain acts only on the gene within its respective domain and not beyond (Bode et 
al., 2003) (Figure 1.7). They can also increase the rate of transcription depending upon 
their location (Bode et al., 2000). It has been established that if the element is located 
immediately downstream from a promoter, transcription is hindered, whereas a more 
distant location can help transcription by allowing RNA polymerase to bind, and by 
relieving the supercoils in the DNA ahead of the enzyme (Bode et al., 2006).  
Heng et al found that S/MARs are flexibly bound to the nuclear matrix and that this 
binding is dynamic in nature (Heng, et al., 2004) (Figure 1.8). Heng et al believe that 
the changing of the S/MARs that bind to the matrix is not due to a lack of binding 
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space for them, and that it must be regulated by the cell in order to meet its DNA’s 
structural requirements and the cell’s functional needs (Heng, et al., 2004). A 
correlation that was observed between gene expression and the transgene’s proximity 
to the matrix which highlights the significance of DNA’s proximity and contact with the 
matrix for transcription, and it appears to be vital for transcription to take place. 
(Vassetzky et al., 2000) experimented with the cMYC gene and its S/MAR and found 
that transcription of the gene actively takes place when the S/MAR is anchored and 
bound to the matrix. When gene expression was analysed it was found that not all the 
transgenes were being expressed but that the level of expression correlated with the 
number of transgenes associated with the matrix. (Bode et al., 1995) found that the 
S/MAR immediately downstream of the IFNB1 gene binds to the matrix as the gene is 
to be transcribed and, simultaneously, the S/MAR region becomes DNaseI insensitive 
indicating it is bound whereas the gene’s coding region becomes sensitive (Figure 1.8). 
It is also believe that the stronger the S/MAR, the longer it is able to bind, which would 
directly affect gene expression. Just as proteins with roles in replication associate with 
S/MARs, so do proteins with an influence on transcription, such as SAF-B, certain 
lamins, histones, and high mobility group proteins (HMG-I/Y). SAF-B (scaffold 
attachment factor B) has been found to associate with RNA polymerase II in addition 
to serine-/arginine-rich RNA processing factors (SR proteins), which in turn associate 
with factors of the transcription machinery (Nayler et al., 1998). Nayler et al even 
proposed that SAF-B creates a base upon which transcription complexes in close 
proximity to actively transcribed genes are assembled (Nayler et al., 1998). 
Transcription factors have been found to bind to a meshwork of protein composed of 
lamins, which are believed to have a role in organizing interphase chromatin. This 
leads to the assumption that lamins serve as a part of the nuclear matrix that may 
stablize active transcription complexes (Bode et al., 2003).  A- and B-type lamins are 
capable of binding to S/MARs by associating with an open conformation single strand 
of S/MAR DNA, or by binding to the minor groove (Luderus et al., 1994).Additionally, 
histone H1 binds to S/MAR elements. It is a protein that packages chromatin leading to 
transcriptional silencing (Garrard, 1991) by cooperative binding (Zhao et al., 1993). It 
was found that HMG-I/Y isoforms prefer binding to A-rich tracts such as those found 
on the S/MARs, leading them to act as D-proteins (mimicking Distamycin), 
subsequently dislodging histone H1 and consequently derepressing S/MAR 
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transcription and repressing non- S/MAR transcription by shifting the histones to the 
non- S/MAR DNA (Zhao et al. 1993). Martens et al have found that another histone, 
H3, was found at many S/MAR sites analysed within their experiment and that these 
were all found to be acetylated, which is an indication of an actively transcribed region 
of the genome (Martens et al., 2002). 
Martens et al found that the transcriptional coactivator protein p300/CBP binds to 
S/MAR elements via the SAF-A protein (Martens et al., 2002). It also binds to several 
transcription factors and has been found to be involved in regulating transcription at 
promoters and enhancers in addition to S/MARs. Further it was shown to have 
acetyltransferase activity and can associate with other proteins such as p/CAF 
(Martens et al., 2002) which also exhibit such activity. Therefore p300/CBP is capable 
of acetylating histone tails (Struhl, 1998) which occurs at actively transcribed regions of 
the genome, and can also acetylate transcription factors which can either lead to 
transcriptional activation or repression (Sterner and Berger, 2000). Although 
transcription was not found to occur when p300/CBP is bound it has been suggested 
that it may make local chromatin ready to be transcribed.  
 An experiment involving the use of a plasmid containing the β-IFN S/MAR element 
was conducted by Jenke et al (Jenke et al., 2002). In it they attempted to co-purify 
vectors (one containing an S/MAR and the other one without the element) that had 
been transfected into cells, with the nuclear matrix. They found the S/MAR-containing 
plasmid in the purified lysate whereas the other plasmid was not, suggesting the 
association of this S/MAR plasmid to the matrix. A study by Baiker et al also confirmed 
this by the use of nuclear fractionation procedures where this same S/MAR plasmid 
was associated with the nuclear matrix (Baiker et al., 2000). They were also able to 
demonstrate that this association occurred via proteins through the use of fluorescent 
in-situ hybridisation, and that this plasmid can also be seen to associate with 
chromosomes. Furthermore, Jenke et al were able to show that if this S/MAR element 
was linked just downstream of an active transcription unit, this was sufficient for an 
episome to remain mitotically stable and replicate by associating to the nuclear matrix 
in vivo via the matrix protein SAF-A (Jenke et al., 2004).  
Considering all the roles S/MARs play in nuclear matrix attachment, DNA replication, 
and gene transcription, it is clear that they may have some useful applications in gene 
therapy. There have been several studies in the use of S/MAR elements in plasmid 
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vectors that have proven the element’s role in maintaining the vector as an episome 
for many generations without integration into the genome. By counteracting 
methylation and allowing histone acetylation (Dang et al., 2000) an S/MAR-containing 
plasmid manages to avoid silencing and exhibits continuous transgene expression. 
Silencing is a eukaryotic defence system against the expression of foreign DNA, which 
is achieved by the methylation of CpG dinucleotides found in high abundance in non-
mammalian organisms (Miranda and Jones, 2007). Methylated DNA is condensed and 
takes on a heterochromatin structure leading to transgene silencing, except in the 
presence of an insulator element such as an S/MAR (Goetze et al., 2005) whose 
properties allow the DNA to maintain an open, non-methylated conformation. 
Furthermore, the vector is able to bind to the nuclear matrix and replicate as the 
chromosomes do by using the cell’s machinery, and get distributed and passed on to 
daughter cells in actively dividing cell lines, even without the use of selection, normally 
used to ensure maintenance of the plasmid and sustained gene expression (Jenke et 
al., 2004; Schaarschmidt et al., 2004). 
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(Brown, 2002) 
Figure 1.7 Adapted from Brown, 2002. S/MARs can act as transcriptional insulators for genes from any 
effects resulting from regulatory modules in the surrounding genome. As shown in the figure above, 
when no insulator element, or S/MAR, is positioned between regulatory modules such as enhancers, for 
example, and a gene, the effect of the module can be exerted upon the gene downstream. However, 
when an S/MAR is present between them, the modules may exert their effects within their domain and 
not beyond the S/MAR element, thus insulating the gene from the surrounding influences of other 
regulatory modules. 
 
(Heng et al, 2004) 
Figure 1.8 Adapted from Heng et al, 2004. This figure shows S/MAR elements that are attached to the 
nuclear matrix (red dots, as indicated in the figure) and those which are not attached (green dots). The 
S/MAR element located prior to the gene brings the gene to be transcribed in proximity to the 
transcription machinery bound to the nuclear matrix, in order for transcription to occur. 
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1.10 S/MAR Studies 
 
A number of studies have been conducted where plasmids containing the human β-IFN 
S/MAR element were transfected into cells and tested for their ability to replicate and 
be passed on to daughter cells after many rounds of replication. In these studies the 
element was inserted within the open reading frame of the reporter gene eGFP and 
expression of this gene was assessed. Additionally, the status of the plasmid was 
examined to find whether it remains episomal or integrates into the host genome. 
Many, but not all, studies have reported the safety of using this S/MAR-based plasmid 
as a vector for gene transfer due to a lack of evidence of genomic integration. 
However, success in efficiently expressing a desired transgene has not been reported 
by everyone and has proven to be variable. The following paragraphs outline the 
studies conducted testing this vector and its applications. 
Of the successful experiments conducted with an S/MAR-based vector where 
expression proved to be unsilenced is that conducted by Manzini et al. The aim of this 
experiment was to create transgenic pigs expressing the eGFP driven by the CMV 
promoter using the S/MAR plasmid as a vector (Manzini et al., 2006). The vector was 
transferred into sperm using Sperm-Mediated Gene Transfer (SMGT). The sperm was 
then used to fertilise sows’ eggs by laparoscopic insemination. The tissues were 
collected from 18 fetuses from 2 different sows at day 70 of the pregnancy, where cell 
differentiation and organ development was complete and only growth 
(embryogenesis) remained to take place during the rest of the pregnancy. The negative 
control in this experiment was 9 fetuses that were produced from sperm that was not 
incubated with the exogenous DNA. Tissue samples were taken from skeletal muscle, 
heart, liver, kidney, and lung from each fetus. A PCR conducted on total genomic DNA 
extracted from the tissues of the fetuses confirmed that the vector sequence was 
present in 12 of the 18 fetuses in every tissue analysed. A PCR on the HIRT extracts of 
these samples indicated that the vector was present as an episome in each of these 
tissues. A Southern Blot was conducted using the total genomic DNA and the HIRT 
extracts from each tissue of 4 of the positive foetuses. The DNA band patterns were 
the same in each case and showed episomal retention of the vector with no evidence 
of integration into the host genome. From the band intensity the copy number was 
estimated to be less than 10 copies per cell. A plasmid rescue on HIRT extracts of 2 
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tissues from each of the 4 positive foetuses supported the episomal status of the 
vector. Restriction digests of the plasmids grown up after the rescue experiment 
confirmed that the vector was episomal and had not been altered. Expression was 
assessed by RT PCR in 3-5 tissues of each of the 12 positive foetuses. It was found that 
the transcript could be detected in each tissue tested for 9 of the foetuses. Expression 
was also detected by Western Blotting, epifluorescence, and confocal microscopy. 
They found expression of eGFP in 62-88% of the cells from each sample, and these 
percentages did not differ significantly between different foetuses or different tissues. 
These findings strongly suggest no integration had occurred, and Manzini et al believe 
that if it does occur it would be uncommon and sporadic and would take place at the 
embryogenesis stage of pregnancy, which is the stage after the foetuses were taken 
out and analysed in this experiment (Manzini et al., 2006).  
Another successful experiment was undertaken by Jenke et al (Jenke et al., 2005). In 
this study the aim was to use a vector containing an S/MAR and carrying a gene coding 
for a short hairpin RNA (shRNA) controlled by an RNA polymerase III promoter. shRNA 
is used to suppress gene expression and this study uses the bcr-abl model system to 
silence the expression of a fusion protein, the gene of which is created as a result of a 
chromosomal rearrangement, which causes leukemic transformation (Daley et al., 
1990). This system was tested in K562 cells which are bcr-abl positive and expression 
was assessed using Western and Northern Blotting. The cells were tranfected with the 
vector, put under selection for 14 days, then allowed to proliferate for 28 days. As a 
positive control the vector was linearised and transfected into the cells and was found 
by Southern Blotting to have integrated. The results showed a significant reduction in 
the growth of the cells containing the vector episomally, meaning the vector was 
expressing the shRNA that was successfully inhibiting the translation of the bcr-abl 
fusion transcript into the protein that leads to cellular transformation and thus 
overgrowth. However the cells where the vector had integrated in the control did not 
show a significant difference in comparison to the negative control which contained 
untransfected cells, possibly due to the expression cassette being deleted as a result of 
the integration, or silencing possibly as a result of integration position. On the other 
hand, it is possible that the cells that had the vector integrated and were expressing 
the shRNA effectively were outgrown by those that did not have the vector sequence 
or were not expressing it effectively and therefore were unable to be identified. The 
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cells were tested again after 4 months and were found to still retain the vector 
episomally, and the effect on gene silencing had continued to be effective and 
unchanged.  
A study by Schaarschmidt et al showed similarly positive results in the use of this 
S/MAR-based vector (Schaarschmidt et al., 2004). The study involved the transfection 
of CHO and HeLa cells with an S/MAR vector containing an eGFP reporter gene driven 
by the CMV promoter. The control was the same vector without the S/MAR. Following 
a period of selection post transfection a number of positive clones were picked for 
each cell line and the cells were allowed to proliferate. Southern Blotting on HIRT 
extracts confirmed that 9/10 CHO cell clones and 5/5 HeLa clones were positive for the 
episome. All the control clones using the control plasmid in the positive CHO and HeLa 
clones were negative for the episome, and the Southern Blot for these samples 
showed integration. In a previous study conducted by Baiker et al the same vectors 
were used to transfect CHO cells and the same results had already been achieved 
(Baiker et al., 2000). They had additionally found that these cells maintained an 
average of 4-13 copies per cell with little variation between 20-50 generations after 
transfection. 
While some studies showed sustained expression and maintenance of these S/MAR-
based vectors over many cell generations, others showed variable results in terms of 
the S/MAR vector’s expression of a given transgene. A study by Papapetrou et al 
examined the use of the S/MAR vector expressing the eGFP transgene driven by the 
CMV promoter in several hematopoietic progenitor cells to assess its expression and 
episomal status generations after transfection (Papapetrou et al., 2006). The plasmid 
was first tested in two progenitor cells lines: K562 which is a human chronic myeloid 
leukemia blast crisis cell line, and MEL which is a murine erythroleukemia cell line. A 
population of cells were transfected and and selected with G-418 for 3 weeks. Then 
each population was divided into two populations, one where selection was 
maintained and the other where it was removed, and the cells were allowed to 
proliferate for over 100 generations. The cells of each population remained G-418 
resistant and eGFP expression declined only slightly with time. A non-radioactive 
Southern Blot using 10µg of total genomic DNA showed a single band of the expected 
plasmid size which suggested episomal status, and this was further confirmed by 
plasmid rescue. The vector was retained by less than 1% of the cells, which was 
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calculated by the initial number of cells transfected divided by the number of positive 
clones established after the selection period. The average plasmid copy number per 
cell in the K562 population was 2.5. Similar results were obtained using another 
population of primary fibroblast-like human cells that were isolated from umbilical 
cord blood where the cells were allowed to proliferate for 30 generations.  
The MEL cells, on the other hand, lost eGFP expression by 7 days post-transfection and 
it could not be detected by FACs or immunofluorescence as it had been with the K562 
cells. The use of the more sensitive method RT-PCR showed that eGFP was still being 
expressed but at very low levels. When CD34+ enriched cells derived from umbilical 
cord blood were tested the plasmid was not detected using Southern Blotting or 
plasmid rescue, even when the cells were expanded and 1x107 cells were used for the 
HIRT extract. The episome was only detected using PCR, and the vector was calculated 
to only be present in approximately 1% of the cells. Despite the similarity observed 
between the different cell types where only an average of 1% of the cells contained 
the vector as an episome, transgene expression was undoubtedly variable. Papapetrou 
et al conclude that cosidering S/MAR elements utilize cellular factors which allow the 
vector containing them to express transgenes and replicate, it would be logical to 
assume that the differences found in cellular backgrounds from one cell type to the 
next could justify the differences observed of the same vector’s status, expression 
and/or episome copy numbers between different cell lines (Papapetrou et al., 2006). 
These could be factors specific to different tissues or between species. However, even 
though expression in the MEL cells did decline it did not affect vector maintenance and 
passing down to daughter cells. 
Thus far all the studies have reported positive results in their assessment of the 
S/MAR-based vector being replicated and passed down to daughter cells for many 
generations. However, one has reported a different conclusion. In a study by Argyros 
et al, the S/MAR vector was tested in vivo in mouse liver. It contained the luciferase 
transgene and was driven by either the CMV promoter or the human AAT promoter 
(Argyros et al., 2008). The vectors were delivered by hydrodynamic injection, and three 
weeks post transduction hepatectomies was performed on the livers. The livers were 
allowed to regain their original mass before the animals were sacrificed and the liver 
cells examined for the presence of the vectors. It was found that expression for all the 
plasmids had declined to near background levels except for the S/MAR plasmid 
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containing the AAT promoter which was slightly higher than the other three constructs 
after 6 months. Southern Blotting and Plasmid Rescue experiments confirmed that the 
plasmids had remained episomal. However, they discovered that the vector had not 
been replicated within these cells. Bacterial methylation on a plasmid is lost after being 
replicated twice in mammalian cells. Restriction digest tests using enzymes that can 
cut only at sites where the DNA is unmethylated using vector DNA extracted from the 
liver 6 months post-transduction indicated that the plasmid was not replicated within 
these cells in the duration of this period. Argyros et al concluded that in murine 
hepatocytes the vectors were able to remain passively but were not being actively 
replicated. They also concluded that the decline in expression observed over a long 
period of time was due to silencing of the promoter rather than the loss of plasmid 
DNA, as just transducing the liver cells without hepatectomies showed that the S/MAR 
construct, although not replicating episomally, was passively maintained and was able 
to uphold sustained expression for 6 months. 
The studies outlined have shown that an S/MAR-based vector can behave differently 
as a result of many different factors such as the transgene expressed, the promoter 
driving it, or the cell type in which it is used which appears to be a major factor. This 
may be due to species origin or cell/tissue-specific factors which would cause 
differences in the S/MAR vector’s episomal replication and/or expression.  
 
1.11 S/MAR Database and Alternative S/MARs 
 
The S/MAR that has been used in most of the studies to date, where the element has 
been inserted within a vector for gene delivery, is the human β-IFN S/MAR, or 
variations of it, and it is the most well characterised S/MAR element to date. But there 
are other S/MARs that have been identified in different regions of the genome, serving 
similar insulator/enhancer functions. These S/MARs have been collected in an online 
database (http://smartdb.bioinf.med.uni-goettingen.de/) and are defined as S/MARs 
on the basis of several essential characteristics previously discussed, such as containing 
a base-unpairing region (BUR), the ability to bind to the nuclear matrix, to act as an 
origin of replication, and to bind S/MAR-binding proteins previously characterised such 
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as SAF-A or SATB1. The database also provides the references of the studies conducted 
on each putative S/MAR that led it to be characterised as such an element. 
 
1.11.1 The c-MYC Proto-oncogene S/MAR Element 
 
One such S/MAR element that was identified through the database is the murine c-
MYC gene S/MAR. It was identified as an S/MAR from the studies conducted by Girard-
Reydet and Cai et al (Girard-Reydet et al., 2004; Cai et al., 2003). Girard-Reydet et al 
found that in mice the region upstream of the c-myc promoter contains a matrix 
attachment region, proven by digesting the genomic DNA with DNase I, purifying the 
nuclear matrix, extracting the DNA still bound to the matrix, radiolabeling it, then using 
it as a hybridisation probe in order to identify the S/MAR region (Girard-Reydet et al., 
2004). In this study they also found that an origin of replication site exists within this 
S/MAR region. Cai et al found that the nuclear protein SATB1 (Special AT-rich Binding 
Protein) binds to the MYC gene locus (Cai et al., 2003). This protein has a high affinity 
to double stranded BUR DNA which are, in themselves, AT-rich regions of DNA. These 
studies confirmed the presence and site of the c-myc S/MAR. 
The c-myc gene itself is a proto-oncogene whose product is a nuclear transcription 
factor (Bruckert et al., 2000). When mutation occurs this proto-oncogene has been 
identified as the most frequently amplified, and therefore over-expressed, gene in 
patients with Acute Myeloid Leukaemia (AML) (Bruckert et al., 2000). Yet its over-
expression alone has not been found to induce transformation and only leads to 
tumorigenesis if expressed in addition to other oncogenes (Cole, 1986). In AML it is 
generally amplified late in tumorigenesis and is often found as a Double Minute (DM) 
(Bruckert et al., 2000). DM’s are extrachromosomal pieces of DNA made of chromatin, 
just as normal chromosomes, but lack a centromere, telomeres, and are found as 
circular pieces of DNA (Barker, 1982; Thomas et al., 2004). In a review of 33 cases of 
AML, 76% of the cases were found with c-MYC double minutes (Barker, 1982; Thomas 
et al., 2004). This ability to amplify and exist as a double minute may be related to the 
c-MYC’s S/MAR element that allows the propagation of this amplified circular piece of 
DNA that needs neither a centromere nor telomeres to replicate within tumour cells. 
As it has been seen that S/MAR elements may act as origins of replication themselves, 
perhaps it is possible that the S/MAR is the element that is keeping the over-amplified 
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c-myc region a double minute and allowing expression. These characteristics would 
make the c-MYC S/MAR an interesting alternative S/MAR to test in replicating cells. 
 
1.12 Aims and Objectives 
 
S/MAR-based plasmid vectors are proposed to lead to improved long-term transgene 
expression and episomal maintenance of vectors in actively replicating cells, and to 
protect from vector integration into the host genome. It is also proposed that arresting 
transfected cells containing the S/MAR-based vectors prior to proliferation improves 
long-term transgene expression as a direct result of the presence of the S/MAR 
element. 
The main aim of the work presented in this thesis was to investigate the use of S/MAR-
based vectors in expressing a transgene and in maintaining the vector episomally for 
many cell generations in proliferating muscle cells, the comparison of these 
parameters to its non-S/MAR counterpart control, and the enhancement of the S/Mar 
based vector in order to further its development for use as a safe and effective vector 
for gene delivery. Several secondary aims were conducted to complement the main 
aim of the thesis. These included: 
 
- The assessment of these vectors in different cell lines. 
- The assessment of these vectors in myotubes.  
- The improvement of transgene expression by means of changing the promoter 
driving transgene expression. 
- The improvement of long term transgene expression by arresting cells in G0/G1 
phase of the cell cycle, or quiescence, post-transfection. 
- The investigation of the use of other S/MAR elements, besides the β-IFN S/MAR 
element, in plasmid vectors. 
- The construction of the ideal minicircle vector including an S/MAR element. 
 
The objectives for each chapter were created in order to fulfil the aims. 
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Chapter 3 Objectives: 
 
1) The assessment and comparison of eGFP transgene expression by β-IFN 
S/MAR-based vector pEPI-eGFP in 3 replicating cells lines C2C12, HepG2, and 
HeLa in order to elucidate long-term transgene expression and the differences 
of this expression between different cell lines. The C2C12 cell line was chosen 
as the skeletal muscle cell line, the HepG2 cell line was chosen as it represented 
a different tissue type and had a longer doubling time than the other two cell 
lines chosen, and the HeLa cell line was chosen as a control due to the 
assessment of pEPI-eGFP within this cell line in previous studies.  
2) The comparison of initial and long term eGFP transgene expression between 
S/MAR-based vector pEPI-eGFP and its non-S/MAR counterpart control vector 
eGFP-C1 in the three cell lines chosen. 
3) The assessment of episomal/integrant status of the transfected vectors pEPI-
eGFP and eGFP-C1 at the final day of the experiment in the three cell lines 
chosen. 
4) The assessment of initial and long term eGFP transgene expression from a 
‘mini’- β-IFN-S/MAR-containing vector pEPI-M18 as compared to pEPI-eGFP and 
eGFP-C1, and the investigation of its episomal/integrant status, in C2C12 cells. 
5) The assessment of long term eGFP expression by pEPI-eGFP, eGFP-C1, and 
pEPI-M18 in C2C12 cells differentiated into myotubes. 
 
Chapter 4 Objectives: 
 
1) The cloning of vectors CeGFP-C1 and CpEPI-eGFP, whereby the CMV promoter 
was replaced by the CAGG promoter in the eGFP expression cassette within 
each construct. 
2) The cloning of vector CMYC-pEPI in order to create a vector with an eGFP 
expression cassette including the c-myc S/MAR element within its open reading 
frame. 
3) The cloning of an eGFP expression cassette including the β-IFN-S/MAR element 
into a minicircle-producing parental plasmid, in order enable the creation of 
minicircles. 
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Chapter 5 Objectives: 
 
1) The assessment of initial and long-term eGFP transgene expression of the 
S/MAR-based vector and the non-S/MAR control vector using a different 
promoter (CAGG replaced CMV) to improve transgene expression by these 
vectors (CpEPI-eGFP and CeGFP-C1) in C2C12 cells. 
2) The assessment of long term eGFP expression by CpEPI-eGFP and CeGFP-C1 in 
C2C12 cells differentiated into myotubes 
3) The investigation of episomal/integrant status of CpEPI-eGFP and CeGFP-C1 at 
the final day of the experiment. 
 
Chapter 6 Objectives: 
 
1) To use the data that was obtained from testing pEPI-eGFP in the HepG2 and 
HeLa cell lines in Chapter 3 to enhance long term transgene expression in 
C2C12 cells. 
2) The assessment of long term eGFP expression in C2C12 cells after the cell cycle 
arrest in G0/G1/quiescence of CpEPI-eGFP and CeGFP-C1 transfected C2C12 
cells for the maximum amount of time possible, without resulting in total cell 
death, using two different methods. Transgene expression was compared 
between the two vectors, and between the two methods used for cell cycle 
arrest. 
3) The assessment of long term eGFP expression by CpEPI-eGFP and CeGFP-C1 
arrested in G0/G1/ quiescence in C2C12 cells differentiated into myotubes 
4) The investigation and comparison of episomal/integrant status of the vectors in 
all transfected populations on the final day of the experiment. 
 
Chapter 7 Objectives: 
 
1) The assessment of the requirement for the use of antibiotic selection for 
enhanced trangene expression after cell cycle arrest was conducted post-
transfection with CpEPI-eGFP and CeGFP-C1 in C2C12 cells by the comparison 
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of long-term eGFP transgene expression between transfected populations put 
under four different conditions:  
a) Transfected eGFP positive cells were sorted by FACs then allowed to 
proliferate. 
b) Transfected eGFP positive cells were sorted by FACs, arrested in G0/G1 for 
7 days, then allowed to proliferate. 
c) Transfected cells were arrested in G0/G1 for 7 days, selected with 
antibiotics for 10 days, then allowed to proliferate. 
d) Transfected cells were selected with antibiotics for 10 days then allowed to 
proliferate. 
2) The assessment of initial and long-term eGFP transgene expression from a C-
MYC S/MAR-containing vector (CMYC-pEPI) and the comparison of eGFP 
transgene expression resulting from vectors CpEPI-eGFP and CeGFP-C1 under 
all 4 conditions (a)-(d) as stated above. 
3) The investigation of episomal/integrant status of the transfected vectors CMYC-
pEPI, CpEPI-eGFP, and CeGFP-C1 in C2C12 cells at the final day of the 
experiment under all 4 conditions (a)-(d) as stated above. 
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Chapter 2: Materials and Methods  
 
2.1. Materials 
2.1.1. General Buffers and Chemical Reagents 
 
- Boric Acid (Sigma, B6768) 
- Dextran sulphate (Sigma, 8906) 
- EDTA (Ethylenediaminetetraacetic acid) (Sigma, E-5134) 
- Ethanol (Analar, VWR, 10107) 
- Glacial acetic acid (Sigma, A9967) 
- Glycerol (Sigma, G-2025) 
- Isopropanol (propan-2-ol, Analar, VWR, product number 102246L) 
- KCl (Sigma, P9541) 
- Methanol (Sigma, 322415) 
- Na3citrate (Sigma, S1804) 
- NaCl (Sigma, S-7653) 
- NaOH (Sigma, S8045) 
- Phosphate Buffered Saline (PBS) (PBS tablets, Dulbecco A, OXOID, BR0014G) 
- Trizma Base (tris[hydroxymethyl]aminomethane) (Sigma, T-1503) 
- Tween 20 (polyoxyethylenesorbitan monolaurate, Sigma, P-1379) 
 
2.1.2. Cell Culture 
 
2.1.2.1. Cell Types 
The murine and human derived cell lines used in this thesis are described below: 
C2C12 cell line: A myogenic subclone of an adherent skeletal muscle cell line of 
murine origin (Yaffe and Saxel, 1977). These cells can differentiate rapidly to form 
contractile myotubes and produce characteristic muscle proteins. This cell line is 
tumorigenic and variably polyploid. 
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HeLa cell line: An adherent cervical epithelial cell line derived from an 
adenocarcinoma and of human origin, first described by Scherer (Scherer, 1954). Its 
morphological aspects are described in Macville et al (Macville et al., 1999). 
HepG2 cell line: An adherent hepatocellular cell line derived from a hepatocellular 
carcinoma and of human origin (Aden et al., 1979).  
Further details of the features of the above cell lines can be found at the European 
Collection of Animal Cell Cultures (ECACC) www.ecacc.org.uk and the American Type 
Culture Collection (ATCC) http://www.lgcstandards-atcc.com. 
 
2.1.2.2. General Cell Culture Materials and Reagents 
 
- 6 well dishes (Nunc, 140675) 
- Cell Culture Flasks (175 cm2) (Nunc, 178883) 
- Cell Culture Flasks (80 cm2) (Nunc, 178905) 
- Cell lines: C2C12, HeLa, HepG2 (ATCC: http://www.lgcstandards-atcc.com) 
- Cryotubes (nunc, 366656) 
- Dimethyl Sulphoxide (DMSO) (Sigma, D2650) 
- Dulbecco’s Modified Eagle Medium (DMEM) (Sigma, D2650) 
- Foetal Calf Serum (FCS) (Sigma, F7524) 
- Gentamicin (Sigma, G-1397) 
- Horse Serum (Sigma, H1270) 
- L-Glutamine 100x (200mM) (Sigma, G7513) 
- Lipofectamine 2000 (Invitrogen, 11668019) 
- Methionine-Depleted Medium (Sigma, D0422) 
- Penicillin Streptomycin (10mg) (Sigma, P4333) 
- Trypsin/EDTA 10x (Sigma, T4049) 
 
2.1.3. Bacterial Culture 
 
2.1.3.1. General Bacterial Culture Materials and Reagents 
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-  Ampicillin (Sigma, A9518) 
- Agarose (Invitrogen, 15510-027) 
- Bactoagar (Beckton, Dickinson and Co, 214010) 
 - Chloramphenicol (Sigma, C0378) 
- Electroporation cuvettes, 0.1cm (Invitrogen, P41050) 
- Ethidium Bromide (Sigma, E-1510) 
- Kanamycin (Sigma, 60615) 
- LB Broth (Sigma, L-3022) 
- LB SOC provided with OneShot TOP10 Electrocomp E.Coli (Invitrogen, C404052) 
- NTP mix (Bioline, BIO-39050) 
- OneShot TOP10 Electrocomp E.Coli (Invitrogen, C404052) 
- Plasmid Maxiprep Kit (Endofree) (Qiagen, 12362) 
- Plasmid Miniprep Kit (Qiagen, 27104) 
- QIAquick Gel Extraction Kit (250) (Qiagen, 28706)  
- Quick Ligation Kit (New England Bioloabs, M2200S) 
- Restriction Enzymes (New England Biolabs) 
- T4 DNA Polymerase (Promega, M421A) 
- XL-1 Blue supercompetent Cells E.coli (Stratagene, 200236) 
- OneShot TOP10 Electrocomp E.coli (Invitrogen, C404052) 
- JM110 Competent (Dam/Dcm negative) Cells E.coli (Stratagene, 200239) 
 
2.1.3.2. Plasmid Vectors Recieved/Purchased 
 
pBACe3.6 RPCI Mouse BAC clone: containing cMYC S/MAR element (Sanger 
Institute, Cambridge,    UK) 
 
peGFP-C1: A 4.7kb eukaryotic expression construct containing the human immediate 
early cytomegalovirus (CMV) promoter driving the enhanced green fluorescent protein 
(eGFP) reporter gene terminated by the SV40 polyadenylation signal, a multiple 
cloning site (MCS) containing restriction sites, the pUC origin of replication for vector 
propagation in E.coli, the SV40 origin of replication for vector propagation in 
mammalian cells expressing the SV40 T-antigen, a bacterial promoter to drive the 
expression of the Tn5 Kanamycin resistance gene within E.coli, the early SV40 
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promoter driving the expression of the Neomycin resistance gene within mammalian 
cells terminated by the Herpes Simplex Virus thymidine kinase (HSV TK) 
polyadenylation signal (purchased from Clontech). 
 
 
 
Figure 2.1 Vector map of eGFP-C1 construct. 
 
pEPI-eGFP: A 6.7kb eukaryotic expression construct containing the human immediate 
early cytomegalovirus (CMV) promoter driving the enhanced green fluorescent protein 
(eGFP) reporter gene terminated by the SV40 polyadenylation signal, a multiple 
cloning site (MCS) containing restriction sites, the pUC origin of replication for vector 
propagation in E.coli, the SV40 origin of replication for vector propagation in 
mammalian cells expressing the SV40 T-antigen, a bacterial promoter to drive the 
expression of the Tn5 Kanamycin resistance gene within E.coli, the early SV40 
promoter driving the expression of the Neomycin resistance gene within mammalian 
cells terminated by the Herpes Simplex Virus thymidine kinase (HSV TK) 
polyadenylation signal, and the β-IFN S/MAR element. As indicated the S/MAR 
element contains a high A-T content and 5 polyadenylation signals within it (kindly 
donated by J. Bode). 
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Figure 2.2 Vector map of pEPI-eGFP construct. 
 
pEPI-M18: A 5.4kb eukaryotic expression construct containing the human immediate 
early cytomegalovirus (CMV) promoter driving the enhanced green fluorescent protein 
(eGFP) reporter gene terminated by the SV40 polyadenylation signal, a multiple 
cloning site (MCS) containing restriction sites, the pUC origin of replication for vector 
propagation in E.coli, the SV40 origin of replication for vector propagation in 
mammalian cells expressing the SV40 T-antigen, a bacterial promoter to drive the 
expression of the Tn5 Kanamycin resistance gene within E.coli, the early SV40 
promoter driving the expression of the Neomycin resistance gene within mammalian 
cells terminated by the Herpes Simplex Virus thymidine kinase (HSV TK) 
polyadenylation signal, and the ‘mini-S/MAR’ (733bp) element derived from the β-IFN 
S/MAR element (kindly donated by J. Bode). 
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Figure 2.3 Vector map of pDD345 construct. 
 
pDD345: A 5.1kb vector containing the Adeno-Associated Virus (AAV-2) type 2 wild-type  
cis acting terminal repeats (5’ and 3’ ITRs) cloned into the pBR322   
plasmid backbone. Between these terminal repeats are a copy of the CAGG promoter, which 
does not drive the expression of any transgene, a multiple cloning site (MCS), and a 
copy of the SV40 polyadenylation sequence. The remainder of the vector contains an 
expression cassette expressing the Ampicillin resistance gene, and an origin of 
replication from pMB1 for vector propagation in E.coli. 
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2.1.3.3. Plasmid Vectors Constructed within RHUL 
 
 
 
 
Figure 2.4 Vector map of CeGFP-N3 construct. 
 
CeGFP-N3: A 5kb eukaryotic expression construct containing the human 
cytomegalovirus early enhancer/chicken β-actin (CAGG) promoter driving the 
enhanced green fluorescent protein (eGFP) reporter gene terminated by the SV40 
polyadenylation signal, a multiple cloning site (MCS) containing restriction sites, the 
pUC origin of replication for vector propagation in E.coli, the SV40 origin of replication 
for vector propagation in mammalian cells expressing the SV40 T-antigen, a bacterial 
promoter to drive the expression of the Tn5 Kanamycin resistance gene within E.coli, 
the early SV40 promoter driving the expression of the Neomycin resistance gene 
within mammalian cells terminated by the Herpes Simplex Virus thymidine kinase (HSV 
TK) polyadenylation signal. 
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Figure 2.5 Vector map of CeGFP-C1 construct. 
 
CeGFP-C1: A 5kb eukaryotic expression construct containing the human 
cytomegalovirus early enhancer/chicken β-actin (CAGG) promoter driving the 
enhanced green fluorescent protein (eGFP) reporter gene terminated by the SV40 
polyadenylation signal, a multiple cloning site (MCS) containing restriction sites, the 
pUC origin of replication for vector propagation in E.coli, the SV40 origin of replication 
for vector propagation in mammalian cells expressing the SV40 T-antigen, a bacterial 
promoter to drive the expression of the Tn5 Kanamycin resistance gene within E.coli, 
the early SV40 promoter driving the expression of the Neomycin resistance gene 
within mammalian cells terminated by the Herpes Simplex Virus thymidine kinase (HSV 
TK) polyadenylation signal. 
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Figure 2.6 Vector map of CpEPI-eGFP construct. 
 
CpEPI-eGFP: A 7kb eukaryotic expression construct containing the human 
cytomegalovirus early enhancer/chicken β-actin (CAGG) promoter driving the 
enhanced green fluorescent protein (eGFP) reporter gene terminated by the SV40 
polyadenylation signal, a multiple cloning site (MCS) containing restriction sites, the 
pUC origin of replication for vector propagation in E.coli, the SV40 origin of replication 
for vector propagation in mammalian cells expressing the SV40 T-antigen, a bacterial 
promoter to drive the expression of the Tn5 Kanamycin resistance gene within E.coli, 
the early SV40 promoter driving the expression of the Neomycin resistance gene 
within mammalian cells terminated by the Herpes Simplex Virus thymidine kinase (HSV 
TK) polyadenylation signal, and the β-IFN S/MAR element. As indicated the S/MAR 
element contains a high A-T content and 5 polyadenylation signals within it. 
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Figure 2.7 Vector map of CMYC-pEPI construct. 
 
CMYC-pEPI: A 6.7kb eukaryotic expression construct containing the human 
cytomegalovirus early enhancer/chicken β-actin (CAGG) promoter driving the 
enhanced green fluorescent protein (eGFP) reporter gene terminated by the SV40 
polyadenylation signal, a multiple cloning site (MCS) containing restriction sites, the 
pUC origin of replication for vector propagation in E.coli, the SV40 origin of replication 
for vector propagation in mammalian cells expressing the SV40 T-antigen, a bacterial 
promoter to drive the expression of the Tn5 Kanamycin resistance gene within E.coli, 
the early SV40 promoter driving the expression of the Neomycin resistance gene 
within mammalian cells terminated by the Herpes Simplex Virus thymidine kinase (HSV 
TK) polyadenylation signal, and the cMYC S/MAR element. the region spanning a part 
of the cMYC S/MAR element has a very low GC content. It is also shown that the cMYC 
S/MAR element contains 3 polyadenylation signals within its sequence. 
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2.1.4. Immunostaining  
2.1.4.1. Antibodies 
 
Primary Antibodies: 
- Mouse monoclonal anti-GFP antibody (Abcam, ab1218) 
- Rabbit polyclonal anti-lysenin (Peptide Institute Inc; Osaka, Japan) 
Secondary Antibodies: 
- Alexa Fluor 488 goat anti-mouse IgM antibody (Invitrogen, A21042) 
-488 swine anti-rabbit IgG (SouthernBiotech, 6310-01) 
 
2.1.4.2. General Immunostaining Materials and Reagents 
 
- 8-well chamber slide (Lab-Tek, 70415) 
- Bovine Serum Albumin (BSA) (Sigman, B-4287) 
- Lysenin (Peptide Institute Inc; Osaka, Japan) 
- Normal Goat Serum 
- Paraformaldehyde (Sigma, 158127) 
- Triton X-100 (Sigma, T8787) 
- DAPI Vectashield mounting medium (Vector Laboratories, H-100) 
 
2.1.5. DNA Extraction Reagent 
 
- DNAzol® (Talron Biotech L.T.D., DN127) 
 
2.1.6. Fluorescent In-Situ Hybridisation (FISH) Reagents: 
 
- DAPI II Counterstain (Abbott Molecular, 06J50-001) 
- Demecolcine (Sigma, D7358) 
- Formamide (Sigma, F7508) 
- Human COT-1 DNA (Abbott Molecular, 06J31-001) 
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- Nick Translation Kit (including: nick translation enzyme, 10x nick translation buffer, 
dATP, dCTP, dGTP, and dTTP solutions, nuclease-free water) (Abbott Molecular, 07J00-
001) 
- NP-40 (Abbott Molecular, 07J05-001) 
- Red dUTP (Abbott Molecular, 02N34-050) 
- Rubber Cement (Fielders) 
- Single stranded DNA from salmon testes (Sigma, D7656) 
 
2.1.7. Polymerase Chain Reaction (PCR) Reagents and Primers: 
 
- 2x PCR MasterMix (GeneSys Ltd.) 
- The primers located within the Kanamycin resistance gene, optimal annealing temp 
60.6°C: 
Forward primer strand (called Kan-F), Tm 58.8°C: 
5’-TGTCAAGACCGACCTGTCC-3’ 
Reverse primer strand (called Kan-R), Tm 57.3°C: 
5’-AATATCACGGGTAGCCAACG-3’ 
- The primers used to amplify the cMYC S/MAR element from the BAC clone, optimal 
annealing temperature 59.5°C: 
Forward primer strand (called cMYC-F), Tm 73.9°C, extra bases added at 5’ for efficient 
restriction digestion of product (green), XhoI site (red): 
5’-GTATACTCGAGCTTCCCAGAACCTGGAAACC-3’ 
Reverse primer strand (called cMYC-R), Tm 72.2°C extra bases added at 5’ for efficient 
restriction digestion of product (green), EcoRI site (red): 
5’-GTATAGAATTCGCTCGGCTGAACTGTGTTCT-3’ 
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2.2. Methods 
 
2.2.1. Cell Culture Methods 
 
2.2.1.1. Culture and maintenance of cells 
 
Growth medium: DMEM, 10% FBS, 20mM L-Glutamine, 1x Penicillin Streptomycin 
 
Cells were grown and maintained at 37°C, 8% CO2. On reaching approximately 70% 
confluency cells were passaged. Dishes were washed 1x in PBS containing 0.02% EDTA 
to remove calcium and allow adherent cells to be released. Cells were then treated 
with trypsin diluted in PBS/0.02%EDTA, pre-warmed to 37°C, and incubated at 37°C for 
a maximum of 5 minutes. The detachment of the adherent cells was monitored under 
the microscope. Once detached, cells were resuspended in 10ml growth medium pre-
warmed to 37°C and the solution was spun for 5 minutes at 650g at room temperature 
to pellet the cells. The supernatant was then discarded, the pellet was resuspended in 
1ml fresh growth medium, and the cells were counted and plated at the required 
density.  
2.2.1.2. Frozen Cell Storage 
 
Sub-confluent cultures of cells were trypsinised and counted. For every 2x106 cells, 1ml 
of growth medium was added. Then, an equal amount of a solution composed of 20% 
DMSO and growth medium was added, for a final concentration of 10% DMSO. 1ml 
aliquots were dispensed immediately into cryotubes, put in a Cryo 1° freezing 
container (Nalgene) containing isopropyl alcohol which provides a -1°C/minute cooling 
rate, and stored in a -80°C freezer. The next day the cryotubes were transferred to a 
liquid nitrogen storage tank for long-term storage. 
 
2.2.1.3. Thawing Frozen Cell Stocks 
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Cryotubes containing frozen cells were immediately immersed in a 37°C water bath for 
rapid thawing to avoid cell death. Once thawed the cells were transferred to a falcon 
tube  and slowly and gently resuspended in 20ml growth medium pre-warmed to 37°C. 
The cells were spun for 5 minutes at 650g. The supernatant was discarded, the pellet 
resuspended in growth medium, and then seeded to the required density. Cells were 
maintained at 37°C in a humidified atmosphere containing 8% CO2. 
2.2.1.4. Induction of Myogenic Differentiation In C2C12 Cultures 
 
Differentiation medium:  DMEM, 1% Horse Serum, 40mM L-Glutamine, 1x Penicillin 
Streptomycin 
 
C2C12 cells were plated at a confluency of approximately 70%. The cells were washed 
once the following day with pre-warmed PBS, then switched to pre-warmed 
differentiation medium. The cells were washed and the medium replaced daily for 5-10 
consecutive days. 
 
2.2.1.5. Lipofection: Liposome-Mediated DNA Transfection  
 
C2C12 and HeLa cells were plated at a density of 1x105 cells per 10cm2 dish area and 
HepG2 cells at 5 x105 cells per 10cm2 to achieve a confluency of approximately 70% the 
following day. For a 10cm2 area dish, a total of 4µg of plasmid was suspended in 250µl 
of serum-free DMEM in one sterile eppendorf or falcon tube, and 10µl of 
Lipofectamine 2000 reagent was suspended in 250µl of serum-free DMEM in another 
sterile eppendorf or falcon tube. The solutions were left to incubate for 5 minutes 
before gently mixing the two solutions together and leaving them to incubate for 20 
minutes. The growth medium on the cells was replaced with 2ml of fresh pre-warmed 
medium and the plasmid/lipofectamine solution was then added to the medium. Cells 
were incubated in a 37°C in a humidified atmosphere containing 8% CO2 for 24 hours. 
Negative controls for each experiment consisted of untreated cultures, or cultures 
treated with DNA or lipid only. 
The amount of each plasmid transfected was calculated in order that the same number 
of plasmid molecules of each plasmid was transfected into each culture rather than 
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the same amount (µg), considering the plasmids tested were of different sizes. Plasmid 
DNA whose sequences had no resemblance to the plasmids being tested, in order to 
avoid recombination, was used to keep the total amount (µg) of DNA being transfected 
in each transfection reaction the same (plasmid pDD345). 
2.2.1.6. G-418 Sensitivity Curves  
 
C2C12 and HeLa cells were plated in triplicates at 1x105 cells per 10cm2 dish area and 
HepG2 cells at 5 x105 cells per 10cm2. After 24 hours Geneticin (G-418) was added to 
the growth media at concentrations ranging between 0.1mg-1mg G-418/ml. G-
418/growth media was replaced daily for 7 days. At day 7 the cells were trypsinised 
and pelleted and resuspended in 1ml PBS. 0.1ml of a 0.4% trypan blue stock solution 
was added to the cell suspension and gently mixed. An aliquot of cells was examined 
under a phase contrast microscope at 5x magnification and the number of non stained 
viable cells was counted. The lowest concentration at which no viable cells remained 
by day 7 was the concentration used for selection. This was determined as 0.6mg/ml 
G-418 for the HeLa and C2C12 cell lines and 0.8mg/ml G-418 for the HepG2 cell line. 
 
2.2.1.7. C2C12 Cell Arrest In G0 Phase of Cell Cycle   
 
Low serum methionine-depleted medium: Methionine-depleted DMEM, 2% FBS, 
20mM L-Glutamine, 1x Penicillin Streptomycin 
Cells were plated at 5x104 per 10cm2 dish area in low serum methionine-depleted 
medium. The cells were washed once in pre-warmed PBS before changing the medium 
daily for 7 consecutive days. 
 
2.2.1.8. Reserve Cell Isolation 
 
This method was conducted as in the studies by Kitzman et al and Yoshida et al 
(Yoshida,N. 1998; Kitzmann,M. 1998). C2C12 cells were differentiated for 10 days in 
differentiation medium. Myotubes, which are more sensitive to trypsinisation than 
myoblasts, were trypsinised with 0.15% trypsin and washed with PBS repeatedly until 
all the myotubes had detached and only mononuclear cells had remained adherent to 
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the flask, as determined by observation under a phase contrast microscope. The 
adherent cells were then trypsinised and plated into fresh flasks in growth medium in 
order to reactivate the quiescent reserve cells.  
 
2.2.2 Bacterial Culture and Molecular Cloning 
 
2.2.2.1. Preparation of selective agar  
 
LB broth with 1% agar was sterilised by autoclaving. The solution was then allowed to 
cool to 40°C and antibiotics were added under sterile conditions and the solution was 
mixed well. For Ampicillin and Kanamycin plates, the final antibiotic concentration was 
50µg/ml. For Tetracycline the required final concentration was 10µg/ml, and for 
Chloramphenicol it was 60µg/ml. The agar was then poured onto plates under sterile 
conditions and the agar was allowed to set. The plates were stored at 4°C. 
 
2.2.2.2. Bacterial streaks  
 
A small sample of a single bacterial colony was collected from a fresh culture plate 
with a flame sterilised inoculation loop and dispersed in 1 ml of LB broth. The loop was 
again flame sterilised, dipped in the broth, and used to streak a loop full of bacterial 
culture across the surface on one edge of a LB agar plate containing the appropriate 
antibiotic. Further streaks were then made along adjacent regions of the plate. The 
plate was then incubated upside down at 37°C. Plates were sealed by parafilm and 
stored at 4°C, where the bacteria remained viable for approximately 2-4 weeks.  
 
2.2.2.3. T4 DNA Polymerase mediated conversion of 5’ overhangs to blunt ended 
termini 
 
T4 DNA Polymerase from Promega was used to fill the 5’ protruding termini with 
dNTPs of DNA fragments digested by restriction enzymes in order to generate blunt 
ended DNA fragments. 5 units of T4 DNA Polymerase/µg was added to 1X T4 DNA 
Polymerase Buffer as supplied by Promega and 40µM of dNTPs. Alternatively, if the 
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restriction digest buffer was compatible with the function of the T4 DNA Polymerase, 
the enzyme was added directly to the restriction digest reaction after the digestion 
incubation had terminated, in addition to 40µM of dNTPs. The reaction was incubated 
at 37°C for 5 minutes and was stopped by heating at 75°C for 10 minutes.  
 
2.2.2.4. Ligation of a DNA insert into a plasmid vector backbone 
 
Insert and backbone DNA fragments to be ligated were run on 0.8-2% agarose-EtBr 
containing gels, visualised, and excised with a sterile scalpel under low UV radiation. 
The fragments were extracted from the gels and purified using Qiagen’s QiaQuick Gel 
Extraction Kit according to the manufacturer’s protocol. The fragments were typically 
dissolved in 10-20µl of sterile ddH2O and kept on ice or frozen at -20°C. The 
concentration of the purified fragments was determined by the use of the ND-100 
NanoDrop spectrophotometer. The molar ratio of vector : insert typically used was 1:3 
for ligations involving cohesive ends. Ligation ratios were altered to 1:2, 1:6, or 1:10 
when the ration 1:3 proven unsuccessful. The formula used for calculating the molar 
ratios from the mass ratios was: 
 
molar ratio insert/vector = vector(ng) x insert size(kb) / insert(ng) x vector size(kb)  
 
The vector backbone and insert were ligated using New England Biolabs’ Quick Stick 
Ligase according to the manufacturer’s protocol, in a 21µl reaction at room 
temperature for 5 min. The ligations were purified using Qiagen’s QiaQuick Gel 
Extraction Kit according to the manufacturer’s protocol prior to elecroporation. 
 
2.2.2.5. Plasmid DNA transformation of bacteria by electroporation 
 
LB SOC was pre-warmed to room temperature. OneShot Top10 Electrocompetent 
E.Coli Cells (Invitrogen) were thawed on ice. Once thawed 1-5ng of pre-chilled plasmid 
DNA, not exceeding a volume of 10% of the solution containing the electrocompetent 
bacterial cells, was added to the 30µl of cells. The tube was gently flicked to mix the 
solutions. The contents were then transferred to a pre-chilled 0.1cm electroporation 
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cuvette. The electroporator (BioRad) was set at 50µF and 150Ω, the powerpack at 
1500V, 25mA and 25W, and the cells were electroporated.  Electroporated cells were 
swiftly transferred to 1ml LB-SOC media and incubated in a 37°C shaking incubater at 
250rpm for 45 minutes. The cells were then plated onto selective agar plates pre-
warmed to 37°C overnight for a maximum of 16 hours. 
 
2.2.2.6. Screening of transformants 
 
After plating the cells onto selective media and incubating for 16 hours, a single colony 
was picked under sterile conditions with the a sterile pipette tip and used to inoculate 
5ml of autoclaved LB broth, pre-warmed to 37°C, containing the appropriate antibiotic. 
This was then placed in a 37°C incubator and shaker set at 250rpm for 8 hours. DNA 
was extracted from 1.5ml of preculture as per the Qiagen Miniprep Kit protocol. For a 
maxi-prep, 0.25ml of preculture was used to inoculate 250ml sterile LB broth 
containing the required antibiotic and was grown in the incubator/shaker overnight for 
a maximum of 16 hours. The solution was then spun at 4°C at 3000g for 30 minutes to 
pellet the bacteria. The plasmid was then extracted as per the Qiagen Maxiprep Kit 
protocol. Plasmid DNA was further characterised by restriction analysis and gel 
electrophoresis. This procedure was repeated for 10 individual bacterial colonies 
unless stated for cloning purposes where multiple batches of 24 colonies were typically 
tested. 
 
2.2.2.7. Analysis of DNA By Restriction Endonuclease Digestion and Electrophoresis 
 
10x TBE (1 Litre): 108g Tris Base, 55g Boric Acid, 40ml EDTA (pH 8.0) dissolved in 1L 
double distilled H20. 
10x DNA Loading Buffer: 50% glycerol, 100mM Na3EDTA, 1% SDS, 0.1% 
bromophenol blue 
 
In order to verify the quality of each plasmid preparation, approximately 1µg of 
plasmid DNA was digested with one or more restriction enzymes with corresponding 
sites within the construct. Digests were carried out according to the manufacturer’s 
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(New England Biolabs (NEB), Promega, or Fermentas) recommended conditions and 
buffers in a 50µl total reaction volume, and incubations were carried out in water 
baths. Then a sample of digested plasmid DNA (~100-200ng) was mixed with the 
appropriate volume of 5x loading buffer, and loaded into the well of a typically 0.8% 
agarose gel. A DNA molecular weight marker and undigested samples of plasmid DNA 
were loaded into wells alongside the sample, and electrophoresed at 50-100V. 1 x TBE 
was used as the electrophoresis buffer. Ethidium bromide was incorporated into a gel 
prior to gel setting at a concentration of 0.5µg/ml, and the DNA fragments were 
visualised under UV light. Gel images were recorded electronically on a digital imaging 
system (UVP) or by photographic film with an automatic Polaroid DS34 direct screem 
instant camera.  
 
2.2.2.8. Amplification and purification of plasmid DNA 
 
The small scale purification of plasmid DNA (Mini-Prep) was carried out by the use of 
Qiagen’s mini-prep plasmid DNA purification kit as per the manufacturer’s protocol 
from a 5-10ml starter culture grown at 37°C for 8 hours. 
The larger scale amplification of plasmid DNA (Maxi-Prep) was conducted by the 
dilution of a starter culture by 1:1000 in 150-200ml sterile LB broth containing the 
appropriate antibiotic, grown overnight at 37°C in a shaking incubator rotating at 
250rpm. The plasmid was purified by the use of Qiagen’s maxiprep kit. DNA isolation 
using this kit was based upon the binding of DNA to the anion-exchange resin columns 
under low-salt and pH conditions. A medium-salt wash removed protein, RNA, and 
other low molecular weight impurities. Finally, a high-salt buffer wash led to the 
elution of the DNA, which was concentrated and desalted and precipitated with 
isopropanol. The DNA was resuspended in sterile ddH2O at room temperature and 
stored at -20°C. 
2.2.2.9. Glycerol stocks: 
 
600µl of an overnight bacterial culture was put into a cryotube and 300µl of 
autoclaved 80% glycerol was added, gently mixed, and immediately stored at -80°C. 
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2.2.2.10. Plasmid Vectors Construction At RHUL Lab 
 
- CeGFP-C1: This vector was constructed by excising the CMV promoter from peGFP-
C1 and ligating the CAGG promoter excised from the CeGFP-N3 vector. This was done 
by digesting CeGFP-N3 with SalI, blunting with T4 DNA Polymerase, then digesting with 
ApaLI to yield the insert fragment of 1288bp, and another 3718bp fragment. peGFP-C1 
was digested with AfeI, blunted with T4 DNA Polymerase, then digested with ApaLI 
yielding a 968bp fragment and the 3763bp backbone into which the CAGG promoter 
was inserted. The 1288bp CAGG promoter was ligated into the 3763bp peGFP-C1 
backbone as a cohesive-blunt directional ligation.  
  
- CpEPI-eGFP: This vector was constructed by excising the CMV promoter from pEPI-
eGFP and ligating the CAGG promoter excised from the CeGFP-N3 vector. This was 
done by digesting CeGFP-N3 with SalI, blunting with T4 DNA Polymerase, then 
digesting with ApaLI to yield the insert fragment of 1288bp, and another 3718bp 
fragment. pEPIeGFP was digested with AfeI, blunted with T4 DNA Polymerase, then 
digested with ApaLI yielding a 968bp fragment and the 5726bp backbone into which 
the CAGG promoter was inserted. The 1288bp CAGG promoter was ligated into the 
5726bp pEPI-eGFP backbone as a cohesive-cohesive directional ligation. 
 
- CMYC-pEPI: This vector was constructed by amplifying the cMYC S/MAR element by 
PCR from the BAC clone template containing the element (pBACe3.6 RPCI Mouse BAC 
clone) and inserting it into peGFP-C1. The amplified cMYC S/MAR fragment was 
flanked with an XhoI restriction site at its 5’ end and an EcoRI site at its 3’end. peGFP-
C1 contains EcoRI and XhoI sites within its multiple cloning site. The amplified product 
and peGFP-C1 were digested with EcoRI and XhoI, and the product composed of the 
cMYC S/MAR element was inserted into the peGFP-C1 backbone as a cohesive-
cohesive directional ligation. The cMYC S/MAR element was then excised from the 
vector by digestion with AgeI and ApaI, and CeGFP-C1 was also digested with AgeI and 
ApaI, and the cMYC S/MAR was ligated into the CeGFP-C1 backbone as a cohesive-
cohesive directional ligation. 
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2.2.3. Fluorescence Immunostaining of cells 
 
4% paraformaldehyde fixing solution (100ml): 4g paraformaldehyde, 10mM 
NaOH, 10ml of 10x PBS, pH adjusted to 7.4 with 1M HCl, final volume adjusted to 
100ml with distilled H2O 
 
2.2.3.1. eGFP immunostaining for the enhancement of fluorescence signal from eGFP 
positive cells 
 
Cells were plated in 1cm2 chamber wells at the required density and left in the 
incubator overnight to adhere. The following day cells were washed once in PBS pre-
warmed to 37°C. The cells were incubated in 4% paraformaldehyde fixing solution pre-
warmed to 37°C for 5 minutes in order to fix the cells. The cells were rinsed twice in 
PBS. Next, they were incubated in PBS/0.1% Triton for 10 minutes to permeabilise the 
cells’ membranes to facilitate antibody entry. Cells were rinsed again twice in PBS. 20% 
Normal Goat Serum/PBS was added to the cells and incubated for 30 minutes. Mouse 
monoclonal primary anti-GFP antibody diluted 1 in 400 in 5% Horse Serum/PBS was 
added and kept at 4°C overnight. The next day the cells were rinsed once and then 
washed twice for 5 minutes in 5% Horse Serum/PBS. The goat anti-mouse secondary 
antibody diluted 1 in 200 in 5% Horse Serum/PBS was added and the cells were 
incubated at room temperature for 1 hour in the dark. Next they were rinsed once and 
washed 3 times for 10 minutes in PBS. The wells were peeled off the slide, DAPI 
mounting medium was dropped onto the cells, and the slide was covered with a 
coverslip. The slides were left at room temperature overnight to set and the 
fluorescence was detected and images captured the next day at 490nm by the use of a 
Leica 800 fluorescence microscope at 10x magnification. 
 
2.2.3.2. Immunostaining for the detection of lysenin/eGFP positive cells 
 
Cells were plated in 1cm2 chamber wells at the required density and left in the 
incubator overnight to adhere. The following day the medium was removed and the 
cells were washed once in PBS pre-warmed to 37°C. The cells were incubated in 4% 
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paraformaldehyde fixing solution pre-warmed to 37°C for 5 minutes in order to fix the 
cells. The cells were rinsed twice in PBS. They were incubated for 30 minutes at room 
temperature in 2% BSA/PBS. Next, 0.5µg/ml Lysenin diluted in 2% BSA/PBS was added 
to the cells and incubated at room temperature for 1 hour. In this step the lysenin 
bound to sphingomyelin present in large amounts on the cell surface of reserve cells. 
The cells were rinsed again twice in PBS. For co-staining for eGFP, the cells were 
incubated in 0.1% Triton/PBS for 10 minutes to permeabilise the cells’ membranes to 
facilitate antibody entry, rinsed twice with PBS, and incubated in 20% Normal Goat 
Serum/PBS for 30 minutes. Rabbit anti-lysenin primary antibody diluted 1 in 200 in 2% 
BSA/PBS was added and, if staining for GFP, the mouse monoclonal primary anti-GFP 
antibody diluted 1 in 400 in 5% Horse Serum/PBS was also added at this stage. This 
was incubated at 4°C overnight. The next day the cells were rinsed once and then 
washed twice for 5 minutes in 5% Horse Serum/PBS. The secondary antibody swine 
anti-rabbit diluted 1 in 200 in 2% BSA/PBS was added and incubated in the dark at 
room temperature for 1 hour. If also staining for GFP, goat anti-mouse secondary 
antibody diluted 1 in 200 in 5% Horse Serum/PBS was added as well at this stage. Next 
the cells were rinsed once and washed 3 times for 10 minutes in PBS. Finally, the wells 
were peeled off the slide, DAPI mounting medium was dropped onto the cells, and the 
slide was covered with a coverslip. The slides were left at room temperature overnight 
to set and the fluorescence was detected and images captured the next day at 490nm 
by the use of a Leica 800 fluorescence microscope at 10x magnification. 
 
2.2.4. Total DNA extraction 
 
DNAzol® Genomic DNA Isolation reagent was used to extract total DNA from cells 
according to the manufacturer’s protocol. This extraction technique is based upon the 
use of guanidine – detergent lysing solution which hydrolyzes RNA and selectively 
precipitates DNA from the lysate with ethanol (Chomczynski et al., 1997). Total DNA 
was resuspended in sterile ddH2O and stored at -20°C. 
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2.2.5. HRP-Labelled Southern Blotting  
 
Pre-hybridisation Buffer: 0.5M NaCl, 5% blocking reagent (supplied with kit), made up to 10ml 
pre-hybridisation buffer ECL Gold (supplied with kit). 
20x SSC (1 Litre): 3M NaCl, 0.3M Na3Citrate, pH adjusted to 7 using 1M HCl, final volume 
adjusted to 1L with distilled H2O. 
15µg of extracted total genomic DNA was digested with EcoRI which cuts once within the 
plasmids tested. The digested DNA was run on a 0.8% agarose gel in TBE buffer at 100V for 2 
hours. The gel was then transferred to a UV gel visualiser in order to confirm digestion and 
images were taken. The gel was exposed to UV light for 1 minute to cross-link the DNA and 
then soaked in 0.5M NaOH for 30 minutes to denature the DNA. Next, Whatman paper cut to 
the size of the gel was soaked in 5x SSC and placed on a flat surface covered in cling film. The 
gel was placed on the paper, followed by a piece of Hybond N+ membrane also cut to the size 
of the gel. Three more Whatman papers soaked in 2x SSC were placed over the membrane, 
followed by a stack of tissues and a weight of 500g atop the stack. Blotting was done for 2 
hours. Next, the membrane was soaked in 5x SSC for 10 minutes. It was then soaked in 1.5x 
SSC for 10 minutes. The membrane was then placed in pre-hybridisation buffer in the 
hybridisation container, pre-warmed to 42°C, for 1 hour. 
During the pre-hybridisation step the probe was prepared by the use of Amersham HRP Direct 
Labelling Kit. The template used was the eGFP sequence found in the plasmids tested, 
generated by PCR amplification. The template fragments were run on a gel to confirm the 
correct size, then cut out and purified with Qiagen’s QiaQuick Gel Extraction Kit. 100ng of 
template was resuspended in distilled water to a final volume of 10µl. The probe was 
completely denatured to become single stranded by placing the eppendorf containing  the 
probe in boiling water for 5 minutes then immediately placing in an ice water bath. Following a 
quick spin in the centrifuge the labelling was then carried out as per protocol provided with 
the labelling kit, and probe was directly labelled with Horseradish Peroxidase enzyme. 
Hybridisation of the probe to the target DNA on the membrane was carried out by adding the 
labelled probe to the pre-hybridisation solution, mixing well, and leaving to hybridise 
overnight. 
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The next day the rinsing solutions that consisted of 2x SSC and 0.5x SSC were pre-warmed to 
42°C. The membrane was washed in the 2x SSC first for 20 minutes, then the 0.5x SSC for 20 
minutes, both at 42°C in the hybridisation oven. 
To visualise the locations where the probe hybridised to target DNA the Amersham ECF 
Chemifluorescent substrate was added to the membrane in a dark room as per protocol 
provided with the substrate and left to react for 1 minute. The membrane was placed in a 
plastic sleeve and an autoradiography film Amersham Hyperfilm was placed on top between 5 
minutes and overnight depending upon the sensitivity required. The film was developed by 
being placed in developer, rinsed in distilled water, then placed in fixer, rinsed in distilled 
water, then air dried.  
 
2.2.6. Fluorescent In-Situ Hybridisation (FISH) 
 
Fixative Solution: A solution of 3:1 methanol : acetic acid. 
Hybridisation Buffer (7ml): 1g Dextran sulphate, 5.5ml formamide, 0.5ml 20x SSC, 
final volume made up to 7ml with distilled H2O. 
Hypotonic Solution: 0.4% KCl, 0.4% Na3citrate 
Denaturant Solution: 70% formamide, 2x SSC. 
Wash A: 50% formamide, 2x SSC. 
Wash B: 2x SSC 
Wash C: 2xSSC, 0.1% NP40 
 
1x105 cells were typically plated and grown to 85% confluency in a flask. Demecolcine 
was added to the medium for a final concentration of 1µg/ml and incubated in a 37°C, 
8% CO2, humidified chamber for 1 hour to block mitosis of the cells at metaphase 
where the chromosomes are most condensed. Next the cells were trypsinised and 
pelleted. The pellet was gently resuspended in 2ml hypotonic solution pre-warmed to 
37°C by flicking the tube until the pellet was resuspended. This was incubated in a 37°C 
water bath for 7 minutes in order to release the nuclei. Next the nuclei were pelleted 
by centrifugation at 650rpm for 5 minutes, and gently resuspended in 2ml freshly 
made Fixative Solution and was incubated at room temperature for 30 minutes. The 
nuclei were pelleted again by centrifugation, and resuspended again in 2ml fresh 
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Fixative Solution and incubated at room temperature for 20 minutes. The nuclei were 
pelleted once more and resuspended in 250µl fresh fixative. This was stored at -20°C 
until use.  
For chromosome spreads, glass slides were used that were aged by immersing for 24 
hours in 3% HCl/ 70% Methanol/ 27% H2O. The slides were rinsed 3 times in distilled 
H2O and are stored at 4°C until use. To prepare chromosome spreads the glass slides 
were allowed to air dry and the cell suspensions in fixative were kept on ice. 50µl of 
the nuclei suspension was pipetted and dropped onto the glass slides from a height of 
approximately 1 meter. The fixative was allowed to evaporate and the slides were left 
at room temperature overnight to dry.  
To prepare the slides for staining they were dehydrated by immersing in a 70%, 80%, 
and 100% ethanol series for 2 minutes at each concentration. The slides were allowed 
to air dry, then the chromosomes were denatured by placing in Denaturant Solution 
pre-warmed to 40°C for 1 minute, pre-warmed to 60°C for 1 minute, and pre-warmed 
to 76°C for 5 minutes. They were then placed back in the denaturing solution pre-
warmed to 60°C for 1 minute, and the solution was pre-warmed to 40°C for 1 minute. 
These stepwise increased in temperature keep the condensed chromosomes from 
adopting a ‘fuzzy’ appearance which can result from sudden large temperature 
changes. The slides were again dehydrated in an ethanol series as described above and 
allowed to air dry.  
To prepare the probe the Nick Translation Kit from Abbott Molecular was used as per 
the protocol supplied. The probe template used was the eGFP-C1/CeGFP-C1 vector. An 
eppindorf was pre-cooled on ice, and the following components were added in: 1µg of 
template DNA, 2.5µl of 0.2mM Red-dUTP, 5µl of 0.1mM dTTP, 10µl of 0.3mM dNTP 
mix, 5µl of 10X nick translation buffer, 10µl of nick translation enzyme, and a volume 
of nuclease-free H2O to make the final reaction volume up to 50µl. The solution was 
briefly vortexed and centrifuged, then incubated at 15°C overnight for 16 hours. The 
reaction was then arrested by heating in a water bath at 70°C for 10 minutes. The 
solution was then briefly centrifuged and stored on ice or at -20°C until further use.  
Once the probe was generated and purified using Qiagen’s QiaQuick Gel Extraction Kit 
1µl of probe mixed with 1µl of 10mg/ml sonicated salmon sperm DNA from Sigma, 1µl 
of sonicated Human Cot-1 DNA from Abbott Molecular, and 7µl of Hybridisation Buffer 
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per slide. The components were mixed well and the DNA was denatured by placing the 
eppendorf on a heating block at 76°C for 5 minutes. 
Hybridisation was carried out by applying 10µl of the probe mixture to each slide and 
immediately covering with a glass coverslip and avoiding creating bubbles. The edges 
of the coverslips were sealed with rubber cement and allowed to air dry for 5 minutes 
at room temperature. The slides were incubated upsidedown at 37°C, 8% CO2, 
humidified chamber for 48 hours for hybridisation to take place. 
After hybridisation the rubber cement was peeled off and the slides were immersed in 
Wash A at 43°C for 10 minutes. The slides were gently shaken and the coverslips fell 
off at this stage. The slides were washed again in Wash A at 43°C for 10 minutes 2 
more times. Next they were washed with Wash B at 43°C for 10 minutes. Finally, they 
were washed in Wash C at 43°C for 5 minutes. The slides were allowed to completely 
air dry. 10µl DAPI mounting medium was applied to each slide and was covered by a 
coverslip. The slides were visualised using a CARV II non-laser Confocal Imager 
fluorescence microscope from Image Solutions at 100x magnification. 
 
2.2.7. Fluorescent Activated Cell Sorting (FACS) and flow 
cytometry analysis 
 
2.2.7.1. Analysis of Enhanced Green Fluorescent Protein (eGFP) expression by flow 
cytometry 
 
1x105 cells were typically analysed by flow cytometry for the expression of eGFP at 
appropriate intervals after transfection with vectors carrying eGFP expression 
cassettes. Cells to be analysed were trypsinised, pelleted, and the pellet resuspended 
in 500µl of 1% PFA/PBS solution. The samples were stored in the dark at 4°C for a 
maximum of 5 days until analysis. The cells were analysed using a Beckman Coulter 
EPICS XL flow cytometer with the use of XL System II™ software (at the Dept. of 
Immunology, ICSM, Chelsea Westminster Hospital, South Kensington by colleagues 
Timos Papagatsias and Takis Athanasopoulos) or a BD Biosciences FACSCalibur flow 
cytometer with the use of FACScomp™ software (at Royal Holloway). Cells were gated 
using non-transfected fixed cells according to forward scatter and side scatter in order 
to distinguish single cells from doublets or cell clumps (see Figure 2.8). eGFP gating 
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was also conducted using untransfected cells according to cell count and FITC 
fluorescence, where any cells from test samples emitting fluorescence greater than the 
gate set by the negative control were considered to be eGFP positive and counted as 
such, as was determined with the positive control consisting of cells 24 hours post 
transfection with the vector CeGFP-C1 containing an eGFP expression cassette (see 
Figure 2.9). The mean fluorescence intensity (MFI) was determind by the flow 
cytometer by measuring the fluorescence of each individual eGFP positive cell that is 
passed through, then calculating the mean intensity of those positive cells. 
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Figure 2.8 Flow cytometry gating of C2C12 cells using untransfected cells according to forward scatter 
and side scatter.  
 
 
 
Figure 2.9 Flow cytometry FITC gating of C2C12 cells using untransfected C2C12 cells as a negative 
control according to cell count and FITC fluorescence (A). (B) shows C2C12 cells 24 hours post 
transfection with a vector containing an eGFP expression cassette (CeGFP-C1) indicating the presence of 
eGFP positive cells within the sample population. 
 
101 
 
2.2.7.2. Cell cycle analysis by flow cytometry  
 
Hypotonic Solution: 0.4% KCl, 0.4% Na3citrate 
DAPI staining solution: 10 mM Tris-HC1 (pH 7.5), 0.1% Triton X-100, and 4 µg/ml 
DAPI 
 
1x103-1x104 cells were typically analysed by flow cytometry to determine the 
percentage of cells in each phase of the cell cycle, taken at appropriate intervals from 
C2C12 cell cultures in low serum methionine depleted medium. Cells to be analysed 
were trypsinised, pelleted, and the pellet resuspended in 400µl hypotonic solution. 
The solution was pipetted thoroughly and incubated at 37°C for 7 min in order to 
release the nuclei from the cells. Next the nuclei were pelleted by centrifugation at 
650rpm for 5 minutes, and gently resuspended in 800µl DAPI staining solution and the 
tube was gently flicked to mix. The samples were kept on ice for a maximum of 30 
minutes before being analysed by a PAS2 flow cytometer (Partec, Münster, Germany) 
by UV excitation light generated by a mercury lamp, and data was analysed and graphs 
generated using Windows™ FloMax® software. 
2.2.7.3. Fluorescent Activated Cell Sorting (FACS) 
 
1x105 cells were sorted for eGFP positive cells. Cells to be sorted were trypsinised, 
pelleted, and the pellet resuspended in 300µl growth medium. The samples were kept 
on ice until analysed (at the University College London Wolfson Institute of Biomedical 
Research by colleague Thomas Adejumo) in a Beckman Coulter MoFlo XDP Cell Sorter 
with the use of Summit software. The negative control used was untransfected C2C12 
cells and the positive control was C2C12 cells 24 hours post transfection with the 
vector CeGFP-C1 containing an eGFP expression cassette. The cells were gated 
according to forward scatter and side scatter to distinguish single cells from doublets 
(see Figure 2.10). eGFP gating was set by comparison of the negative control with the 
positive control (see Figure 2.11). Samples were sorted on the basis of the determined 
gating, and eGFP positive cells were resuspended in growth medium and replated. 
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Figure 2.10 FACS gating of C2C12 cells according to forward scatter and side scatter to discriminate 
doublets from single cells. 
 
 
Figure 2.11 FACS gating for eGFP positive C2C12 cells using untransfected cells and cells 24 hours post 
transfection with a vector containing an eGFP expression cassette (CeGFP-C1).  
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2.2.8. Polymerase Chain Reaction (PCR) 
 
PCR was carried out in 25µl volumes in sterile tubes in a PTC-200 Peltier Thermal 
Cycler. Each PCR reaction contained 12.5µl GeneSys MasterMix, which included 1x 
amplification buffer, 10µM dNTPs, 1.5mM MgCl, and thermostable DNA polymerase, 
1µl of 10µM forward primer, 1µl of 10µM reverse primer, 10µl of template DNA at the 
required concentration, and 0.5µl sterile ddH2O. The PCR cycle began with 2 minutes 
at 94°C, then 35 cycles of 30 seconds at 94°C for denaturation, 30 seconds at optimal 
annealing temperature previously determined by a temperature gradient, and 45 
seconds at 72°C for elongation. Following this was 10 minutes at 72°C for final 
elongation. PCR generated fragments were stored at 4°C and and analysed by 
electrophoresis. The primers were designed by Primer3 program, and a pair of forward 
and reverse primers were chosen based upon the similarities of their lengths, GC 
content, and melting temperatures (Tm). In order to determine the optimal annealing 
temperature for each set of primers a PCR reaction was set up using 1ng of template 
DNA and run according to the program described above. A temperature gradient 
ranging from 65-72°C was conducted for the annealing temperature, and the optimal 
annealing temperature was chosen after electrophoresis of the PCR products based 
upon the absence of non-specific sequence amplification and the qualitatively 
determined brightness of the band, denoting efficient target sequence amplification. 
 
2.2.9. Statistical Analyses: 
 
eGFP positive cell populations were assumed to have normal distributions. NCSS 
program was used to conduct the statistical analyses. For the comparison of two 
populations a student’s T-test was used. For 3 or more populations a One-way ANOVA 
test was conducted. The post-hoc Tukey-Kramer test was used when comparing 3 or 
more populations to determine which groups differed significantly to others where 
significance was confirmed by the student’s T-test or ANOVA. Significance was set at P 
< 0.05. 
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CHAPTER 3: Evaluation of The Expression and Episomal 
Establishment Of S/MAR Vectors in The Human Epithelial 
Cervial Cancer Cell Line HeLa, Murine Myoblast Cell Line 
C2C12, and Human Hepatocyte Cell Line HepG2 
 
3.1. Introduction: 
 
The aim of the experiments in this chapter was to investigate the expression and 
episomal status of a plasmid vector containing an S/MAR element following 
transfection into human epithelial cervical cancer cell line HeLa, the murine skeletal 
muscle cell line C2C12, and the human hepatocyte cell line HepG2 over time, 
compared with those of a control vector in order to investigate the effects of the 
presence of the S/MAR element. The S/MAR vector, pEPI-eGFP, was a plasmid 
containing a CMV-driven eGFP reporter gene, with the 2.0kb human IFN-β S/MAR 
element positioned at the 3’ end of the reporter gene within the open reading frame, 
and preceding the 5’ end of the SV40 polyadenylation signal. The vector also contained 
a Neomycin resistance gene driven by the SV40 promoter (vector maps in Chapter 2: 
Materials & Methods). The control vector, eGFP-C1, was composed of the same 
elements and sequences as pEPI-eGFP, but lacked the S/MAR element.  
All cell lines used were immortal lines in order to be able to investigate the expression 
and retention of the vectors tested in replicating cells after many cell divisions over 
time. The C2C12 line, as indicated in Chapter 1 Introduction (section 1.3.3), was 
considered a suitable skeletal muscle line for the purposes of the investigations in this 
thesis. The other two cell lines were chosen for other reasons. In considering the 
differences observed in different cell lines in the expression and retention of these 
vectors over time in studies reviewed in Chapter 1 Introduction (section 1.10), cell lines 
with different characteristics to C2C12 were chosen in order to investigate whether 
any differences may be observed and, if so, what these variations may indicate. Thus 
the HepG2 line was chosen as it represented a different tissue type, and also had a 
longer doubling time than the other two cell lines chosen. Hela was chosen as a control 
line, as the integration status of eGFP-C1 and pEPI-eGFP in HeLa cells over time had 
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already been investigated by Schaarschmidt et al (Schaarschmidt et al., 2004). 
However, the expression of these vectors in this cell line had not yet been evaluated. 
Also evaluated was the ‘pEPI-M18’ vector, devised and kindly provided by J. Bode, in 
C2C12 cells. This vector was a plasmid composed of the same elements and sequences 
as pEPI-eGFP, except a 0.7kb segment derived from the human β-IFN S/MAR, termed 
‘mini S/MAR’, replaced the full length S/MAR. This mini S/MAR element was created by 
a recombination event which had occurred within the full length S/MAR element after 
the long-term cultivation of a population of CHO-K1 cells transfected with a minicircle 
containing the full length S/MAR element, leading to a decrease in S/MAR size from 
4kb to 0.7kb. A region of 1.2kb had been excised from within the S/MAR element. This 
occurred in two separate independent events where the deletions were found to be 
identical. This vector, termed ‘pEPI-M18’ had indicated improvements within 
populations transfected by it over those containing pEPI-eGFP, in terms of percentage 
of positive cells and mean fluorescence intensity (personal communication with J. 
Bode).This vector was tested in order to determine whether this shorter version of the 
β-IFN S/MAR would be able to confer the same properties to its vector as the full 
length element. If successful, the smaller size of the vector would allow it a larger 
carrying capacity for therapeutic transgenes to be inserted than pEPI-eGFP. 
Samples were analysed by PCR at several time points to determine whether copies of 
the vector sequences remained present within the transfected populations over time. 
Flow cytometry and immunostaining of the samples were used as assessments of the 
expression of the eGFP reporter gene over time in each population, thus giving an 
indication of the efficacy, in terms of both number of positive cells and level of 
expression, of each vector tested at expressing the transgene over time. Southern 
blotting, plasmid rescue, and fluorescent in-situ hybridisation was used to determine 
the episomal/integrant status of the transfected vectors at the final day of the 
experiments. 
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Table of plasmid vectors tested in this chapter: 
 
Vector Name Vector 
Feature 
Promoter- 
Transgene 
Antibiotic 
Resistance 
Vector 
Length (kb) 
eGFP-C1 No S/MAR 
element 
CMV-eGFP Kan/Neo 4.7 
pEPI-eGFP Full-length 2kb 
β-IFN S/MAR 
element 
CMV-eGFP Kan/Neo 6.7 
pEPI-M18 Truncated 0.7kb 
β-IFN S/MAR 
element 
CMV-eGFP Kan/Neo 5.4 
 
Table 3.1 Vectors used in this chapter, indicating the name, the presence of an S/MAR element, the 
transgene promoter, the transgene used for assessment studies, the antibiotic resistance gene, and the 
length (kb) of each construct. 
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3.2. Results 
 
3.2.1 Experimental Design 
 
To carry out the aims of this chapter, cell populations of three cell lines were 
transfected with each vector, selected for neomycin resistence, and passaged for many 
generations. This was conducted by plating two 75cm2 flasks with 7.5x105 HeLa cells 
each, three 75cm2 flasks with 7.5x105 C2C12 cells each, and two 75cm2 flasks with 
37.5x105 HepG2 cells each. After 24 hours the cells had reached ~70% confluency. 
Three flasks of cells, one of each cell line, were transfected with the control vector 
eGFP-C1, three flasks were transfected with the S/MAR vector pEPI-eGFP, and the final 
flask, which contained C2C12 cells, was transfected with the vector containing the 
‘mini-S/MAR’, pEPI-M18, by lipofection (see Chapter 2: Materials & Methods). 24 
hours after transfection each transfected population of cells was analysed under a 
fluorescent microscope to confirm the presence of eGFP positive cells, to ensure that 
the cells had been successfully transfected with plasmid. Cell samples were collected 
from each population for analysis and the remaining cells were seeded into 25cm2 
flasks at a density of 5x104 cells for the HeLa and C2C12 cell populations, and of 1x105 
cells for the HepG2 populations. The cells were put under selection by the addition of 
Geneticin (G-418) to the culture media at the appropriate concentration for each cell 
line (see Chapter 2: Materials & Methods). Fresh media containing G-418 was added to 
each culture every 48 hours, and the cells were passaged when culture confluency 
reached ~70%. Selection was maintained for 21 days, and on the final day cell samples 
were again collected from each population for analysis. The remaining cells were re-
seeded again into fresh flasks, and the HeLa and C2C12 populations were passaged for 
a further 39 days, and the HepG2 populations for a further 99 days, due to the longer 
doubling time of HepG2 cells. On the final day of the experiment, Day 60 for HeLa and 
C2C12 and Day 120 for HepG2, cell samples were collected again from each population 
for analysis.  
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3.2.2 Detection of Vector Sequences in Transfected HeLa, C2C12, and HepG2 
Populations By Polymerase Chain Reaction (PCR) 
 
PCR analyses were conducted on samples taken on Days 1, 21, and 60 for HeLa and 
C2C12 transfected populations, and Days 1, 21, and 120 for the HepG2 transfected 
populations. 50ng of total DNA extracted from each sample was used per PCR reaction. 
The primers used were designed by Primer3 and lie within the Kanamycin resistance 
gene present in eGFP-C1, pEPI-eGFP, and pEPI-M18. The PCR was run for 35 cycles and 
the expected product size was 503bp. Products were run on 0.8% agarose gels 
counterstained with ethidium bromide and visualised under UV light see Materials  & 
Methods). PCR on each sample confirmed the presence of eGFP-C1 and pEPI-eGFP 
vectors within cells in the transfected HeLa and HepG2 populations, and of eGFP-C1, 
pEPI-eGFP, and pEPI-M18 vectors within the transfected C2C12 populations (see Figure 
3.1) 
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(A) HeLa: 
 
(B) C2C12: 
 
(C) HepG2: 
 
Figure 3.1 PCR analysis of 50ng of total HeLa DNA (A) or HepG2 DNA (C) transfected with eGFP-C1 or 
pEPI-eGFP, and C2C12 DNA (B) transfected with eGFP-C1, pEPI-eGFP, or pEPI-M18 vector on samples 
taken at Days 1, 21, and 60 (or Day 120 in the case of HepG2). The negative controls were 50ng 
untransfected C2C12, HeLa, or HepG2 genomic DNA, and H20. The primers used were within the 
Kanamycin resistance gene, and product size expected was 503bp. Copies of the vectors were present 
within cells of the transfected populations in each cell line at each time point. 
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3.2.3 Transgene Expression Analysis of Transfected Cell Populations By Flow 
Cytometry And Immunostaining 
 
Transfected cell populations were analysed by flow cytometry and immunostaining to 
assess eGFP transgene expression at three different time-points: Day 1, Day 21, and 
Day 60 for HeLa and C2C12 cells, and Day 1, Day 21, and Day 120 for HepG2 cells. Day 
1 was 24 hours post transfection, Day 21 was the final day of selection, Day 60 was the 
final day of the experiment for the HeLa and C2C12 cells where cells were allowed to 
proliferate in growth medium for 39 days post selection, without selection pressure, 
and Day 120 the final day of the experiment for the HepG2 cells where cells were 
allowed to proliferate in growth medium for 99 day post-selection, without selection 
pressure. 
For flow cytometry analysis, cells were fixed in 1% PFA/PBS and 1x105 cells were 
analysed per sample. The mean percentage of eGFP positive cells and the mean 
fluorescence intensity of the positive cells were measured (as described in Chapter 2: 
Materials & Methods). 
For the immunostaining 1x104 cells of each sample were seeded into 1cm2 chamber 
slide wells and then fixed after 24 hours in 4% PFA/PBS prior to staining. The cells were 
stained in order to amplify the eGFP signal using mouse anti-eGFP primary antibody 
and goat anti-mouse secondary antibody conjugated with green fluorescent Alexa 
Fluor 488 dye.  
The staining was conducted in triplicates (n = 3), 200 cells were counted per image, 
and of those 200 the number of positive cells was counted. The percentages ± the 
standard error of the mean (SEM) were calculated for each transfected population at 
each of the three chosen time points. The mean percentages of each transfected 
population at each time point were statistically compared, as were the transfected 
populations at all time points for each cell line, by One-Way ANOVA. The post-hoc 
Tukey-Kramer test was used to determine the means that were significantly different 
to other means in group comparisons (3+ transfected populations). 
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3.2.3.1 Expression Analysis Of HeLa Cell Populations Transfected With eGFP-
C1 or pEPI-eGFP 
 
Figure 3.2 shows the mean percentage of positive cells in the transfected populations 
determined by cell counts from the immunostaining images (a), and the mean 
percentages of eGFP positive cells as measured by flow cytometry (b). Data from Day 1 
indicate that the transfection efficiencies of eGFP-C1 and pEPI-eGFP in this experiment 
were comparable to one another (eGFP-C1 mean number of eGFP positive cells= 62.4% 
(flow cytometry) and 50.3 ± 3.4% (immunostaining); pEPI-eGFP number of eGFP 
positive cells= 54.5% (flow cytometry) and 48.5 ± 4.8% (immunostaining)). This was 
confirmed by an ANOVA analysis on the cell counts data where no significant 
difference was found between the percentage of positive cells in the eGFP-C1 and 
pEPI-eGFP transfected populations at Day 1 (P = 0.8).  
On the final day of selection at Day 21 all cells which survived selection theoretically 
contained a copy of the vector sequence. However, Figure 3.2 (a,b) show a decline in 
the percentage of eGFP positive cells from Day 1 to Day 21, which suggests that gene 
silencing was a possible reason for the lack of detectable eGFP expression, although 
this would require further examination, possibly by measuring gene transcripts by a 
method such as Qunatitative Reverse Transcriptase-PCR (Q-RT-PCR). The decline in 
eGFP positive cells was indicated by the mean percentages of positive eGFP-C1 and 
pEPI-eGFP transfected cells (means of 9.4% from flow cytometry and 2.3 ± 0.7% from 
the immunostaining cell counts; means of 18% from the flow cytometry and 4 ± 1.5% 
from the immunostaining cell counts, respectively). The ANOVA analysis showed that 
there was no significant difference in the percentage of positive cells between the two 
populations at Day 21 (P = 0.4).  A further decrease in the percentage of positive cells 
in both populations was evident at Day 60. The data indicate that a very small 
percentage of cells continued to express the transgene at Day 60 (for the eGFP-C1 
population means of 0.3% from flow cytometry and 1.25 ± 0.4% from the 
immunostaining cell counts; and for the pEPI-eGFP population means of 2.3% from the 
flow cytometry and 0% from the immunostaining cell counts), and that the mean 
percentage of positive cells in the eGFP-C1 transfected population was significantly 
higher than that in the pEPI-eGFP transfected population (P = 0.04).  This is illustrated 
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by the representative immunostaining images in Figure 3.3 which show the decline 
observed in eGFP positive cells over time in both transfected populations. 
Figure 3.4 shows the mean fluorescence intensity of the eGFP-C1 and pEPI-eGFP 
transfected populations, which is an indication of the mean level of transgene 
expression resulting from the transfected vector in each population. In taking the flow 
cytometry data shown for Day 1 with the data shown by immunostaining images, 
which were all taken at the same exposure, there was evidence to suggest that there 
was a higher proportion of eGFP-C1 transfected cells that produced more transgene 
product per cell than was produced by pEPI-eGFP transfected cells. In the 
immunostaining images this can be subjectively noted by the brightness and colour 
intensity of the positive cells (Figure 3.3).  
Figure 3.4 shows that the mean fluorescence intensity of the eGFP positive cells 
declined in the eGFP-C1 population between Days 1 and 21, but remained similar 
between Days 21 to 60; and in the pEPI-eGFP population the mean fluorescence 
intensity declined from Day 1 to Day 60, which would indicate a decrease in the 
amount of transgene expressed per cell over time. The representative immunostaining 
images were also in support of this as the brightness and intensity of the positive cells 
at Day 21 and Day 60 in both populations were less than those observed in the Day 1 
images, as was also subjectively observed (Figure 3.3).  
Total eGFP fluorescence is an indication of the total amount of eGFP expressed in a 
given population of transfected cells. This is calculated by multiplying the mean 
percentage of eGFP positive cells by the mean fluorescence intensity. Figure 3.5 shows 
that an evident decline had occurred in the total amount of transgene expressed in 
both the eGFP-C1 and pEPI-eGFP transfected populations from Day 1 to Day 21, and a 
further decrease between Days 21 and 60. 
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Figure 3.2(a) Mean percentages ± SEM (error bars) of eGFP positive cells derived from cell counts of 
immunostaining images of HeLa cells transfected with eGFP-C1 or pEPI-eGFP vector at 24 hours post 
transfection (Day 1), the final day of selection after a 21 day selection period (Day 21), and the 39
th
 day 
of proliferation without any selective pressure post-selection (Day 60). The values above each bar 
indicate the percentage of positive cells. The chart shows that the transfection efficiencies of the two 
vectors in this experiment were relatively high and comparable to one another before significantly 
declining from Day 1 to Day 60, but there were significantly more positive cells in the eGFP-C1 
transfected population at Day 60 than in the pEPI-eGFP population. n = 3. 
 
 
Figure 3.2(b) Flow cytometry analysis of the percentage of eGFP positive HeLa cells transfected with 
eGFP-C1 or pEPI-eGFP vector at 24 hours post transfection (Day 1), the final day of selection after a 21 
day selection period (Day 21), and the 39
th
 day of proliferation without any selective pressure post-
selection (Day 60), where 1x10
5
 cells were analysed per sample. A decline in the percentage of eGFP 
positive cells with time was evident in both the eGFP-C1 and pEPI-eGFP transfected populations. 
114 
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pEPI-eGFP
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Figure 3.3 eGFP immunostaining of fixed HeLa cells transfected with eGFP-C1 or pEPI-eGFP vector at 24 
hours post transfection (Day 1) (images A and B, respectively), the final day of selection after a 21 day 
selection period (Day 21) (images C and D, respectively), and the 39
th
 day of proliferation without any 
selective pressure post-selection (Day 60) (images E and F, respectively). The negative control was 
untransfected HeLa cells stained for eGFP (image G). Green indicates eGFP positive cells and blue is the 
DAPI staining of the nuclei. These images are visual representations of the eGFP positive cells of the 
transfected populations and support the flow cytometry and cell counting data. A qualitative 
observation of the positive cells of the eGFP-C1 transfected cells at Day 1 is they were brighter and 
fluoresced more intensely than those of the pEPI-eGFP transfected cells, indicating higher transgene 
expression in eGFP-C1 transfected cells. The Day 21 images show a decrease in brightness and 
fluorescence of positive cells of both transfected populations, and a decrease in the amount of positive 
cells. By Day 60 no eGFP positive cells could be detected in the pEPI-eGFP transfected population. Bar, 
90µm. 
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 Figure 3.4 Flow cytometry analysis of the mean fluorescence intesity of eGFP positive HeLa cells 
transfected with eGFP-C1 or pEPI-eGFP vector at 24 hours post transfection (Day 1), the final day of 
selection after a 21 day selection period (Day 21), and the 39
th
 day of proliferation without any selective 
pressure post-selection (Day 60), where 1x10
5
 cells were analysed per sample. The values above the 
bars are the exact MFI values. These data suggest that on average the eGFP-C1 transfected cells 
produced more transgene product per cell than pEPI-eGFP transfected cells at Day 1. It also suggests 
that the mean fluorescence intensity declined in the eGFP-C1 population between Days 1 and 21, but 
remained similar between Days 21 to 60. In the pEPI-eGFP population the mean fluorescence intensity 
declined from Day 1 to Day 60, which would indicate a decrease in the amount of transgene expressed 
per cell over time. 
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Figure 3.5 Flow cytometry analysis of the total eGFP fluorescence of HeLa cells transfected with eGFP-C1 
or pEPI-eGFP vector at 24 hours post transfection (Day 1), the final day of selection after a 21 day 
selection period (Day 21), and the 39
th
 day of proliferation without any selective pressure post-selection 
(Day 60), where 1x10
5
 cells were analysed per sample. The data indicates a decline in the total amount 
of eGFP transgene expression in both transfected populations over time. 
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3.2.3.2 Expression Analysis of C2C12 Cell Populations Transfected With 
eGFP-C1, pEPI-eGFP, or pEPI-M18 
 
Figure 3.6 shows the mean percentages ± the standard error of the mean (SEM) (n = 3) 
of positive cells in the transfected populations as found by cell counts from the 
immunostaining images (a), and the mean percentages of eGFP positive cells as 
measured by flow cytometry (b). Figure 3.6 (a) indicates that the transfection 
efficiency of the eGFP-C1 vector was the highest of the three vectors, followed by the 
pEPI-M18 vector, and finally the pEPI-eGFP vector which had the lowest efficiency in 
this experiment, according to the percentage of positive cells counted from the 
immunostaining images (means of 25.5± 1.6%, 20 ± 1.1%, and 10.8 ± 0.7% positive 
cells, respectively; P = 0.0033). Figure 3.6 (b) flow cytometry data supports the 
conclusion that pEPI-eGFP had a lower transfection efficiency than both the other 
plasmids (means of 37% positive cells in the eGFP-C1 transfected population, 42.1% for 
pEPI-M18, and 25.4% for pEPI-eGFP).  
A decline was observed in the percentage of eGFP positive cells in each transfected 
population over time. On the final day of selection at Day 21 a decline in mean 
percentages of positive cells was observed from Day 1, which would indicate that there 
was a decrease in the amount of transgene expression per cell over time, or the loss of 
the vector from the cells that were transfected. The data also showed that on Day 21 
the eGFP-C1 transfected population had a significantly higher mean percentage of 
positive cells than the pEPI-M18 and pEPI-eGFP transfected populations (means of 13.3 
± 2.1%, 4 ± 1.2%, and 0% respectively as indicated by cell counting; P = 0.0088). The 
mean percentages decreased further in all three populations by Day 60, where the 
only population that still contained positive cells was the eGFP-C1 transfected 
population (mean of 2 ± 0.8% as indicated by cell counting). However, the mean 
percentage of positive cells within the eGFP-C1 population was significantly greater 
than that of the pEPI-M18 and pEPI-eGFP transfected populations at Day 60 (P = 
0.038).  
The decrease in mean percentage of positive cells was also shown by the flow 
cytometry data (at Day 21 means of 28.7% in the eGFP-C1 population, 4.9% in the 
pEPI-M18 population, 5.1% in the pEPI-eGFP population, and at Day 60 means of 0.9%, 
0.3%, and 1.7% respectively). Consistent with the charts were the immunostaining 
118 
 
images, illustrative of each transfected population at each time point (Figure 3.7), 
which were all taken at the same exposure and also indicated the decline observed in 
eGFP positive cells over time in the three populations. 
Figure 3.8 shows the mean fluorescence intensities of the eGFP positive cells of the 
eGFP-C1, pEPI-eGFP, and pEPI-M18 transfected populations as measured by flow 
cytometry. The data suggests that on Day 1 the eGFP-C1 and pEPI-M18 transfected 
populations had similar mean expressions, and that on average, cells in these two 
populations produced more transgene product per cell than those in the pEPI-eGFP 
transfected cells. The immunostaining images, suggest that there was a higher 
proportion of pEPI-M18 transfected cells that produced more transgene product per 
cell than eGFP-C1 or pEPI-eGFP transfected cells at Day 1, as was subjectively judged 
by the brightness and colour intensity of the positive cells (see Figure 3.7) 
Figure 3.8 also indicates that the mean fluorescence intensity declined with time in all 
three transfected populations, which would indicate a decrease in the amount of 
transgene expressed per cell over time. The immunostaining images could only 
support this in the case of the pEPI-M18 transfected population where the intensity of 
the positive cells was, subjectively, lower at Day 21 than at Day 1. No difference in 
intensity was apparent in the case of the eGFP-C1 transfected population from Day 1 
to Day 21, however both the flow cytometry and the immunostaining images suggest 
that the expression in the positive cells of the eGFP-C1 population at Day 21 was 
greater than that in the positive cells of the pEPI-M18 transfected population. No 
positive cells were detected by Day 21 in the pEPI-eGFP transfected population by 
immunostaining. However, the fact that the flow cytometry data showed that positive 
cells were still present within each population at Day 60, yet the immunostaining 
showed that by Day 60 positive cells could only be detected in the eGFP-C1 transfected 
population, indicates that the positive cells of the eGFP-C1 population did have the 
highest mean fluorescence intensity of the three transfected populations at Day 60. 
The total eGFP fluorescence is shown in Figure 3.9 and, not surprisingly, shows an 
evident decline in the total amount of transgene expressed in all three transfected 
populations over time. 
C2C12 cells have the ability to differentiate and fuse into myotubes when grown under 
low serum medium. In order to investigate the effects differentiation may have upon 
the expression of the transgene, 5x104 cells were isolated from each transfected 
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population at the three time points (Day1, 21, and 60) and seeded into 1cm2 chamber 
slide wells. The cells were differentiated by changing the medium to differentiation 
medium for 5 days (as described in Chapter 2: Materials & Methods). The cells were 
then fixed in 1% PFA/PBS and immunostained for eGFP. The images obtained 
illustrated that faintly eGFP positive myotubes were detected in the pEPI-eGFP 
transfected population at Day 21 (Figure 3.10) where no positive myoblasts had been 
observed prior to differentiation (Figure 3.7). Yet, the decline in expression was still 
evident for all three populations where fewer positive myotubes were present in the 
eGFP-C1 transfected population and no positive myotubes were detected in the pEPI-
eGFP or pEPI-M18 populations at Day 60, as was the case with the undifferentiated 
myoblasts.    
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Figure 3.6(a) Mean percentages ± SEM (error bars) of eGFP positive cells derived from cell counts of 
immunostaining images of C2C12 cells transfected with eGFP-C1, pEPI-eGFP, or pEPI-M18 vector at 24 
hours post transfection (Day 1), the final day of selection after a 21 day selection period (Day 21), and 
the 39
th
 day of proliferation without any selective pressure post-selection (Day 60). The values above 
the bars indicate the mean percentage of eGFP positive cells. The chart shows that the transfection 
efficiency of the eGFP-C1 vector was the highest of the three vectors, followed by the pEPI-M18 vector, 
and finally the pEPI-eGFP vector which had the lowest efficiency in this experiment. A significant decline 
in the percentage of positive cells was evident by Day 21 for all three transfected populations. n = 3. 
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Figure 3.6(b) Flow cytometry analysis of the percentage of eGFP positive C2C12 cells transfected with 
eGFP-C1, pEPI-eGFP, or pEPI-M18 vector at 24 hours post transfection (Day 1), the final day of selection 
after a 21 day selection period (Day 21), and the 39
th
 day of proliferation without any selective pressure 
post-selection (Day 60), where 1x10
5
 cells were analysed per sample. The values above the bars indicate 
the mean percentage of eGFP positive cells. A decline in the percentage of eGFP positive cells with time 
was evident in all three transfected populations. 
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Figure 3.7 eGFP immunostaining of C2C12 cells transfected with eGFP-C1, pEPI-eGFP, or pEPI-M18 
vector at 24 hours post transfection (Day 1) (images A, B, and C, respectively), the final day of selection 
after a 21 day selection period (Day 21) (images D, E, and F, respectively), and the 39
th
 day of 
proliferation without any selective pressure post-selection (Day 60) (images G, H, and I, respectively). 
The negative control was untransfected C2C12 cells stained for eGFP (image J). Green indicates eGFP 
positive cells and blue is the DAPI staining of the nuclei. A qualitative observation of the positive cells of 
the pEPI-M18 transfected cells at Day 1 is they were brighter and fluoresced more intensely than those 
of the eGFP-C1 and pEPI-eGFP transfected cells indicating higher transgene expression in those cells. 
The staining also shows a decrease in the number of positive cells in all three transfected populations 
from Day 1 to Day 60. Bar, 90µm. 
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Figure 3.8 Flow cytometry analysis of the mean fluorescence intensities of eGFP positive C2C12 cells 
transfected with eGFP-C1, pEPI-eGFP, or pEPI-M18 vector at 24 hours post transfection (Day 1), the final 
day of selection after a 21 day selection period (Day 21), and the 39
th
 day of proliferation without any 
selective pressure post-selection (Day 60), where 1x10
5
 cells were analysed per sample. The values 
above the bars are the exact values of mean fluorescent intensity. These data suggest that eGFP-C1 and 
pEPI-M18 transfected cells produced similar amounts of eGFP per cell, and that there was a higher 
proportion of cells in these two transfected populations that produced more transgene product per cell 
than pEPI-eGFP transfected cells at Day 1. It also suggests that the mean fluorescence intensity declined 
from Day 1 to Day 60 in all three transfected populations, which would indicate a decrease in the 
amount of transgene expressed per cell over time. 
 
 
124 
 
 
Figure 3.9 Flow cytometry analysis of the total eGFP fluorescence of eGFP positive C2C12 cells 
transfected with eGFP-C1, pEPI-eGFP, or pEPI-M18 vector at 24 hours post transfection (Day 1), the final 
day of selection after a 21 day selection period (Day 21), and the 39
th
 day of proliferation without any 
selective pressure post-selection (Day 60), where 1x10
5
 cells were analysed per sample. The values 
above the bars indicate the total eGFP fluorescence.The data indicates a large decline in the total 
amount of eGFP transgene expression in all three transfected populations over time. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
125 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 eGFP immunostaining of C2C12 cultures transfected as myoblasts with eGFP-C1, pEPI-eGFP, 
or pEPI-M18 vector and differentiated into myotubes under differentiation medium for 5 days prior to 
fixing and staining. The transfected populations were differentiated at three time points. Day 1 indicates 
the eGFP-C1, pEPI-eGFP, and pEPI-M18 transfected populations that were put into differentiation 
medium 24 hours post transfection (images A, B, and C, respectively), Day 21 indicates the populations 
that were put under differentiation medium on the final day of selection after a 21 day selection period 
(images D, E, and F, respectively), and Day 60 indicates the populations that were put into 
differentiation medium on the 39
th
 day of proliferation without any selective pressure post-selection 
(images G, H, and I, respectively). The negative control was untransfected C2C12 myotubes (image J). 
Green indicates eGFP positive cells and blue is the DAPI staining of the nuclei. The images show the 
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presence of eGFP positive myotubes in each transfected population at Day 1 and at Day 21. At Day 60 
eGFP positive myotubes were detected in the eGFP-C1 transfected population but not in the pEPI-eGFP 
or the pEPI-M18 transfected cells, where expression had been silenced or was expressed at levels too 
low to be detected by this method. Bar, 90µm. 
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3.2.3.3 Expression Analysis of HepG2 Cell Populations Transfected With 
eGFP-C1 or pEPI-eGFP 
 
Figure 3.11 shows the mean percentages ± the standard error of the mean (SEM) (n = 
3) as found by cell counts of the immunostaining images (a) and the mean percentages 
of eGFP positive cells within the populations as indicated by flow cytometry (b). The 
Day 1 data shown in Figure 3.11 (a) indicate that  the transfection efficiency of the 
eGFP-C1 vector was similar to that of the pEPI-eGFP vector in this experiment (means 
of 32 ± 3.2% and 23.8 ± 0.5% positive cells, respectively; P = 0.07). However, Figure 
3.11 (b) flow cytometry data suggests that the transfection efficiency of eGFP-C1 was 
higher (mean of 14.8% positive cells in the eGFP-C1 transfected population and 2.8% 
for pEPI-eGFP).  
An increase was observed in the mean percentage of eGFP positive pEPI-eGFP 
transfected HepG2 cells over time. The cell counting data showed an from Day 1 to 
Day 21 (mean of 47.3 ± 2% at Day 21) and a further increase between Days 21 and 120 
(mean of 64.3 ± 3.9% at Day 120). This finding was supported by the flow cytometry 
data (mean of 44.9% at Day 21 and 60.6% at Day 120) and the immunostaining images 
where the increase in the proportion of positive cells can be noted (see Figure 3.12). 
This trend was not observed in the eGFP-C1 transfected cells where the cell counting 
data showed that the mean percentage of positive cells in this population decreased 
from Day 1 (mean of 2 ± 0.6% at Day 21, and of 0% at Day 120), and that these values 
were significantly lower than those of the pEPI-eGFP transfected population at Days 21 
and 120 (P = 0.0001). The flow cytometry data did not suggest a decline between Days 
1 and 21 of the positive cells in the eGFP-C1 transfected population (mean of 14.8% 
positive cells at Day 1 and of 17.7% at Day 21) but did between Days 21 and 120 (mean 
of 2.3% at Day 120). The immunostaining images were also illustrative of this observed 
decline in the eGFP-C1 population see (Figure 3.12). 
In contrast to the case with the HeLa and C2C12 experiments, it was noted here that 
the percentages of positive cells quantified by cell counting of immunostained cell 
images were greater than those percentages obtained by flow cytometry analysis.  
Figure 3.13 shows the mean fluorescence intensity of the eGFP positive cells of the 
eGFP-C1 and pEPI-eGFP transfected populations as measured by flow cytometry. The 
data suggests that the eGFP-C1 transfected cells expressed more transgene per cell, on 
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average, than the pEPI-eGFP transfected cells throughout the entire period of the 
experiment. It also suggests that the mean fluorescence intensity continually increased 
in both populations from Day 1 until Day 120. The immunostaining images, which were 
all taken at the same exposure, suggest that the eGFP-C1 transfected cells did express 
a larger amount of transgene than the pEPI-eGFP transfected cells at Day 1. The 
images also show, subjectively, an increase in intensity in the pEPI-eGFP cells when 
comparing Day 1 to Day 120.  
The total eGFP fluorescence is shown in Figure 3.14 and indicates a considerable 
increase in the total amount of transgene expressed in the pEPI-eGFP transfected 
population over time, which was not noted in the eGFP-C1 transfected population, 
where a decline was seen between Days 21 and 120. 
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Figure 3.11(a) Mean percentages ± SEM (error bars) of eGFP positive cells derived from cell counts of 
immunostaining images of HepG2 cells transfected with eGFP-C1 or pEPI-eGFP vector at 24 hours post 
transfection (Day 1), the final day of selection after a 21 day selection period (Day 21), and the 99
th
 day 
of proliferation without any selective pressure post-selection (Day 120). The chart shows that the 
transfection efficiency of eGFP-C1 was similar to that of pEPI-eGFP. An increase was observed in the 
pEPI-eGFP transfected cells from Day 1 to Day 21 and a further increase between Days 21 and 120, 
whereas a decrease was shown in the eGFP-C1 transfected and the mean percentages were significantly 
lower than those of the pEPI-eGFP transfected populations at Days 21 and 120. n = 3. 
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Figure 3.11(b) Flow cytometry analysis of the percentage of eGFP positive HepG2 cells transfected with 
eGFP-C1 or pEPI-eGFP vector at 24 hours post transfection (Day 1), the final day of selection after a 21 
day selection period (Day 21), and the 99
th
 day of proliferation without any selective pressure post-
selection (Day 120), where 1x10
5
 cells were analysed per sample. The data suggests that the 
transfection efficiency of the eGFP-C1 vector was higher than that of the pEPI-eGFP vector in this 
experiment. An increase was observed in the mean percentage of eGFP positive pEPI-eGFP transfected 
HepG2 cells over time, whereas a decrease had occurred in the eGFP-C1 transfected cells between Days 
1 and 120. 
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Figure 3.12 eGFP immunostaining of fixed HepG2 cells transfected with eGFP-C1 or pEPI-eGFP vector at 
24 hours post transfection (Day 1) (images A and B, respectively), the final day of selection after a 21 day 
selection period (Day 21) (images C and D, respectively), and the 99
th
 day of proliferation without any 
selective pressure post-selection (Day 120) (images E and F, respectively). The negative control was 
untransfected HepG2 cells stained for eGFP (image G). Green indicates eGFP positive cells and blue is 
the DAPI staining of the nuclei. These images are visual representations of the eGFP positive cells of the 
transfected populations and support the flow cytometry and cell counting data. A subjective observation 
is that the eGFP-C1 transfected positive cells fluoresce more intensely than the pEPI-eGFP transfected 
positive cells at Day 1. The eGFP-C1 images (top row) indicate a decline in the amount of eGFP positive 
cells over time. The pEPI-eGFP images (second row) show that the amount of positive cells increased 
from Day 1 to 21, and again from Day 21 to 120. Bar, 90µm. 
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Figure 3.13 Flow cytometry analysis of the percentage of eGFP positive HepG2 cells transfected with 
eGFP-C1 or pEPI-eGFP  vector at 24 hours post transfection (Day 1), the final day of selection after a 21 
day selection period (Day 21), and the 99
th
 day of proliferation without any selective pressure post-
selection (Day 120), where 1x10
5
 cells were analysed per sample. The data suggests that the eGFP-C1 
transfected cells expressed more transgene per cell, on average, than the pEPI-eGFP transfected cells 
throughout the entire period of the experiment. It also suggests that the mean fluorescence intensity 
continually increased in both populations from Day 1 until Day 120. 
 
 
 
Figure 3.14 Flow cytometry analysis of the percentage of eGFP positive HepG2 cells transfected with 
eGFP-C1 or pEPI-eGFP vector at 24 hours post transfection (Day 1), the final day of selection after a 21 
day selection period (Day 21), and the 99
th
 day of proliferation without any selective pressure post-
selection (Day 120), where 1x10
5
 cells were analysed per sample. The data shows a considerable 
increase in the total amount of transgene expressed in the pEPI-eGFP transfected population over time, 
which was not noted in the eGFP-C1 transfected population. 
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3.2.4 Investigation OF Episomal/Integrant Status Of Transfected Vectors In 
C2C12 Cells By Southern Blotting 
 
Southern blotting is a method used to detect specific DNA sequences and can confirm 
whether a vector has remained in an episomal status or has integrated into the host 
genome. The kit used was the Amersham ECL Direct Nucleic Acid Labelling and 
Detection Kit. This involved the direct labelling of the DNA probe generated by PCR of 
the eGFP gene (probe size 503bp) with Horseradish Peroxidase (HRP) enzyme. The 
labelled probe was then hybridised to complementary sequences on the blot and 
detected by the addition of HRP’s substrate, luminol, upon which the breakdown leads 
to the release of light. This light was captured on autoradiography film (Materials & 
Methods).  
Southern blotting was conducted on C2C12 cells transfected with eGFP-C1 or pEPI-
eGFP plasmid. Samples were taken at Days 1, 7, 21, 30, 40, and 60 and tested. 15µg of 
total extracted DNA from each sample was digested overnight with EcoRI and loaded 
per lane. A band at 6.7kb, which is the size of pEPI-eGFP, can be seen in each lane from 
Day 1 to Day 40, and a 4.7kb band for eGFP-C1 could be seen from Day 1 to Day 30 
(Figure 3.15).  The blot indicates that a greater number of copies of pEPi-eGFP 
persisted in the C2C12 cells for more cell divisions than the eGFP-C1 plasmid as an 
episome. No evidence of integration was detected for either population of cells at any 
time point. However, the method was not sensitive enough to detect any plasmid 
sequence at Day 60, and it is clear that copies were present within each population as 
was shown in the PCR results. Therefore this method may not be able to detect 
integration if it had occurred at a low frequency in a small percentage of the cells. For 
this reason, a more sensitive method was required. 
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Figure 3.15 Southern blot conducted on C2C12 cells transfected with eGFP-C1 or pEPI-eGFP plasmid. 
Samples were taken at Days 1, 7, 21, 30, 40, and 60 post-transfection. 15µg of total extracted DNA from 
each sample was digested overnight with EcoRI and loaded per lane. A 6.7kb sized band can be seen in 
each pEPI-eGFP lane from Day 1 to Day 40, and a 4.7kb sized band in each eGFP-C1l lane from Day 1 to 
Day 30.  The blot indicates that pEPI-eGFP persists in C2C12 cells for more cell divisions than eGFP-C1 as 
an episome. No evidence of integration can be detected for either population of cells at any time point. 
However, this method is not sensitive enough to detect the presence of the vector copies, as integrants 
or as episomes, at Day 60. 
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3.2.5 Investigation oF Episomal/Integrant Status of Transfected Vectors In 
C2C12 Cells By Plasmid Rescue 
 
Plasmid rescue is conducted by the extraction of the total gnomic DNA of a sample and its 
transformation it into bacteria, which are then plated onto selective agar (Materials & 
Methods). The appearance of colonies indicates the presence of plasmid within the sample 
that was transformed and denotes the episomal status of a vector. It does not, however, 
negate nor confirm integration if it occurs. 1µg of total genomic DNA extracted from eGFP-C1- 
and pEPI-eGFP-transfected samples taken at Days 1, 7, and 21 and electroporated into XL-1 
Blue E.coli. The eGFP-C1 sample at Day 1 yielded 8000 colonies and the pEPI-eGFP sample at 
Day 1 yielded 3200 colonies. The eGFP-C1 sample collected on Day 7 had 2424 colonies and 
the pEPI-eGFP sample had 26. At Day 21 no colonies could be detected from either the eGFP-
C1 or pEPI-eGFP sample (Figure 3.16). This indicates either integration of the plasmids into 
C2C12 host genome, or the reduction of the plasmid copy number per cells to a level 
undetectable by this method. Considering no colonies were detected beyond Day 21, this 
method was found not to be suitable for the purposes of this experiment as it was not 
sensitive enough. 
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(A) eGFP-C1 
 
   
 
(B) pEPI-eGFP 
 
 
Figure 3.16 Kanamycin agar plates showing XL-1 Blue E.coli colonies that had been transformed by 
electroporation with 1µg of genomic DNA extracted from C2C12 cells transfected with eGFP-C1 plasmid 
(A) or pEPI-eGFP plasmid (B) from samples collected at Day 1, Day 7, and Day 21 post-transfection. Both 
plasmids appear to be lost at a very high rate and cannot be detected by 21 days post-transfection 
despite Day 21 being the last day of selection. 
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3.2.6 Hypothetical Calculation of Plasmid Copy Number to Determine 
Experimental Sensitivity Required to Detect Episomal Copies Within the 
C2C12 Populations At Day 60  
 
It is clear that the sensitivity of Southern blotting and plasmid rescue used in this 
chapter have proven insufficient for the purpose of detecting the vector sequence, 
episomal or integrated in status, in the multiclonal populations transfected and tested. 
No vector sequences could be detected by the final day of the experiment although 
the data from the flow cytometry analysis indicated that some cells in the samples 
continued to express eGFP, in addition to the PCR data which clearly showed that 
copies of the vector sequences initially transfected were present within some cells of 
the populations.  
An analysis was performed here which calculated the hypothetical number of plasmid 
copies that may be found in the transfected populations by the end of the experiment. 
The number of copies can then be converted to an amount in grams, which would 
indicate the experimental sensitivity required to detect episomes. The calculations for 
the analysis require a number of assumptions. The first is that the number of cells 
containing the episomal vector was the percentage observed by flow cytometry, so if 
1.7% of cells proved eGFP positive in the pEPI-eGFP-transfected C2C12 cells, then it 
was assumed that that was the proportion of cells still carrying the vector. The second 
assumption was that each of the positive cells had an average of 8 plasmid copies per 
cell. This was based on previous studies which had reported average copy numbers to 
be 2.5-13 per cell (Schaarschmidt et al in 2004, Papapetrou et al 2006), therefore 8 was 
chosen as the average. Further, the size of the mouse genome was estimated to be 
2.7x109 bp, respectively (www.genome.gov National Human Genome Research 
Institute). 
The calculations were conducted is as follows: 
C2C12 cells are of murine origin, therefore the size of the genome per cell is 2.7x109 
bp. If 15µg were used per sample for Southern Blotting, this would be the equivalent 
to using the collective DNA of 4.49x106 cells. This was calculated according to the 
following formula: 
# of DNA molecules = ((total amount of DNA (ng)) x (6.022x1023 molecules/mole)) 
                                     ((length of DNA molecule (bp) x (1x109) x 650) 
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The number 6.022x1023 is Avogadro’s constant. This is the number of molecules 
present in one mole. The number 650 represents the average weight of 1 base pair in 
double stranded DNA. In order to find the molecular weight of a double stranded DNA 
molecule, the weight of one base pair is multiplied by the number of base pairs of the 
molecule. In order to calculate the number of moles per gram from the molecular 
weight of a molecule, the inverse of this value is taken and multiplied by 1x109 in order 
to obtain the answer in nanograms. It was calculated that 0.005ng, or 5.05pg, of pEPI-
eGFP would be present per 15µg of total DNA, therefore the sensitivity of the Southern 
blot would have been required to be in the scale of picograms, and considering 
plasmid rescue required only 1µg of total DNA, its sensitivity would need to be in the 
femtograms.  
The values were calculated for the S/MAR populations only since these were the 
populations that contained the highest percentages of eGFP positive cells by the final 
day of the experiment and would therefore theoretically contain the largest amount of 
vector sequence copies. As can be seen, the amounts are very low and would not be 
possible to detect using the Southern blotting or plasmid rescue methods employed. It 
is clear that with multiclonal populations there is a greater difficulty in detecting the 
vector than if a single clone was picked and grown, where the same integration events 
would be present in each cell.  
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3.2.7 Investigation OF Episomal/Integrant Status Of Transfected Vectors In 
HeLa, C2C12, and HepG2 Final Day Samples By Fluorescent In-Situ 
Hybridisation (FISH) Analysis  
 
FISH was used to determine the episomal and/or integrant status of the transfected 
vectors, as conducted in several other S/MAR vector studies (Stehle et al., 2007; Baiker 
et al., 2000). Samples of 1x105 cells were taken from each transfected population at 
the final day of the experiment (Day 60 for HeLa and C2C12 and Day 120 for HepG2 
transfected populations) and were arrested at metaphase to yield condensed 
chromosomal structures. The cells were fixed and dropped onto aged slides to burst 
the nuclei and expose the DNA, which was then probed for the transfected vector 
sequences. The probe was generated by random priming using eGFP-C1 as a template, 
where dTTPs were in direct competition with labelled dUTP, thus resulting in labelled 
probes in a range of sizes (as described in Chapter 2: Materials & Methods). Following 
hybridisation and washing, the bound probe was visualised directly by fluorescence 
microscopy at 100X magnification. Probe detected around the chromosomes or 
associated with them indicate episomal status of the vector. Probe detected at the 
same position on both arms of a chromosome suggest integration of the vector into 
the host genome, as sister chromatids of a chromosome are replicates of each other 
and the probe would therefore bind at the same position on both chromatids. 
However, the possibility that the plasmid sequence preferentially binds to certain 
sequences present on both arms of each chromatid also cannot be excluded, therefore 
any evidence towards integration that is detected must remain potential. Also, the 
stronger the signal, the more probe is bound, which indicates a larger amount of 
plasmid sequence present.  
An average of 50 spreads were analysed, and of those, 5-10 positive spreads were 
found and analysed for each sample. Of the positive spreads, the number of integrated 
spreads, if present, was counted. The negative controls in this experiment were 
untransfected HeLa, C2C12, and HepG2 cells (Figures 3.17 (C), 3.19 (C), and 3.21 (C), 
respectively). The positive controls used for this experiment were HeLa (Figure 3.17 (A) 
and (B)), C2C12 (Figure 3.19 (A) and (B)), and HepG2 (Figure 3.21 (A) and (B)) cells 24 
hours post transfection with eGFP-C1 or pEPI-eGFP plasmid. From the images taken 
under the fluorescence microscope it can be seen that a large amount of plasmid was 
present within the positive control cells, as the fluorescence signal emitted was very 
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strong. It is also clear that much of the plasmid observed was clustered together. A 
subjective observation is that eGFP-C1 transfected HeLa, C2C12, and HepG2 cells more 
effectively than pEPI-eGFP, as the amount of signal spots emmiting fluorescence in the 
eGFP-C1 images was greater than those seen in the pEPI-eGFP images in all three cell 
lines. 
FISH analysis on the Day 60 sample of the HeLa cells transfected with eGFP-C1 or pEPI-
eGFP suggests that pEPI-eGFP remained present as an episome, with no evidence of 
integration (0/6 spreads) (Fig. 3.18 (A)). eGFP-C1 appears to have integrated into the 
genome of transfected HeLa cells (1/6 spreads), however episomal copies of the vector 
were also present (Figure 3.18 (B)).  
FISH analysis on Day 60 of the C2C12 cells transfected with eGFP-C1, pEPI-eGFP, or 
pEPI-M18 indicates that pEPI-eGFP remained present as an episome with no evidence 
of integration (0/6 spreads) (see Figure 3.20 (A)), whereas eGFP-C1 (see Figure 3.20 
(B)) and pEPI-M18 (see Figure 3.20 (C)) vectors had been found on duplicate arms of 
the same chromosome, which suggested integration into the host genome (5/7 in the 
eGFP-C1 transfected population and 3/8 in the pEPI-M18 transfected population), in 
addition to episomal copies of both vectors being present. 
FISH analysis on Day 120 of the HepG2 cells transfected with the pEPI-eGFP or eGFP-C1 
showed no evidence of integration of either vector into the host genome (0/6 and 0/5 
spreads, respectively), and episomal copies of the vectors were present within positive 
cells (see Figure 3.22 (A) and (B), respectively). A subjective observation was that the 
pEPI-eGFP transfected positive cells contained a greater amount of episomal copies of 
the vector pEPI-eGFP at Day 120 in comparison to the amount of eGFP-C1 episomal 
copies in the eGFP-C1 transfected positive cells.   
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(A) HeLa cells 24 hr after transfection with pEPI-eGFP 
 
(B) ) HeLa cells 24 hr after transfection with eGFP-C1 
 
(C)HeLa cells untransfected 
 
 
Figure 3.17 Fluorescent In-Situ Hybridisation positive controls of HeLa cells 24 hours post transfection 
with pEPI-eGFP (A) or eGFP-C1 (B) vector. Vector copies can be seen as the bright red fluorescing spots, 
and genomic DNA is blue as it was counterstained with Dapi. The vector was seen as mostly clustered 
together and associated with the chromosomes. There was, subjectively, a greater amount of eGFP-C1 
vector present within the eGFP-C1 transfected cells than there was pEPI-eGFP vector present within the 
pEPI-eGFP transfected cells. Image (C) was the negative control of untransfected HeLa cells. Bar, 5µm.
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Transfected HeLa Cells Day 60 
(A) pEPI-eGFP 
 
 
(B) eGFP-C1 
 
 
 
 
Figure 3.18 Fluorescent In-Situ Hybridisation of HeLa cells transfected with pEPI-eGFP (A) or eGFP-C1 
vector (B), Day 60 samples tested. Genomic DNA is counterstained with Dapi (blue). Image (A) shows 
that pEPI-eGFP is present as an episome with no evidence of integration. Image (B) suggests integration 
of eGFP-C1 into the HeLa host genome (1 out of 6 spreads), in addition to being retained as an episome. 
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(A) C2C12 cells 24 hr after transfection with pEPI-eGFP 
 
(B) C2C12 cells 24 hr after transfection with eGFP-C1 
 
(C)C2C12 cells untransfected 
 
Figure 3.19 Fluorescent In-Situ Hybridisation positive controls of C2C12 cells 24 hours post transfection 
with pEPI-eGFP (A) or eGFP-C1 (B) vector. Vector copies can be seen as the bright red fluorescing spots, 
and genomic DNA is blue as it was counterstained with DAPI. The vector was seen as mostly clustered 
together and associated with the chromosomes. There appeared to be a greater amount of eGFP-C1 
vector present within the eGFP-C1 transfected cells than there was pEPI-eGFP vector present within the 
pEPI-eGFP transfected cells. Image (C) was the negative control of untransfected C2C12 cells. Bar, 5µm. 
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Transfected C2C12 cells Day 60: 
(A) pEPI-eGFP 
 
 
(B)eGFP-C1 
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(C)pEPI-M18 
 
 
 
Figure 3.20 Fluorescent In-Situ Hybridisation of C2C12 cells transfected with pEPI-eGFP (A), eGFP-C1 (B), 
or pEPI-M18 vector (C), Day 60 samples tested. Red fluorescent spots indicate where the probe has 
hybridised to plasmid sequence. Genomic DNA is counterstained with DAPI (blue). Image (A) shows 
pEPI-eGFP present as an episome with no evidence of integration (0/6 spreads). Images (B) and (C) 
suggest eGFP-C1 and pEPI-M18 integration onto the C2C12 host genome (5/7 and 3/8 integrant spreads, 
respectively) in addition to some copies being present as episomes. 
 
 
146 
 
(A) HepG2 cells 24 hr after transfection with pEPI-eGFP 
 
(B) HepG2 cells 24 hr after transfection with eGFP-C1 
 
(C)HepG2 cells untransfected 
 
Figure 3.21 Fluorescent In-Situ Hybridisation positive controls of HepG2 cells 24 hours post transfection 
with pEPI-eGFP (A) or eGFP-C1 (B) vector. Vector copies can be seen as the bright red fluorescing spots, 
and genomic DNA is blue as it was counterstained with DAPI. The vector was seen as mostly clustered 
together. There was, subjectively, a greater amount of eGFP-C1 vector present within the eGFP-C1 
transfected cells than there was pEPI-eGFP vector present within the pEPI-eGFP transfected cells. Image 
(C) was the negative control of untransfected HepG2 cells. Bar, 5µm. 
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Transfected HepG2 cells Day 60  
(A) pEPI-eGFP 
 
 
(B)eGFP-C1 
 
 
Figure 3.22 Fluorescent In-Situ Hybridisation of HepG2 cells transfected with pEPI-eGFP (A) and eGFP-C1 
vector (B), Day 60 samples tested. Red fluorescent spots indicate where the probe has hybridised to 
plasmid sequence. Genomic DNA is counterstained with DAPI (blue). Images (A) and (B) show that pEPI-
eGFP and eGFP-C1 were present as episomes with no evidence of integration into the HepG2 host 
genomes (0/5 and 0/6 spreads, respectively). Image (A) suggests that there is a larger number of 
episomes in the pEPI-eGFP transfected cells than the eGFP-C1 transfected cells. 
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3.2.8 Summary of Results: HeLa Cell Line 
 Flow Cytometry 
 
FISH 
 
Vector Day 
PCR Cell 
Counts  
 
(% 
positive 
cells) 
% positive 
cells 
MFI Total 
Immunostaining 
# of Slides 
Indicating 
Integration  
Episomal 
1 √ 50.3 ± 3.4 62.4 91.6 5714.9 ++ 
21 √ 2.3 ± 0.7 9.4 26.7 249.9 + 
eGFP-C1 
60 √ 1.25 ± 0.4 0.3 34.4 9.6 + 
1/6 √ 
1 √ 48.5 ± 4.8 54.5 55.3 3006.1 ++ 
21 √ 4 ± 1.5 18 24.9 448.0 + 
pEPI-eGFP 
60 √ 0 2.3 10.4 23.5 - 
0/6 √ 
 
Table 3.2 Table summarising the results obtained in this chapter for transfected HeLa cells, indicating each vector that was transfected and the time point at which samples were 
extracted and analysed. PCR results are presented where a ‘√’ denotes that the Kanamycin sequence was amplified and a band was present; Cell Counts indicates the percentage 
of positive cells as counted from immunostained images of transfected populations; Flow Cytometry results presented include the percentage of positive cells per transfected 
population, the mean fluorescence intensity (MFI) of the positive cells, and the total amount of expression which was the product of expression and number of positive cells; the 
Immunostaining data is presented by ‘-‘ indicating the absence of positive cells, ‘+’ indicating the presence of less than 10 positive cells, and ‘++’ indicating the presence of more 
that 10 positive cells; the FISH data is presented as the number of slides which suggested an integration event having occurred out of the total number of slides analysed on Day 60 
only, a ‘√’ in the episomal column indicated the presence of episomal copies of the vector observed on the slides, and a ‘-‘ indicates none was observed. 
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3.2.9 Summary of Results: C2C12 Cell Line 
 Flow Cytometry 
 
Immunostaining FISH 
 
Vector Day 
PCR Cell 
Counts 
% 
positive 
cells 
MFI Total Myoblasts Myotubes 
Southern 
Blotting 
Plasmid 
Rescue 
Integrant 
Samples 
Episome 
Present 
1 √ 25.5± 
1.6 
37 59.8 2212 ++ ++ √ √ 
21 √ 13.3 ± 
2.1 
28.7 41.3 1185.3 + ++ √ - 
eGFP-C1 
60 √ 2 ± 0.8 0.9 19.1 17.8 + + - - 
5/7 √ 
1 √ 10.8 ± 
0.7 
25.4 37.6 956.2 + + √ √ 
21 √ 0 5.1 23.3 119.1 - + √ - 
pEPI-
eGFP 
60 √ 0 1.7 15.9 26.6 - - - - 
0/6 √ 
1 √ 20 ± 1.1 42.1 61.4 2582.5 ++ + N/A N/A 
21 √ 4 ± 1.2 4.9 20 98.2 + + N/A N/A 
pEPI-
M18 
60 √ 0 0.3 17.8 5.5 - - N/A N/A 
3/8 √ 
Table 3.3 Table summarising the results obtained in this chapter for transfected C2C12 cells, indicating each vector transfected and the time point at which samples were analysed. 
PCR results are presented where a ‘√’ denotes that the Kanamycin sequence was amplified and a band was present; Cell Counts indicates the percentage of positive cells as 
counted from immunostained images of transfected populations; Flow Cytometry results presented include the percentage of positive cells per transfected population, the mean 
fluorescence intensity (MFI) of the positive cells, and the total amount of expression (the product of expression and number of positive cells); Immunostaining data is shown by ‘-‘ 
indicating no positive cells, ‘+’ indicating the presence of less than 10 positive cells, and ‘++’ indicating more that 10 positive cells; Southern Blotting data is presented as a ‘√’ to 
indicate the presence of a band,‘-‘ to indicate no band, and N/A if the experiment was not conducted with the samples; Plasmid rescue data is shown with a ‘√’ to indicate the 
presence of colonies after transformation, and ‘-‘ to indicate no colonies; FISH data is presented as the number of slides suggesting integration out of the total number of slides 
analysed on Day 60 only, a ‘√’ in the episomal column indicated the presence of episomal copies of the vector observed on the slides, and a ‘-‘ indicates none was observed. 
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3.2.10 Summary of Results: HepG2 Cell Line 
 Flow Cytometry 
 
FISH 
 
Vector Day 
PCR Cell 
Counts  
 
(% 
positive 
cells) 
% positive 
cells 
MFI Total 
Immunostaining 
Integration Episomal 
1 √ 32 ± 3.2 14.8 39.9 592.1 ++ 
21 √ 2 ± 0.6 17.7 57.9 1023.1 + 
eGFP-C1 
120 √ 0 2.3 109 248.5 - 
0/6 √ 
1 √ 23.8 ± 0.5 2.8 15.6 43.8 ++ 
21 √ 47.3 ± 2 44.9 31.1 1394.8 ++ 
pEPI-eGFP 
120 √ 64.3 ± 3.9 60.6 66.2 4012.4 ++ 
0/5 √ 
 
Table 3.4 Table summarising the results obtained in this chapter for transfected HepG2 cells, indicating each vector that was transfected and the time point at which samples were 
extracted and analysed. PCR results are presented where a ‘√’ denotes that the Kanamycin sequence was amplified and a band was present; Cell Counts indicates the percentage 
of positive cells as counted from immunostained images of transfected populations; Flow Cytometry results presented include the percentage of positive cells per transfected 
population, the mean fluorescence intensity (MFI) of the positive cells, and the total amount of expression which was the product of expression and number of positive cells; the 
Immunostaining data is presented by ‘-‘ indicating the absence of positive cells, ‘+’ indicating the presence of less than 10 positive cells, and ‘++’ indicating the presence of more 
that 10 positive cells; the FISH data is presented as the number of slides which suggested an integration event having occurred out of the total number of slides analysed on Day 
120 only, a ‘√’ in the episomal column indicated the presence of episomal copies of the vector observed on the slides, and a ‘-‘ indicates none was observed.
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3.3. Discussion 
 
3.3.1 pEPI-eGFP showed no evidence of integration into HeLa, C2C12, or 
HepG2 host genome  
 
Consistent with other studies conducted, where a β-IFN S/MAR vector was transfected 
into replicating cells and integration of the vector into the host genome was 
investigated (as covered in Chapter 1: Introduction, Section 1.10), the S/MAR vector 
pEPI-eGFP was found not to integrate in the host genome of any of the three cell lines 
tested in this study, indicating that the S/MAR element may have had a protective role 
against integration of the vector. 
 
3.3.2 Levels of transgene expression varied between transfected cells in 
HeLa, C2C12, and HepG2 cells 
 
The expression studies indicated that the levels of expression of the eGFP transgene 
differed between cells of the same line in a population transfected with the same 
vector. In each population, some cells were brightly eGFP fluorescent whereas others 
were barely visibly fluorescent. Where some cells may have contained enough copies 
which led to high levels of eGFP expression, thus making the eGFP more easily 
detectable in positive cells, other cells may have contained such few copies that eGFP 
was not detectable, but the copy number was sufficient for the expression of adequate 
levels of Neomycin resistance gene transcripts, thus conferring resistance and enabling 
survival under selection. This is plausible considering that these transfected 
populations were multiclonal, and is supported by a study by Papapetrou et al where it 
was found that, although an S/MAR episome can be passed down to progeny cells, it is 
not divided amongst them equally, and the equal distribution of episomes between 
daughter cells is not regulated by the cell (Papapetrou et al., 2006). Therefore, where 
vectors had remained episomal, in this case it was the pEPI-eGFP vector in the HeLa, 
C2C12, and HepG2 cells and the eGFP-C1 vector in the HepG2 cells as shown by FISH, 
and the episome numbers were variable between cells, variable total transgene 
expression resulted per cell.  And where the vector sequences were present as 
integrants, in this case the eGFP-C1 and pEPI-M18 vectors in HeLa and C2C12 cells, 
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variable amounts of integration events may have occurred in each cell, also leading to 
variable transgene expression per cell. 
 
3.3.3 The comparison of flow cytomtery to cell counting of eGFP positive 
immunostained cells in HeLa, C2C12, and HepG2 transfected populations  
 
It can be noted that the percentages of positive cells in each HeLa and C2C12 
transfected population, as quantified by cell counting of immunostained cell images, 
varied from those percentages obtained by flow cytometry analysis, as the former 
values were generally found to be lower. Considering that flow cytometry involves the 
use of a detector which is able to detect fluorescence at levels which may not be 
within a range that can be detected by the naked human eye alone, a greater 
percentage of low eGFP-expressing cells can be identified, leading to greater values of 
total positive cells being counted within a population in comparison to those obtained 
by the method of cell counting. However, a different case was observed with the 
HepG2 cells, which may be attributed to the method by which the HepG2 cell type 
grows in culture, differing to that of the HeLa and C2C12 cells. The difference lies in the 
fact that HepG2 cells tend to grow in clumps or tight clusters, as can be observed in the 
immunostained images (see Figure 3.12), and therefore the clusters may have been 
present in the samples being quantified for eGFP positive cells. In a flow cytometer, 
such clusters which contained positive cells may have been quantified as a single cells, 
whereas in cell counts of immunostained images, the DAPI-stained nuclei clearly define 
each individual cell, leading to the quantification of a greater number of positive cells 
within clusters, and hence a greater total percentage of positive cells. 
 
3.3.4 Most eGFP-C1, pEPI-eGFP, and pEPI-M18 transfected cells which 
survived selection were not eGFP positive in transfected HeLa and C2C12 
populations 
 
A decline in the percentage of eGFP positive cells and transgene expression in eGFP-C1 
and pEPI-eGFP transfected Hela cell populations and eGFP-C1, pEPI-eGFP, and pEPI-
M18 transfected C2C12 cell populations was observed over time. This decline was, 
surprisingly, noted from Day 1 to Day 21, after a 21 day period of selection, where 
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100% of cells surviving selection must have contained vector copies so that expression 
of the Neomycin resistance gene was at a level sufficient for survival.  
One factor that may have accounted for the decline observed in eGFP expression in 
the transfected HeLa and C2C12 cells was the status of the transfected vector within 
the cells. If integrated into the genome, as was suggestively the case for the eGFP-C1 
and pEPI-M18 vectors, the site of integration of the vector would have determined the 
levels of expression of the transgene. Schubeler et al explained that when an S/MAR 
was located at a distance of 4kb from the transcription start site within genomic DNA 
expression was sustained, whereas a distance less than 2.5kb led to the suppression of 
gene expression (Schubeler et al., 1996). Therefore, if the vector had integrated into a 
region of euchromatin, where the DNA was frequently transcribed, and was within 
optimal proximity to a genomic S/MAR, leading the vector sequence to be in a position 
easily transcribed by the transcription machinery at the nuclear matrix, then 
expression would have been expected to be high (Schubeler et al., 1996). If it had 
integrated into heavily packaged DNA such as heterochromatin, where expression was 
low and infrequent, and/or at a position that was at a non-optimal distance from a 
genomic S/MAR, then vector transgene expression would have been expected to be 
low (Schubeler et al., 1996).  
In addition to the position of the integrants within the genome, the orientation in 
which the vector had integrated would also have had a significant effect on expression. 
When a plasmid is integrated, certain elements within it may get disrupted as it 
changes from a circular to a linear form. In the case where any part of the Neomycin 
resistance cassette was disrupted by integration and the cells were unable to express 
the gene, these cells would have perished under selection and would have ceased to 
exist within the cell population. Integration that occured where any part of the eGFP 
expression cassette was disrupted, such as the eGFP gene, its promoter, or its 
polyadenylation signal, would have led to the disruption of eGFP transcription, and 
could thus have led to Neomycin resistant cells that did not express eGFP, as eGFP 
expression was not essential for cell survival under selection. 
As for the non-integrating vector pEPI-eGFP, the decline in expression and percentage 
of positive cells can be accounted for differently. This decline had also been observed 
in the study by Papapetrou et al using pEPI-eGFP in K562 and MEL cells (as described in 
Chapter 1: Introduction section 1.10), where low copy numbers of the vector were 
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present within the transfected populations, yet expression levels had declined 
dramatically (Papapetrou, et al., 2006). 
One factor which may have contributed to this was the use of selection. Schubeler et al 
explained that with the use of selection a selection bias is created where cells 
expressing below a threshold level of the protein required for resistance will be 
eliminated, and those where expression is initially very high may have expression 
silenced and would thus also be eliminated from selection (Schubeler et al., 1996). It is 
plausible that the decline in intensity observed in these populations from Day 1 to Day 
21 was due to the elimination of many cells that may have expressed eGFP but did not 
express sufficient Neomycin resistance protein to survive selection, and were thus 
eliminated from the population. 
Another factor may be that the CMV promoter driving eGFP transgene expression had 
been silenced. 
 
3.3.5 CMV promoter may be responsible for transgene silencing in HeLa and 
C2C12 cells 
 
One possibility for the observed decline in eGFP expression despite cell survival 
throughout selection is transgene silencing. The PCR and FISH results showed that 
copies of the vectors were still present within cells of the transfected populations by 
the final day of selection, however the flow cytometry and immunostaining showed 
that a very low proportion of the population were expressing eGFP. Yet, these cells 
were still able to express Neomycin in order to survive selection. This indicated that a 
certain factor was specifically disrupting eGFP transgene expression, which may have 
been a cellular-mediated silencing of the CMV promoter. 
The silencing of gene expression can be a result of the methylation of a promoter by 
mammalian cells, and in this case, the methylation of the CMV promoter driving the 
eGFP transgene. In the study by Argyros et al the CMV promoter was analysed and was 
found to contain 3 main CpG-rich regions which form a 444bp island (Argyros et al., 
2008). In addition to this island were other CpG rich areas within this promoter that 
were equally able to be methylated (Argyros et al., 2008). More disruptive to 
expression is the recruitment of methyl-DNA binding proteins and histone 
deacetylases that can further change chromatin structure and block transcription (as 
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reviewed in Chapter 1: Introduction, Section 1.7.2). Thus methylation and its 
implications may, wholly or in part, be the cause for the observation that a large 
proportion of Neomycin resistent cells were not simultaneously eGFP positive, both in 
cases where vector had or had not integrated. One way to investigate this would have 
been to add 5’-Azacytidine, a methyltransferase inhibitor, to the medium of each cell 
population, at a time point where the cells were still Neomycin resistant but had lost 
eGFP fluorescence, such as several days before the final day of selection. The inhibition 
of DNA methylation would have led to an observable increase in eGFP transgene 
expression if the cause of the repression had been, at least in part, due to the 
methylation of the CMV promoter. 
It has been proposed that CMV promoter activity is meant to be a transient one, and 
that this characteristic is what allows CMV to be so ubiquitously expressed (Mocarski 
et al., 1990). It is also known that the CMV promoter can be downregulated, even 
where stably integrated (Mocarski et al.,1990).  This downregulation is due, at least in 
part, to cellular factors which influence CMV-driven expression, and could have 
contributed to the decline observed in eGFP expression. Different cell types express 
different factors which lead them to express a given transgene at varying efficiencies, 
sometimes as a result of the promoter driving transgene expression. This was shown in 
the study previously described by Papapetrou et al where different types of cells were 
transfected with the same vectors and it was found that silencing occurred in one cell 
type, the MEL cells, but not in the K562 or CD34+ enriched cells (Papapetrou et al., 
2006) (as described in Chapter 1: Introduction, section 1.10). In the case of the CMV 
promoter, studies have shown that the human CMV virus has a limited number of 
tissues that it infects, and the cells in which it can replicate must express the 
transcription factors necessary to transcribe its genes, namely the CMV immediate-
early enhancer/promoter (Koedood et al., 1995). In cells where the replication of the 
virus cannot be sustained, the transcription factors required for this promoter are 
lacking, and without the transcripts controlled by this promoter, no replication can 
occur (Mocarski et al., 1990). In an experiment by Mocarski transgenic mice were 
created expressing a CMV-driven transgene (Mocarski et al., 1990). This served as a 
representative of the tissue types the CMV virus can naturally replicate in, and would 
explain the variation observed in expression between cell types and tissues when using 
the CMV immediate-early enhancer/promoter. Some of the tissues which Mocarski 
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found it to infect included endothelial cells, smooth muscle cells of the arteries, the 
inner ear and eye, nerve cells, kidneys, the pancreas, and some parts of the liver and 
spleen. It was found that the amount of expression varied between tissues, which 
showed that CMV-driven expression was cell-type dependent. 
The CMV promoter is made up of 4 types of repeat elements which have been found 
to bind specific nuclear proteins and form complexes (Boshart et al., 1985; Ghazal et 
al., 1987). These repeats are the 17bp, 18bp, 19bp, and 21bp repeats, each found 3-5 
times in the promoter/enhancer region of CMV. The 18bp element has a consensus 
sequence which allows the Nuclear Factor κB (NFκB) to bind. NFκB is a transcription 
factor that is known to play a role in the expression of several cellular and viral genes 
(Baeuerle and Henkel, 1994). The 19bp repeats can bind the cAMP Response Element-
Binding (CREB)/Activating Transcription Factor (ATF). The binding of these factors has 
been shown to activate and enhance CMV activity (Hunninghake et al., 1989; 
Stamminger et al., 1990), and it is thought that for CMV to achieve its full activity the 
transcription factors NFκB and CREB/ATF must be present. It is interesting to note that 
CREB and ATF are believed to be important transcription factors involved in the early 
expression of viral genes (Adam et al., 1996), especially considering that CMV is a viral 
promoter. In a study by Niller et al several agents were used to stimulate the 
production of these factors in transfected cells containing a transgene expression 
cassette controlled by the CMV promoter (Niller et al., 1991). It was found in MRC5 
and HeLa cell cultures that CMV had become strongly re-activated (Niller et al., 1991). 
Thus the decrease in CMV-driven expression observed in the HeLa cells may be 
attributed, in part, to insufficient amounts of NFκB, the gene of which is almost 
inactive in HeLa cells (Niller et al., 1991) and CREB/ATF. Although C2C12 myoblasts 
have also been found to express NFκB (Guttridge et al., 1999) and CREB (Mori et al., 
1993), as do HeLa cells, it is possible that low amounts are expressed, which may have 
contributed to the decline in CMV-driven eGFP expression in these cells.  
3.3.6 Long term CMV-driven transgene expression was observed in HepG2 
cells 
 
The HepG2 cells transfected with the eGFP-C1 and pEPI-eGFP plasmids exhibited a 
remarkably different pattern of expression than the HeLa and C2C12 populations, as 
was shown by the increase in mean fluorescence intensity of the positive cells in each 
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population with time. This may, in part, be due to cellular factors, as it has been found 
that NFkB is expressed in HepG2 cells, and is present in a constitutively active form 
(Pogliaghi et al., 1995). CREB-1 has also been found to be highly expressed in HepG2 
cells, and ATF-1 has also found to be expressed (Whetstine and Matherly, 2001). Hence 
the presence of these factors may have account for the constitutive expression of 
CMV-driven eGFP transgene expression within this cell line.  
Interestingly, the CMV promoter driving the expression of a luciferase transgene was 
found to be silenced in vivo in mouse liver over time in a study by Argyros et al, 
whereas this was not the case in the study in this chapter involving the human 
hepatocyte cell line HepG2 (Argyros et al., 2008). This discrepancy may be explained by 
the availability of different factors in HepG2 cells which may not be found in liver cells 
in vivo, as it was found that in rat liver cells, although NFkB was found to be present, it 
was in an inactive form where its activation required induction by stress factors and 
inflammatory cytokines (Pogliaghi et al., 1995; Grimm and Baeuerle, 1993). 
 
3.3.7 Differentiation of C2C12 myoblasts may ameliorate CMV-driven eGFP 
expression 
 
Although it was difficult to determine whether expression was higher in the myotubes 
than it was in the myoblasts based on the immunostaining images, the images did 
reveal positive myotubes in the pEPI-eGFP transfected population in the Day 21 
sample where no positive myoblasts had been detected prior to differentiation. This 
could be explained in one of two ways.  
The first is that, in addition to factors that are required for continuous CMV-driven 
expression that bind consensus sequences on the promoter, there also exist factors 
which negatively influence promoter activity which may stop being expressed by the 
cell upon differentiation, leading to enhanced expression. Kothari et al believe that the 
21bp repeat in the CMV promoter binds to factors that negatively regulate the 
promoter’s activity, such as the transcriptional activator Multiprotein Bridging Factor 1 
(MBF1) and  the transcription factor YY1 (Kothar et al.,. 1991), and repress expression, 
leading to silencing (Kothari et al., 1991; Sinclair et al., 1992). When these 21bp 
repeats were deleted in an experiment by Kothari et al, an increase in expression was 
observed in undifferentiated T2 (teratocarcinoma) cells (Kothari et al., 1991). Kothari 
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et al also observed the presence of MBF1 in undifferentiated monocytes (Kothari et al., 
1991). Once these cells were differentiated, MBF1 was undetectable in the cells and 
CMV activity was amplified. In differentiated cells the amount of MBF1 decreases and 
expression is seen to increase. Gossett et al showed that in C2C12 cells MBF1 is 
expressed in myoblasts and, upon differentiation, its expression is significantly reduced 
(Gossett et al., 1989). Gossett et al also found that myoblasts could not express this 
factor at higher levels, as this would interfere with their ability to differentiate (Gossett 
et al., 1989). This may suggest that eGFP transgene expression had been ameliorated 
by differentiation due to the reduction in MBF1. Studies by Loser et al suggest this is 
plausible as he observed that CMV-driven expression was improved in his studies 
involving the differentiation of several different cell types (Loser et al., 1998).  
The second possibility for the observed improvement in expression may have also, in 
part, been due to an accumulation of eGFP within the terminally differentiated C2C12 
myotubes which had not been diluted by cell division. 
 
3.3.8 The pEPI-M18 vector containing the ‘mini-S/MAR’ showed evidence of 
integration into the C2C12 host genome 
 
Although it has been shown in several studies (Manzini et al., 2006; Jenke et al., 2005; 
Schaarschmidt et al., 2004; Papapetrou et al., 2006) that a plasmid containing an 
S/MAR sequence within the open reading frame of a gene prevents the plasmid from 
integrating into the host genome, and as was also demonstrated in this study by the 
use of FISH on the Day 60 samples of the pEPI-eGFP transfected HeLa, HepG2, and 
C2C12 populations, FISH conducted on the sample derived at Day 60 of the pEPI-M18 
transfected C2C12 population showed evidence that the plasmid containing a 
fragment of the S/MAR, termed ‘mini-S/MAR’, within the eGFP open reading frame, 
appeared to have integrated into the host genome. If truly integrated, then one 
possible explanation for this is that the ‘mini-S/MAR’ sequence did not include one or 
more essential elements present in the β-IFN S/MAR which gave the β-IFN S/MAR the 
ability to confer protective qualities to its vector, such as the prevention of integration. 
The results obtained in a study by Jenke et al may assist in explaining this finding, 
where a fragment of the original S/MAR element was inserted into a plasmid as a 
dimer or as a tetramer (Jenke et al., 2004). The aim of their study was to identify the 
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minimal essential part of the S/MAR that would function as well as the full length 
sequence. In the study, a 155bp sequence was isolated, chosen on the basis that it was 
the core unwinding element of the full length S/MAR where specific factors that also 
associate with the nuclear matrix are able to bind. It was inserted within the 
transcription unit in the place of the full length S/MAR as a dimer or tetramer 
sequence. Southern blotting and FISH indicated that all the vectors containing the 
dimer sequence had intergrated into the genome, whereas those carrying the 
tetramers did not and remained episomal. Jenke et al believed that they were able to 
discover the minimal sequence necessary for the S/MAR to function, and that SAF-A, 
which is a DNA-matrix binding protein, is involved in the recognition of this minimal 
sequence (Jenke et al., 2004). Kip et al and Fackelmayer and Richter explained that 
SAF-A can bind to DNA at its AT-rich domains (Kipp et al., 2000; Fackelmayer and 
Richter, 1994). When a cluster of such a domain is available, it allows the protein to 
bind more strongly to the sequence. Jenke et al concluded that multimers can be 
recognised and bound to SAF-A successfully only if they are of a minimum critical 
length, below which they will not be recognised (Jenke et al., 2004). This length 
requirement was fulfilled by the tetramer but not by the dimer. In the study, the dimer 
was 310bp, the tetramer was 465bp. The ‘mini-S/MAR’ in this study was 733bp and 
was above said critical length and was therefore not expected to integrate. Yet, the 
FISH data showed potentially that integration had occurred. Therefore, it is possible 
that the ‘mini-S/MAR’ did not include the specific 155bp sequence necessary to be 
recognised by SAF-A, which were included in the dimer and tetramer elements in the 
study by Jenke et al, thus leading to integration (Jenke et al., 2004). To date no studies 
have been conducted on the mini-S/MAR element and it is possible that the sequence 
does not contain essential elements of the β-IFN S/MAR, such as the SAF-A binding 
site, that may confer or contribute to the S/MAR’s ability to prevent integration and 
allow episomal retention of a transfected vector. The potential integration of the pEPI-
M18 vector further highlights the importance of certain regions within the S/MAR 
element which contribute to this ability, without which this ability would be lost. 
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3.3.9 Episomal copies of each vector were found in transfected cells at the 
final day of the experiment in HeLa, C2C12, and HepG2 populations 
 
Positive cells analysed by FISH showed that copies of each vector were present as 
episomes within transfected cells in HeLa and C2C12 cells 60 days post-transfection, 
and in HepG2 cells after 120 days. It is interesting to note that even in the cases where 
evidence had suggested vector integration into the host genome, such as eGFP-C1 or 
pEPI-M18, episomal forms of the vectors were still present within cells by the final day 
of the experiment. Although these vectors may have been getting diluted out of the 
populations by cell division, this shows that foreign plasmid DNA can remain within 
cells for many generations as separate extrachromosomal units without necessarily 
integrating under selection. A method for quantifying the number of vector copies 
within eGFP positive cells is Quantitative PCR (Q-PCR), and would have been a useful 
tool in the analysis of vector copy number per cell in these experiments. 
 
3.3.10  The amount of eGFP present in HepG2 cells transfected with eGFP-C1 
or pEPI-eGFP increased with time 
 
The increase observed in the mean fluorescence intensity in the transfected HepG2 
cells was progressive. This suggests that eGFP expression had accumulated, and eGFP 
protein was passed on to daughter cells. Daughter cells which inherited the vector 
sequence continued to express more eGFP transgene, which lead to a further increase 
in the amount of the protein, which was once again passed down to the progeny cells, 
and so on, leading to a cumulative increase in the mean fluorescence intensity with 
time. An interesting experiment to investigate this would be the use of Q-RT-PCR in 
order to quantify the amount of eGFP mRNA transcripts present within the cell 
populations. 
 
3.3.11 Transfection of HepG2 cells with pEPI-eGFP lead to increased numbers 
of positive cells over time 
 
In the pEPI-eGFP transfected HepG2 population the percentage of positive cells rose 
continually over time. The increase observed in the percentage of positive cells after a 
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period of selection in this population was due to the death and elimination of cells not 
containing the vectors. Furthermore, seeing as the number of eGFP positive cells and 
the total eGFP increased in the pEPI-eGFP transfected population much more 
significantly than in the eGFP-C1 cells from Day 1 to Day 21, it can be inferred that the 
pEPI-eGFP vector copies were retained in a manner which allowed better expression, 
and/or were of a higher average vector copy number per cell.  
It is difficult to explain the rise in the percentage of positive cells observed between 
Days 21 and 120 where no selection pressure was applied and therefore the cells that 
may have lost copies of the vector would have been able to survive and replicate. A 
possible explanation for this is that when the number of positive cells was quantified 
at the end of the selection period many cells negative for eGFP were still within the 
culture and were still in the process of dying. Following their death most of the 
population was then eGFP positive, and copies of the vector were very effectively 
retained and expressed from Day 21 until Day 120, thus indicating that the vector was 
effectively retained and passed on to daughter cells as an episome, considering no 
evidence of integration was found when investigated using FISH.  
Another explanation for the increase in the percentage of positive cells is that during 
selection, by retaining the vector sequence, the positive cells had also acquired a 
growth advantage besides the growth/survival advantage conferred by the Neomycin 
expression cassette, which led to increased levels of proliferation in these cells within 
the population, which were then able to dominate the population due to the speed of 
their growth, even after selection was removed. Considering that the cells were not 
under selection between Days 21 to 120 it is difficult to infer as to the nature of this 
growth advantage.  
 
3.3.12 eGFP-C1 was lost with HepG2 cell divisions over time leading to a 
decrease in positive cells 
 
As with the transfected HeLa and C2C12 populations, the percentage of eGFP-C1 
transfected HepG2 cells declined over time. The fact that the mean fluorescence 
intensity continued to rise over time in spite of the decline in the percentage of 
positive cells within the population could denote that the decline in the percentage of 
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positive cells could be attributed to a loss in episome copies with cell division, and not 
due to transgene silencing.  
 
3.3.13 eGFP-C1 does not always integrate into the host genome under 
selection 
 
It is also interesting to note that evidence towards eGFP-C1 integration does not 
always occur in every population transfected with it and grown under selection, as was 
the case with the HepG2 cells. Although the possibility of low frequency integration 
cannot be excluded, it was not detected. It is possible that the slower rate of cell 
division of these cells led to a slower rate of vector dilution, where the Neomycin 
expression cassette was transcribed at an adequate amount in positive cells during 
selection, which eliminated the need for vector integration into the host genome in 
order to survive selection.  
 
3.3.14 pEPI-eGFP was effectively retained in HepG2 cells due to the presence 
of the S/MAR element in the vector 
 
It is clear that the pEPI-eGFP vector allowed continuous, long term transgene 
expression, without CMV promoter silencing, and with no evidence of integration into 
the host genome in HepG2 cells. It is also evident that without the S/MAR element, the 
vector would not have been retained as well within the cells, and the number of 
positive cells within the population would have declined, as was shown with the eGFP-
C1 vector. This could be attributed to potential of the S/MAR element to be 
epigenetically marked, leading to retention within the cells and their replication and 
passing on to daughter cells (as shown in studies described in Chapter 1: Introduction 
section 1.10).   
It has been shown that S/MAR vector transgene expression and the efficiencies of 
being retained in replicating cell lines can be variable according to the cell line (as 
described in Chapter 1: Introduction section 1.10). Yet, S/MAR elements found 
intrinsically in cells all serve similar functions, regardless of the cell type. Therefore, it 
is possible that certain qualities of HepG2 cells may have contributed to the success of 
pEPI-eGFP retention within these cells over many generations. One main and obvious 
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difference between the HepG2 cells and the C2C12 and HeLa cells is their rate of 
division. It is possible that the longer length of the cell cycle in HepG2 cells allowed the 
reporter gene to have more time to be expressed and accumulated thus leading to 
high levels within the cells. The slower rate of division may have also carried other 
benefits, such as allowing more time from the moment the S/MAR plasmid entered 
the nucleus to the time of cell division for the plasmid to be epigenetically marked, as 
the cell would normally mark endogenous DNA, or allowing the cell more time to mark 
a larger amount of vector before replication. This may have led to a higher number of 
vector copies retained per cell, and thus a higher level of total expression.  
In a study by Courbet et al different rates of DNA replication, and hence fork rate 
progression, were found to influence the number of origins that were attached to the 
nuclear matrix and, consequently, those which were initiated during replication in 
different cell lines (Courbet et al., 2008). This is significant considering that the S/MAR 
element has been found to attach to the nuclear matrix and act as an origin of 
replication (as reviewed in Chapter 1: Introduction, Section 1.9). Thus, the efficiency of 
the initiation of replication of pEPI-eGFP in this study may have been influenced by the 
rate of DNA replication in each cell line used in this experiment.  
In the study by Courbet et al it was found that initiation sites were determined in G1 
(Courbet et al., 2008), a step called origin decision point (Li et al., 2003), and that the 
attachment of origins of replication to the matrix may be required for the initiation of 
replication from these origins (Courbet et al., 2008). Courbet et al used cell lines 471 
and 474, isolated from Chinese hamster lung fibroblast GMA32 cells, where each line 
was found to have a different rate of DNA synthesis during replication (Courbet et al., 
2008). In 471 cells, the replication fork was found to travel quickly, at an average speed 
of 1.3kb/min, whereas in 474 cells the average rate was 0.6kb/min. These differences 
in speed, it was found, were directly related to the density of initiation events. In the 
‘fast’ 471 cells, initiation events occurred at a low density, where 80% of initiation 
events in a region of DNA occurred at previously characterised origin of replication, 
oriGNAl3, and the remaining events were distributed between 5 other separate 
origins. In the ‘slow’ 474 cells, a higher density of events were observed, where 
initiation had occurred evenly between oriGNAl3 and the other 5 origins. Hence, 
during fast conditions, large replicons were formed due to the anchorage of origins 
with high affinities to the nuclear matrix, and during slower conditions, smaller 
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replicons were formed as a larger number of origins, which may not necessarily have 
had high affinities to the nuclear matrix, were also anchored and initiated.  
HepG2 cells have a relatively long doubling time in comparison to those of HeLa and 
C2C12 cells. The doubling time for HepG2 cells is ~48hrs (www.cell-lines-services.de), 
for HeLa is ~22hrs (Mu et al., 1997), and for C2C12 is ~12hrs (Kitzmann et al., 1998). It 
has also been shown that the rate of DNA synthesis in HeLa cells in S phase is 
3.6kb/min (Collins 1978; Painter and Schafer, 1969), which is even quicker than the 
‘fast’ cell line 471 in the study by Courbet et al (Courbet et al., 2008). Considering that 
HeLa cells have been found to maintain a low copy number of pEPI-eGFP 
(Schaarschmidt et al., 2004) with such a fast doubling time, and that only very low 
levels of transgene expression were observed by the final day of the experiment in this 
study, and that HepG2 cells transfected with pEPI-eGFP were shown to have a large 
amount of transgene expression with no evidence of vector integration by the final 
day, it is possible that the longer cell cycle of the HepG2 cells indicates a slower rate of 
fork progression, which in turn may have played a role in the attachment of the S/MAR 
vector to the nuclear matrix. This may have led to a greater amount of pEPI-eGFP 
anchoring to the matrix, and thus a greater incidence of replication initiation from the 
S/MAR element within this vector.  
3.3.15 Fluorescent In-Situ Hybridisation (FISH) Method To Show Vector 
Status In Transfected Populations Of Three Cell Lines 
 
Several methods to determine the episomal/integrant status of the transfected vectors 
at the final day of the experiments were attempted before choosing fluorescent in-situ 
hybridisation (FISH), such as Southern blotting and plasmid rescue. However, it has 
these methods were insufficiently sensitive for the purposes of this thesis, as was 
shown experimentally and by the hypothetical calculation, where it was found that the 
sensitivity of the Southern blotting would have to be in the picograms, and that of the 
plasmid rescue in femtograms, in order for these techniques to work in this setting.  
Considering the approach taken in conducting the experiments in this chapter, where 
populations were transfected with vector and then selected, without the picking of 
clones, a greater difficulty in vector status determination would ensue. The study by 
Papapetrou et al (described in Chapter 1: Introduction, Section 1.10) demonstrated 
that the detection of plasmid sequences transfected into heterogenous uncloned 
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populations, where no single clones where subsequently isolated, by Southern blotting 
or plasmid rescue in order to verify the status of the vector can be ineffective when 
the percentage of positive cells is very low, and a more sensitive method would be 
required, as was the case in this thesis investigation (Papapetrou et al., 2006). 
Papapetrou et al therefore attempted to verify the episomal state of the vector by 
amplifying the entire vector sequence by using closely apposed primers to yield a band 
of the vector’s size if present in a circular form (Papapetrou et al., 2006). However, 
they found that the efficiency of PCR amplification decreased when a vector the size of 
pEPI-eGFP (6.7kb) was attempted to be amplified.  
FISH is an extremely sensitive method used to locate a specific sequence within 
genomic DNA and can also be used to identify plasmid DNA that has been transfected 
into cells, thus indicating episomal/integrant status. A large number of cells can be 
screened and the sequence being probed can be visualised under a microscope. As this 
has been used to successfully distinguish between episomes and integrants in 
transfected multiclonal populations in studies of S/MAR vector (Stehle et al., 2007; 
Baiker et al., 2000), FISH was chosen as the most suitable and appropriate method to 
utilise for the purposes of the experiments conducted in this study.  
Although FISH effectively managed to demonstrate vector status in the samples tested 
in this study, a disadvantage was that, considering multiclonal populations of cells 
were being screened, even where no integration was detected in a sample and the 
vector was found in an episomal state, the possibility of low levels of integration could 
not be totally excluded. Another disadvantage is that even if fluorescence spots 
indicating the presence of the vector sequence were observed at similar positions on 
both arms of a given chromosome, the possibility that that these spots were episomal 
copies present at these regions due to the plasmids preferentially binding to certain 
sequences present on both arms of each chromatid, as opposed to conclusively being 
there due to the integration of the vector sequences, cannot be excluded. This method 
is also limited in that plasmid copy number cannot be quantified, and thus only 
qualitative observations can be made on the amounts of copies present per cell. In 
order to quantify plasmid copy number, a method such as Q-PCR would be required to 
be used.  
Unfortunately, only a small number of positive spreads could be analysed by this 
method in these experiments, owing to the fact that very few positive spreads were 
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observed per slide for each population. In order to have been able to make more 
definitive conclusions on the integration status of each vector in each transfected 
population, a minimum of 20 positive spreads would have been required to be 
screened in order to be able to have a confidence level of 95%. Other sensitive 
methods that could be utilized to detect integration in multiclonal populations that 
could have been applied in this study include Linear Amplification-Mediated (LAM) 
PCR, which involves not only the detection of integrants, but can also identify the 
location of integration within the host genome. Another such method is 
pyrosequencing, which allows the sequencing of DNA and hence the detection of 
integrants and their positions within the genome. 
It was observed that the HeLa and C2C12 cells that were analysed by FISH 24 hours 
post-transfection contained large areas where the probe had hybridised to large 
amounts of clustered plasmid vector. However, it cannot be determined by FISH alone 
whether these large clusters were plasmid that had already entered the nucleus, 
whether these clusters represented plasmid that had been present within the cells but 
had not yet entered the nucleus, or a combination of both. Nonetheless, it is clear that 
large amounts of vector had been taken up by these cells 24 hours after transfection 
with lipofection. 
In evaluating the quality of the FISH images and metaphase spreads obtained, it is clear 
that in some cases the spreading of the chromosomes was not optimal. This could 
have been improved by the exposure of the slides to hot water vapour before adding 
the cells onto the slides, then exposing them again to the vapour followed by drying 
them on a hot surface (Henegariu et al., 2001). The addition of a few drops of acetic 
acid to the slides after adding the cells could also have improved chromosome 
spreading (Henegariu et al., 2001).  
Some chromosomes also appeared ‘puffy’ or distorted in architecture. Large changes 
in the thermal temperature of slides can lead to the distortion of chromosomes and 
their architecture (Henegariu et al., 2001). Furthermore, the use of a thermocycler 
heating block could have improved the quality of the chromosomes (Henegariu et al., 
2001) by adding the solutions directly to the slides, such as the denaturant solution 
when denaturing the chromosomes, and the pre-hybridisation buffer when applying 
probe to the slides, and then gradually increasing the temperature of the slides. 
Unfortunately, a thermocycler heating block was not available and, although care was 
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taken to gradually increase/decrease the temperatures of the slides during the 
experiment using water baths at different temperatures (as described in Chapter 2: 
Materials & Methods), this may have contributed to the distortion observed in several 
of the spreads. 
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3.4. Concluding Remarks 
 
The findings suggesting the integration of eGFP-C1 in the HeLa and C2C12 cell lines, 
and the lack of evidence of integration of pEPI-eGFP in the HeLa, C2C12, and HepG2 
cell lines are in line with what was observed in several studies (as reviewed in Chapter 
1: Introduction, Secction 1.10), including the study by Baiker et al, where FISH was 
conducted on CHO cells transfected with eGFP-C1 or pEPI-eGFP vectors, showing that, 
after 100 cell generations, eGFP-C1 had integrated into variable sites in the host 
genome, whereas pEPI-eGFP had not (Baiker et al., 2000). HeLa cells were used in this 
study as a control cell line, and the evidence towards integration of eGFP-C1 and 
against that of pEPI-eGFP in HeLa cells is also as was revealed in a study by 
Schaarschmidt et al where the episomal status of the same vectors were investigated 
in HeLa cells (Schaarschmidt et al., 2004). 
Although copies of both eGFP-C1 and pEPI-M18 were present as episomes in the cells 
on the final day of the experiment, as were copies of pEPI-eGFP, they were also shown 
that they had potentially integrated into the host genome, therefore making them 
potentially unsafe candidates for use as vectors in gene therapy. However, if pEPI-
eGFP were to be a potential candidate for use in muscle cells for gene therapy for 
Muscular Dystrophy, then transgene expression must essentially be improved, as the 
vector would be required to express a significant enough amount of protein in order to 
have an effect on improving the diseased condition. 
One potential method of improving expression would be to change the promoter 
driving the transgene. Furthermore, the sequence of the expression cassette in a 
vector can have an effect on different characteristics of the vector besides the rate of 
expression, such as DNA conformation, vector stability, and ease of base unpairing and 
DNA unwinding, which would affect nuclear matrix binding, replication, and 
transcription (Papapetrou et al., 2006). Using a different promoter could alter these 
properties. Therefore, it was essential to test another promoter which may have 
enabled a more open conformation at the promoter region of the eGFP transgene, 
which in itself could significantly improve the expression of pEPI-eGFP. Another 
promoter may also avoid silencing due to methylation, which would also result in 
longer-term transgene expression. Thus, a different promoter was tested in C2C12 
cells in Chapter 5, after the generation of the vectors, described in Chapter 4. 
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Chapter 4: The Generation of Vectors CeGFP-C1, CpEPI-
eGFP, CMYC-pEPI, and the Ideal Minicircle S/MAR Vector 
 
4.1 Introduction: 
 
In addition to the vectors that were purchased or kindly donated to be studied for the 
purposes of this thesis, several expression vectors were also required to be 
constructed in order to be tested for episomal retention and transgene expression in 
the C2C12 murine skeletal muscle cell line. These newly constructed vectors included 
CeGFP-C1, CpEPI-eGFP, and CMYC-pEPI. For vectors CeGFP-C1 and CpEPI-eGFP, the 
CAGG promoter was inserted into the vectors and replaced the CMV promoter in 
eGFP-C1 and pEPI-eGFP. For vector CMYC-pEPI, the murine c-myc 1.7kb S/MAR 
element was inserted 3’ to the eGFP transgene in CeGFP-C1. Several other vectors 
were also required to be constructed in order to enable the construction of these 
vectors (Table 4.1). 
An ideal vector was also designed and attempted to be constructed. This vector was an 
S/MAR-containing minicircle. Chen et al developed a new plasmid vector, devoid of 
bacterial backbone, based upon the Streptomyces temperate phage integrase ØC31 –
mediated site-specific intramolecular recombination technology (Chen et al., 2003). 
This construct, designed by Chen et al, was used in this thesis in order to attempt to 
produce minicircles. The parent plasmid undergoes recombination at two specifically 
inserted sites, attB and attP, resulting in a minicircle containing the transcription unit 
only, and a miniplasmid (maxicircle) containing the bacterial backbone. The principle is 
based on the destruction of the unrecombined parent plasmid, and miniplasmid after 
recombination has taken place, by the insertion of the endonuclease I-SceI gene and I-
SceI recognition sequences outside the minicircle unit in order to linearize the 
maxicircle and unrecombined parental plasmids, which would eventually be digested 
by exonucleases within the cell, leaving the minicircle intact (Figure 4.1). 
The limitation that exists to using minicircles as vectors is that they are only well 
sustained in non-dividing cells and may not be passed on to daughter cells over many 
generations. In order to overcome this problem and optimize minicircle performance, 
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maintenance in cells, and transgene expression, an S/MAR element can be inserted 
into minicircle. In a study by Nehlsen et al using a 4kb minicircle made by Flp 
recombinase technology, containing only a transcription unit and an S/MAR element, it 
was found that the vector was established without selection pressure and was stably 
propagated over many cell generations without integration (Nehlsen et al., 2006). The 
study showed that S/MAR-containing minicircles are potentially very powerful and 
effective tools if used as gene delivery vectors, as they appeared to overcome many of 
the obstacles that currently limit the field of gene therapeutics, and can even be 
considered to be ‘ideal vectors’. Therefore, S/MAR-containing minicircles were 
attempted to be constructed to be tested in C2C12 cells in this thesis, containing only 
an eGFP transgene expression cassette, driven by the CMV promoter, and the human β 
-IFN S/MAR element. 
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Vector Name Transgene 
Promoter 
Transgene S/MAR Length (kb) 
eGFP-C1 CMV eGFP none 4.7 
CeGFP-C1 CAGG eGFP none 5.0 
pEPI-eGFP CMV eGFP Β-IFN S/MAR 6.7 
CpEPI-eGFP CAGG eGFP Β-IFN S/MAR 7.0 
eGFP-N3 CMV eGFP none 4.7 
CeGFP-N3 CAGG eGFP None 5.0 
pEPI-N3 CMV eGFP Β-IFN S/MAR 6.7 
CMYC-pEPI CAGG eGFP c-MYC S/MAR 6.7 
p2θC31 empty empty none 9.7 
p2θC31.LacZ CMV LacZ none 14.0 
p2θC31.eGFP CMV eGFP none 11.3 
p2θC31.eGFP.S/MAR CMV eGFP Β-IFN S/MAR 13.3 
 
Table 4.1 Vectors used and created in this chapter, indicating name, the transgene promoter, the 
transgene used for assessment studies, the presence of an S/MAR element, and the length (kb) of each 
construct. 
172 
 
  
 
  
           
Figure 4.1 The 14kb minicircle parental plasmid p2ØC31.LacZ expressing the LacZ transgene is shown 
above. The BAD promoter induced by L-arabinose, added into the LB media, initiates the transcription of 
the C31 phage recombinase, which leads to the formation of the 4.6kb minicircle (lower left vector) 
containing the transcription unit, and the 9.7kb maxicircle (lower right vector) containing the backbone 
including all the bacterial sequences, which is then linearized by I-SceI, and eventually degraded by 
bacterial exonucleases. 
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4.2 Results: 
  
4.2.1 The insertion of the CAGG promoter into eGFP-C1 and pEPI-eGFP by 
molecular cloning 
 
The CAGG promoter was excised from CeGFP-N3 in order to replace the CMV 
promoter in vectors eGFP-C1 and pEPI-eGFP. This was conducted by the digestion 
CeGFP-N3 with SalI, blunting with T4 DNA Polymerase (Materials & Methods), then 
digesting with ApaLI to yield the promoter, which was a fragment size of 1288bp, and 
the 3718bp plasmid backbone fragment (Figures 4.2 and 4.3).  
eGFP-C1 was digested with AfeI, blunted, then digested with ApaLI to yield the 3763bp 
backbone fragment into which the CAGG promoter was to be inserted, and the 968bp 
CMV promoter fragment to be discarded (Figures 4.2 and 4.3). pEPI-eGFP was 
digested as eGFP-C1, yielding the 5726bp backbone into which the CAGG promoter 
was to be inserted, and the 968bp CMV promoter fragment to be discarded (Figures 
4.2 and 4.4).  
The 1288bp CAGG promoter was ligated into the 3763bp eGFP-C1 plasmid backbone, 
and in a separate reaction with the 5726bp pEPI-eGFP plasmid backbone, as sticky-
blunt directional ligations (see Methods and Materials). The ligated vectors were 
transformed by electroporation into Top10 electrocompetent E.coli which were then 
plated onto Kanamycin agar plates. Colonies were picked from the selective agar 
plates, grown up as mini-preps, then plasmid was extracted and digested in order to 
identify the clones which contained the vectors CAGG-eGFP-C1 and CAGG-pEPI-eGFP 
(termed CeGFP-C1 and CpEPI-eGFP).  
Plasmids extracted from the mini-preps were digested with AseI and EcoRI. Expected 
fragment sizes for CeGFP-C1 were 1468bp and 3552bp, and 1481bp, 1951bp, and 
3551bp for CpEPI-eGFP if the cloning had been successful (Figures 4.5 and 4.6). The 
successful clones were identified, grown as maxi-preps, and plasmid was extracted in 
preparation for transfection. Further digests were conducted after growing the clones 
as maxi-preps in order to re-confirm the plasmid sequences. They were digested with 
Eco010901 and MluI, with expected fragment sizes for CeGFP-C1 of 2212bp and 
2808bp, and for CpEPI-eGFP of 2211bp and 4772bp (Figures 4.5 and 4.7).
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Figure 4.2 Schematic diagram of plasmid maps used to clone CeGFP-C1 and CpEPI-eGFP, indicating 
restriction sites utilised. Plasmid CeGFP-N3 was digested with SalI and ApaLI. Plasmids CeGFP-C1 and 
CpEPI-eGFP were digested with AfeI and ApaLI. The CAGG promoter insert was then ligated into the 
CeGFP-C1 and CpEPI-eGFP backbones by a sticky-blunt directional ligation. 
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Figure 4.3 A 0.8% agarose gel of the plasmid CeGFP-N3 (middle lane) digested by SalI, blunted, then digested by ApaLI to 
yield the CAGG promoter insert fragment of 1288bp, then excised for ligation, and the 3718bp backbone fragment. eGFP-C1 
(right lane) was digested by AfeI, blunted, then digested with ApaLI to yield the 968bp CMV promoter fragment and the 
3763bp backbone, excised for ligation. The left lane contained a 1kb ladder. 
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Figure 4.4 A 0.8% agarose gel of pEPIeGFP (right lane) digested by AfeI, blunted, then digested with ApaLI to yield a 968bp 
CMV promoter fragment and the 5726bp backbone, excised for ligation. The left lane contained a 1kb ladder. 
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Figure 4.5 The maps of constructs CeGFP-C1 and CpEPI-eGFP indicating restriction enzyme sites AseI, 
MluI, EcoRI, and Eco01091 which were used to confirm the successful cloning of these vectors. 
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Figure 4.6 A 0.8% agarose gel of mini-prep clones digested by AseI and EcoRI to identify the successfully 
cloned CeGFP-C1 and CpEPI-eGFP. Clones 1-8 were potential CeGFP-C1 vectors, and the expected sizes 
of the fragments were 1468bp and 3552bp if successful. Clone #5 was chosen as the successfully 
created CeGFP-C1 vector. Clones 9-15 were potential CpEPI-eGFP vector, and the expected sizes of the 
fragments were 1481bp, 1951bp, and 3551bp if successful. Clone #11 was chosen as the successfully 
created CpEPI-eGFP vector. The left lane contained a 1kb ladder. 
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Figure 4.7 A 0.8% agarose gel of CeGFP-C1 (middle lane) and CpEPI-eGFP (right lane) plasmids digested 
with Eco010901 and MluI to re-confirm the vector sequences. Expected fragment sizes for CeGFP-C1 
were 2212bp and 2808bp, and for CpEPI-eGFP were 2211bp and 4772bp, which was confirmed by the 
gel. The left lane contained a 1kb ladder. 
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4.2.2 The insertion of the c-myc S/MAR element into CeGFP-C1 by PCR and 
molecular cloning  
 
In order to insert the c-myc S/MAR element into CeGFP-C1, the sequence was first 
identified in the S/MART database (http://smartdb.bioinf.med.uni-goettingen.de/). 
The BAC clone containing the sequence was obtained from the Wellcome Trust Sanger 
Institute, and primers were designed to amplify the sequence by PCR (Materials & 
Methods). The primers contained overhangs of restriction sites so that the PCR 
product would be flanked by a XhoI restriction site at its 5’ end and an EcoRI site at its 
3’end. CeGFP-C1 also contained EcoRI and XhoI sites, both located at its MCS site 
downstream of the eGFP gene (Figure 4.8). Both the product and the plasmid were 
digested with EcoRI and XhoI, and the c-myc S/MAR was then inserted by a directional 
sticky-sticky ligation into the CeGFP-C1 backbone to create CMYC-pEPI (Figure 4.9). 
The correct CMYC-pEPI clone was identified by digesting 8 minipreps with AseI and 
BamHI, where the correct clone yielded three fragments of sizes 1067bp, 2145bp, and 
3521bp (Figure 4.10).  
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Figure 4.8 Schematic diagram of plasmid map of CeGFP-C1 (top image) and the c-myc S/MAR insert 
fragment (lower image), indicating restriction sites utilised to construct CMYC-pEPI. The c-myc S/MAR 
element was ligated into the CeGFP-C1 backbone by a sticky-sticky directional ligation. 
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Figure 4.9 The map of constructs CMYC-pEPI indicating restriction enzyme sites AseI and BamHI, which 
were used to confirm the successful cloning of this vector. 
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Figure 4.10 A 0.8% agarose gel of 8 minipreps for the potential CMYC-pEPI vector, digested with AseI 
and BamHI. Fragment sizes expected for the correct clone were 1067bp, 2145bp, and 3521bp. The 
correct clone was chosen as indicated. The left lane contained a 1kb ladder. 
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4.2.3 The generation of eGFP-expressing minicircles/ S/MAR minicirlces 
 
The parental plasmid p2θC31, which is the plasmid used to generate minicircles, 
contained the lacZ transgene (p2θC31.lacZ) driven by the CMV promoter when it was 
received. Cloning strategies were designed in order to insert the eGFP transgene into 
the vector, replacing the lacZ transgene. This construct (p2θC31.eGFP) could then be 
used to generate eGFP expressing minicircles. An insert containing the eGFP transgene 
followed by the β-IFN S/MAR element was also planned to be cloned into the p2θC31 
parental plasmid (p2θC31.eGFP.S/MAR) in order to generate eGFP expressing S/MAR-
containing minicircles. These constructs were to be transfected into C2C12 cells to 
assess expression and episomal status, and the S/MAR-containing minicircles were to 
be tested to determine their ability to replicate as episomes within dividing cells.   
 
Construct 1: p2θC31.eGFP 
 
The cloning of p2θC31.eGFP involved digesting eGFP-N3 with AflII, blunting with T4 
DNA polymerase, then digesting with XhoI, generating a 3.7 kb backbone to be 
discarded, and a 1kb insert which included the eGFP transgene and the SV40 polyA 
sequence. p2θC31.LacZ was digested with ApaI, blunted, then digested with XhoI, 
yielding a 10.3kb backbone, and a 3.9kb fragment containing the lacZ transgene and 
the SV40 polyA signal, which was to be discarded (Figures 4.11 and 4.12). The 1kb 
insert from eGFP-N3 was ligated by a sticky-blunt directional ligation into the 
p2θC31.LacZ backbone, creating the construct p2θC31.eGFP (Figure 4.13). The correct 
ligation of construct p2θC31.eGFP was confirmed by obtaining the correct restriction 
pattern when digesting separately with BcgI and with BsrGI (Figure 4.14). The digest 
with BcgI of the correct construct should yield 5.6kb, 3.4kb, 1.9kb, and 0.4kb 
fragments, and with BsrGI should yield 9.8kb and 1.5kb sized fragments. All these 
fragments were observed when the construct was digested, with the exception of the 
0.4kb fragment which was too small and faint to appear on the gel. Another gel with a 
greater amount of BcgI-digested p2θC31.eGFP DNA could have been run on a gel 
containing a greater percentage of agarose, such as 1.2%, in order to enable 
visualisation of this band. 
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Figure 4.11 Schematic diagram of plasmid maps used to clone p2θC31.eGFP, indicating restriction sites 
utilised. Plasmid eGFP-N3 was digested with AflII, blunted, then digested with XhoI. Plasmid 
p2θC31.LacZ was digested with ApaI, blunted, then digested with XhoI. The insert was then ligated into 
the p2θC31.LacZ backbone by a sticky-blunt directional ligation. 
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Figure 4.12 A 0.8% agarose gel indicating the fragments to be cloned to create vector p2θC31.eGFP. 
eGFP-N3 was digested with AflII, blunted, then digested with XhoI yielding a 3.7 kb backbone to be 
discarded, and a 1kb insert which included the eGFP transgene and the SV40 polyA sequence. 
p2θC31.LacZ was digested with ApaI, blunted, then digested with XhoI, yielding a 10.3kb backbone, and 
a 3.9kb fragment containing the lacZ transgene and the SV40 polyA signal, which was to be discarded. 
The left lane contained a 1kb ladder. 
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Figure 4.13 The map of construct p2θC31.eGFP indicating restriction enzyme sites BcgI and BsrGI which 
were used to confirm the cloning of the eGFP transgene and SV40 polyA into the p2θC31 backbone. 
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Figure 4.14 A 0.8% agarose gel confirming the correct cloning of p2θC31.eGFP. From left to right, lane 1: 
1kb ladder; lane 2: undigested p2θC31.eGFP; lane 3: p2θC31.eGFP digested with BcgI showing 
fragments of sizes 5.6kb, 3.4kb, and 1.9kb; lane 4: p2θC31.eGFP digested with BsrGI showing fragments 
of sizes 9.8kb and 1.5kb. 
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Construct 2: p2θC31.eGFP.S/MAR 
Unfortunately, although several cloning strategies were devised in order to construct 
p2θC31.eGFP.S/MAR, none had proven successful. Several of the strategies employed 
are be demonstrated here. 
Strategy 1: 
The plasmid pEPI-eGFP was digested fully and linearized with MluI, then partially 
digested with AseI (Figure 4.15) at different concentrations of AseI in order to find the 
optimal concentration of enzyme which would yield a maximum amount of the 
fragment required to be inserted into the p2θC31 backbone, containing the CMV 
promoter, eGFP transgene, S/MAR element, and SV40 polyA signal, which was 3.6kb. 
The fragment sizes yielded from this partial digest were 5.3, 4.4, 3.6, 3.0, 2.2, and 
1.3kb (Figure 4.16). Once the 3.6kb fragment was excised from the gel it was blunted 
with T4 DNA polymerase. p2θC31 was linearized with XhoI and blunted to yield a 
backbone of 9.7kb into which the insert would be ligated in a blunt-blunt non-
directional ligation. However, many attempts using this strategy did not lead to the 
successful of p2θC31.eGFP.S/MAR. An example gel (Figure 4.17) demonstrated how 
the backbone seemed to keep recircularising without the insert being ligated, as 
digestion of the correct clone by AseI would have yielded 9kb and 4.2kb fragments or 
8.2kb and 5 kb fragments in the case of an inverted insert. Yet, only single fragments of 
approximately 9.7kb were shown. De-phosphorylation of the backbone was also 
attempted prior to ligation using shrimp alkaline photphatase, and the ratios of 
vector:insert for the ligation reaction were altered and varied (Materials& Methods), 
but still with no success. 
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Figure 4.15 Schematic diagram of plasmid maps used to clone p2θC31.eGFP.S/MAR, indicating 
restriction sites utilised. Plasmid pEPI-eGFP was digested with MluI to completion, then partially 
digested with AseI. p2θC31 was linearised with XhoI. 
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Figure 4.16 A 0.8% agarose gel of 12.5μg of pEPI-eGFP digested to completion with MluI, and then 
partially digested with variable amounts (0.05-5U) of AseI to determine the optimal units of enzyme 
required to be used in order to yield the greatest amount of the 3.6kb fragment to be used in cloning 
p2θC31.eGFP.S/MAR. The fragment sizes yielded from this partial digest were 5.3, 4.4, 3.6, 3.0, 2.2, and 
1.3kb. As determined from this gel, the optimal amount of units was 5U. The right lane contained a 1kb 
ladder. 
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Figure 4.17 A 0.8% agarose gel of plasmid extracted from minipreps after cloning attempt of 
p2θC31.eGFP.S/MAR, digested with AseI. The large fragments observed in each lane indicate variable 
amounts of the 9.7kb p2θC31 which seems to have recircularized without the ligation of the insert, then 
linearised by digestion with AseI. A construct with the insert  digested with AseI would have yielded 9kb 
and 4.2kb fragments or 8.2kb and 5 kb fragments in the case of an inverted insert. The first and last 
lanes contained a 1kb ladder. 
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Strategy 2: 
 
Considering the cloning strategy employed to create p2θC31.eGFP had been 
successful, it was adapted in order to attempt to create p2θC31.eGFP.S/MAR. 
Considering that the β-IFN S/MAR-containing vector available in the lab was pEPI-
eGFP, which was essentially the S/MAR element inserted into the eGFP-C1 plasmid, 
and in order to create p2θC31.eGFP the eGFP-N3 vector had been utilised due to the 
convenient location of the restriction enzymes sites which had made the directional 
cloning possible, the S/MAR element would first need to be inserted into the eGFP-N3 
backbone. This was conducted by digesting pEPI-eGFP plasmid, that had been 
transformed into Dam negative E.coli, with BsrGI and XbaI, as XbaI is subject to Dam 
methylation. The resulting fragments were the 4.6kb backbone to be discarded, and 
the 2kb insert to be ligated into the eGFP-N3 backbone, which had also been 
transformed into Dam negative E.coli and digested with BsrGI and XbaI to yield a 4.7kb 
backbone fragment, and a 23bp fragment which was too short to detect on a 0.8% 
agarose gel (Figure 4.18). 
Minipreps of the ligations were grown, and the successful clone, pEPI-N3, was isolated 
and digested with AseI to show that the ligation had been successful (Figure 4.19). 
Expected fragment sizes were 5.3 and 1.4kb from the AseI digest, indicating that the 
cloning had been a success (Figure 4.20).  
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Figure 4.18 Schematic diagram of plasmid maps used to clone pEPI-N3, indicating restriction sites 
utilised. Both plasmids eGFP-N3 (top image) and pEPI-eGFP (lower image) were digested with BsrGI and 
XbaI. 
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Figure 4.19 The map of construct pEPI-N3 indicating restriction enzyme sites for AseI, which was used to 
confirm the cloning of the S/MAR element into the eGFP-N3 backbone. 
 
 
 
 
 
 
Figure 4.20 A 0.8% agarose gel confirming the successful cloning of pEPI-N3. From left to right, lane 1: 
1kb ladder; lane 2: undigested pEPI-N3; lane 3: pEPI-N3 digested with AseI yielding 5.3 and 1.4kb 
fragments. 
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Next, the same strategy applied for the cloning of p2θC31.eGFP was applied. pEPI-N3 
was  digested with AflII, blunted with T4 DNA polymerase, then digested with XhoI, 
generating a 3.7kb backbone to be discarded, and a 3kb insert which included the 
eGFP transgene, the S/MAR element, and the SV40 polyA sequence. p2θC31.LacZ was 
digested with ApaI, blunted, then digested with XhoI, yielding a 10.3kb backbone, and 
a 3.9kb fragment containing the lacZ transgene and the SV40 polyA signal, which was 
to be discarded (Figures 4.21 and 4.22). The 3kb insert from pEPI-N3 was ligated by a 
sticky-blunt directional ligation into the p2θC31.LacZ backbone, in order to create the 
construct p2θC31.eGFP.S/MAR.  
The correct ligation of construct p2θC31.eGFP.S/MAR was attempted to be confirmed 
by digesting with AseI. A correctly cloned p2θC31.eGFP.S/MAR vector digested with 
AseI should yield fragment sizes of 8 and 5kb (Figures 4.23 and 4.24). BsrGI was also 
used to attempt to confirm this cloning. A correctly cloned p2θC31.eGFP.S/MAR vector 
digested with BsrGI should yield fragment sizes of 9.8 and 3.5kb (Figures 4.24 and 
4.25). Unfortunately, many attempts at cloning p2θC31.eGFP.S/MAR using this 
strategy were also unsuccessful, even when de-phosphorylation of the backbone was 
attempted prior to ligation using shrimp alkaline photphatase, and the ratios of 
vector:insert for ligation were altered and varied (Materials & Methods). 
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Figure 4.21 Schematic diagram of plasmid maps used to clone p2θC31.eGFP.S/MAR, indicating 
restriction sites utilised. Plasmid pEPI-N3 (above) was digested with AflII, blunted, then digested with 
XhoI. Plasmid p2θC31.LacZ (below) was digested with ApaI, blunted, then digested with XhoI. The insert 
was then attempted to be ligated into the p2θC31.LacZ backbone by a sticky-blunt directional ligation. 
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Figure 4.22 A 0.8% agarose gel indicating the fragments to be excised and cloned in order to create 
vector p2θC31.eGFP.S/MAR. From left to right: lane 1: 1kb ladder; lane 2: pEPI-N3 digested with AflII 
and XhoI yielding a 3kb insert to be excised from the gel, and a 3.7kb backbone to be discarded; lane 3: 
p2θC31.LacZ digested with ApaI and XhoI, yielding a 10.3kb backbone, and a 3.9kb fragment to be 
discarded. 
 
 
 
 
Figure 4.23 The map of construct p2θC31.eGFP.S/MAR indicating restriction enzyme sites AseI and 
BsrGI, which were used to confirm the cloning of this vector. 
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Figure 4.24 A 0.8% gel of 10 different miniprep samples of transformants grown after transformation 
with potentially cloned p2θC31.eGFP.S/MAR vector, digested with AseI. A correctly cloned 
p2θC31.eGFP.S/MAR vector digested with AseI should yield fragment sizes of 8 and 5kb. As shown, none 
of the samples digested contained a correctly cloned p2θC31.eGFP.S/MAR sequence, and indicated 
unexpected fragment sizes. Left lane contained a 1kb ladder. 
 
 
 
10kb
3kb
 
 
 
Figure 4.25 A 0.8% gel of 10 different miniprep samples of transformants grown after transformation 
with potentially cloned p2θC31.eGFP.S/MAR vector, digested with BsrGI. A correctly cloned 
p2θC31.eGFP.S/MAR vector digested with BsrGI should yield fragment sizes of 9.8 and 3.5kb. As shown, 
none of the samples digested contained a correctly cloned p2θC31.eGFP.S/MAR sequence, and 
indicated unexpected fragment sizes. Left lane contained a 1kb ladder. 
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4.3 Discussion: 
 
The constructs CeGFP-C1, CpEPI-eGFP, CMYC-pEPI, and p2θC31.eGFP were all 
successfully cloned. In the cases of CeGFP-C1, CpEPI-eGFP, CMYC-pEPI, these vectors 
will all be transfected into C2C12 cells, and expression and episomal status will be 
assessed in subsequent chapters to ascertain the efficiency of the CAGG promoter as 
opposed to the CMV, in the cases of CeGFP-C1, CpEPI-eGFP, and to investigate the 
efficiency of the novel vector CMYC-pEPI. 
The successful cloning of p2θC31.eGFP meant that eGFP-expressing minicircles could 
be generated. However, minicircles are unable to replicate within dividing cells (Chen 
et al., 2003; Aryros et al., 2011), which would lead to a rapid loss of vector, and hence 
expression, within a dividing C2C12 population transfected with these minicircles. The 
vector p2θC31.eGFP was created in order to make minicircle vectors, which would act 
as one of the controls required for a study which would have involved the evaluation 
of an S/MAR-containing eGFP-expressing minicircle transfected into a replicating 
population of C2C12 cells, whose persistence within dividing cells was theorised to be 
superior to its non-S/MAR counterpart (Argyros et al., 2011). However, considering 
that, despite many repeated attempts using several different strategies had resulted in 
an inability to successfully clone p2θC31.eGFP.S/MAR, S/MAR-containing eGFP-
expressing minicircles could not be generated using this minicircle system, and hence 
the study was not undertaken. 
It is difficult to ascertain the reason behind the failure to clone p2θC31.eGFP.S/MAR. 
Using strategy 1 where both ends of the insert and vector had been blunted may have 
posed a challenge for the insert to ligate into the backbone. Despite de-
phosphorylation and varying the ratio of vector:insert, most of the restriction patterns 
indicated the re-circularisation of the parental plasmid p2θC31. Subsequently, a new 
strategy was designed and attempted. Yet, after many repeated attempts it was still 
found that p2θC31.eGFP.S/MAR was not being created, and the restriction digests of 
the plasmid extracted from numerous minipreps indicated, in addition to re-
circularisation of the backbone without the inclusion of the insert, some strange 
restriction patterns. A possible explanation was that p2θC31.eGFP.S/MAR may have 
been ligating successfully, but that the competent E.coli cells into which they were 
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being electroporated were rearranging the DNA, or that the DNA created was 
unstable. Several studies have indicated that DNA with repetitive and/or high AT 
contents, such as S/MAR elements, pose a great difficulty in being cloned (Glockner et 
al., 2002; Gardner 2001). Furthermore, plasmid supercoiling could lead to the 
formation of DNA secondary structures with elements of such characteristics, which 
would lead to their rearrangement or deletion (Leach and Lindsey, 1986; Malagon and 
Aguilera, 1998).  
Other minicircle systems have been developed in order to create minicircles, and could 
be used in future studies to create S/MAR-containing minicircles. One such system, 
which has already been used to successfully create an S/MAR-containing minicircle, 
involves the use of the Cre-recombinase system (Argyros et al., 2011). In this system, 
an expression cassette within a parental minicircle plasmid is flanked by loxP sites. 
These are the sites where intramolecular recombination occurs by the Cre 
recombinase upon its expression. As with the construct produced by Chen et al, the 
recombination leads to the formation of a maxicircle containing all the bacterial 
sequences, and a minicircle containing only the expression cassette and the loxP sites 
(Argyros et al., 2011). Other minicirlce-creating systems have also been created, 
utilising other recombinases such as the λ integrase (Darquet et al., 1999), or the Flp 
recombinase (Nehlson et al., 2006). Such systems could also be used in order to create 
S/MAR-containing minicircles in future studies. 
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Chapter 5: Expression and Episomal Status Assessment of 
Control and S/MAR Vectors Driven By The CAGG 
Promoter 
 
5.1 Introduction 
 
In this chapter, a different promoter was tested, replacing the Cytomegalovirus (CMV) 
promoter used to drive eGFP expression from the eGFP-C1 and pEPI-eGFP vectors in 
Chapter 3, in an attempt to improve the transgene expression in C2C12 cells. This 
promoter was the hybrid CMV enhancer/chicken β-actin (CAGG) promoter. The 
rationale behind choosing this promoter was that several studies have shown it to be 
ubiquitously expressed (as described in Chapter 1: Introduction, Section 1.8), and it 
may be less prone to silencing by methylation, as the promoter itself is of mammalian, 
and not of viral, origin. Moreover, it is possible that the CAGG promoter would also 
alter the conformation of the eGFP-C1 or pEPI-eGFP vectors which could, according to 
Stehle et al facilitate access of the ORC and initiator proteins, resulting in improved 
transgene expression and/or vector maintenance within the cells (Stehle et al., 2003),.  
In this study the expression of the eGFP transgene in eGFP-C1 and pEPI-eGFP was 
tested under the control of the CAGG promoter (vectors named CeGFP-C1 and CpEPI-
eGFP, respectively) (vector maps in Chapter 2: Materials & Methods). The analysis 
conducted on the cell samples derived included PCR in order to investigate the 
presence of the vector sequences within each population. Flow cytometry and 
immunostaining allowed the assessment of the expression of the eGFP reporter gene 
over time in each population, the trends observed in each population in comparison to 
the other, and therefore, ultimately, an indication of the efficacy of each vector tested 
at expressing the transgene over time. Flow cytometry was conducted with the 
transfected myoblast populations, and immunostaining on transfected myoblasts 
differentiated into myotubes. The investigation of expression in myotubes was 
important considering that, in vivo, transfected myoblasts eventually differentiate and 
fuse together to form myotubes, and the expression of a transgene within myotubes is 
essential for the amelioration of diseases such as Muscular Dystrophy. Fluorescent In-
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Situ Hybridisation (FISH) was used to investigate the status of the vectors within the 
cells as episomal vectors and/or as integrants. 
 
 
 
 
Table of plasmid vectors tested in this chapter: 
 
Vector Name Vector 
Feature 
Promoter- 
Transgene 
Antibiotic 
Resistance 
Vector 
Length (kb) 
CeGFP-C1 No S/MAR 
element 
CAGG-eGFP Kan/Neo 5.0 
CpEPI-eGFP Full-length 2kb 
β-IFN S/MAR 
element 
CAGG-eGFP Kan/Neo 7.0 
 
Table 5.1 Vectors used in this chapter, indicating the name, the presence of an S/MAR element, the 
transgene promoter, the transgene used for assessment studies, the antibiotic resistance gene, and the 
length (kb) of each construct. 
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5.2 Results  
 
5.2.1 A Comparison Of Stress-Induced Duplex Destabilisation (SIDD) Profiles 
Generated For CMV-Driven Vectors eGFP-C1 and pEPI-eGFP, and CAGG-
Driven Vectors CeGFP-C1 and CpEPI-eGFP 
 
The Stress-Induced Duplex Destabilisation (SIDD) profiles of the CeGFP-C1 and CpEPI-
eGFP plasmids were generated in order to assess the conformations of the vectors and 
identify the areas that were easily base-unpaired. These profiles were compared to 
those of the CMV-driven eGFP-C1 and pEPI-eGFP vectors. The SIDD profiles of the 
eGFP-C1, CeGFP-C1, pEPI-eGFP, and CpEPI-eGFP plasmids were calculated by the 
WebSIDD program designed by Dr. Craig Benham of the UC Davis Genome Centre 
(http://genomics.ucdavis.edu/benham/sidd/). This program contains an algorithm 
designed to calculate and predict the areas and amounts of double stranded DNA 
duplex destabilisation when put under superhelical stress based on the DNA’s specific 
base pair sequence (Bode et al., 2006). In superhelical DNA there are sites at which 
strand separation occurs. The unpairing at these sites is usually quite necessary, such 
as at promoter regions where transcription proteins bind to initiate transcription, at 
replication sites, or at scaffold attachment sites (S/MARs) where DNA binds to the 
nuclear matrix via proteins (as detailed in Chapter 1: Introduction, Section 1.9). The 
algorithm is able to predict the amount of energy required at each unpairing region for 
the destabilisation and denaturation to occur. The energy calculated includes the 
chemical energy required for the paired bases to be separated, the tortional energy 
which is the twisting of the single strands after separation, and the free energy, which 
is the supercoiling that occurs in the surrounding areas of the destabilised region (Bi 
and Benham, 2004). It also takes into account the negative superhelicity that is 
imposed upon the plasmid sequence as a result of the base unpairing that occurs at 
easily destabilised regions (Bi and Benham, 2004). A profile is then produced for the 
entire DNA sequence that, when aligned with a map of the DNA sequence, denotes 
regions such as open reading frames, promoters, and matrix attachment regions etc. 
that can destabilise and unpair, and the energy required for them to do so.  
In the S/MAR vector studies conducted by Giannakopoulos et al, the SIDD profiles of 
vectors were calculated using the WebSIDD program (Giannakopoulos et al.,2009). 
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Similarly, the four plasmids in this study were calculated in order to compare the ease 
with which the promoters destabilise, as this may give an indication of transcription 
efficiency.  
The resulting profiles generated showed that the unpairing at the promoter regions 
occured at the start of the CMV and CAGG promoters. CMV in eGFP-C1 required 
approximately 6.0 kcal/mol (G(x)) for strand separation to occur, whereas CAGG in 
CeGFP-C1 required approximately 3.0 kcal/mol (Figure 5.1); and CMV in pEPI-eGFP 
required approximately 9.0 kcal/mol, whereas CAGG in CpEPI-eGFP required 
approximately 8.0 kcal/mol (Figure 4.2). As can be seen, the unpairing that occured in 
the CMV and CAGG promoters of eGFP-C1 and CeGFP-C1, respectively, required less 
energy than was required for the CMV and CAGG promoters in the S/MAR-containing 
pEPI-eGFP and CpEPI-eGFP vectors, respectively. This was due to the presence of the 
S/MAR element that is so easily destabilised throughout the entire 2.0kb region that it 
induces negative supercoiling in the surrounding regions, which leads to an increase in 
the amount of energy needed for other areas to denature (Giannakopoulos et al., 
2009). This was also observed in the unpairing regions surrounding the origins of 
replication when comparing the control plasmids to the S/MAR-containing plasmids, 
where the same regions were destabilised in each vector, but the control plasmids 
required less energy for strand separation than the S/MAR-containing plasmids did.  
It was also clear that the CMV-driven eGFP-C1 and pEPI-eGFP vectors had a higher 
energy requirement to base-unpair than their corresponding CAGG promoter-driven 
plasmids. Furthermore, the CAGG promoter contained more destabilised regions 
within its sequence than the CMV promoter, which was demonstrated in both the 
control and S/MAR-containing plasmids (Figures 5.1 and 5.2). This indicated that the 
CAGG promoter had a more open conformation than the CMV promoter in these 
plasmids, which suggested the possibility of superior expression of the reporter gene 
when driven by the CAGG promoter. 
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(A) eGFP-C1 Vector 
 
(B) CeGFP-C1 Vector 
 
 
 
Figure 5.1 SIDD profile of eGFP-C1 with the CMV promoter (A) and of CeGFP-C1 with the CAGG 
promoter (B), calculated using WebSIDD program. Regions requiring lower amounts of energy 
(G(x)[kcal/mol]) to base unpair were centred around the origins of replication, and the SV40 promoter 
region drivng the Neomycin resistance gene. The start of the promoter region of eGFP-C1 ~6.0 kcal/mol 
for denaturation whereas that of CeGFP-C1 required ~3.0 kcal/mol for denaturation, which was half of 
that needed for denaturation of the promoter region of eGFP-C1, indicating a more open DNA 
conformation. The remainder of the promoter region of eGFP-C1 required higher amounts of energy for 
unpairing, whereas the CAGG promoter in CeGFP-C1 contained other regions of high base unpairing 
potential, which may allow easier access for transcription factors to bind. 
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(A) pEPI-eGFP Vector 
 
(B) CpEPI-eGFP Vector 
 
 
Figure 5.2 SIDD profile of pEPI-eGFP with the CMV promoter (A) and of CpEPI-eGFP with the CAGG 
promoter (B), calculated using WebSIDD program. Regions of base unpairing which required relatively 
less energy (G(x) [kcal/mol]) to destabilise were at the origins of replication, the SV40 promoter region 
drivng the Neomycin resistance gene, and the S/MAR region. The 2kb S/MAR region required such low 
amounts of energy to unpair that it induced supercoiling in the surrounding regions, leading to an 
increase in the energy required for other areas to denature. Therefore, the 5’ region of the CMV 
promoter required ~9.0 kcal/mol for denaturation, and the remainder of the promoter region required 
greater energy in the pEPI-eGFP vector. This may impair transcription factor access which could lead to 
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less effective expression of the reporter gene. The 5’ region of the CAGG promoter in CpEPI-eGFP 
required less energy for denaturation than that of pEPI-eGFP, which was ~8.0 kcal/mol. The CAGG 
promoter also contained a second region of destabilisation not observed in the CMV promoter, meaning 
its propensity to unpair was greater than that of the CMV promoter, which may allow easier access for 
transcription factors to bind. 
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5.2.2 Experimental Design 
 
In order to test CAGG promoter driven expression in C2C12 cells and compare the 
S/MAR-containing vector CpEPI-eGFP with the control, CeGFP-C1, the experiment was 
conducted as follows. 2.5x105 C2C12 cells were plated into 25cm2 flasks. After 24 
hours the cells had reached ~70% confluency, and were transfected with control 
vector CeGFP-C1, or CpEPI-eGFP, by lipofection (as described in Chapter 2: Materials & 
Methods). 24 hours after transfection each population of cells was analysed under a 
fluorescent microscope to confirm the presence of eGFP positive cells, which indicated 
that the cells had been successfully transfected with plasmid. Four replicates were 
conducted, and cell samples were collected from each population for analysis, with the 
remaining cells from each population seeded into fresh 25cm2 flasks at a density of 
5x104 cells. At this point the cells were put under selection by the addition of Geneticin 
(G-418) to the cultures’ media. Fresh media containing G-418 was added to each 
culture every 48 hours, and the cells were passaged when culture confluency reached 
~70%. Selection was maintained for 21 days, and on the final day of selection cell 
samples were again collected from each population for analysis. The remaining cells 
were seeded again into fresh flasks, and the cells were passaged for a further 39 days. 
On the final day of the experiment, Day 60, cell samples were again collected from 
each population for analysis.  
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5.2.3 Detection of CeGFP-C1 and CpEPI-eGFP Vector Sequences In 
Transfected C2C12 Cells By Polymerase Chain Reaction (PCR) 
 
PCR was conducted on samples taken on Days 1, 21, and 60 for C2C12 cells transfected 
with CeGFP-C1 or CpEPI-eGFP. 50ng of total DNA extracted from each sample was used 
per PCR reaction. The primers used were designed by Primer3 and lie within the 
Kanamycin resistance gene present in the transfected vectors. The PCR was run for 35 
cycles and the expected product size was 503bp. Products were run on 0.8% agarose 
gels counterstained with ethidium bromide and visualised under UV light. PCR results 
confirmed the presence of CeGFP-C1 or CpEPI-eGFP vector sequences within the 
transfected populations at each time point tested (Figure 5.3). 
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Figure 5.3 PCR conducted on 50ng of total C2C12 DNA transfected with CeGFP-C1 or CpEPI-eGFP 
plasmid run on samples taken at Days 1, 21, and 60. The positive controls were 10ng of CeGFP-C1, and 
10ng of CpEPI-eGFP, and, and the negative controls were 50ng untransfected C2C12 genomic DNA, and 
H20. The primers used were within the Kanamycin resistance gene, and product size expected was 
503bp. The PCR was run for 35 cycles and products were run on a 0.8% agarose gel. Copies of the 
vectors were present within cells of the transfected populations at each time point tested. 
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5.2.4 Expression Analysis of CeGFP-C1 and CpEPI-eGFP Transfected C2C12 
Myoblasts Using Flow Cytometry 
 
Expression of 1x105 C2C12 myoblasts transfected with either CeGFP-C1 or CpEPI-eGFP 
plasmid were analysed by flow cytometry at Day 1 (24 hours post-transfection), Day 21 
(final day of a 21 day selection period), and Day 60 (final day of experiment after 39 
day of cell proliferation without selection pressure after the 21 day period of selection) 
to determine the mean percentage of positive cells and the mean fluorescence 
intensity of each population. The percentages, mean fluorescence intensity, and total 
eGFP ± the standard error of the means (SEM) were plotted (n = 4) (Figures 5.4-5.6, 
respectively). Statistical tests were applied using NCSS statistics program to determine 
significance. The test used to compare the transfected populations to each other at 
each time point, and to compare all of the groups at of the time points was One-Way 
ANOVA. The P-value was set to 0.05 and indicated a significant difference between 
groups if P<0.05. The post-hoc Tukey-Kramer test was used to determine specifically 
which groups differed significantly from other groups. 
 At Day 1 the flow cytometry analysis indicated that CeGFP-C1 transfected a 
significantly higher percentage of C2C12 cells than CpEPI-eGFP (means of 63.1 ± 0.4% 
positive CeGFP-C1 transfected cells and of 23 ± 0.3% CpEPI-eGFP transfected cells; P = 
0.03) (Figure 5.4). The CeGFP-C1 transfected population also had a higher mean 
fluorescence intensity (mean of 9803 ± 455.7 for CeGFP-C1 and of 950.8 ± 26.4 for 
CpePIeGFP; P = 0.03) (Figure 5.5) and hence a higher total expression (means of 
618803.2 ± 31925 for CeGFP-C1 and of 22506.3 ± 900.1 for CpEPI-eGFP; P = 0.03) 
(Figure 5.6). 
By Day 21, there was no significant difference found between the percentages of eGFP 
positive cells of the CeGFP-C1 and CpEPI-eGFP transfected populations (means of 0.3 ± 
0.03% and 0.3 ± 0.03 respectively; P = 1.0), the mean fluorescence intensities (means 
of 694 ± 107.1 and 476.3 ± 63.5 respectively; P = 0.2), or the total expression (means of 
174.7 ± 31.7 and 122 ± 26.9 respectively; P = 0.3). However, the decline in the 
percentage of positive cells for both transfected populations was significant between 
Days 1 and 21 as was indicated by the Tukey-Kramer test. The decline in the mean 
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fluorescence intensity was significant between Days 1 and 21 in the CeGFP-C1 
transfected population, however it was not significant between these time points in 
the CpEPI-eGFP transfected population, also as was indicated by the Tukey-Kramer 
test. 
Again, there was no significant difference found between the CeGFP-C1 and CpEPI-
eGFP transfected populations by Day 60 in the mean percentage of positive cells 
(means of 0.01 ± 0% and 0.03 ± 0.03% respectively; P = 1), the mean fluorescence 
intensity (means of 316.3 ± 316.3 and 305.3 ± 305.3 respectively, P = 0.79), and hence 
the total eGFP expression (means of 11.1 ± 11.1 and 30.5 ± 30.5 respectively; P = 0.79). 
The decline was not significant for either of the transfected populations in the 
percentage of positive cells, mean fluorescence intensities, or total eGFP expression 
between Days 21 and 60, as was indicated by the Tukey-Kramer test. 
It can be seen from these results that although the two populations contained a large 
proportion of eGFP positive cells at Day 1, expression and percentage of positive cells 
declined markedly with time, and the levels between the two populations were 
comparable by Day 60. However, eGFP positive cells could still be detected within the 
populations by the final day of the experiment, indicating that a small percentage of 
the populations were able to continually express eGFP protein and contained copies of 
the vectors over time. 
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Figure 5.4 Flow cytometry analysis of percentage of eGFP positive C2C12 cells transfected with CeGFP-
C1 or CpEPI-eGFP vector at 24 hours post transfection (Day 1), the final day of selection after a 21 day 
selection period (Day 21), and the 39
th
 day of proliferation without any selective pressure post-selection 
(Day 60), where 1x10
5
 cells were analysed per sample.  The mean value is shown above the columns and 
the error bars represent ± SEM (n = 4). At Day 1 the CeGFP-C1 cells had a significantly larger amount of 
positive cells than the CpEPI-eGFP. By Day 21 the percentages had decreased significantly and the 
amounts for both populations were not significantly different to each other. A non significant decrease 
was observed from Day 21 to Day 60, and the percentages of positives in the populations remained 
comparable. 
 
 
210 
 
 
 
 
Figure 5.5 Flow cytometry analysis of the mean fluorescence intesity of eGFP positive C2C12 cells 
transfected with CeGFP-C1 or CpEPI-eGFP vector at 24 hours post transfection (Day 1), the final day of 
selection after a 21 day selection period (Day 21), and the 39
th
 day of proliferation without any selective 
pressure post-selection (Day 60), where 1x10
5
 cells were analysed per sample. The mean value is shown 
above the columns and the error bars represent ± SEM (n = 4). On Day 1 the CeGFP-C1 cells had a 
significantly higher mean expression than the CpEPI-eGFP. By Day 21 the mean had significantly 
decreased in the CeGFP-C1 population but had not significantly decreased in the CpEPI-eGFP population, 
and the expression levels for both populations were not significantly different. A non significant 
decrease was observed by Day 60, and the mean expressions of both populations remained comparable 
to each other. 
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Figure 5.6 Total eGFP of eGFP positive C2C12 cells transfected with CeGFP-C1 or CpEPI-eGFP vector at 
24 hours post transfection (Day 1), the final day of selection after a 21 day selection period (Day 21), and 
the 39
th
 day of proliferation without any selective pressure post-selection (Day 60), where 1x10
5
 cells 
were analysed per sample. The mean value is shown above the columns and the error bars represent ± 
SEM (n = 4).  The total eGFP fluorescence values were converted to log as the data was spread over a 
wide range. As can be seen on Day 1 the CeGFP-C1 cells had a significantly higher mean expression than 
the CpEPI-eGFP. By Day 21 the total expression had decreased markedly for both populations, and the 
total eGFP in the populations were not significantly different to one another. A non significant decrease 
was observed by Day 60, and the total expression of both populations remained comparable. 
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5.2.5 Expression Analysis Of CeGFP-C1 and CpEPI-eGFP Transfected C2C12 
Cells Differentiated Into Myotubes By Immunostaining 
 
The differentiation of transfected myoblasts into myotubes may have an effect upon 
transgene expression of the CeGFP-C1 and CpEPI-eGFP plasmids. 5x104 cells were 
isolated from each transfected population at Day 1 (24 hours post-transfection), Day 
21 (final day of a 21 day selection period), and Day 60 (final day of experiment after 39 
day of cell proliferation without selection pressure after the 21 day period of selection) 
and seeded into 1cm2 chamber slide wells. The cells were differentiated by changing 
the medium from growth medium to differentiation medium for 5 days. The cells were 
then fixed in 1% PFA/PBS and immunostained for eGFP (as described in Chapter 2: 
Materials & Methods).  
The results of the staining suggested that the CeGFP-C1 transfected myotubes, 
differentiated from Day 1 myoblasts, expressed more eGFP than the equivalent CpEPI-
eGFP transfected myotubes, as indicated by the brightness and intensity of eGFP 
fluorescence (Figure 5.7 (A) and (B)). Myotubes, which were differentiated from a 
sample of transfected myoblasts derived at Day 21, indicated that eGFP positive 
myotubes were present in both transfected populations, however the amount of 
expression was, again, greater in the CeGFP-C1 transfected population than in the 
CpEPI-eGFP transfected population as was subjectively noted, as the cells appeared 
brighter, though only marginally (Figure 5.7 (C) and (D)). The CeGFP-C1 myotubes 
expressed a lower amount of eGFP on Day 21 than they did on Day 1, whereas the 
CpEPI-eGFP cells expressd more than they did on Day 1, judging by the brightness of 
fluorescence. No eGFP was detected by immunofluorescence in either the CeGFP-C1 or 
the CpEPI-eGFP myotubes that were differentiated from myoblasts derived from the 
Day 60 cultures (Figure 5.7 (E) and (F)), suggesting silencing of the transgene, a loss of 
vector, or insufficient sensitivity of this method to detect lower levels of transgene 
expression. 
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Figure 5.7 eGFP immunostaining of C2C12 myotube cultures transfected with CeGFP-C1 or CpEPI-eGFP 
vector and differentiated into myotubes for 5 days before fixing. Samples from the transfected 
populations were differentiated at three time points. Day 1 indicates the CeGFP-C1 and CpEPI-eGFP 
transfected populations that were put into differentiation medium 24 hours post transfection (images A 
and B respectively), Day 21 indicates the populations that were put under differentiation medium on the 
final day of selection after a 21 day selection period (images C and D, respectively), and Day 60 indicates 
the populations that were put into differentiation medium on the 39
th
 day of proliferation without any 
selective pressure post-selection (images E and F, respectively). The negative control was untransfected 
C2C12 myotubes (image G). Green indicates eGFP positive cells and blue is the DAPI staining of the 
nuclei. The images indicate that CeGFP-C1 myotubes expressed more eGFP at Day 1 than the CpEPI-
eGFP myotubes. At Day 21 eGFP positive myotubes were detected in both populations, however there 
was more eGFP protein in the CeGFP-C1 myotubes than the CpEPI-eGFP, subjectively, as was judged by 
the brightness of the signal. Expression in the myotubes increased from Day 1 to Day 21 in the CpEPI-
eGFP transfected population, as the Day 21 myotubes were brighter. At Day 60 no eGFP positive 
myotubes were detected in the CeGFP-C1 or the CpEPI-eGFP transfected populations, denoting 
expression had either been silenced or expressed at levels too low to be detected by this method. Bar, 
90µm. 
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5.2.6 Investigation Of Episomal/Integrant Status Of CeGFP-C1 and CpEPI-
eGFP Vectors In Transfected C2C12 Cells By Fluorescent In-Situ 
Hybridisation (FISH) Analysis On Final Day Samples  
 
FISH was used to determine the episomal and/or integrant status of the transfected 
vectors (as conducted in Results Chapter 3, and as described in Chapter 2: Materials & 
Methods). The positive controls used in this experiment were C2C12 cells 24 hours 
post transfection with CpEPI-eGFP or CeGFP-C1 (Figure 5.8 (A) and (B), respectively). 
The negative controls in this experiment were untransfected C2C12 cells (Figure 5.8 
(C)). From the images taken under the fluorescence microscope it can be seen that a 
large amount of plasmid was present within the positive control cells, as the 
fluorescence signal was very strong. It was also clear that much of the plasmid 
observed was clustered together. 
FISH analysis showed no evidence of the CpEPI-eGFP plasmid integration into the host 
genome (0/6 positive spreads) (Figure 5.9 (A)). However, the data is suggestive of 
CeGFP-C1 plasmid integration into the genome (4 integrant spreads out of 5 positive 
spreads) (Figure 5.9 (B)). FISH has also shown that copies of CpEPI-eGFP and CeGFP-C1 
were also still present as episomes in their respective populations after many rounds 
of replication. 
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(A)C2C12 cells 24 hr after transfection with CpEPI-eGFP 
 
(B)C2C12 cells 24 hr after transfection with CeGFP-C1 
 
(C)C2C12 cells untransfected 
 
 
Figure 5.8 Fluorescent In-Situ Hybridisation positive control of C2C12 cells 24 hours post transfection 
with the CpEPI-eGFP plasmid (A) and CeGFP-C1 plasmid (B). Vector copies can be seen as the bright red 
fluorescing red spots. Genomic DNA was counterstained with Dapi (blue). A large amount of vector was 
present within the transfected cells, and the plasmid was found mostly clustered together. The negative 
control was untransfected C2C12 cells (C) indicating no background. Bar, 5µm.
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Transfected C2C12 cells Day 60 
 
(A)CpEPI-eGFP 
 
 
 (B)CeGFP-C1 
 
 
 
Figure 5.9 Fluorescent In-Situ Hybridisation of C2C12 cells transfected with CpEPI-eGFP plasmid (A) or 
CeGFP-C1 plasmid (B), of samples collected at Day 60. Single white arrows indicate red fluorescence 
spots where the probe has hybridised to plasmid sequence and denotes the episomal status of the 
plasmid. The double arrows mark spots of potential integration. Genomic DNA was counterstained with 
Dapi (blue). From these images it can be seen that CpEPI-eGFP plasmid has been retained as an episome 
with no evidence of integration (0/6 positive spreads). CeGFP-C1 appears to have integrated into the 
C2C12 host genome (4 integrant spreds out of 5 positive spreads) in addition to being retained as an 
episome by Day 60.  
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5.2.7 Summary of Results: 
 
 Flow Cytometry 
 
FISH 
 
Vector Day 
PCR 
% positive 
cells 
MFI Total 
Immunostaining 
of Myotubes 
Integration Episomal 
1 √ 63.1 ± 0.4 9803 ± 455.7 618803.2 ± 
31925 
+ 
21 √ 0.3 ± 0.03% 694 ± 107.1 174.7 ± 31.7 + 
CeGFP-C1 
60 √ 0.01 ± 0% 316.3 ± 316.3 11.1 ± 11.1 - 
0/6 √ 
1 √ 23 ± 0.3 950.8 ± 26.4 22506.3 ± 900.1 + 
21 √ 0.3 ± 0.03% 476.3 ± 63.5 122 ± 26.9 + 
CpEPI-
eGFP 
60 √ 0.03 ± 0.03% 305.3 ± 305.3 30.5 ± 30.5 - 
4/5 √ 
Table 5.2 Table summarising the results obtained in this chapter for transfected C2C12 cells, indicating each vector that was transfected and the time point at which samples were 
extracted and analysed. PCR results are presented where a ‘√’ denotes that the Kanamycin sequence was amplified and a band was present; Flow Cytometry results presented 
include the percentage of positive cells per transfected population, the mean fluorescence intensity (MFI) of the positive cells, and the total amount of expression which was the 
product of expression and number of positive cells; the Immunostaining data is presented by ‘-‘ indicating the absence of positive myotubes, ‘+’ indicating the presence of less 
than 10 positive myotubes, and ‘++’ indicating the presence of more that 10 positive myotubes; the FISH data is presented as the number of slides which suggested an integration 
event having occurred out of the total number of slides analysed on Day 60 only, a ‘√’ in the episomal column indicated the presence of episomal copies of the vector observed on 
the slides, and a ‘-‘ indicates none was observed. 
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5.3 Discussion: 
 
5.3.1 Transgene expression driven by the CAGG promoter from CeGFP-C1 
and CpEPI-eGFP vectors declined with time  
 
The aim of the experiments presented in this chapter was to investigate the expression 
of the CAGG driven eGFP reporter gene in the CeGFP-C1 and CpEPI-eGFP vectors in 
C2C12 cells, and to investigate whether these vectors integrate into the host genome. 
SIDD profiles were generated of the plasmids in order to investigate the regions within 
the DNA sequences that have a high propensity for base unpairing, and the amount of 
energy required for denaturation to occur. The CMV promoter had less regions of 
destabilisation than the CAGG promoter, and required a greater amount of enery for 
strand separation, as was shown by comparing the control plasmids to one another 
and the S/MAR-containing plasmids to one another. This lower energy requirement of 
the CAGG promoter led to the hypothesis that replacing the CMV promoter with the 
CAGG promoter to drive the reporter gene may result in improved expression, 
especially in the S/MAR-containing vector where the destabilisation of the S/MAR 
element led to negative supercoiling in the surrounding region which led to the higher 
energy requirements for CAGG promoter strand separation in relation to the control 
vector CeGFP-C1.  
Considering that the CMV-containing vectors were not tested at the same time as the 
CAGG-containing vectors in C2C12 cells, expression from the two different promoters 
cannot be directly compared. However, it is clear that the expression profile over time 
of the C2C12 cells transfected with CeGFP-C1 and CpEPI-eGFP in this chapter show a 
similar trend as the C2C12 cells transfected wtih eGFP-C1 and pEPI-eGFP in Chapter 3 
in terms of the decline in expression. At Day 1 cells were eGFP positive but by Day 21 
the percentage of positive cells and expression had declined in both populations, as 
indicated by flow cytometry. By Day 60 the percentage of positive cells and the 
expression of both populations were comparable and at very low levels, as observed in 
the eGFP-C1 and pEPI-eGFP transfected C2C12 cells in Chapter 3. Likewise, the 
immunostaining of the myotubes showed a similar trend where no eGFP positive 
myotubes could be detected by Day 60 in either population.  
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However, an important difference was observed, albeit subjectively, which was the 
increase in the brightness of the eGFP positive myotubes from Day 1 to Day 21 in the 
CpEPI-eGFP transfected population, which may indicate superior long term expression 
of the CAGG promoter from the S/MAR-containing plasmid than that of the CMV 
promoter in the S/MAR-containing plasmid. Although eGFP positive myotubes were 
present in the pEPI-eGFP transfected population at Day 21 in Chapter 3, a decrease 
and not an increase in fluorescence was observed between Days 1 and 21. It is 
interesting to note, however, that this increase in fluorescence intensity was not found 
in the C2C12 myoblasts transfected with either of the vectors CeGFP-C1 or CpEPI-eGFP 
by flow cytometry, and may have occurred exclusively in the myotubes due to the 
different factors present within differentiated cells as compared to undifferentiated 
ones, or an accumulation of eGFP, as discussed in Chapter 3 Discussion.  
 
5.3.2 Total eGFP expression and percentage of positive cells of CeGFP-C1 
transfected C2C12 cells were greater than those Of CpEPI-eGFP transfected 
cells at Day 1 
 
The flow cytometry data demonstrated that CeGFP-C1 transfected a larger number of 
cells and expressed eGFP more efficiently than CpEPI-eGFP, as was shown by the 
percentage of positive cells, the mean fluorescence intensity, and thus the total eGFP 
expression of the samples derived at Day 1. This difference in the mean percentage of 
positive cells and expression on Day 1, and thus the transfection efficiency, may be 
attributed to plasmid size. Kreiss et al found that transfection efficiency is inversely 
proportional to plasmid size where the greater the size of the plasmid, the lower the 
efficiency of transfection and thus the total expression (Kreiss et al., 1999). CeGFP-C1 
(5kb) is smaller in size than CpEPI-eGFP (7kb), which may explain the difference found 
between the transfection efficiencies of the two vectors. 
The supercoiling of a plasmid is another factor that can influence transfection 
efficiency (Maucksch et al., 2009). A study by Cherng et al confirmed that the 
transfection efficiency with the use of polyplexes of supercoiled DNA is greater than 
that of open-circular and/or heat-denatured plasmid DNA, whose efficiencies are 
similar to one another (Cherng et al., 1999). It is possible that the lack of an S/MAR 
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element in eGFP-C1 allowed the plasmid to be more tightly supercoiled as it was being 
produced in bacteria. The S/MAR element, as previously explained, has AT rich tracts 
that easily unpair, which may have led to a more open DNA conformation such as 
open-circular, hence leading to a lower transfection efficiency.  
Another factor which may have influenced transgene expression by CpEPI-eGFP was 
the negative supercoiling in the surrounding regions of the S/MAR, namely at the 
CAGG promoter region. As the S/MAR element must be inserted within an open 
reading frame of a transcribed gene for it to function as an element that prevents the 
plasmid from being integrated into the genome and maintains it as an episome, as 
reported in the literature (Chapter 1: Introduction, Section 1.10), the destabilisation at 
the site of the S/MAR, as shown by the SIDD profiles generated, led to negative 
supercoils being introduced further down in the plasmid in the promoter region, which 
resulted in the CAGG promoter in CpEPI-eGFP to require a relatively greater amount of 
energy for strand separation than the same promoter in the CeGFP-C1 plasmid. This 
phenomenon was demonstrated in the study by Giannakopoulos et al 
(Giannakopoulos et al., 2009). If the unwinding of DNA requires more energy, then the 
frequency of transcription would be lower than that of DNA that can unwind in the 
necessary places with more ease and less energy. And, as concluded by 
Giannakopoulos et al, supercoiling at the promoter region would lead to the cell’s 
transcription factors to have more difficulty in expressing the gene due to impaired 
access to the promoter (Giannakopoulos et al., 2009). Thus, this may have contributed 
to the lower mean fluorescence intensity of the CpEPI-eGFP transfected cell population 
compared with the control vector CeGFP-C1. 
An additional factor that may also have accounted for the differences in mean 
expression resulting from the two vectors was the efficiency of the polyadenylation 
signal at the 3’ end of the eGFP transgene. Considering that the S/MAR element was 
located within the open reading frame of a transcribed gene and before the SV40 
polyadenylation signal, the S/MAR was also transcribed, and it has been observed that 
the β-IFN S/MAR has 5 polyadenylation stop codons within it (vector map in Chapter 2: 
Materials & Methods). Different types of polyadenylation sequences exist, some more 
efficient than others, which can have an effect on gene expression (Azzoni et al., 2007). 
A study done by Azzoni et al comparing the three polyA signals BGH, Synt, and SV40 
showed that each one had a different amount of purine-rich sequences which gave 
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each signal a different capacity  to form single-stranded DNA structures, which in turn 
influenced transcription efficiency (Azzoni et al., 2007). Based on this, it is possible that 
cells transfected with CeGFP-C1 expressed greater amounts of eGFP than the CpEPI-
eGFP transfected cells was due to the presence of the efficient SV40 polyA signal as 
part of the eGFP expression cassette in CeGFP-C1. CpEPI-eGFP contained the S/MAR 
sequence directly after the eGFP gene at its 3’ end and prior to the SV40 signal at its 5’ 
end, and the possibility that the stop signals within the S/MAR element were not as 
efficient as the SV40 signal cannot be excluded.  
It is also possible that the resulting mRNA transcript which included part, or all, of the 
S/MAR sequence was not as stable a transcript as that transcribed from CeGFP-C1, 
which led to lower protein expression, as was found in a study by O’Rourke et al, 
where the sequence of a transcribed transgene affected the stability and half-life of 
the mRNA transcript, and thus the level of reporter protein within cells (O’Rourke et 
al., 2002). 
 
5.3.3 Evidence of CeGFP-C1 integration into the C2C12 host genome was 
found whereas none was found of CpEPI-eGFP 
 
In investigating the presence of the plasmid sequences using PCR it was found that a 
copy of each plasmid was present at every time point tested within their respective 
populations. The FISH data showed that there was no evidence of CpEPI-eGFP 
integration into the C2C12 host genome by Day 60 and that it was found as an 
episome, whereas the CeGFP-C1 plasmid may have integrated in addition to being 
present extrachromosomally. As mentioned in Chapter 3, not having observed any 
integration events within the CpEPI-eGFP transfected population does not rule out the 
possibility that integration may still have occurred, however this would indicate that 
integration, if it did occur, happened at a lower frequency than that of the CeGFP-C1 
plasmid. Hence, the S/MAR element could have a protective role which keeps its 
plasmid mostly, if not completely, episomal in status within C2C12 cells.  
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5.4 Concluding Remarks 
 
The potential integration of CeGFP-C1 makes this vector an unsuitable candidate for 
use in gene therapy due to safety issuses, as was found with eGFP-C1 in Chapter 3. 
However, there was no evidence of integration of CpEPI-eGFP, and episomal copies 
were present within the cells by Day 60, again indicating the possibility of a protective 
role of the β-IFN S/MAR element in preventing integration of the vector into the host 
genome. Nonetheless, transgene expression levels and the percentage of positive cells 
in the CpEPI-eGFP transfected population were very low at the end of the experiment, 
as was observed in Chapter 3 where CMV was used to drive eGFP expression. It is 
possible that the low levels in total expression may have, in part, been due to a a 
relatively low amounts of episomal vector copies retained per cell with time, and not 
as a result of transgene silencing, when considering the fact that there was no 
significant difference or decline in the mean expression of this population between 
Days 1 and 60. Therefore, an improvement in vector retention and maintenance is 
clearly essential before CpEPI-eGFP can be used as a tool for gene therapy. Improving 
vector retention was the focus of the following chapter: Chapter 6. 
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Chapter 6: Analysis Of Long-Term Transgene Expression 
and Vector Status Of CpEPI-eGFP and CeGFP-C1 In C2C12 
Cells Held In G0/G1 Phase of The Cell Cycle/Quiescence 
Post-Transfection 
 
6.1. Introduction 
 
As concluded in Chapter 5, it is important to find a mechanism which allows a larger 
amount of plasmid copies to be retained episomally in order to have a greater amount 
of reporter protein expression. As was observed in Chapter 3, the HepG2 cells, which 
are slow dividing cells with a relatively long cell cycle, retained pEPI-eGFP episomally 
after many cell divisions, and expression was at high levels by the final day of the 
experiment. As was discussed in Chapter 3 discussion, the long cell cycle may indicate 
a slower rate of replication fork progression, which in turn may influence the 
attachment of the S/MAR vector to the nuclear matrix. A slower rate of fork 
progression leads to a greater amount of replicons during DNA replication, and hence a 
greater amount of attachment points between origins of replication and the nuclear 
matrix (Courbet et al., 2008). In view of the fact that the S/MAR element has been 
proposed to also act as an origin of replication in pEPI-eGFP within mammalian cells (as 
reviewed in Chapter 1: Introduction, Section 1.9), this may have led to a greater 
amount of pEPI-eGFP S/MAR-matrix binding, and thus a greater amount of pEPI-eGFP 
may have been anchored to the matrix, leading to an increased incidence of replication 
initiation from the S/MAR element, and a larger amount of vector being retained 
within the cells. A relatively faster rate of replication fork progression in C2C12 cells 
would indicate fewer points of attachment, where those of relatively lower affinity to 
the matrix remaining unattached (Courbet et al., 2008). This would lead to attached 
origins initiating before unattached origins (Courbet et al., 2008) and, in considering 
the speed of the cell cycle, may not allow the binding of sufficient amounts of pEPI-
eGFP to the matrix, leading to fewer copies of vector being replicated and retained 
within the cells. 
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It was found that initiation sites are determined in the G1 phase of the cell cycle, a 
step called origin decision point (Li et al., 2003),  and that pre-initiation complexes are 
assembled on all origins, dominant or latent, in G1 (as reviewed in Chapter 1: 
Introduction, Section 1.9.1). A longer cell cycle, and hence a relatively slower rate of 
division, may have allowed the transfected HepG2 cells to have had more time from 
the moment pEPI-eGFP entered the nucleus for the plasmid to be epigenetically 
marked. It is this epigenetic marking which allows the vector to be continually 
propagated with divisions, expressed, and retained, as the marking occurs as a result 
of the S/MAR’s presence within the plasmid (Bode et al., 2006). It is plausible that by 
attempting to arrest cells that have a relatively short cell cycle, such as C2C12 cells 
(Kitzman et al., 1998), in quiescence or in the G0/G1 phase for a period of time, that 
this may achieve several things. First, that it may lead to a decrease in the replication 
fork rate during the first S phase once the cells have been switched media as they 
prepare to arrest, leading to more origins, with various affinities to the matrix, binding 
to the matrix. Second, that during the extended arrest time in G0/G1 that the cells 
would be given more time for more S/MAR vector (CpEPI-eGFP) copies to anchor to 
the nuclear matrix, for pre-initiation complexes to be assembled on these vectors, and 
for these vectors to be epigenetically marked (Chapter 1: Introduction, Sections 1.7-
1.9). And third, that once these cells were released from arrest, considering that the 
organisation of replicons and hence origin initiation, is carried out in the same manner 
as it is in the previous S phase, before having to revert back to the usual replicon 
organisation characteristic of the cell during replication (Courbet et al., 2008), that the 
vectors bound to the matrix would be replicated and consequently marked by the cell. 
Such marks may include termination marks which remain present on replicated DNA 
until mitosis (Courbet et al., 2008), hence leading to further replication of the vectors 
in daughter cells for many generations. 
The G0 phase of the cell cycle and quiescence can both be defined as “a reversible 
withdrawal from the cell cycle” where the cells are not proliferating and have stepped 
out of the cell cycle (Blow and Hodgson, 2002), and the terms ‘quiescence’ and ‘G0’ are 
often used interchangeably. For the aims of this chapter, C2C12 was an ideal cell line 
to use as the cells can be put into quiescence or G0/G1 phase of the cell cycle, as 
demonstrated by Yoshida et al and Kitzman et al (Yoshida et al., 1998; Kitzmann et al., 
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1998) (as described in Chapter 1: Introduction, Section 1.3.3). Both methods were used 
to induce cells post-transfection into quiescence (as described in Chapter 2: Materials 
& Methods,) and were compared in this chapter.  
In this study, C2C12 cells were transfected with CeGFP-C1 or CpEPI-eGFP plasmid. The 
CAGG promoter was used to drive transgene expression instead of the CMV promoter 
in these vectors for two reasons. The first was that, although there did not appear to 
be a large difference between CAGG- or CMV-driven expression as expression was 
extremely low and eGFP positive myotubes were not detected by immunostaining by 
Day 60, the immunostaining in Chapter 4 suggested an increase in eGFP expression in 
the positive myotubes in the CpEPI-eGFP population from Day 1 to Day 21, which was 
not observed in the pEPI-eGFP transfected population in Chapter 3. The second reason 
was that the SIDD profiles generated in Chapter 4, where the CMV- and the CAGG-
driven constructs were compared, indicated a more open DNA conformation at the 
site of the CAGG promoter constructs CeGFP-C1 and CpEPI-eGFP and, in accordance 
with Riu et al’s study (as described in Chapter 1: Introduction, Section 1.7), a more 
open conformation and an active DNA state could lead to the DNA being marked with 
euchromatin-associated markers (Riu et al., 2007). 
The aims of this chapter were to transfect cycling C2C12 cells with CeGFP-C1 and 
CpEPI-eGFP, then hold them in quiescence or G0/G1 using two separate experimental 
methods, followed by analysing and comparing long term expression as a result of the 
arrest. Overall transgene expression was analysed at several time points, the 
expression resulting from the groups held in quiescence/G0/G1 by two separate 
methods were compared, and the expression profiles resulting from the S/MAR 
containing vectors (CpEPI-eGFP) in each group were compared to those resulting from 
the control vectors of each group (CeGFP-C1). Furthermore, the integrant/episomal 
status of each vector was investigated. The analysis conducted on the cell samples in 
order to fulfil the aims of this study included PCR to confirm the presence of the vector 
sequences within each population. Flow cytometry and immunostaining allowed the 
assessment of the expression of the eGFP reporter gene over time in each population 
and the trends observed in each population in comparison to the others. Finally, FISH 
was used to investigate the status of the vectors within the cells as episomal vectors 
and/or as integrants.
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Table of plasmid vectors tested in this chapter: 
 
Vector Name Vector 
Feature 
Promoter- 
Transgene 
Antibiotic 
Resistance 
Vector 
Length (kb) 
CeGFP-C1 No S/MAR 
element 
CAGG-eGFP Kan/Neo 5.0 
CpEPI-eGFP Full-length 2kb 
β-IFN S/MAR 
element 
CAGG-eGFP Kan/Neo 7.0 
 
Table 6.1 Vectors used in this chapter, indicating the name, the presence of an S/MAR element, the 
transgene promoter, the transgene used for assessment studies, the antibiotic resistance gene, and the 
length (kb) of each construct. 
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6.2. Results 
6.2.1 Experimental Design 
 
The experiment was conducted as follows (Figure 6.1). Two 185cm2 flasks were seeded 
with 18.5x105 C2C12 cells. After 24 hours, when the confluency had reached ~70%, 
one flask was transfected with CeGFP-C1 and the other with CpEPI-eGFP, by lipofection 
(as described in Chapter 2: Materials & Methods). 24 hours post transfection each 
population of cells was viewed under a fluorescent microscope to confirm the 
presence of eGFP positive cells, which indicated that the cells had been successfully 
transfected with plasmid. Cell samples were collected from each of the two 
transfected populations for analysis. Next, the remaining cells of the CeGFP-C1 and 
CpEPI-eGFP populations were each seeded into eight 25 cm2 flasks, at 5x104 cells per 
flask. Four flasks of the CeGFP-C1 population and four flasks of the CpEPI-eGFP 
population were cultured in 2% horse serum DMEM medium for 10 days in order to 
differentiate the myoblasts and yield a culture of myotubes and quiescent reserve 
cells. The myotubes were separated from the reserve cells (as described in Chapter 2: 
Materials & Methods). In order to confirm that reserve cells were C2C12 myoblasts 
that had been induced into quiescence, samples were fixed immediately after isolation 
from the myotubes, as any delay in this process could lead to reserve cell reactivation, 
then immunostained for the presence of lysenin, as conducted in a study by Nagata et 
al (Nagata et al., 2006). Nagata et al had found that quiescent muscle satellite cells, in 
addition to quiescent reserve cells isolated from a differentiated culture of C2C12 cells, 
contain a high level of the lipid sphingomyelin on the plasma membrane (Nagata et al., 
2006). Upon activation, the levels of sphingomyelin decrease. Lysenin is a protein that 
binds specifically to sphingomyelin (Yamaji et al., 1998). In their study, Nagata et al 
used lysenin to label these quiescent cells, then used a fluor-conjugated antibody 
against lysenin to stain and thus identify quiescent cells within a population (Nagata et 
al., 2006). The reserve cells in this study were identified using the same method (as 
described in Chapter 2: Materials & Methods). The cells were also simultaneously 
stained for eGFP in order to confirm that of the reserve cells isolated, some were eGFP 
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positive and therefore had contained the transfected vectors within their nuclei whilst 
in quiescence.  
The reserve cells isolated from the myotubes in each transfected population were then 
trypsinised and re-seeded into fresh flasks. The cells were put into growth medium to 
re-activate them from quiescence, and G-418 was added to eliminate cells that did not 
contain the vectors CeGFP-C1 or CpEPI-eGFP. These groups of cells will herein be 
referred to as ‘Reserve CeGFP-C1’ and ‘Reserve CpEPI-eGFP’. Selection was maintained 
for 10 days. Fresh media containing G-418 was added to each culture every 48 hours, 
and the cells were passaged when culture confluency reached ~70%. On the final day 
of selection cell samples were collected again from each flask for analysis. The 
remaining cells were re-seeded into fresh flasks, and the cells were passaged for a 
further 39 days. On the final day of the experiment, cell samples were collected again 
from each flask for analysis.  
The other four flasks of the CeGFP-C1 population and the four flasks of the CpEPI-eGFP 
population were put under low serum (1% FCS) methionine-depleted medium 24 
hours post transfection in order to arrest the cells at the G0/G1 phase of the cell cycle 
(Kitzman et al., 1998). Methonine is needed for cells to grow, but is not essential for 
cell viability (Nadal-Ginard, 1978). These groups of cells will herein be referred to as 
‘G0 CeGFP-C1’ and ‘G0 CpEPI-eGFP’. When kept in this medium for an extended period 
of time the cells remain in G0/G1 until the medium is changed back to growth 
medium. In order to investigate the percentage of cells in G and S phases in relation to 
the amount of time the cells were kept in this medium, samples were taken at several 
time points, cells’ nuclei were isolated, genomic DNA was stained with DAPI, and the 
fluorescence signal of the DAPI was quantified for each nucleus by flow cytometry (as 
described in Chapter 2: Materials & Methods).  
The signal obtained of DAPI fluorescence in the flow cytometer depends upon the 
amount of DNA present within a cell. In the G1 phase of the cell cycle cells have not 
replicated their DNA yet. In the S phase, the cells begin to replicate their DNA and a 
quantifiably greater signal, which is variable according to the stage of S phase the cells 
are in, is emitted. By G2 phase all DNA in a cell has been replicated, and therefore 
doubled, meaning the stained nuclei would give a signal intensity that is double that 
obtained from nuclei of cells in the G1 phase. This is how each phase was determined. 
Cells held in G0 are cells that have been arrested in the G1 phase of the cell cycle. 
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Vermeulen et al have confirmed that cells that pass the checkpoint at the end of G1 
phase cannot go back into G1 and must complete the cell cycle (Vermeulen et al., 
2003). Those which do not and are serum-starved may enter directly from G1 into G0. 
If the cells are starved after they have passed G1 into S phase, they have been found to 
be required to complete the cell cycle and pass through mitosis before entering the 
quiescent state (Pardee 1974).  
The cells were cultured in low serum methionine-depleted medium and arrested for 7 
days, after which the medium was changed back to growth medium for 24 hours to 
allow the cells to recover and re-enter the cell cycle. The cells were then put under 
selection for 10 days by the addition of Geneticin (G-418) to the cultures’ media, fresh 
media containing G-418 was added to each culture every 48 hours, and the cells were 
passaged when culture confluency reached ~70%. On the final day of selection cell 
samples were collected from each flask for analysis. The remaining cells were re-
seeded into fresh flasks, and the cells were passaged for a further 39 days. On the final 
day of the experiment, cell samples were collected again from each flask for analysis.   
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Figure 6.1 Flow diagram depicting experimental sequence. C2C12 cells transfected with CeGFP-C1 (blue) 
or CpEPI-eGFP (red), separated each into 8 flasks, 4 of each in the ‘Reserve’ group and 4 in the ‘G0’ 
group. The ‘Reserve’ group refers to the cells that were differentiated, then had the myotubes 
separated from the reserve cells. The ‘G0’ group refers to the cells that were held in G0 phase of the cell 
cycle using methionine depleted media. The cells in both groups were then put under selection prior to 
proliferation in growth medium for 39 days. The green triangle marks the time points at which samples 
were taken from each flask for further analysis. 
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6.2.2 Differentiation Of eGFP Positive C2C12 Myoblasts Transfected With 
CeGFP-C1 and CpEPI-eGFP Into Myotubes 
 
In order to induce cells within a cycling population of C2C12 cells to enter quiescence it 
was necessary to first differentiate them into myotubes by switching the cells from 
growth medium to differentiation medium (as described in Chapter 2: Materials & 
Methods). The myoblasts then commit to either a path of differentiation into 
myotubes, or enter quiescence and become reserve cells. C2C12 cells were transfected 
with CeGFP-C1 or CpEPI-eGFP, then allowed to differentiate for 10 days. Fluorescence 
and phase contrast images were taken of eGFP positive myotubes in the differentiating 
cultures to show the progression from myoblasts to myotubes. An observed difference 
was noted between both the number of cells and the expression levels, as judged by 
the brightness of eGFP fluorescence, of cells transfected with CeGFP-C1 (Figure 6.2, 
row A, Day 1) and of those transfected with CpEPI-eGFP (Figure 6.2, row C, Day 1), 
which were greater than those of the CpEPI-eGFP population at Day 1. By Day 2 the 
cells had been in low serum medium for 24 hours and could be seen to have changed 
morphology by lengthening and thinning. By Day 4 many myoblasts had fused together 
to form long myotubes (Figure 6.2, rows B and D, Day 4). The intensity of the eGFP 
appeared to increase as differentiation proceeded in the CpEPI-eGFP transfected 
population, either due to an accumulation of eGFP protein or an increase in expression 
as a result of differentiation. Interestingly, this was not observed in the CeGFP-C1 
transfected population. By Day 7 longer myotubes were observed in both populations 
(Figure 6.2, rows B and D, Day 7), and eGFP positive myotubes were present in both 
transfected populations at this time point (Figure 6.2, rows A and C, Day 7).  
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Transfected With CeGFP-C1 
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Transfected With CpEPI-eGFP 
(C) 
 
(D) 
 
 
 
Figure 6.2 Fluorescence images of C2C12 cells transfected with CeGFP-C1 plasmid (row A), and phase 
contrast images of the same cells (row B), and of cells transfected with CpEPI-eGFP plasmid (row C), and 
their phase contrast images (row D), differentiating after being put under low serum medium 24hrs 
post-transfection. An observed difference was found of the amount of positive cells and the intensity of 
the eGFP between the CeGFP-C1 and CpEPI-eGFP transfected cells on Day 1, where they were greater in 
the CeGFP-C1 population. By Day 2 the cells had begun to change morphology and elongate. By Day 5 
many cells had fused together to from myotubes, and by Day 7 longer and larger myotubes were 
observed. It appeared that the intensity of eGFP fluorescence increased in the CpEPI-eGFP transfected 
population with time, but not in the CeGFP-C1 transfected population. Bar, 90µm. 
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6.2.3 Confirmation Of eGFP Positive Reserve Cell Isolation By Lysenin/eGFP 
Immunostaining 
 
Reserve cells were isolated after the myoblast culture had been differentiated for ten 
days by a series of washes with a low concentration of trypsin (as described in Chapter 
2: Materials & Methods). This caused the myotubes to detach first from the flask, 
leaving the reserve cells still attached to the substrate. The reserve cells were then 
detached using a higher concentration of trypsin and plated into fresh flasks. 
C2C12 cells were also seeded into chamber slide wells, differentiated, and the 
myotubes separated from the reserve cells. These cells were not trypsinised but were 
rinsed with PBS and immediately fixed in 4% PFA/PBS prior to staining. Rabbit anti-
lysenin and mouse anti-eGFP primary antibodies were used, and swine anti-rabbit and 
goat anti-mouse secondary antibodies labelled with red fluorescent Alexa Fluor 488 
dye and green fluorescent Alexa Fluor 488 dye, respectively. The staining was 
conducted in duplicates and images were taken under fluorescence microscopy. From 
the images taken it was evident that both the CeGFP-C1 and CpEPI-eGFP transfected 
populations had contained eGFP positive reserve cells (Figure 6.3). It was also shown 
that not all the cells that had remained in the chamber wells after trypsinisation were 
reserve cells, as many did not stain positive for lysenin.  
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Figure 6.3 Immunostaining of C2C12 cell samples transfected with CeGFP-C1 or CpEPI-eGFP and stained 
for eGFP (images A and D, respectively) or lysenin (images B and E, respectively), and overlayed images 
of the eGFP and lysenin staining (images C and F, respectively) are shown. Cells were fixed immediately 
after the isolation of myotubes from reserve cells and stained with anti-Lysenin in order to identify 
reserve cells (red), and anti-eGFP in order to indentify eGFP-positive cells (green), then mounted with 
Dapi mounting medium to stain the nuclei (blue). White arrows point out eGFP positive lysenin positive 
cells. The images were taken under a fluorescence microscope and were overlayed in order to 
determine the presence of eGFP positive reserve cells within the two populations. The images show that 
eGFP positive reserve cells were identified in both transfected populations and thus confirmed that the 
plasmids transfected were present in the nuclei of the quiescent C2C12 reserve cells in the 
differentiated cultures. The lysenin staining also showed that some differentiated cells that had not 
fused into myotubes, but were not reserve cells either as they did not stain positive for lysenin, still 
remained within the culture. The negative control was a sample of proliferating untransfected C2C12 
cells stained for eGFP and lysenin, images overlayed (image G).  Bar, 90µm. 
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6.2.4 Analysis of Cell Cycle Arrest Of C2C12 Cells Held In G0 By Flow 
Cytometry 
 
Nuclei of untreated proliferating C2C12 cells and of C2C12 cells put under low serum 
methionine depleted medium, where samples were taken at days 2, 5, and 7, were 
isolated (as described in Chapter 2: Materials & Methods). The genomic DNA was 
stained with DAPI and the number of nuclei was plotted against the fluorescence 
intensity of the DAPI from each nucleus in order to determine the percentage of cells 
in each phase of the cell cycle. The percentages of cells in each phase were plotted 
(Figure 6.4) where the blue peak represents cells in the G0/G1 phase, the red 
represented cells in the S phase, and the green peak represented cells in the G2/M 
phase. Figure 5.4 shows representative distributions obtained at Days 0 and Day 7, and 
indicate the decrease in the number of cells in S phase after cells were put in low 
serum methionine depleted medium for 7 days, as cells in the G1 phase entered and 
were arrested in the G0 phase without progression into the S phase.  
The analysis was conducted in triplicate (n = 3), the SEM values were calculated, and 
the values plotted (see Figure 6.5). Untreated proliferating C2C12 cells (Day 0 sample) 
contained 42.1% ± 1.9% in the G0/G1 phase, 44.7% ± 1.5% in the S phase, and 13.2% ± 
0.4% in the G2/M phase, thus indicating a large amount of cells were actively 
proliferating and were in the S phase. At Day 2 (two days after the addition of the low 
serum methionine depleted medium) the number of cells in the G0/G1 phase had 
already increased to 61.5% ± 0.4%, the number of cells in the S phase had declined to 
20.1% ± 0.2%, and the number of cells in the G2/M phase had increased to 18.4% ± 
0.6%. This showed that many cells that had previously been in the S phase had passed 
through the G2/M phase and entered the G0/G1 phase. At Day 5 the number of cells in 
each phase remained similar to those at Day 2, where those in the G0/G1 phase made 
up 62.8% ± 2.3 of the population, those in S phase made up 18.2 % ± 0.5 of the 
population, and those in the G2/M phase made up 18.9% ± 1.9 of the population. At 
Day 7 the percentage of cells in G0/G1 phase was 74.1% ± 4.7, in S phase 5% ± 1.6, and 
in G2/M phase 20.9% ± 4. It is clear that by Day 7 the number of cells arrested in 
G0/G1 phase had increased and those in S phase had further declined and passed into 
the G2/M phase. The percentages in the G2/M phase had remained similar 
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throughout, possibly indicating that the number of cells passing the checkpoint from S 
phase into G2/M was similar to the number of cells passing from G2/M phase into 
G0/G1 phase. It was also observed that a large amount of cell death had occurred by 
Day 7, and fewer cells were present and still viable for flow cytometry analysis. 
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(A) Percentage of C2C12 cells in G0/G1, S, and G2/M phase proliferating 
under growth medium 
 
(B)Percentage of C2C12 cells in G0/G1, S, and G2/M phase after 7 days in 
methionine depleted medium 
 
 
 
Figure 5.4 Flow cytometry analysis of cell cycle status of untreated C1C12 population at Day 0 (image A) 
and of C2C12 cells after 7 days in low serum methionine depleted medium (image B).  Nuclei were 
isolated from each sample and their genomic DNA was stained with DAPI. The number of nuclei were 
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counted (counts) and plotted against their fluorescence intensity (FL4 DAPI). The G2/M peak showed 
cells in this phase emitted double the intensity of those cells in the G0/G1 phase due to the completion 
of the doubling of genomic DNA once the cells have entered G2 phase. The blue peak in the charts 
represents cells in the G0/G1 phase which, in the untreated cells comprised 40.04% of the population, 
and at Day 7 comprised 68.81%. The red represents cells in S phase and comprised 46.52% of the 
untreated cell population, and 8.11% at Day 7. The green peak represents cells in the G2/M phase and 
comprised 13.44% of the total population of untreated cells, and 23.08% at Day 7.  It can be seen that 
the number of cells in G0/G1 phase had increased after 7 days in low serum methionine depleted 
medium, and that the number of cells in S phase had declined, suggesting that most cells that had exited 
the S phase continued in the cell cycle until they reached the G1 phase, where they were able to arrest 
in G0. 
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Figure 6.5 Chart of mean percentages ± SEM (error bars) (n = 3) of C2C12 cells in G0/G1, S, and G2/M 
phases after 0, 2, 5, and 7 days under low serum methionine depleted medium. From Day 0 to Day 2 the 
number of cells in the G0/G1 phase increased, the number of cells in the S phase declined, and the 
number of cells in the G2/M phase had increased, suggesting that many cells that had previously been in 
the S phase had passed through the G2/M phase and entered the G0/G1 phase. At Day 5 the number of 
cells in each phase remained similar to those at Day 2. The number of cells arrested in G0/G1 phase had 
increased by Day 7 and those in S phase had further declined and passed into the G2/M phase.  
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6.2.5 Identification Of eGFP Positive Cells Within CeGFP-C1 and CpEPI-eGFP 
Transfected Cultures Held In G0 For 7 Days By Fluorescence Microscopy 
 
24 hours after C2C12 cells were transfected with CeGFP-C1 or CpEPI-eGFP plasmid the 
medium was changed from growth medium to methionine-depleted low-serum 
medium. Cells were kept in this medium for 7 days. Fluorescent images of the cells 
were taken at Days 1, 3, 5, and 7 and showed that although a large number of cells 
perished when kept under this condition for an extended period of time, eGFP positive 
cells were still present within both transfected populations by Day 7 (Figure 6.6). 
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(B) 
 
(C) 
 
(D) 
 
 
Figure 6.6 Fluorescence images of eGFP positive C2C12 cells transfected with CeGFP-C1 (row A) or 
CpEPI-eGFP (row C). Day 1 is 24hrs post transfection and the first day of the addition of the low serum 
methionine depleted medium. The difference can be noted between the number of cells transfected by 
CeGFP-C1 and the expression levels, both of which were subjectively observed to be greater than those 
of the CpEPI-eGFP transfected population at Day 1. It is clear that eGFP positive cells were present in 
both transfected cultures after being put in low serum methionine depleted medium for 7 days. Phase 
contrast images of cells transfected with CeGFP-C1 (row B) and cells transfected with CpEPI-eGFP (row 
D) show a decline in the amount of cells present due to cell death following deprivation of methionine in 
the low serum medium. Bar, 90 µm. 
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6.2.6 Investigation Of The Presence Of Vector Sequences Within CeGFP-C1 or 
CpEPI-eGFP Transfected Populations By PCR 
 
PCR analysis was conducted on samples taken on Day 1, Final Day Selection, and Final 
Day from G0 CeGFP-C1, Reserve CeGFP-C1, G0 CpEPI-eGFP, and Reserve CpEPI-eGFP 
populations. 50ng of total DNA extracted from each sample was used per PCR reaction, 
and it was run for 35 cycles. The primers used were designed by Primer3 and lie within 
the Kanamycin resistance gene present in the transfected vectors. The PCR was run for 
35 cycles and the expected product size was 503bp. Products were run on 0.8% 
agarose gels counterstained with ethidium bromide and visualised under UV light. PCR 
on all the samples confirmed the presence of CeGFP-C1 or CpEPI-eGFP vectors in their 
respective transfected G0 and Reserve groups at each time point tested (Figure 6.7) 
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Figure 6.7 PCR analysis conducted on 50ng of total C2C12 DNA transfected with CeGFP-C1 or CpEPI-
eGFP plasmid in the G0 and Reserve groups, run on samples taken at Day 1, Final Day Selection, and 
Final Day.  The positive controls were 10ng of CeGFP-C1 and 10ng of CpEPI-eGFP, and the negative 
controls was H20. The primers used were within the Kanamycin resistance gene, and product size 
expected was 503bp. The PCR was run for 35 cycles and the products were run on a 0.8% agarose gel. 
Copies of the vectors were present within cells of the respective transfected populations in both the G0 
and Reserve groups at each time point tested. 
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6.2.7 Transgene Expression Analysis Of Reserve CeGFP-C1, Reserve CpEPI-
eGFP, G0 CeGFP-C1, and G0 CpEPI-eGFP Myoblast Populations By Flow 
Cytometry 
 
eGFP expression of 1x105 C2C12 myoblasts transfected with CeGFP-C1 or CpEPI-eGFP 
in the Reserve and G0 groups was analysed by flow cytometry at Day 1 (24 hours post-
transfection), final day of selection (after a 10 day selection period post holding in G0 
or quiescence in reserve cells), and Final Day (final day of experiment after 39 days of 
cell proliferation without selection pressure after the period of selection) to determine 
the mean percentage of positive cells and the mean fluorescence intensity of each 
population. The percentages, mean fluorescence intensity, and total eGFP ± the 
standard error of the means (SEM) (n = 4) were charted (Figures 6.8-6.10). The total 
eGFP fluorescence values were converted to log as the data was spread over a wide 
range. Statistical tests were applied using NCSS statistics program to determine 
significance. The test used to compare the transfected populations to each other at 
each time point, and to compare all of the groups at of the time points was One-Way 
ANOVA. The P-value was set to 0.05 and indicated a significant difference between 
groups if P<0.05. The post-hoc Tukey-Kramer test was used to determine specifically 
which groups differed significantly from other groups. 
From the flow cytometry results obtained of the Day 1 samples it was found that the 
transfection efficiency and the expression of the CeGFP-C1 plasmid were significantly 
higher than those of the CpEPI-eGFP plasmid, as the percentage of cells transfected 
(means of 47.9 ± 0.2% and 7.1 ± 0.2% respectively) (Figure 6.8), the mean expression 
(mean of 12266.5 ± 310.9 and 2744.3 ± 122.4 respectively) (Figure 6.9), and the total 
expression (means of 586793.8 ± 12764 and 19490.6 ± 996.3 respectively) (Figure 
5.10) of the CeGFP-C1 plasmid were significantly higher (P value = 0.001).  
By the final day of selection, where all the surviving cells contained a copy of the 
plasmid sequence and expressed the Neomycin resistance gene, the percentage of 
cells that were eGFP positive had decreased significantly in the CeGFP-C1 transfected 
populations, but not significantly in the CpEPI-eGFP populations (Figure 6.8). An 
ANOVA test concluded that there was no significant difference between all four groups 
at the final day of selection in the percentage of cells found to be eGFP positive (means 
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of 6.2 ± 2.0% for the CeGFP-C1 Reserve population, 3.6 ± 0.3 for the CpEPI-eGFP 
Reserve population, 8.9 ± 0.4% for the CeGFP-C1 G0 population, and 5.6 ± 1.8% for the 
CpEPI-eGFP G0 population; P = 0.09).  
The mean fluorescence intensities of the transfected populations declined from Day 1 
to the final day of selection (Figure 6.9). There was a difference in the mean 
expressions between the transfected populations at the final day of selection, where 
the CeGFP-C1 Reserve and G0 populations had similar mean fluorescence intensities 
but were significantly higher than the mean intensities of the CpEPI-eGFP Reserve and 
G0 populations, whose intensities were similar to one another (means of 1851 ± 245.1 
for the CeGFP-C1 Reserve population, 998 ± 53.1 for the CpEPI-eGFP Reserve 
population, 2082 ± 200.3 for the CeGFP-C1 G0 population, and 903 ± 93.2 for the 
CpEPI-eGFP G0 population; P = 0.0001). 
After calculating the total expression of each group at the final day of selection, it was 
found that the total expression of the CeGFP-C1 Reserve and G0 groups did not differ 
from each other, and the total expression of the CpEPI-eGFP Reserve and G0 groups 
did not from each other (Figure 6.10) as indicated by the Tukey-Kramer test. However, 
the CeGFP-C1 G0 group was found to have a total expression significantly greater than 
both the CpEPI-eGFP Reserve and G0 groups, but not the CeGFP-C1 Reserve group, 
whose total expression did not differ significantly from any of the groups on the final 
day of selection (means of 11235.8 ± 3152.7 for the CeGFP-C1 Reserve population, 
3557.6 ± 280.2 for the CpEPI-eGFP Reserve population, 18394.2 ± 1444.2 for the 
CeGFP-C1 G0 population, and 5282.4 ± 2196 for the CpEPI-eGFP G0 population; P value 
= 0.001).  
By the final day of the experiment, the percentage of eGFP positive cells and the mean 
fluorescence intensities did not decline significantly in the Reserve CeGFP-C1, the 
Reserve CpEPI-eGFP, or the G0 CpEPI-eGFP populations from Day 21, but did decline 
significantly in the G0 CeGFP-C1 populations from Day 21. Interestingly, the 
percentage of eGFP positive cells by the final day of the experiment did not differ 
significantly between the groups (means of 2.5 ± 2% for the CeGFP-C1 Reserve 
population, 0.5 ± 0.09% for the CpEPI-eGFP Reserve population, 3 ± 1.5% for the 
CeGFP-C1 G0 population, and 0.9 ± 0.5% for the CpEPI-eGFP G0 population; P = 0.46), 
nor did the mean expression (means of 934.3 ± 103.8 for the CeGFP-C1 Reserve 
population, 977.5 ± 461.9 for the CpEPI-eGFP Reserve population, 911.3 ± 209.8 for 
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the CeGFP-C1 G0 population, and 729.8 ± 231.6 for the CpEPI-eGFP G0 population; P 
value = 0.9) or, hence, the total expression (means of 2319.2 ± 1806.4 for the CeGFP-
C1 Reserve population, 594.8 ± 354.8 for the CpEPI-eGFP Reserve population, 2734.1 ± 
1199.3 for the CeGFP-C1 G0 population, and 933.2 ± 755.9 for the CpEPI-eGFP G0 
population; P = 0.5).   
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Figure 6.8 Flow cytometry analysis of the mean percentage ± SEM(error bars) (n = 4) of eGFP positive 
C2C12 cells transfected with CeGFP-C1 or CpEPI-eGFP vector. The figures above the bars indicate the 
values of the mean percentages of positive cells. The Day 1 CeGFP-C1 and CpEPI-eGFP transfected 
populations were split into two groups each: ‘Reserve’ and ‘G0’, and each group was composed of four 
replicates. ‘Reserve’ denotes transfected myoblasts that were put under differentiation medium 24 
hours post-transfection for 10 days yielding eGFP positive quiescent reserve cells and myotubes. ‘G0’ 
denotes transfected myoblasts that were induced into the G0 phase of the cell cycle 24 hours post 
transfection and were held arrested in G0 for 7 days. After holding the cells in quiescence/G0 the cells 
were put under G-418 selection for 10 days. Samples were taken and analysed at 24 hours post 
transfection (Day 1), the final day of selection (Final Day Selection), and the final day of the experiment 
after proliferation without any selective pressure post-selection (Final Day), where 1x10
5
 cells were 
analysed per sample. At Day 1 the percentage of CeGFP-C1 transfected eGFP positive cells was markedly 
higher than that of the CpEPI-eGFP group. By the final day of selection there was no significant 
difference between any of the four groups. By Day 60 there was a decline in the percentage of eGFP 
positive cells for the four groups, however none of them differed significantly from one another.  
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Figure 6.9 Flow cytometry analysis of the mean fluorescence intesity ± SEM(error bars) (n = 4) of eGFP 
positive C2C12 cells transfected with CeGFP-C1 or CpEPI-eGFP vector. The figures above the bars 
indicate the mean fluorescence intensity values. The Day 1 CeGFP-C1 and CpEPI-eGFP transfected 
populations were split into two groups each: ‘Reserve’ and ‘G0’, and each group was composed of four 
replicates. ‘Reserve’ denotes transfected myoblasts that were put under differentiation medium 24 
hours post-transfection for 10 days yielding eGFP positive quiescent reserve cells and myotubes. ‘G0’ 
denotes transfected myoblasts that were induced into the G0 phase of the cell cycle 24 hours post 
transfection and were held arrested in G0 for 7 days. After holding the cells in quiescence/G0 the cells 
were put under G-418 selection for 10 days. Samples were taken and analysed at 24 hours post 
transfection (Day 1), the final day of selection (Final Day Selection), and the final day of the experiment 
after proliferation without any selective pressure post-selection (Final Day), where 1x10
5
 cells were 
analysed per sample. At Day 1 the mean expression of CeGFP-C1 transfected eGFP positive cells was 
markedly higher than that of the CpEPI-eGFP group. By the final day of selection, the CeGFP-C1 Reserve 
and G0 populations had similar mean fluorescence intensities but were significantly higher than the 
mean intensities of the CpEPI-eGFP Reserve and G0 populations, whose intensities were similar to one 
another. By Day 60 there was no significant difference between any of the groups in terms of mean 
expression. 
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Figure 6.10 The total eGFP fluorescence ± SEM (error bars) (n = 4) of eGFP positive C2C12 cells 
transfected with CeGFP-C1 or CpEPI-eGFP vector. The figures above the bars indicate the mean total 
eGFP fluorescence. The Day 1 CeGFP-C1 and CpEPI-eGFP transfected populations were split into two 
groups each: ‘Reserve’ and ‘G0’, and each group was composed of four replicates. ‘Reserve’ denotes 
transfected myoblasts that were put under differentiation medium 24 hours post-transfection for 10 
days yielding eGFP positive quiescent reserve cells and myotubes. ‘G0’ denotes transfected myoblasts 
that were induced into the G0 phase of the cell cycle 24 hours post transfection and were held arrested 
in G0 for 7 days. After holding the cells in quiescence/G0 the cells were put under G-418 selection for 10 
days. Samples were taken and analysed at 24 hours post transfection (Day 1), the final day of selection 
(Final Day Selection), and the final day of the experiment after proliferation without any selective 
pressure post-selection (Final Day), where 1x10
5
 cells were analysed per sample. The total eGFP 
fluorescence values were converted to log as the data was spread over a wide range. At Day 1 the total 
expression of CeGFP-C1 eGFP positive cells was markedly higher than that of the CpEPI-eGFP group. By 
the final day of selection the groups of cells transfected with CeGFP-C1 (the Reserve group and the G0 
group) did not differ from each other in their mean expressions, nor did the groups of cells transfected 
with CpEPI-eGFP (the Reserve group and the G0 group) differ from one other. However, the CeGFP-C1 
G0 group expressed a significantly larger amount of eGFP than the CpEPI-eGFP Reserve and G0 
populations. The CeGFP-C1 Reserve population had a mean intensity that did not differ significantly 
from any of the groups. By Day 60 none of the groups differed significantly in terms of total expression. 
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6.2.8 Expression Analysis of Reserve CeGFP-C1, Reserve CpEPI-eGFP, G0 
CeGFP-C1, and G0 CpEPI-eGFP Myotube Populations By Immunostaining 
 
The differentiation of transfected myoblasts into myotubes may have an effect upon 
transgene expression from the CeGFP-C1 and CpEPI-eGFP plasmids. 5x104 cells were 
isolated from each transfected population at Day 1 (24 hours post-transfection), Final 
Day Selection (final day of a 10 day selection period post-holding in G0/quiescence in 
reserve cells), and Final Day (final day of experiment after 39 days of cell proliferation 
without selection pressure after the 10 day period of selection) and seeded into 1cm2 
chamber wells. The cells were differentiated by changing the medium to 
differentiation medium for 5 days. The cells were then fixed in 4% PFA/PBS and 
immunostained for eGFP.  
The results of the staining showed that on the final day of selection and at Final Day, 
eGFP was detected in the G0 CeGFP-C1, G0 CpEPI-eGFP, and Reserve CpEPI-eGFP 
transfected populations (Figure 6.11), but none was found in the Reserve CeGFP-C1 
transfected population. The images suggest that the amount of eGFP positive cells in 
the populations which contained positive cells, and their fluorescence intensities, 
increased by the final day of selection in comparison to Day 1. The images also suggest 
that the amount of eGFP positive myotubes and their brightness were similar in the G0 
CeGFP-C1 and G0 CpEPI-eGFP populations, and both were greater in these two 
populations than in the Reserve CpEPI-eGFP population. These observations may 
indicate that holding C2C12 cells in G0 for 7 days post transfection may lead to 
improved and long-term transgene expression over holding the cells in quiescence in 
reserve cells. 
It can also be seen from the images that the CeGFP-C1 and CpEPI-eGFP transfected 
cells in the G0 group did not fuse together during differentiation. The G0 CpEPI-eGFP 
population contained some myotubes at the final day of selection time point, however 
the G0 CeGFP-C1 population at the same time point did not, nor did either population 
at the Final Day time point. 
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Figure 6.11 eGFP immunostaining of fixed C2C12 myoblasts transfected with CeGFP-C1 or CpEPI-eGFP 
vector and differentiated into myotubes under differentiation medium for 5 days. Samples from the 
transfected populations were differentiated at three time points: Days 1, Final Day Selection, and Final 
Day. Day 1 indicates the CeGFP-C1 and CpEPI-eGFP transfected populations that were put into 
differentiation medium 24 hours post transfection (images A and F respectively). Final Day Selection 
indicates G0 CeGFP-C1, Reserve eGFP-C1, G0 pEPI-eGFP, and Reserve pEPI-eGFP populations put under 
differentiation medium on the final day of selection after a 10 day selection period post-holding in 
G0/quiescence in Reserve cells (images B, D, G, and I, respectively). Final Day indicates G0 CeGFP-C1, 
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Reserve eGFP-C1, G0 pEPI-eGFP, and Reserve pEPI-eGFP populations put into differentiation medium on 
the 39
th
 day of proliferation without any selective pressure, post-selection (images C, E, H, and J, 
respectively). The negative control was untransfected C2C12 myotubes (image K). Green indicates eGFP 
positive cells and blue is the DAPI staining of the nuclei. The images show that on the final day of 
selection and at Final Day, eGFP positive myoblasts/myotubes were detected in the G0 CeGFP-C1, G0 
CpEPI-eGFP, and Reserve CpEPI-eGFP transfected populations, but none were found in the Reserve 
CeGFP-C1 transfected population. A subjective observation is that the amount of eGFP positive cells in 
the populations that contained them, and their fluorescence intensities, increased in final day of 
selection in comparison to Day 1. Another observation is that the amount of eGFP positive myotubes 
and their brightness were similar in the G0 CeGFP-C1 and G0 CpEPI-eGFP populations, and both were 
greater in these two populations than in the Reserve CpEPI-eGFP population. It can also be seen from 
the images that the CeGFP-C1 and CpEPI-eGFP transfected cells in the G0 group did not fuse together 
during differentiation. The G0 CpEPI-eGFP population contained some myotubes at the final day of 
selection time point, however the G0 CeGFP-C1 population at the same time point did not, nor did 
either population at the Final Day time point. Bar, 90µm. 
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6.2.9 Investigation Of Episomal/Integrant Status Of CpEPI-eGFP and CeGFP-
C1 Vectors In Transfected C2C12 Cells Of The Reserve And G0 Groups By 
Fluorescent In-Situ Hybridisation (FISH) Analysis On Final Day Samples 
 
FISH was used to determine the episomal and/or integrant status of the transfected 
vectors (as conducted in Chapters 3 & 4). The positive controls used in this experiment 
were C2C12 cells 24 hours post transfection with CpEPI-eGFP or CeGFP-C1 (Figure 6.12 
(A) and (B), respectively). The negative controls in this experiment were untransfected 
C2C12 cells (Figure 6.12 (C)). From the images taken under the fluorescence 
microscope it can be seen that a large amount of plasmid was present within the 
positive control cells, as the fluorescence signal emitted was very strong. It was also 
clear that much of the plasmid observed was clustered together.  
The FISH images indicated that the CpEPI-eGFP plasmid in the Reserve group may have 
integrated into the host genome (4 integrant spreads of 9 positive spreads) (Figure 
6.13 (A)), as was the evidence shown for the CeGFP-C1 plasmid of the Reserve group (3 
out of 6 integrant spreads) (Figure 6.13 (B)), in addition to episomal copies still being 
present within both populations. It is interesting to note that evidence of integration 
of an S/MAR-containing plasmid has been found, suggesting that holding the 
transfected reserve cells in quiescence and then putting them under selection for 10 
days lead to its potential integration. 
The G0 CpEPI-eGFP and CeGFP-C1 samples analysed showed that CpEPI-eGFP and 
CeGFP-C1 were retained as episomes without any evidence of integration into the host 
genome (0/6 and 0/5 integrant spreads, respectively) (Figure 6.14 (A) and (B)).  
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(A) C2C12 cells 24 hr after transfection with CpEPI-eGFP 
 
(B) C2C12 cells 24 hr after transfection with CeGFP-C1 
 
(C)C2C12 cells untransfected 
 
 
Figure 6.12 Fluorescent In-Situ Hybridisation positive control of C2C12 cells 24 hours post transfection 
with the CpEPI-eGFP plasmid (A) and CeGFP-C1 plasmid (B). The plasmid can be seen as the bright red 
fluorescing red spots. Genomic DNA was counterstained with Dapi (blue). As can be seen there was a 
large amount of vector present within the transfected cells, and the plasmid was found mostly clustered 
together. The negative control was untransfected C2C12 cells (C) indicating no background. Bar, 5µm.
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Transfected C2C12 cells Final Day of experiment 
 
(A)Reserve CpEPI-eGFP 
 
 
(B)Reserve CeGFP-C1 
 
 
 
 
Figure 6.13 Fluorescent In-Situ Hybridisation of C2C12 Reserve CpEPI-eGFP sample (A) and Reserve 
CeGFP-C1 (B) sample taken on the final day of the experiment. Single white arrows indicate red 
fluorescence spots where the probe has hybridised to plasmid sequence and denotes the episomal 
status of the plasmid. The double arrows mark spots of  potential integration. Genomic DNA was 
counterstained with Dapi (blue). From these images it can be seen that CpEPI-eGFP and CeGFP-C1 could 
have integrated into the C2C12 host genome (4/9 and 3/6 integrant spreads, respectively) in addition to 
being retained as an episome by Day 60. 
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(A)G0 CpEPI-eGFP 
 
 
 
(B)G0 CeGFP-C1 
 
 
 
Figure 6.14 Fluorescent In-Situ Hybridisation of C2C12 G0 CpEPI-eGFP sample (A) and G0 CeGFP-C1 (B) 
sample taken on the final day of the experiment. Single white arrows indicate red fluorescence spots 
where the probe has hybridised to plasmid sequence and denotes the episomal status of the plasmid. 
Genomic DNA was counterstained with Dapi (blue). No evidence of integration was found of CpEPI-eGFP 
and CeGFP-C1 into the C2C12 host genome (0/6 and 0/5 integrant spreads, respectively), and vector 
copies in both populations were found present in episomal form. 
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6.2.10 Summary of Results: 
 
 Flow Cytometry 
 
FISH 
 
Vector Day 
PCR 
% 
positive 
cells 
MFI Total 
Immuno-
staining 
of 
Myotubes 
Integra-
tion 
Epi-
somal 
1 √ 47.9 ± 
0.2 
12266.
5 ± 
310.9 
586793
.8 ± 
12764 
++ 
Final Day 
Selection 
√ 6.2 ± 2.0 1851 ± 
245.1 
11235.
8 ± 
3152.7 
- 
CeGFP-
C1 
Reserve 
Final Day 
Exp 
√ 2.5 ± 2% 934.3 ± 
103.8 
2319.2 
± 
1806.4 
- 
3/6 √ 
1 √ 7.1 ± 0.2 2744.3 
± 122.4 
19490.
6 ± 
996.3 
+ 
Final Day 
Selection 
√ 3.6 ± 0.3 998 ± 
53.1 
3557.6 
± 280.2 
+ 
CpEPI-
eGFP 
Reserve 
Final Day 
Exp 
√ 0.5 ± 
0.09 
977.5 ± 
461.9 
594.8 ± 
354.8 
++ 
4/9 √ 
1 √ 47.9 ± 
0.2 
12266.
5 ± 
310.9 
586793
.8 ± 
12764 
++ 
Final Day 
Selection 
√ 8.9 ± 0.4 2082 ± 
200.3 
18394.
2 ± 
1444.2 
++ 
CeGFP-
C1 G0 
Final Day 
Exp 
√ 3 ± 1.5 911.3 ± 
209.8 
2734.1 
± 
1199.3 
++ 
0/5 √ 
1 √ 7.1 ± 0.2 2744.3 
± 122.4 
19490.
6 ± 
996.3 
+ 
Final Day 
Selection 
√ 5.6 ± 1.8 903 ± 
93.2 
5282.4 
± 2196 
++ 
CpEPI-
eGFP  
G0 
Final Day 
Exp 
√ 0.9 ± 0.5 729.8 ± 
231.6 
933.2 ± 
755.9 
++ 
0/6 √ 
 
Table 6.2 Table summarising the results obtained in this chapter for transfected C2C12 cells, indicating 
each vector that was transfected and the time point at which samples were extracted and analysed. PCR 
results are presented where a ‘√’ denotes that the Kanamycin sequence was amplified and a band was 
present; Flow Cytometry results presented include the percentage of positive cells per transfected 
population, the mean fluorescence intensity (MFI) of the positive cells, and the total amount of 
expression which was the product of expression and number of positive cells; the Immunostaining data 
is presented by ‘-‘ indicating the absence of positive myotubes, ‘+’ indicating the presence of less than 
10 positive myotubes, and ‘++’ indicating the presence of more that 10 positive myotubes; the FISH data 
is presented as the number of slides which suggested an integration event having occurred out of the 
total number of slides analysed on Day 60 only, a ‘√’ in the episomal column indicated the presence of 
episomal copies of the vector observed on the slides, and a ‘-‘ indicates none was observed. 
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6.3. Discussion: 
 
6.3.1 Transfection efficiency of CeGFP-C1 was superior to that of CpEPI-
eGFP in C2C12 cells 
 
As was demonstrated by the percentage of positive cells present in each transfected 
population on Day 1 by flow cytometry, the ability of CeGFP-C1 to transfect C2C12 cells 
was greater than that of CpEPI-eGFP. This was also observed in the previous results 
chapter (Chapter 4) and was discussed in the Chapter 4 Discussion (Section 4.3.2). 
 
6.3.2 Transgene expression resulting from CeGFP-C1 was superior to that 
from CpEPIeGFP at Days 1 and Final Day Selection 
 
The mean fluorescence intensities of the CeGFP-C1 transfected populations were 
found to be significantly greater at Days 1 and Final Day Selection to those of the 
CpEPI-eGFP transfected populations, as shown by flow cytometry. This difference was 
also found in the previous results chapter (Chapter 4), where several explanations for 
this finding included the difference in size between the two vectors, the degrees of 
positive/negative supercoiling of each vector due to the presence/absence of the 
S/MAR element, and the potential effects, due to the existence of several 
polyadenylation signals within the S/MAR element, on mRNA transcript stability of the 
transgene as expressed from CpEPI-eGFP. For a full discussion of these issues please 
refer to Chapter 4: Discussion (Section 4.3.2).  
 
6.3.3 Percentage of positive cells and transgene expression was comparable 
between all groups of transfected myoblasts by the final day of the 
experiment 
 
Despite the fact that the vectors were held in transfected cells using two different 
methods, and the fact that one vector contained an S/MAR element and the other did 
not, it was found by flow cytometry that there was no significant difference in the 
percentage of positive cells or mean fluorescence intensity between the transfected 
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populations by the final day of the experiment. This result had also occurred despite 
the fact that CeGFP-C1 and CpEPI-eGFP were shown to potentially have integrated into 
the host genome in the Reserve group, whereas no evidence of integration had been 
apparent in the G0 group. This shows two things. First, that holding the cells in G0 may 
have had a positive effect on vector retention and in the prevention of vector 
integration. This is especially significant considering that the percentage of positive 
cells and the levels of expression of both CeGFP-C1 and CpEPI-eGFP were not 
significantly different to those in the populations where CeGFP-C1 and CpEPI-eGFP 
appeared to have integrated into the host genome. And second, that there was a 
difference between holding cells in quiescence in reserve cells to holding cells in G0 
using methionine depleted low serum media, as in one evidence that the vectors had 
integrated was present whereas in the other there was not.  
6.3.4. Differences Exist In Vector Status Between Cells Held In G0 And Those 
Held In Quiescence In Reserve Cells Post Transfection With CeGFP-C1 and 
CpEPI-eGFP  
 
One of the aims of this chapter was to determine whether expression and vector 
status resulting from holding transfected cells in G0 by the use of low serum 
methionine-depleted medium was different to that obtained by holding the cells in 
quiescence in reserve cells. The flow cytometry data and the statistical analyses 
suggested that there was no significant difference between any of the four groups in 
the mean percentage of positive cells or the mean fluorescence intensity by the final 
day of the experiment. However, the FISH data suggest that differences may exist, 
when considering the finding that potential integration of both the CeGFP-C1 and 
CpEPI-eGFP vectors into the host genome was found when the transfected cells were 
held in quiescence in reserve cells, whereas no evidence of integration of either vector 
was observed in the transfected populations held in G0. It is difficult to consider any 
reasons why both vectors would integrate in the Reserve group but not in the G0 
group, as there is no experimental evidence in this chapter or in the literature to 
confirm that C2C12 myoblasts induced into G0 are different to quiescent reserve cells, 
besides the experimental manner in which they were induced (differentiation of a 
culture in low serum media as opposed to culturing in low serum methionine depleted 
media). 
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6.3.5 Evidence of a vector containing the β-IFN S/MAR element integrated in 
the C2C12 host genome 
 
A result which had not been noted in previous experiments in this thesis, nor in many 
S/MAR studies (as reviewed in Chapter1: Introduction, section 1.10), was the evidence 
pointing towards the integration of a vector containing a β-IFN S/MAR element within 
the open reading frame of a transgene, CpEPI-eGFP in this case, into the host genome. 
The cause of the possible integration is unclear, however it shows that holding 
transfected cells in quiescence as reserve cells by differentiation of a culture, followed 
by 10 days of selection, could have lead to the integration of the vector into the host 
genome. If the manipulation of primary myoblasts ex vivo prior to transplantation into 
a patient were being considered, this method of manipulation may not be considered 
suitable due to the safety implications associated with integration. 
6.3.6 A Proportion Of Cells Within The ‘Reserve’ And ‘G0’ Populations Had 
Not Been Arrested 
 
It was found by lysenin staining that not all mononucleated cells that were isolated 
after differentiating the CeGFP-C1 and CpEPI-eGFP transfected C2C12 cells were 
reserve cells, as not all of them had stained positive for lysenin. This indicates that 
there was a possibility that within the isolated reserve cell population, a proportion of 
eGFP positive cells had not been induced into quiescence to become reserve cells, 
which are all lysenin positive/CD34 positive/MyoD negative (Nagata et al., 2006; 
Beauchamp et al., 2000). 
Nagata et al showed that in a C2C12 differentiating culture, besides the presence of 
quiescent reserve cells and myotubes, there were also some mononucleated 
differentiated cells, as indicated by negative staining for lysenin and positive staining 
for myogenin, which is expressed in differentiated cells, and not in myoblasts or 
reserve cells (Nagata et al., 2006). These cells lose their ability to proliferate once they 
have differentiated, and are diluted out of the population by continuous passaging. 
Therefore, any cells of this type that was isolated with the reserve cells within the 
transfected culture would have been lost and would not be considered to have 
influenced the outcome of the experiment. 
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However, there also existed a subset of cells which were still cycling, and were not 
quiescent. In the study by Nagata et al it was found that a proportion of cells which 
were isolated with the reserve cells incorporated BrdU even after 4 days in 
differentiation medium and did not stain positive for lysenin (Nagata et al., 2006). 
These cells would be undifferentiated myoblasts which would stain negative for 
lysenin and CD34, where some would stain positive for MyoD and others would be 
MyoD negative (Beauchamp et al, 2000). These cells, had they been transfected with 
CeGFP-C1 or pEPI-eGFP and isolated with the reserve cell population, would have 
survived selection and comprised a proportion of the populations that were being 
passaged and investigated in this study. This indicates that the results obtained do not 
represent those derived of a pure culture of cells that were arrested in quiescence in 
reserve cells post-transfection. 
It was also found that not all the cells of the CeGFP-C1 and CpEPI-eGFP transfected 
populations that were put in methionine-depleted medium were arrested in G0, as 
~5% were still in S phase and ~25% in G2/M phase of the cell cycle at Day 7. Even 
though it was shown that a majority of the transfected cells had been arrested for 
several days in G0/G1, this indicates that eGFP positive cells that had not been 
arrested in G0/G1 may have also survived selection and had been present in the G0 
CeGFP-C1 and G0 CpEPI-eGFP populations. This indicates that the results obtained, as 
in the reserve group, also do not represent those derived of a pure culture of cells that 
were arrested in G0 in myoblasts post-transfection. 
 
6.3.7. C2C12 myoblasts can lose their abilty to fuse into myotubes   
 
It can be noted from the eGFP immunostaining images of the cells that were put under 
low serum medium in order to differentiate (Section 5.2.8: Figure 5.11) that some of 
the transfected populations did not form myotubes, as in the samples taken at the 
final day of selection from the G0 CpEPI-eGFP and G0 CeGFP-C1 populations and the 
Day 60 sample from the Reserve CpEPI-eGFP population, and others only formed a 
few, as in the sample taken at the final day of selection from the G0 CpEPI-eGFP 
population. A differentiating culture contains several types of cells such as reserve 
cells, myotubes, cycling myoblasts, and mononucleated differentiated cells (Nagata et 
al., 2006). When a culture is induced to differentiate but does not form myotubes it is 
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possible that some cells in the culture had initiated differentiation, if the culture had 
become confluent at any point, which can occur in situations where cells are passaged 
for an extended period of time. This confluency can occur as a result of overgrowth 
before passaging, or due to cell clumping and/or uneven spreading of the cells in a 
flask where one region is more populated and thus more confluent than another 
region of the same flask. When this occurs and differentiation is initiated in some cells, 
these cells lose their ability to proliferate or to form myotubes. These cells are 
considered to be differentiated myoblasts, identified by negative staining for lysenin 
and positive staining for myogenin (Nagata et al., 2006). 
Another subset of these cells retain the ability to proliferate but lose the ability to 
differentiate. These cells remain slowly cycling in a differentiated culture and identified 
as undifferentiated myoblasts by staining lysenin negative/CD34 negative/MyoD 
negative or positive (Beauchamp et al, 2000). Therefore, a culture that is put under low 
serum medium and contains a few myotubes but many mononucleated cells may 
contain reserve cells, mononucleated differentiated cells, and undifferentiated cells. 
This can explain the variability in the differentiation capacities of the transfected 
cultures observed. 
In this case it was difficult to assess the expression of the transgene of the transfected 
vectors in myotubes, as the different populations had differentiated in varying, 
unquantified, and undetermined amounts, and it was uncertain whether the eGFP 
positive cells were positive due to an accumulation of the protein in cells that were 
cycling more slowly due to the confluency of the culture, or due to differentiation. A 
method useful for the determination of total eGFP expression in this case would be 
Quantitative Reverse-Transcriptase Polymerase Chain Reaction (Q-RT-PCR), where 
cDNA of eGFP mRNA extracted from each sample could be made, which would then be 
quantified against a standard curve, hence determining the total amount of eGFP 
mRNA transcripts per sample. Other methods include Western Blotting or Enzyme-
Linked Immunosorbent Assay (ELISA) using anti-eGFP antibodies, which allow the 
quantification of total eGFP protein in each sample.   
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6.3.8 Populations of myoblasts that were differentiated showed eGFP 
positive myoblasts/myotubes were present from Day 1 to Final Day in G0 
CeGFP-C1, G0 CpEPI-eGFP, and Reserve CpEPI-eGFP, but not in Reserve 
CeGFP-C1, populations 
 
In differentiating the transfected cells of each group, it was found that positive 
cells/myotubes were found up to the final day of the experiment in all groups except 
the CeGFP-C1 transfected population of the Reserve group, as indicated by 
immunostaining (Section 5.2.8: Figure 5.11). In this group, the cells/myotubes were 
eGFP-negative even at the final day of selection. It was not possible to deduce the 
reason for the absence of eGFP within this population from the experiments 
conducted in this study. However, considering the fact that the flow cytometry data 
indicated that the transfected myoblasts of all groups contained eGFP positive cells, it 
is possible that this lack of expression after differentiation of the culture may be 
related to differentiation. It is possible that CeGFP-C1 in the Reserve group had 
preferentially integrated into regions of the C2C12 genome which stopped being 
expressed upon differentiation, thus leading to a decrease in eGFP transgene 
expression resulting in eGFP positive cells/myotubes not being detected by 
immunostaining. This may be a plausible explanation considering the study by Deato 
and Tijan (Deato and Tijan, 2007) where a decrease was found in the amount of the 
transcription factor TFIID upon differentiation of C2C12 myoblasts, leading to the 
shutting off of genes responsible for proliferation, and an increase in a different core 
promoter complex, resulting in different genes being switched on and transcribed for 
differentiation to occur (Deato and Tijan, 2007). Therefore it is possible that this 
change in transcription factor complexes was responsible for the silencing of the 
transgene upon differentiation. Although episomal copies were found to be present 
within this population by Final Day, it may be that the level of transgene expression 
resulting from these copies was not at a sufficient level to be detected by 
immunostaining.  
Nonetheless, the finding of eGFP positive differentiated myoblasts/myotubes within 
the other three populations was considerable in light of the fact that this had not been 
observed in the previous experiments conducted in this thesis. It also indicated that 
gene expression had not been silenced, and that the CAGG promoter was able to drive 
long-term transgene expression within C2C12 cells.  
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6.3.9 Holding C2C12 cells in G0/G1 for up to 7 day prior to selection may 
prevent vector integration into the host genome 
 
It was interesting to note that in the CeGFP-C1 and CpEPI-eGFP transfected 
populations of the G0/G1 group no evidence of integration had been detected, 
indicating that holding the cells in G0/G1 may prevent vector integration into the host 
genome. This is reminiscent of the lack of vector integration into the HepG2 cells 
observed in Chapter 3 of this thesis. Further investigation would be required to 
investigate the mechanisms by which this may have occurred in future studies. 
6.3.10  The presence of the S/MAR element within CpEPI-eGFP led to 
superior episomal vector retention and passing on to daughter cells within 
C2C12 myoblasts than CeGFP-C1 
 
The transfection efficiency of CeGFP-C1 in the experiment was shown to have been ~6 
fold greater than that of CpEPI-eGFP.  It was also shown that the decline in the 
percentage of positive cells with time in the CpEPI-eGFP population was not significant, 
whereas it was in the CeGFP-C1 population. This indicated that, although the 
percentage of positive cells in the CeGFP-C1 and CpEPI-eGFP transfected populations 
were similar by the final day, that the loss of CpEPI-eGFP episomal copies with cell 
division was less than that of CeGFP-C1, leading to the conclusion that CpEPI-eGFP was 
retained and passed on to daughter cells more effectively by C2C12 cells than CeGFP-
C1. This can be attributed to the the presence of the S/MAR element within the vector, 
considering that the only difference between the sequences of the two vectors was 
the presence S/MAR element within CpEPI-eGFP. This can only be said for the 
transfected cells in the G0/G1 group where no evidence of integration into the host 
genome had been found to occur and transgene expression was, if not completely 
then predominantly, from episomal vector copies. As possible integration had been 
observed by both vectors in the Reserve group, where transgene expression may have 
been a result of a combination of episomal and integrant vector copies of unknown 
proportions of each, no conclusions could be drawn on the aspect of efficiency of 
vector retention within the populations of this group without further investigations. 
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Chapter 7: The Assessment and Comparison of The 
Requirement/Efficacy of Several Vector Establishment 
Methods In The C2C12 in vitro Model of Muscle Cells In 
Leading to Long Term Episomal Transgene Expression by 
CeGFP-C1, CpEPI-eGFP, and Novel S/MAR vector CMYC-
pEPI 
 
7.1  Introduction 
 
In the previous chapter C2C12 cells were held in the G0G1 phase of the cell cycle for 
up to 7 days post transfection with the CeGFP-C1 and CpEPI-eGFP plasmids, and long-
term expression, with no evidence of integration of the vectors, was achieved. It then 
became imperative to determine whether this was attributed to holding the cells in 
G0/G1 post transfection, selection, or the combination of the two, as safe, long-term 
transgene expression from episomal plasmid vectors resulting without the 
requirement for selection would make ideal gene therapy vectors. Therefore, this was 
tested in this chapter. 
The C2C12 cell line was a suitable in vitro model for this investigation, as the cycling 
myoblasts represented activated satellite cells and cycling primary myoblasts 
(Kitzmann et al., 1998; Yoshida et al., 1998), where holding the cells in G0/G1 
represented the proportion of cells that had re-entered quiescence, as is likely to occur 
in vivo. Arresting cycling C2C12 cells after transfection in quiescence or G0/G1 for a 
period of time before allowing them to proliferate for many generations would also be 
an in vitro representation of the sequence of events that can occur after plasmid 
delivery into muscle in vivo. In vivo, if the plasmid delivered was to transfect cycling 
satellite cells, induced into activation due to muscle damage to replenish the muscle 
cell and fibre populations, then a proportion of these cells would return to resting in 
G0, or quiescence, for a period of time before re-activation and replication, again 
triggered by muscle injury. Considering that muscle damage occurs frequently in 
patients with Muscular Dystrophy, the ability to show that a potential gene therapy 
vector carrying a transgene can divide and maintain an adequate copy number per cell 
to ensure sustained, long-term, and sufficient levels of transgene expression within 
dividing muscle cells is essential.  
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A second aim of this chapter was to assess the efficiency with which cycling myoblasts 
transfected with CeGFP-C1 or CpEPI-eGFP achieved long term transgene expression 
without being held in G0 post-transfection or the use of selection, and to determine 
whether a difference would be found between CpEPI-eGFP and the control vector 
CeGFP-C1. This would be an in vitro representation of the proportion of cycling 
myoblasts transfected with vector which would not re-eneter quiescence and divide 
many times before terminal differentiation and the formation of myofibres in order to 
replenish the population in response to damaged fibres where, in vivo, selection is not 
applied. 
As a control in the experiment, and in order to determine whether any significant 
improvement was achieved by the other methods tested in comparison to this more 
conventional method of establishing a vector within a cell line, CeGFP-C1 and CpEPI-
eGFP transfected cells were placed under selection for ten days post-transfection, 
before allowing proliferation without selection.  
One further aim of this study was to test a novel vector containing the murine c-MYC 
S/MAR. This S/MAR element was identified by the studies conducted by Girard-Reydet 
and Cai et al (Girard-Reydet et al., 2004; Cai et al., 2003). The c-myc oncogene has the 
ability to amplify and exist as a double minute (as described in Chapter 1: Introduction 
section 1.11.1). This may be related to the c-MYC’s S/MAR element that allows the 
propagation of this amplified circular piece of DNA that needs neither a centromere 
nor telomeres to replicate within tumour cells. As it has been seen that S/MAR 
elements may act as origins of replication themselves, perhaps it is possible that the 
S/MAR is the element that is maintaining the over-amplified c-myc region as a double 
minute and allowing expression. These characteristics made the c-MYC S/MAR an 
interesting alternative S/MAR to test in replicating cells. Thus this novel S/MAR 
plasmid was created, identical to CpEPI-eGFP in sequence, except for the S/MAR 
elements’ sequences (plasmid map in Chapter 2: Materials & Methods), and will herein 
be referred to as ‘CMYC-pEPI’. In this study, CMYC-pEPI was transfected into C2C12 
cells, and expression and vector status of the transfected populations were compared 
to those of CeGFP-C1 and CpEPI-eGFP transfected populations. 
The analyses conducted on the cell samples derived included PCR to confirm the 
presence of the vector sequences within each population. Flow cytometry allowed the 
assessment of the expression of the eGFP reporter gene over time in each population, 
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and the trends observed in each population in comparison to the others. Finally, FISH 
was used to investigate the status of the vectors within the cells as episomal vectors 
and/or as integrants. 
 
Table of plasmid vectors tested in this chapter: 
 
Vector Name Vector 
Feature 
Promoter- 
Transgene 
Antibiotic 
Resistance 
Vector 
Length (kb) 
CeGFP-C1 No S/MAR 
element 
CAGG-eGFP Kan/Neo 5.0 
CpEPI-eGFP Full-length 2kb 
β-IFN S/MAR 
element 
CAGG-eGFP Kan/Neo 7.0 
CMYC-pEPI Full-length  
c-myc 1.7kb 
S/MAR element 
CAGG-eGFP Kan/Neo 6.7 
 
Table 7.1 Vectors used in this chapter, indicating the name, the presence of an S/MAR element, the 
transgene promoter, the transgene used for assessment studies, the antibiotic resistance gene, and the 
length (kb) of each construct. 
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7.2 Results 
 
7.2.1 Experimantal Design 
 
The experiment was designed as follows (flow chart Figure 7.1). Three 185cm2 flasks 
were seeded with 18.5x105 C2C12 cells. After 24 hours the cells had reached ~70% 
confluency. One flask was transfected with CeGFP-C1, the second with CpEPI-eGFP, 
and the third with CMYC-pEPI by lipofection (as described in Chapter 2: Materials & 
Methods). 24 hours after transfection each population of cells was analysed under a 
fluorescent microscope to confirm the presence of eGFP positive cells indicating that 
the cells had been successfully transfected with plasmid. Cell samples were collected 
from each population for analysis. Each transfected population was then divided into 4 
different groups with designations (A), (B), (C), and (D): 
For group (A) 1x105 cells from each population were sorted by FACs (as described in 
Chapter 2: Materials & Methods) for eGFP positive cells 24 hours post transfection, 
and the positive cells were seeded into three separate 10cm2 flasks. The cells were 
allowed to proliferate for 35 days in growth medium and were passaged each time 
culture confluency reached ~70%. Cell samples from each flask were collected on the 
final day of the experiment for further analysis.  
For group (B) cells were taken from each of the three populations and seeded at a 
density of 1x105 cells into three separate 25cm2 flasks each. These cells were held in 
the G0/G1 phase of the cell cycle in low serum methionine depleted medium for 7 
days and then put through a FACs sorter and sorted for GFP positive cells. They were 
then allowed to proliferate for 35 days in growth medium in 10cm2 flasks and were 
passaged each time culture confluency reached ~70%. Cell samples from each flask 
were collected on the final day of the experiment for further analysis. This condition 
was used to show whether holding the cells in G0/G1 was sufficient to establish the 
plasmid within the cells and was the closest in vitro model to represent what may 
occur in vivo considering selection cannot be used in vivo. 
For group (C) cells were taken from each of the three populations and seeded at a 
density of 1x105 cells into four separate 25cm2 flasks each. These cells were held in 
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G0/G1 phase of the cell cycle in low serum methionine depleted medium for 7 days, 
then put under growth medium for 24 hours. Next, they were put under G-418 
selection for 10 days, fresh media containing G-418 was added to each culture every 
48 hours, and the cells were passaged when culture confluency reached ~70%. On the 
final day of selection cell samples were collected from each population for analysis. 
The remaining cells were seeded again into fresh 10cm2 flasks, and the cells were 
passaged for a further 35 days. Cell samples from each flask were again collected on 
the final day of the experiment for further analysis. This condition was used in Chapter 
5 in order to determine whether the combination of both holding the cells in G0/G1 
followed by selection was essential for the observed long term transgene expression. 
For group (D) cells were taken from each of the three populations and seeded at a 
density of 1x105 cells into four separate 25cm2 flasks each. The cells were then put 
under G-418 selection for 10 days. On the final day of selection cell samples were 
collected from each population for analysis. The remaining cells were seeded again 
into fresh 10cm2 flasks, and the cells were passaged for a further 35 days. Cell samples 
from each flask were again collected on the final day of the experiment for further 
analysis. This condition was used in order to determine whether holding the cells in 
G0/G1 was unnecessary where only selection was essential for vector establishment, 
and acted as a control for the experiment. 
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Figure 7.1 Flow chart diagram of experimental sequence. Three flasks of C2C12 cells were seeded, each 
transfected with a different vector (CeGFP-C1 (blue), CpEPI-eGFP (red), and CMYC-pEPI (yellow)) by 
lipofection. The cells were split into 4 groups (A-D), with three flasks of each transfected population per 
group. Groups A and B were sorted for eGFP positive cells 24 hours post transfection. Group A was then 
passaged for 35 days in growth medium. Group B was held in G0/G1 for 7 days before switching to 
growth medium for 35 days. Group C cells were held in G0/G1 for 7 days, selected with G-418 for 10 
days before switching to growth medium for 35 days. Group D was selected for 10 days then switched to 
growth medium for 35 days. The green triangles mark time points at which cell samples were taken for 
further analysis.
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7.2.2 Stress-Induced Duplex Destabilisation (SIDD) Profile Generated For 
CMYC-pEPI Vector And Compared To CeGFP-C1 And CpEPI-eGFP 
 
The Stress-Induced Duplex Destabilisation (SIDD) profile of the CAGG-driven CMYC-
pEPI vector construct was calculated by the WebSIDD program designed by Dr. Craig 
Benham of the UC Davis Genome Centre (http://genomics.ucdavis.edu/benham/sidd/) 
and compared to those of CeGFP-C1 and CpEPI-eGFP previously calculated in Chapter 4 
(Figure 7.2). As was observed in the S/MAR region of CpEPI-eGFP, the cMYC S/MAR 
region is one that contains extensive strand separation potential, requiring relatively 
minimal energy to do so. However the unpairing region does not span the entire 
length of the S/MAR, which may result in a lower degree of negative supercoiling in 
the regions surrounding the element within this plasmid. The benefit of this is that less 
energy is required, in comparison to the CpEPI-eGFP plasmid, for the CAGG promoter 
region to denature, and the same applies to the region surrounding the origins of 
replication. The profile also resembles that of the CeGFP-C1 and CpEPI-eGFP plasmid in 
its regions where the DNA is most likely to denature, such as promoter and origins or 
replication regions (Figure 7.2), and the energy required for strand separation at the 
start of the CAGG promoter region is in between that of the two vectors, where CAGG 
in CeGFP-C1 requires approximately 3.0 kcal/mol (Figure 7.2(A)); CAGG in CMYC-pEPI 
requires approximately 5.0 kcal/mol, and CAGG in CpEPI-eGFP requires approximately 
8.0 kcal/mol (Figure 7.2 (B) and (C), respectively). From this profile it was expected that 
expression of the reporter gene by CMYC-pEPI would be lower than that by CeGFP-C1, 
but higher than that by CpEPI-eGFP.  
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(A) CeGFP-C1 Vector 
 
(B) CMYC-pEPI Vector 
 
(C)CpEPI-eGFP 
 
 
Figure 7.2 SIDD profile of CeGFP-C1 (A), CMYC-pEPI (B), and CpEPI-eGFP (C) calculated using WebSIDD 
program. Regions requiring lower amounts of energy (G(x)[kcal/mol]) to base unpair are centred around 
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the origins of replication (F1 Ori and pUC Ori), and the SV40 promoter region drivng Neomycin 
resistance gene. The start of the promoter region of CeGFP-C1 requires just over 3.0 kcal/mol for 
denaturation, that of CMY-pEPI requires approximately 5.0 kcal/mol, and that of CpEPI-eGFP requires 
approximately 8.0 kcal/mol. This suggests transgene expression of CMYC-pEPI may be lower than that of 
CeGFP-C1 but greater than that of CpEPI-eGFP. 
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7.2.3 Investigation of The Presence Of CeGFP-C1, CpEPI-eGFP, and CMYC-pEPI 
Vector Sequences Within C2C12 Transfected Populations In Groups (A)-(D) 
By PCR 
 
PCR analysis was conducted on samples taken on Day 1 (24 hours post transfection), 
Final Day of Selection (after 10 days under G-418 selective pressure for groups C (post 
holding in G0) and D; groups A and B were sorted and not selected), and Day 35 Post 
Sorting/Selection, from C2C12 cells transfected with CeGFP-C1, CpEPI-eGFP, or CMYC-
pEPI plasmids. 50ng of total DNA extracted from each sample was used per PCR 
reaction, and it was run for 35 cycles. The primers used were designed by Primer3 and 
lie within the Neomycin resistance gene present in the transfected vectors. The PCR 
was run for 35 cycles and the expected product size was 503bp. Products were run on 
0.8% agarose gels counterstained with ethidium bromide and visualised under UV 
light. PCR on all the samples confirmed the presence of CeGFP-C1, CpEPI-eGFP, or 
CMYC-pEPI vector in each respective transfected population, in samples of each time 
point tested under each of the different conditions (A)-(D) (Figure 7.3). 
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(I) 
 
 
(II) 
 
 
 
 
 
Figure 7.3 PCR analysis conducted on 50ng of total C2C12 DNA transfected with CeGFP-C1, CpEPI-eGFP, 
or CMYC-pEPI plasmid and put under conditions (A) and (B) (image I), and under conditions (C) and (D) 
(image II). Samples were taken on Day 1 and Day 35 post-sorting. The positive controls were 10ng of 
CeGFP-C1, 10ng of CpEPI-eGFP, and 10ng of CMYC-pEPI, and the negative controls were 50ng 
untransfected C2C12 genomic DNA, and H20. The image indicates that there were copies of plasmid 
sequence within each population at each time point. 
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7.2.4 Quantitative Analysis of Long-Term Transgene Expression Of CeGFP-C1, 
CpEPI-eGFP, and CMYC-pEPI Transfected Myoblast Populations Put Under 
Conditions (A)-(D) By Flow Cytometry 
 
Samples from each group (A)-(D) were analysed by flow cytometry at Day 1 (24 hours 
post-transfection) and at Day 35 post sorting/selection (final day of experiment after 
35 days of cell proliferation without selective pressure, after the period of selection) to 
determine the mean percentage of positive cells and the mean fluorescence intensity 
of each population. The mean percentages, mean fluorescence intensity, and total 
eGFP ± the standard error of the means (SEM) (n = 3) were plotted (Figure 7.4-7.6). 
Statistical tests were applied using NCSS statistics program to determine significance. 
The test used to compare the transfected populations to each other at each time 
point, and to compare all of the groups at of the time points was One-Way ANOVA. 
The P-value was set to 0.05 and indicated a significant difference between groups if 
P<0.05. The post-hoc Tukey-Kramer test was used to determine specifically which 
groups differed significantly from other groups. 
 The flow cytometry data showed that at Day 1 the percentage of cells transfected by 
each of the three plasmids CeGFP-C1, CpEPI-eGFP, and CMYC-pEPI were significantly 
different from each other (means of 75.2 ± 3.3%, 43.3 ± 3.3%, and 26.2 ± 1.0% 
respectively; P = 0.007) (Figure 7.4), as were the mean fluorescence intensities (means 
of 22543 ± 501.4, 1844.3 ± 40.6,and 3701.3 ± 80.9 respectively; P = 0.02) (Figure 7.5), 
and hence the total eGFP expressions (means of 1620738 ± 51237, 73801.4 ± 1068, 
and 93424.6 ± 834.9 respectively; P = 0.01) (Figure 7.6). The plasmid which transfected 
the highest percentage of cells and led to the greatest mean expression, and therefore 
the largest amount of total eGFP expression, was the CeGFP-C1 plasmid. The CpEPI-
eGFP plasmid transfected fewer cells than CeGFP-C1 but more than CMYC-pEPI. 
However, mean expression of the CpEPI-eGFP transfected population was lower than 
the other two populations, leading to its total eGFP expression to be the lowest of the 
3 populations. The CMYC-pEPI plasmid transfected the lowest amount of cells but due 
to its mean expression, which was higher than that from CpEPI-eGFP, the CMYC-pEPI 
transfected population’s total expression was higher than that of the CpEPI-eGFP 
transfected population. 
By the final day of the experiment at Day 35 post selection/sorting, in comparing all 
the groups together, many of the groups differed significantly from one another in 
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terms of the percentage of cells found to be eGFP positive (P = 0.01). The populations 
that had the highest percentages of eGFP positive cells and were similar to each other 
yet significantly different to the rest of the populations were the CpEPI-eGFP 
population of group (C) (mean of 2.5 ± 0.3%) and the eGFP-C1 population of group (D) 
(mean of 2.4 ± 0.2%).  The populations that were all similar to each other in their 
percentages of eGFP positive cells with the lowest percentages of eGFP positive cells 
were all the populations (CeGFP-C1, CpEPI-eGFP, and CMYC-pEPI) in group (A) (means 
of 0.3 ± 0.1%, 0.4 ± 0.1%, and 0.7 ± 0.03% respectively) and all the populations in group 
(B) (means of 0.3 ± 0.03%, 0.4 ± 0.03%, and 0.9 ± 0.1% respectively), in addition to the 
CMYC-pEPI population of group (D) (mean of 0.7 ± 0.1%) and the CeGFP-C1 population 
of group (C) (0.8 ± 0.2%). The CMYC-pEPI population of group (C) and the CpEPI-eGFP 
population of group (D) (means of 1.1 ± 0.1% and 1.2 ± 0.1% respectively) both had 
significantly higher percentages of positive cells than the CeGFP-C1 and CpEPI-eGFP 
populations of both groups (A) and (B) (P = 0.01). In comparing all the CeGFP-C1 
populations to one another, the ones of groups (A), (B), and (C) were all comparable, 
whereas that of group (D) had a significantly higher percentage of positive cells (P = 
0.01). In comparing all the CpEPI-eGFP populations to one another, the populations of 
groups (A) and (B) were comparable and had the lowest percentage, followed by 
population of group (D) which was significantly higher, and finally that of group (C) 
which had the highest proportion of positive cells. In comparing the CMYC-pEPI 
populations to one another, those of all the groups (A), (B), (C), and (D) were similar in 
the number of eGFP positive cells with no significant differences. 
In terms of the mean expressions compared amongst the populations of the groups at 
Day 35 post selection/sorting, the only population that was significantly different and 
had the highest mean expression was the CeGFP-C1 population of group (D) (mean of 
417 ± 28.5; P = 0.0004). The only population that did not differ from any of the 
populations was the CeGFP-C1 one of group (A) (mean of 358 ± 57.5). The mean 
fluorescence intensities of all the remaining populations were similar, which included 
the CpEPI-eGFP and CMYC-pEPI populations of group (A) (means of 278.7 ± 9.8 and 
285.7 ± 5.7 respectively), the CeGFP-C1, CpEPI-eGFP, and CMYC-pEPI transfected 
populations of group (B) (means of 274.7 ± 6.9, 284.3 ± 14.6, and 272.7 ± 7.1 
respectively) and of group (C) (means of 269.3 ± 4.2, 290.7 ± 1.2, and 270.7 ± 3.5 
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respectively), and the CpEPI-eGFP and CMYC-pEPI transfected populations of group (D) 
(means of 292.7 ± 4.8 and 275.7 ± 7.8 respectively). 
After calculating the total expression of eGFP of each population and statistically 
analysing the means, it was found that there were significant differences between the 
populations of the different groups (P value = 0.002). The population with the highest 
total expression that was significantly different to all the other groups was the CeGFP-
C1 population of group (D) (mean of 1007.4 ± 53.8). The next significantly highest total 
expression that was not similar to any other group but was significantly lower than the 
CeGFP-C1 population of group (D) was the CpEPI-eGFP population of group (C) (mean 
of 736.7 ±80.9). This was followed by the CpEPI-eGFP population of group (D) (mean of 
340.7 ± 21.7) whose expression was significantly higher than that of the CeGFP-C1 and 
CpEPI-eGFP populations of group (A) (means of 127.4 ± 53.2 and 110.3 ± 12.2 
respectively) and of group (B) (73.6 ± 10.6 and 124.2 ± 16.2 respectively), but was 
comparable to that of the CMYC-pEPI population of group (C) (mean of 288.8 ± 25.0). 
The expression of the CMYC-pEPI population of group (C) was only significantly higher 
than that of the CeGFP-C1 population of group (B). The rest of the populations all had 
amounts of total expression that did not significantly differ from one another and were 
the ones with the lowest total expressions. These populations included all populations 
(CeGFP-C1, CpEPI-eGFP, and CMYC-pEPI) of groups (A) (means of 127.4 ± 53.2, 110.3 ± 
12.2, and 209.3 ± 8.1 respectively) and (B) (means of 73.6 ± 10.6, 124.2 ± 16.2, and 
245.6 ± 19.0 respectively), as well as the CeGFP-C1 population of group (C) (mean of 
214.8 ± 67.5) and the CMYC-pEPI population of group (D) (mean of 184.3 ± 21.5). In 
comparing all the CeGFP-C1 populations to one another the populations of groups (A), 
(B), and (C) were not significantly different from each other, and the population that 
had the highest significant total expression was that of group (D). In comparing all the 
CpEPI-eGFP populations to one another, those of groups (A) and (B) had the lowest 
total expression and were similar to each other. The population with significantly 
higher total expression than groups (A) and (B) was that of group (D). The one with the 
highest was that of group (C). In comparing all the CMYC-pEPI populations to one 
another it was found that none of them differ significantly from each other.
279 
 
 
 
 
Figure 7.4 Flow cytometry analysis of the mean percentage ± SEM (error bars) of eGFP positive C2C12 
cells transfected with CeGFP-C1, CpEPI-eGFP, or CMYC-pEPI plasmid then separated into 4 different 
groups each (A)-(D), with each group composed of three replicates (n = 3). The values above the bars 
represent the mean percentage of eGFP positive cells. Group (A) cells were sorted for eGFP positive cells 
24 hours post transfection, and the positive cells were allowed to proliferate for 35 days. Group (B) cells 
were held in G0 phase of the cell cycle in low serum methionine depleted medium for 7 days, sorted for 
eGFP positive cells, then allowed to proliferate for 35 days. Group (C) cells were held in G0 phase of the 
cell cycle in low serum methionine depleted medium for 7 days, put under growth medium for 24 hours, 
put under G-418 selection for 10 days, then allowed to proliferate for 35 days. Group (D) cells were put 
under G-418 selection for 10 days then were allowed to proliferate for 35 days. At Day 1 the CeGFP-C1 
plasmid transfected the largest number of cells, followed by the CpEPI-eGFP plasmid, and finally the 
CMYC-pEPI plasmid. By Day 35 post sorting/selection the populations that had the highest percentage of 
eGFP positive cells and were similar to each other yet significantly different to the rest of the 
populations were the CpEPI-eGFP population of group (C) and the CeGFP-C1 population of group (D).  
The populations which contained the lowest percentages of positive cells and were all similar to each 
other in their percentages were the CeGFP-C1, CpEPI-eGFP, and CMYC-pEPI populations in group (A) and 
in group (B), in addition to the CeGFP-C1 population of group (C), and the CMYC-pEPI population of 
group (D). The CMYC-pEPI population of group (C) and the CpEPI-eGFP population of group (D) both 
contained a significantly higher proportion of positive cells than the CeGFP-C1 and CpEPI-eGFP 
populations of both groups (A) and (B).  
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Figure 7.5 Flow cytometry analysis of the mean fluorescence intesity ± SEM (error bars) of eGFP positive 
C2C12 cells transfected with CeGFP-C1, CpEPI-eGFP, or CMYC-pEPI plasmid then separated into 4 
different groups each (A)-(D), with each group composed of three replicates (n = 3). The were converted 
to log as the data was spread over a wide range. At Day 1 CeGFP-C1 cells showed the highest mean 
expression, followed by the CMYC-pEPI cells, and finally the CpEPI-eGFP cells. At Day 35 post 
sorting/selection where the mean expressions were compared amongst the populations of the groups, 
all of them were similar to each other. The only sample that was significantly different and had the 
highest mean expression was the CeGFP-C1 population of group (D).  
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Figure 7.6 Total expression ± SEM (error bars) of eGFP positive C2C12 cells transfected with CeGFP-C1, 
CpEPI-eGFP, or CMYC-pEPI plasmid then separated into 4 different groups each (A)-(D), with each group 
composed of three replicates (n = 3). The total eGFP fluorescence values were converted to log as the 
data was spread over a wide range. At Day 1 CeGFP-C1 cells showed the highest total expression, 
followed by the CMYC-pEPI cells, and finally the CpEPI-eGFP cells. By Day 35 post sorting/selection it can 
be seen that the population with the highest total expression was the CeGFP-C1 population of group (D). 
The next significantly highest total expression was achieved by the CpEPI-eGFP population of group (C). 
This was followed by the CpEPI-eGFP population of group (D) whose expression was significantly higher 
than that of the CeGFP-C1 and CpEPI-EGFP populations of group (A) and of group (B), but was 
comparable to that of the CMYC-pEPI population of group (C). The expression of the CMYC-pEPI 
population of group (C) was only significantly higher than that of the CeGFP-C1 population of group (B). 
The rest of the populations all had amounts of total expression that did not significantly differ to one 
another and were the ones with the lowest total expression. These populations included all populations 
(CeGFP-C1, CpEPI-eGFP, and CMYC-pEPI) of groups (A) and (B), as well as the CeGFP-C1 population of 
group (C) and the CMYC-pEPI population of group (D). 
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7.2.5 Investigation Of Episomal/Integrant Status Of CpEPI-eGFP, CeGFP-C1, 
and CMYC-pEPI Vectors In Transfected C2C12 Cell Populations Of Groups (A)-
(D) By Fluorescent In-Situ Hybridisation (FISH) Analysis On Final Day 
Samples 
 
FISH was used to determine the episomal and/or integrant status of the transfected 
vectors, as conducted in the previous chapters (as described in Chapter 2: Materials & 
Methods). The positive controls used in this experiment were C2C12 cells 24 hours 
post transfection with CpEPI-eGFP, CeGFP-C1, or CMYC-pEPI plasmid (Figure 7.7 (i), (ii), 
and (iii), respectively). From the images taken under the fluorescence microscope it 
can be seen that a large amount of plasmid was present within the positive control 
cells, as the fluorescence signal emitted was very strong. It was also clear that much of 
the plasmid observed was clustered together. The negative control in this experiment 
was untransfected C2C12 cells (Figure 7.7 (iv)). 
The images shown for the populations in group (A) indicate that there was no evidence 
of integration of CpEPI-eGFP (0/7 positive spreads) or CeGFP-C1 (0/6 positive spreads) 
into the host genome, and the plasmids were retained as episomes (Figure 7.8 (i) and 
(ii), respectively). Evidence of integration of the CMYC-pEPI into the host genome was 
found (1 integrant spread out of 7 positive spreads), indicating that this plasmid may 
have been able to integrate into the C2C12 genome without selection pressure. CMYC-
pEPI was also found in episomal status in addition to evidence being found for its 
integration (Figure 7.8 (iii)). 
Interestingly, in group (B) none of the vectors were found to have integrated into the 
host genome (0/6 CeGFP-C1, 0/7 CpEPI-eGFP, and 0/6 CMYC-pEPI positive spreads) 
(Figure 7.9 (i)-(iii)).  
Group (C) images of the CpEPI-eGFP and CeGFP-C1 populations show that the vectors 
remained episomal and there was no evidence of integration (0/7 and 0/6 positive 
spreads, respectively) (Figure 7.10 (i) and (ii), respectively). CMYC-pEPI had again 
potentially integrated into the host genome (2 integrant spreads out of 7 positive 
spreads), in addition to being retained episomally (Figure 7.10 (iii)). 
Group (D) images show that once again no evidence of CpEPI-eGFP integration was 
found and the vector remained episomal (0 integrant spreads out of 6 positive 
spreads) (Figure 7.11 (i)), whereas evidence for both CeGFP-C1 and CMYC-pEPI 
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integration into the genome was observed (2/7 and 1/5 integrant spreads, 
respectively) as well as remaining episomal (Figure 7.11 (ii) and (iii)). 
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(i) C2C12 cells 24 hr after transfection with CpEPI-eGFP 
 
 
 
(ii) C2C12 cells 24 hr after transfection with CeGFP-C1 
 
 
 
(iii) C2C12 cells 24 hr after transfection with CMYC-pEPI 
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(iv) C2C12 cells untransfected 
 
 
 
 
Figure 7.7 Fluorescent In-Situ Hybridisation positive control of C2C12 cells 24 hours post transfection 
with the CpEPI-eGFP (A), CeGFP-C1 (B), and CMYC-pEPI (C). The plasmid can be seen as the bright red 
fluorescing spots. Genomic DNA was counterstained with Dapi (blue). As can be seen there was a large 
amount of vector present within the transfected cells, and the plasmid was found mostly clustered 
together. The negative control was untransfected C2C12 cells (D) indicating no background. Bar, 5µm. 
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Group (A) transfected C2C12 cells on Final Day  
 
(i) CpEPI-eGFP 
 
 
(ii) CeGFP-C1 
 
 
(iii) CMYC-pEPI 
 
 
 
Figure 7.8 Fluorescent In-Situ Hybridisation of C2C12 cells transfected with CpEPI-eGFP plasmid (i), 
CeGFP-C1 plasmid (ii), CMYC-pEPI (iii), Day 35 post sorting, group (A). Single white arrows indicate red 
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fluorescence spots where the probe has hybridised to plasmid sequence and denotes the episomal 
status of the plasmid. The double arrows mark spots of  potential integration. Genomic DNA was 
counterstained with Dapi (blue). Images (i) and (ii) show CpEPI-eGFP and CeGFP-C1 copies, were 
retained as episomes with no evidence of integration (0/7 and 0/6 positive spreads, respectively). Image 
(iii) suggests CMYC-pEPI integrated into the C2C12 host genome (1 integrant spread out of 7 positive 
spreads) in addition to being retained as an episome.
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Group (B) transfected C2C12 cells on Final Day  
 
(i) CpEPI-eGFP 
 
 
(ii) CeGFP-C1 
 
 
(iii) CMYC-pEPI 
 
Figure 7.9 Fluorescent In-Situ Hybridisation of C2C12 cells transfected with CpEPI-eGFP (i), CeGFP-C1 (ii), 
or CMYC-pEPI (iii), Day 35 post sorting, group (B). Single white arrows indicate red fluorescence spots 
where the probe has hybridised to plasmid sequence and denotes the episomal status of the plasmid. 
Genomic DNA is counterstained with Dapi (blue). The images show no evidence of integration of the 
vectors in any of the transfected populations (0/6 CeGFP-C1, 0/7 CpEPI-eGFP, and 0/6 CMYC-pEPI 
positive spreads), and the vectors were present as episomes in these cells.
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Group (C) transfected C2C12 cells on Final Day  
 
(i) CpEPI-eGFP 
 
 
(ii) CeGFP-C1 
 
 
(iii) CMYC-pEPI 
 
Figure 7.10 Fluorescent In-Situ Hybridisation of C2C12 cells transfected with CpEPI-eGFP plasmid (i), 
CeGFP-C1 plasmid (ii), or CMYC-pEPI (iii), Day 35 post selection, group (C). Single white arrows indicate 
red fluorescence spots where the probe has hybridised to plasmid sequence and denotes the episomal 
status of the plasmid. The double arrows mark spots of potential integration. Genomic DNA was 
counterstained with Dapi (blue). Images (i) and (ii) show the CpEPI-eGFP and CeGFP-C1 plasmids were 
retained as episomes with no evidence of integration. Image (iii) shows that CMYC-pEPI, was found as 
episomes in addition to appearing to have integrated into the C2C12 host genome (2 integrant spreads 
out of 7 positive spreads, respectively). 
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Group (D) transfected C2C12 cells on Final Day  
 
 (i) CpEPI-eGFP 
 
 
(ii) CeGFP-C1 
 
 
 
(iii) CMYC-pEPI 
 
 
 
Figure 7.11 Fluorescent In-Situ Hybridisation of C2C12 cells transfected with CpEPI-eGFP plasmid (i), 
CeGFP-C1 plasmid (ii), CMYC-pEPI (iii), Day 35 post selection, group (D). Single white arrows indicate red 
fluorescence spots where the probe has hybridised to plasmid sequence and denotes the episomal 
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status of the plasmid. The double arrows mark spots of potential integration. Genomic DNA was 
counterstained with Dapi (blue). Image (i) shows CpEPI-eGFP was retained as an episome with no 
evidence of integration (0/6 spreads). Images (ii) and (iii) show that CeGFP-C1 and CMYC-pEPI were 
present as episomes in addition to appearing to have integrated into the C2C12 host genome (2/7 and 
1/5 integrant spreads, respectively). 
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7.2.6 Summary of Results: 
 Flow Cytometry FISH 
 
Vector Day 
PCR 
% 
Positive 
Cells 
MFI Total Integra-
tion 
Epi-
somal 
1 √ 75.2 ± 3.3 22543 ± 501.4 1620738 ± 51237 √ CeGFP-
C1 
A 
Final 
Day 
√ 0.3 ± 0.1 358 ± 57.5 127.4 ± 53.2 
0/6 
√ 
1 √ 75.2 ± 3.3 22543 ± 501.4 1620738 ± 51237 √ CeGFP-
C1 
B 
Final 
Day 
√ 0.3 ± 0.03 274.7 ± 6.9 73.6 ± 10.6 
0/6 
√ 
1 √ 75.2 ± 3.3 22543 ± 501.4 1620738 ± 51237 √ CeGFP-
C1 
C 
Final 
Day 
√ 0.8 ± 0.2 269.3 ± 4.2 214.8 ± 67.5 
0/6 
√ 
1 √ 75.2 ± 3.3 22543 ± 501.4 1620738 ± 51237 √ CeGFP-
C1 
D 
Final 
Day 
√ 2.4 ± 0.2 417 ± 28.5 1007.4 ± 53.8 
2/7 
√ 
1 √ 43.3 ± 3.3 1844.3 ± 40.6 73801.4 ± 1068 √ CpEPI-
eGFP 
A 
Final 
Day 
√ 0.4 ± 0.1 278.7 ± 9.8 110.3 ± 12.2 
0/7 
√ 
1 √ 43.3 ± 3.3 1844.3 ± 40.6 73801.4 ± 1068 √ CpEPI-
eGFP 
B 
Final 
Day 
√ 0.4 ± 0.03 284.3 ± 14.6 124.2 ± 16.2 
0/7 
√ 
1 √ 43.3 ± 3.3 1844.3 ± 40.6 73801.4 ± 1068 √ CpEPI-
eGFP 
C 
Final 
Day 
√ 2.5 ± 0.3 290.7 ± 1.2 736.7 ±80.9 
0/7 
√ 
1 √ 43.3 ± 3.3 1844.3 ± 40.6 73801.4 ± 1068 √ CpEPI-
eGFP 
D 
Final 
Day 
√ 1.2 ± 0.1 292.7 ± 4.8 340.7 ± 21.7 
0/6 
√ 
1 √ 26.2 ± 1.0 3701.3 ± 80.9 93424.6 ± 834.9 √ CMYC-
pEPI 
A 
Final 
Day 
√ 0.7 ± 0.03 285.7 ± 5.7 209.3 ± 8.1 
1/7 
√ 
1 √ 26.2 ± 1.0 3701.3 ± 80.9 93424.6 ± 834.9 √ CMYC-
pEPI 
B 
Final 
Day 
√ 0.9 ± 0.1 272.7 ± 7.1 245.6 ± 19.0 
0/6 
√ 
1 √ 26.2 ± 1.0 3701.3 ± 80.9 93424.6 ± 834.9 √ CMYC-
pEPI 
C 
Final 
Day 
√ 1.1 ± 0.1 270.7 ± 3.5 288.8 ± 25.0 
2/7 
√ 
1 √ 26.2 ± 1.0 3701.3 ± 80.9 93424.6 ± 834.9 √ CMYC-
pEPI 
D 
Final 
Day 
√ 0.7 ± 0.1 275.7 ± 7.8 184.3 ± 21.5 
1/5 
√ 
 
Table 7.2 Table summarising the results obtained in this chapter for transfected C2C12 cells, indicating 
each vector that was transfected and the time point at which samples were extracted and analysed. PCR 
results are presented where a ‘√’ denotes that the Kanamycin sequence was amplified and a band was 
present; Flow Cytometry results presented include the percentage of positive cells per transfected 
population, the mean fluorescence intensity (MFI) of the positive cells, and the total amount of 
expression which was the product of expression and number of positive cells; the FISH data is presented 
as the number of slides which suggested an integration event having occurred out of the total number 
of slides analysed on Day 60 only, a ‘√’ in the episomal column indicated the presence of episomal 
copies of the vector observed on the slides, and a ‘-‘ indicates none was observed. 
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7.3 Discussion: 
 
7.3.1 CMYC-pEPI transfected cells had greater transgene expression than 
CpEPI-eGFP at Day 1 but had a lower transfection efficiency than both CeFP-
C1 and CpEPI-eGFP. 
 
A general comparison of the SIDD profiles calculated of the three vectors CeFP-C1, 
CpEPI-eGFP, and CMY-pEPI showed similaries in their destabilised regions, such as at 
the CAGG and SV40 promoter regions and the F1 and pUC origins of replication. The 
profiles also indicated that the energy required for strand separation at the start of the 
CAGG promoter region in CMYC-pEPI was greater than that of CeGFP-C1 but lower 
than that of CpEPI-eGFP, which suggested that the levels of transgene expression that 
would result from CMYC-pEPI would be lower than CeGFP-C1 but greater than CpEPI-
eGFP. This was confirmed by flow cytometry, where the mean fluorescence intensity 
and total expression resulting from the CMYC-pEPI vector were significantly higher 
than those resulting from CpEPI-eGFP, and were significantly lower than those 
resulting from CeGFP-C1. 
Considering that the transfection efficiency of CpEPI-eGFP was lower than that of 
CeGFP-C1, as was shown in this chapter by flow cytometry, and as was previously 
found in Chapter 4, and was attributed to the presence of the S/MAR element, whose 
potential for destabilisation may have caused its vector to be in a more open-circular 
conformation as opposed to more a supercoiled one, the transfection efficiency of 
CMYC-pEPI was also expected to be lower than that of CeGFP-C1 due the presence of 
the S/MAR element within its sequence (as discussed in Chapter 4 Discussion: Section 
4.3.2). This was confirmed by flow cytometry, where the percentage of positive cells 
transfected by CeGFP-C1 was significantly greater to that transfected by CMYC-pEPI. 
However, it was also found that CMYC-pEPI’s transfection efficiency was significantly 
lower to that of CpEPI-eGFP, even though both vectors are the same size of 6.7kb. One 
possible explanation is that the most significant and major region of destabilisation in 
CpEPI-eGFP was the S/MAR region, whereas CMYC-pEPI had several regions of 
considerable propensity for strand separation, as was shown by the SIDD profiles, 
leading to a more open vector conformation than CpEPI-eGFP, and thus a lower 
transfection efficiency (Cherng et al., 1999).  
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7.3.2 Holding CeGFP-C1, CpEPI-eGFP, and CMYC-pEPI transfected cells in 
G0/G1 alone did not improve long-term transgene expression over 
unselected transfected populations  
 
Condition (B) under which the cells were put involved holding the transfected cells in 
the G0/G1 phase of the cell cycle by using methionine-depleted low-serum medium for 
7 days and then sorting the eGFP positive cells, before allowing the cells to proliferate 
for 35 days. This condition was tested in order to determine whether holding the cells 
in G0/G1 would suffice to establish a plasmid as an episome, without the requirement 
for selection. The flow cytometry data for CeGFP-C1, CpEPI-eGFP, and CMYC-pEPI 
transfected populations in group (B) indicated that the percentage of positive cells and 
total expression were similar to those seen in the populations of group (A), where the 
cells were transfected, sorted, and then allowed to proliferate for 35 days without any 
selection pressure imposed at any point. Expression was extremely low in every 
transfected population in both groups (A) and (B), and eGFP positive cells made up a 
very small percentage of the transfected populations, none of which differed 
significantly from the others by the final day of the experiment. This finding is 
important in that it has shown that holding transfected cells in quiescence is not 
enough to establish an episome where, upon re-activation of the cells and re-entry 
into the cell cycle, the vector would not be effectively retained by the cells and would 
be diluted out of the population as a result of cell proliferation. The implication of this 
finding in relation to gene therapy is that that targeted quiescent satellite 
cells/primary myoblasts would not effectively pass CeGFP-C1, CpEPI-eGFP, or CMYC-
pEPI vectors to their progeny upon re-activation and throughout proliferation, leading 
to the loss of the vectors and inadequate expression of the therapeutic transgene. 
Thus it has become evident holding cells in G0/G1 alone is not sufficient for increasing 
the number of positive cells and expression using the CpEPI-eGFP vector, and that 
selection plays an important role in the establishment of this vector. This could 
indicate that certain events within the cells, such as further DNA markings, were made 
to the CpEPI-eGFP vector DNA under selection, which lead to the improved expression 
and possibly plasmid retention noted in the CpEPI-eGFP transfected population of 
group (C). 
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7.3.3 Not all S/MAR elements prevent vector integration into the host 
genome  
 
Evidence of CMYC-pEPI plasmid integration into the C2C12 host genome was found in 
the final day samples obtained from CMYC-pEPI transfected populations of groups (A), 
(C), and (D). It was interesting to note that evidence towards the integration of the 
vector had occurred in the group (A) population, even though no selection was 
imposed upon the transfected population in this group. Integration is normally 
expected when selection pressure is applied, unless the plasmid transfected has 
sequences which are also found within the host genome, in which case homologous 
recombination may occur, thus leading to integration. The cMYC S/MAR used in this 
experiment was of murine origin, as was the C2C12 cell line. Therefore it is possible 
that integration had resulted due to recombination between the cMYC S/MAR 
sequence on the plasmid transfected and the cMYC S/MAR sequence within the c-myc 
proto-oncogene locus in the C2C12 cells’ genomic DNA.  
It is known that S/MARs can be found at the 5’ and 3’ ends of genes and also within 
introns (Schubeler et al., 1996), and Boulikas theorised that there are different classes 
of S/MARs, and that the ones that are transcribed are regulated by the cells (as 
described in Chapter 1: Introduction, Section 1.9) (Boulikas, 1995). S/MARs found 
within introns must clearly be transcribed and are not likely to obstruct transcription. 
But not all S/MARs are transcribed, such as the non-intronic variety, and they do not 
function as enhancers as Bode et al had demonstrated in transient expression assays 
(Bode et al., 1995). Bode et al stated that some S/MAR constructs tend to integrate 
into the genome at a higher rate than even their non-S/MAR controls as a result of the 
‘high recombinogenic potential’ of their sequences (Bode et al., 1995). It is possible 
that due to the fact that the cMYC S/MAR is of murine origin, and is a non-intronic 
element naturally located upstream of the c-myc proto-oncogene promoter, that 
integration, if occurring, was most likely as a result of the high recombinogenic 
potential of the sequences. It is interesting to note that it was shown in Chapter 3 that 
pEPI-eGFP, the vector containing the intronic β-IFN S/MAR of human origin (Bode et 
al., 1995), was tested in the two human derived cell lines HepG2 and HeLa, the 
genomes of which no integration was observed. 
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7.3.4 Potential CMYC-pEPI integration into the C2C12 host genome did not 
lead to significant or improved long-term transgene expression as was 
observed for long-term transgene expression by potentially integrated 
CeGFP-C1 
 
It is interesting to note that the integration that was observed of CMYC-pEPI into the 
C2C12 host genome in groups (A), (C), and (D) did nothing to improve the expression of 
the CMYC-pEPI population, where the percentage of positive cells and the total 
expression were all comparable to one another. However, CeGFP-C1 was found to 
potentially have interated into the host genome under condition (D), where the 
transfected cells were put under selection for 10 days, and this led to a significant 
improvement in the resulting total expression and percentage of positive cells of the 
population at the final day of the experiment, total expression was significantly higher 
than any of the populations of any of the groups (A)-(D), and the percentage of 
positive cells was significantly higher than all the populations except the CpEPI-eGFP 
population of group (C), where the percentages were similar and not significantly 
different to each other. 
One explanation for this difference in expression, despite the fact that both vectors 
may have integrated into the host genome, is that integration of the CMYC-pEPI vector 
may have occurred in similar regions within each cell, which is plausible considering 
integration in the CMYC-pEPI transfected populations occurred without the 
requirement for selection pressure, whereas CeGFP-C1 integration only occurred due 
to selective pressure, as the evidence from the FISH data suggests. These regions of 
CMYC-pEPI integration may have not been favourable for the expression of the vector, 
thus leading to the same low level pattern of expression observed in the CMYC-pEPI 
populations of groups (A), (C), and (D). In a study by Heng et al plasmids containing 
reporter transgenes and S/MARs were integrated into the host genome of mouse and 
human cells in order to study positional effects of S/MARs on transgene expression 
within genomic DNA (Heng, et al., 2004). When gene expression was analysed it was 
found that not all the transgenes were being expressed but that the level of expression 
correlated with the number of transgenes associated with the matrix via an S/MAR. 
The expression of a transgene and the number of copies integrated do not show a 
linear relationship or a direct correlation. They also showed that the correlation that 
was observed between gene expression and the transgene’s proximity to the matrix 
297 
 
highlights the significance of DNA’s proximity and contact with the matrix for 
transcription, and it appears to be vital for transcription to take place. In this study 
they also found that when integrating 20-40 copies of the transgene into the genome, 
the expression profile was comparable to that where 1-2 copies were integrated. This 
is because cells are selective about which S/MARs will anchor to the matrix and so not 
every insert will be expressed (Heng et al., 2004). Thus, the position of the integrant is 
crucial, where the integration of multiple copies of a gene does not necessarily lead to 
an increase in gene expression.  
 
7.3.5 Transgene expression was similar in CMYC-pEPI transfected 
populations in groups (A) – (D) 
 
It is interesting to note that integration was not observed in the CMYC-pEPI 
transfected population under condition (B) and yet the expression profile of this 
population was comparable to that of the CMYC-pEPI populations under conditions 
(A), (C), and (D) where the vector had appeared to have integrated into the host 
genome. There are two possibilities which could explain this. The first is that 
expression of the integrants had been silenced and, considering this vector had also 
remained episomal within all the populations, the low and comparable level of 
expression exhibited in each population was due to expression resulting from these 
episomal copies. This would lead to the conclusion that none of conditions (A)-(D) 
affected expression and similar amounts of CMYC-pEPI vector remained episomally 
within C2C12 cells without the requirement, nor potential to improve 
expression/retention, with the use of selection, or holding in G0/G1 prior to selection. 
The second possibility is that holding the CMYC-pEPI population in G0/G1 without 
selection had a more profound effect on expression and number of positive cells 
expressing the transgene, where the eGFP product was produced simply from the 
episomes, with no contribution from integrants, whereas the other populations 
produced eGFP from expression of both their episomal and their integrant copies. In 
this case, the conclusion would be that holding the CMYC-pEPI vector within cells in G0 
for 7 days could be said to have a marked effect upon improving expression of the 
episomal vector. However, neither possibility can be determined from the data 
obtained from these experiments, and further analysis would be required to come to a 
298 
 
solid conclusion. Such further investigations may include the use of LAM PCR to 
identify the regions into which CMYC-pEPI had integrated into the genome in each 
population to identify whether the integrants were positioned in heterochromatin, 
leading to silencing of expression. 
 
7.3.6 Holding CeGFP-C1, CpEPI-eGFP, and CMYC-pEPI transfected cells in 
G0/G1 prevented or decreased the incidence of vector integration into the 
C2C12 host genome 
 
The group (B) transfected cells were held in G0/G1 phase of the cell cycle by using 
methionine-depleted low-serum medium for 7 days and the eGFP positive cells were 
then sorted, before allowing the cells to proliferate for 35 days. Interestingly, the FISH 
results suggested that no integration had occurred in the CeGFP-C1, CpEPI-eGFP, or 
CMYC-pEPI transfected populations, but that episomal copies were detected of each of 
the three vectors within their respective populations. This finding was even more 
surprising in that the CMYC-pEPI vector had shown evidence of integration even when 
no selection pressure had been applied, as in condition (A). It is unclear as to how 
holding the transfected cells in G0/G1 for 7 days before allowing the cells to proliferate 
for 35 days may lead to the prevention or decrease in the frequency of vector 
integration within the host genome. However, considering that the idea of holding 
transfected cells in G0/G1 was conducted in order to give C2C12 cells more time 
before cell replication to epigenetically mark the transfected vectors, it is possible that 
this marking was linked to the lack of integration observed. Even in group (C) where 
the transfected cells were put under selection for 10 days after being held in G0/G1 for 
7 days, the CeGFP-C1 and CpEPI-eGFP vectors were found not to integrate into the 
host genome. This finding had also been observed in the previous chapter (Chapter 5). 
Although CMYC-pEPI had been evidenced to integrate into the host genome in the 
CMYC-pEPI transfected population of group (C), it is possible, as previously discussed, 
that this had occurred as a result of recombination due to a combination of the cMYC 
S/MAR’s high recombinogenic potential and the imposition of selection, and may not 
occur with vectors that do not contain sequences with high recombinogenic potential 
in C2C12 cells, such as CeGFP-C1 and pEPI-eGFP. This highlights the importance of 
using sequences in vectors that do not have the potential to integrate into the host 
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genome if the vectors are to be safe for use in gene therapeutic applications. It also 
highlights the importance of further investigations to compare the epigenetic markers 
imposed on the transfected vectors, which may be different in transfected populations 
of different groups, and which may also differ between the vectors, as this may give an 
indication of the protective effect of holding transfected cells in G0/G1 prior to 
proliferation.  
 
7.3.7 Transgene expression declined more significantly with time in 
populations where CeGFP-C1 integration was not detected  
 
The CeGFP-C1 population of group (D), where the cells were put under selection for 10 
days post transfection and CeGFP-C1 had potentially integrated into the host genome, 
had a significantly higher percentage of positive cells and total expression than the 
CeGFP-C1 populations of groups (A)-(C). As was shown from the PCR data, CeGFP-C1 
vector copies were still present within the cell populations in the CeGFP-C1 
populations of groups (A)-(C), and the FISH analysis indicated that the vector was 
present within cells of these populations as an episome with no evidence of 
integration. Therefore, it is possible that without CeGFP-C1 integration into the host 
genome, expression had declined much more significantly than where it had been 
found to have integrated, regardless of the condition the cells were put under post 
transfection, due to a loss of episome with cell division. However, since the possibility 
that the vector had integrated into the genome in all the populations tested cannot be 
excluded, it is possible then that the vector may have integrated into each of the 
populations, but had done so in regions which did not lead to transgene expression 
levels as high as those that were observed in the CeGFP-C1 population of group (D).  
 
7.3.8 Holding CpEPI-eGFP transfected C2C12 Cells in G0/G1 for 7 days 
followed by selection for 10 days significantly improved long-term transgene 
expression and episomal vector retention over selection alone  
 
The populations within group (C) were transfected then held in G0 for 7 days, followed 
by selection for 10 days, before allowing the cells to proliferate for 35 days. The flow 
cytometry data showed that a statistically significant larger percentage of positive cells 
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and total expression were observed in the Day 35 sample of the CpEPI-eGFP 
population of group (C) than the CpEPI-eGFP populations of groups (A), (B), and even 
(D), where the cells were transfected and put under selection for 10 days before 
allowing them to proliferate for 35 days. This indicates that putting a population of 
cells transfected with CpEPI-eGFP under the conditions of group (C) clearly improves 
the vector’s expression and retention/maintenance in a higher percentage of the cells. 
The PCR data showed that CpEPI-eGFP vector copies were still present within the 
population by the final day of the experiment, and the FISH analysis of this population 
showed plasmid was present within the cells as episomes, with no evidence of 
integration. Without ruling out integration it can still be said that if integration did 
occur it was an infrequent event, considering none was detected.  
In considering the fact that CpEPI-eGFP transfected significantly fewer cells than 
CeGFP-C1 again in this chapter (as was also demonstrated in Chapters 4 and 5), but it 
was demonstrated by flow cytometry that the percentage of positive cells within the 
CpEPI-eGFP transfected population of group (C) was significantly greater to that of the 
CeGFP-C1 population of group (C) by the final day of the experiment, and considering 
that the only difference between CpEPI-eGFP and CeGFP-C1 was the presence of the β-
IFN S/MAR element in the former vector, it can be concluded that CpEPI-eGFP was 
being retained episomally more effectively in proliferating C2C12 cells than CeGFP-C1 
was, and that the observed superior vector retention could be attributed to the 
combination of the use of the β-IFN S/MAR element in the vector, and the holding of 
this vector in cells in G0 post-transfection for 7 days, followed by a 10 day selection 
period, both of which may have allowed the vector to be marked effectively for 
episomal maintenance and retention. 
Interestingly, it was seen in Chapter 5 that the percentage of positive cells and total 
expression of the CeGFP-C1 and CpEPI-eGFP populations held under such conditions as 
that of group (C) were not significantly different to one another, suggesting that 
holding both vectors under the conditions of group (C) had a similar effect on both 
vectors, whereas that was not the case in this chapter, as has been shown. This 
discrepancy between the results of Chapter 5 and this chapter regarding CeGFP-C1 
may indicate that CeGFP-C1 may have not been maintained as an episome within 
C2C12 cells and had been diluted out of the population with cell proliferation. And, 
where a larger amount of CeGFP-C1 may have been initially transfected per cell in 
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Chapter 5 than may have been in the cells in this chapter, resulting in greater amounts 
of vector present within the cells by the final day of the experiment, leading to greater 
total expression which matched the expression and percentage of positive cells of the 
CpEPI-eGFP population, fewer copies may have initially been transfected in this 
chapter in comparison, thus leading to lower total expression and fewer numbers of 
positive cells. This would lead to the conclusion that holding cells transfected with 
CeGFP-C1 in G0/G1 for 7 days followed by selection for 10 days had no direct or 
significant effect on vector retention and/or transgene expression by CeGFP-C1. 
 
7.3.9 CpEPI-eGFP population held in G0 for 7 days followed by selection for 
10 days contained a significantly greater percentage of positive cells and 
expressed greater amounts of transgene than the same population put under 
selection alone post transfection. 
 
A significant finding in this study was the confirmation that holding transfected cells in 
G0/G1 for up to 7 days prior to selection (CpEPI-eGFP population of group (C)) led to 
an improvement in vector retention and passing on to daughter cells in a dividing 
population of C2C12 myoblasts over using selection alone (CpEPI-eGFP population of 
group (D)). This may be an indication that slowing the cells in G0/G1 phase of a rapidly 
proliferating population could lead to an increased number of plasmid vectors being 
epigenetically marked, ultimately improving long-term transgene expression within the 
population.  
 
7.3.10 CpEPI-eGFP population held in G0 for 7 days followed by selection for 
10 days contained a similar percentage of eGFP positive cells by episomally 
retained CpEPI-eGFP as a population containing potentially integrated and 
episomal CeGFP-C1 vector 
 
Holding cells transfected with CpEPI-eGFP in G0 for 7 days, followed by selection for 10 
days before allowing the cells to proliferate significantly improved expression to the 
point where its population had a larger amount of positive cells than any of the other 
populations at the final day of the experiment, except for the CeGFP-C1 population of 
group (D). As it was shown that the CeGFP-C1 population of group (D) had had the 
CeGFP-C1 plasmid potentially integrated into the host genome in addition to being 
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episomal, whereas there was no evidence that the CpEPI-eGFP population of group (C) 
had had the CpEPI-eGFP plasmid integrate and that it had been found to be retained 
episomally, the positive effect of condition (C) on the CpEPIeGFP population was even 
more significant.  
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Chapter 8: Concluding Remarks 
 
8.1 
 
The results obtained in Chapter 3 indicate several things. First, pEPI-eGFP had not been 
found to integrate into any of the three cell lines: HeLa, C2C12, or HepG2. Second, it 
can be seen that the S/MAR plasmid is expressed and maintained differently according 
to cell type. Whereas plasmid expression was high in the HepG2 cells by the final day 
of the experiment, it was very low in the other two cell lines HeLa and C2C12. Variable 
expression of pEPI-eGFP between cell lines is in agreement with the study by 
Papapetrou et al (Papapetrou et al., 2006). 
Expression levels appeared to improve in the C2C12 cells once the myoblasts were 
differentiated into myotubes, either as a result of eGFP accumulation within these 
non-dividing cells or due to different factors expressed as a result of differentiation 
that allow better expression of the plasmids, or perhaps even a combination of both 
these factors.  
The mini-S/MAR plasmid tested in the C2C12 cells did not show sustained transgene 
expression and it was shown to be very low by the final day of the experiment.  
In investigating the status of the vectors within the cells at the final day of the 
experiment evidence was found by FISH analysis for eGFP-C1 integration into the HeLa 
and C2C12 host genomes by the final day of the experiment. It was also found that the 
mini-S/MAR plasmid had potentially integrated into the C2C12 host genome. 
Therefore, these vectors pose a serious safety issue within these cell lines and would 
not be suitable for use as vectors for gene delivery. Interestingly, eGFP-C1 was found 
not to have integrated into the HepG2 host genome, indicating that selection does not 
always lead to the integration of a plasmid that may not contain an S/MAR element.  
 
8.2 
 
Results Chapter 5 aimed to improve transgene expression of the S/MAR plasmid by 
changing the promoter from CMV to CAGG, and again comparing this vector to the 
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control plasmid in C2C12 cells. The SIDD profiles generated for the CAGG vectors 
indicated a more open conformation of the plasmids at the promoter region than that 
of the vectors driven by the CMV promoter. This showed that the sequences that make 
up a vector could have a direct effect upon the configuration of the vector which in 
turn could directly affect transcription and thus expression. Despite the more open 
conformation it was shown that expression declined with time, again to very low 
levels, by the final day of the experiment. As in Chapter 3, no evidence of integration 
was detected of the CpEPI-eGFP plasmid into the C2C12 host genome, however 
evidence for the CeGFP-C1 plasmid’s integration was found again. The transfection 
efficiency of CeGFP-C1 was ~3 fold greater than that of CpEPI-eGFP. Considering this, 
and that by the the final day of selection and final day of the experiment expression 
was similar, and considering the lack of integration of CpEPI-eGFP but the potential 
integration of CeGFP-C1, the CpEPI-eGFP vector could be said to have been retained 
and passed on more effectively in this cell line than CeGFP-C1. 
 
8.3 
 
The next results chapter, Chapter 6, also aimed to improve transgene expression of the 
S/MAR vector, by arresting the cells in G0/G1 for up to 7 days or quiescence for up to 
10 days post-transfection with CeGFP-C1 or CpEPI-eGFP, prior to 10 days of selection, 
and then allowing them to proliferate. When quantified, the expression levels of the 
CpEPI-eGFP and the CeGFP-C1 plasmids in both the G0/G1 and the Reserve groups 
were similar to each other by the final day. Significantly, however, expression was even 
detected in the differentiated myotubes on the final day of the experiment in the 
CpEPI-eGFP G0/G1 and Reserve populations on the final day of the experiment using 
immunostaining, which had not been observed in the first two results chapters. 
Surprisingly, evidence towards CpEPI-eGFP integration into the host genome was 
found in the Reserve group, as it had for CeGFP-C1. The reason for the CpEPI-eGFP 
potential integration into the host genome in cells held under such conditions are not 
clear, and further investigations are required to identify possible causative events. It 
does, however, indicate that cells held in quiescence as reserve cells, achieved by the 
differentiation of a culture of myoblasts, may exist in a different state to those held in 
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G0/G1 by switching the medium to low serum methionine depleted medium. These 
differences are also yet to be elucidated, and require further investigation.  
Conversely, no evidence of CpEPI-eGFP integration in the G0/G1 group was found, 
leading to the conclusion that arresting the cells in G0/G1 may have led to a greater 
amount of epigenetically marked vectors within the cells which led to an improvement 
in long-term expression. CeGFP-C1 was also found not to have integrated into the host 
genome in the G0/G1 group, which led to the theory that holding C2C12 cells in G0/G1 
may confer protection from plasmid vector integration into the host genome.  
It was further concluded in this chapter that CpEPI-eGFP was retained and passed on 
to daughter cells significantly more effectively by C2C12 cells than CeGFP-C1 as an 
episome in the G0/G1 group, as a result of the presence of the S/MAR element within 
the vector. 
 
8.4 
 
Chapter 7 had several aims. One aim was to test a vector containing the c-myc proto-
oncogene S/MAR in place of the β-IFN S/MAR in C2C12 cells. It was found that 
expression levels of this vector declined sharply and resulted in very low and 
comparable percentages of positive cells and total levels of transgene expression by 
the final day of the experiment, regardless of the condition under which the 
transfected cells were put under (conditions (A)-(D)). FISH analysis indicated that this 
vector was present as an episome within the cells, but it is possible that, as with the 
CeGFP-C1 vector, that they were only passively maintained and were being diluted out 
of the population with cell divisions. Evidence was also found for the vector integration 
into the host genome in the cell populations of three of the four conditions: (A), (C), 
and (D). The fact that the vector had potentially integrated under condition (A), where 
no selection was used so the cells were not required to retain the vector in some form 
in order to be able to survive, indicated that the vector may have integrated as a result 
of recombination due to high similarities between its sequences and some found 
within the host genome’s. It was interesting to note that no evidence of integration of 
this vector was found in transfected cells held in G0/G1 in group (B), where no 
selection was subsequently imposed. This may be further evidence to indicate that 
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holding cells in G0/G1 protects from vector integration into the host genome. CMYC-
pEPI did however appear to have integrated into the host genome in group (C) where 
selection was imposed after holding in G0/G1, which may indicate that selection may 
have induced integration of the vector, counteracting the effects of holding in G0/G1. 
There is no direct evidence to support this, however, and further investigations are 
required in order to deduce any solid conclusions. Still, the fact that expression was 
not significantly different between the populations where the vector had potentially 
integrated and was present as episomes, and where it had not integrated and was only 
present as episomes, suggests two things. One, that the observable expression was a 
result of transgene expression resulting from the episomal copies of the vector, and 
two, that this vector was possibly integrating into similar regions within the genome as 
a result of highly recombinogenic sequences which were leading to transgene 
silencing. This is plausible when comparing this vector to CeGFP-C1, where its lack of 
integration into the host genome led to low levels of transgene expression by episomal 
vector copies, yet once evidence had pointed towards its integration, the levels of 
expression were significantly greater, whereas in the case of CMYC-pEPI, low levels of 
expression were present regardless of integration. Considering that the cMYC S/MAR 
was of murine origin, as were C2C12 cells, the possibility of integration due to 
recombination could not be excluded. This showed that not all S/MAR elements can 
confer the unique properties to the plasmids into which they are inserted as the β-IFN 
S/MAR has generally been able to, as has been demonstrated in this thesis and other 
studies (as reviewed in Chapter 1: Introduction, Section 1.10). Hence, a vector 
containing the cMYC S/MAR element has been found to be an unsuitable candidate for 
use as a vector for gene therapy. 
The experiments in Chapter 6 also aimed to determine several other things. First, it 
was important to determine whether holding C2C12 cells post-transfection in G0/G1 
without the imposition of selection would suffice in establishing CpEPI-eGFP or eGFP-
C1 as episomes. It was found that this was not the case, as vector was diluted out of 
the populations with cell division. In fact, the percentages of positive cells and total 
levels of transgene expression were very low in the populations of this group (B), and 
were comparable to those of group (A), where no method of vector establishment was 
imposed. Hence these results made it clear that if this in vitro model was an accurate 
representation of what may occur in vivo, then activated satellite cells transfected with 
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either CeGFP-C1 or CpEPI-eGFP which had committed to differentiation and re-
population of myocytes and myofibres would not retain these vectors, and these 
vectors would eventually either become diluted out of the population or remain 
present in very few copy numbers. These results may also indicate that vector copy 
dilution would also occur in those activated satellite cells that had been transfected 
prior to becoming withdrawn from the cell cycle for a period of time and then re-
activating in response to injury, as being held in G0/G1, or quiescence, was not 
sufficient to establish the vectors. 
The results in this chapter also showed that selection was essential for CpEPI-eGFP 
vector establishment, as the percentage of positive cells and total level of expression 
of this population (group (C)) was significantly greater than those of the CpEPI-eGFP 
populations where no selection had been imposed (groups (A) and (B)). And, once 
again, CpEPI-eGFP was found not to have integrated into the host genome. 
Furthermore, it was found that selection imposed post-arrest in G0/G1 resulted in 
significantly improved vector establishment in a population of CpEPI-eGFP transfected 
cells, as the percent of positive cells and total expression in this group were 
significantly greater than those of the CpEPI-eGFP population where only selection had 
been imposed post-transfection (group (C)). As was shown in Chapter 5, no evidence of 
CpEPI-eGFP integration into the host genome was found, meaning that expression was 
predominantly, if not completely, from vector copies present as episomes within the 
cells. 
When selection was not employed in establishing the CeGFP-C1 vector, similar results 
were seen as the CpEPI-eGFP vector where minimal expression was observed by the 
final day of the experiment. No integration was indicated by FISH in these two 
conditions (A & B), however the presence of some episome was detected within some 
of the cells of these populations. Integration is normally expected to occur under 
selection, therefore without it the CeGFP-C1 vector remained episomal but was slowly 
being diluted out of the populations with each successive replication.  
As in Chapter 5, holding the cells in G0/G1 prior to selection led to a lack of CeGFP-C1 
integration into the host genome, as no evidence of integration had been found. This 
further highlighted the protective effect of holding transfected cells in G0/G1 before 
imposing selection in the prevention of integration into the host genome. However, 
this group of cells did not seem to benefit otherwise from this method of vector 
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establishment, as the percentage of positive cells and total transgene expression were 
at low levels by the final day of the experiment, comparable to those of groups (A) and 
(B) where no selection had been imposed. This further indicated that the significant 
improvement in vector retention of the CpEPI-eGFP population held under the same 
conditions could be attributed to the presence of the β-IFN S/MAR element within the 
vector, as without it the vector was diluted out of the population.  
The only CeGPFP-C1 transfected population of cells which showed comparable 
percentages of positive cells by the final day to CpEPI-eGFP of group (C) was that of 
group (D), where CeGFP-C1 had been found to potentially integrate into the host 
genome. This was a significant finding, indicating that the efficiency of retention of 
episomal vector CpEPI-eGFP was equivalent in a population of proliferating C2C12 
myoblasts to that of potentially stably integrated CeGFP-C1 vector copies within these 
cells, which also contained non-integrated vector copies. However, it was also found 
that this CeGFP-C1 population of group (D) expressed, significantly, the greatest 
amount of total transgene of any of the groups tested on the final day of the 
experiment, which may be due to positional effects of the integrants within the 
genome, the number of transcribed integrants/episomes per cell, and/or to superior 
transgene expression as a result of reduced negative supercoiling affecting the 
accessibility of the promoter due to the presence of an S/MAR element. 
Although an improvement in episomal vector retention and passing on to daughter 
cells by a novel method of vector establishment has been achieved in this study, the 
feasibility of using this method of establishment with this vector in vivo must be 
ascertained. One possible method would be the manipulation of autologous extracted 
precursor cells such as mesangioblasts ex vivo, followed by their expansion, before re-
transplantation into the patient. This ex vivo manipulation would be imperative 
considering the use of selection would be required to establish the vector within the 
cells. It remains to be investigated whether the percentages of positive cells and hence 
the total expression achieved by this method would be sufficient to correct the 
pathology of a patient with muscular dystrophy, however it seems unlikely as there are 
many factors which must be considered. 
In a study by Galvez et al approximately 50% of mesangioblasts grafted back into 
patients reached their target muscle cells (Galvez et al., 2006). In considering that a 
large amount of cell death ensued from arresting the cells in G0/G1 for up to 7 days in 
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this thesis, this method may not be suitable for ex-vivo application considering that the 
number of cells being reimplanted back into the patient would be very low. Following 
this, in a study conducted by Chamberlain, it was found that in order for a significant 
correction to be made, the majority of muscle fibres must be able to accumulate a 
minimum or 20% of wild type levels of functional dystrophin (Chamberlain, 1997). As 
shown in this thesis, the CpEPI-eGFP transfected positive myoblasts which were then 
differentiated into myotubes were able to express the eGFP transgene without 
silencing, where with time the intensity of the eGFP appeared to be increasing, 
suggesting an increase in transgene product with time. However, after cells were put 
under selection where 100% of the cells contained vector copies and were hence 
expected to be eGFP positive, it was found that a majority of them were not positive. 
Furthermore, after 35 days of cell proliferation, only approximately 2.5% of the CpEPI-
eGFP transfected cells held in G0/G1 and then put under selection were found to be 
eGFP positive. Hence, if such a small percentage of satellite cells were able to retain 
the vector, then the proportion of muscle fibres regenerated post damage in MD 
patients by these positive cells would not be a majority, which would indicate that the 
use of this method with this vector may still require further improvement in order to 
elicit a significant correction of muscular pathology, as is required for dystrophic 
patients.  
A second method of utilising this method for the purposes of gene therapy would be 
the direct delivery of the vector into the muscle, by injection or electroporation or 
other methods previously discussed (Chapter 1: Introduction, Section 1.6.2). 
Electroporation resulting in the transfection of satellite cells in vivo was found possible 
to achieve in a study by Peng et al (Peng et al., 2005). The delivery of this vector to 
satellite cells could also be achieved with the use of self-inactivating lentivirus vectors 
(SIN), which have been found not to integrate into the host genome and are able to 
effectively transduce quiescent cells (reviewed in Wanisch and Yanez-Munoz, 2009). 
Any of these delivery methods would then be required to be in combination with an in 
vivo selection system such as that developed by Wong et al (Wong et al., 2011). This 
system involved the insertion of a Bcl-2 transgene expression cassette within an 
S/MAR vector, whose expression within liver cells protected them from the apoptotic 
effects of a bi-weekly administered antibody, Jo2, a Fas antibody which, upon engaging 
with its antigen, leads the antigen to induce cell death (Wong et al., 2011). However, 
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this method poses serious safetly implications, and a selective advantage to 
dystrophin-expressing S/MAR vector-containing cells would be required to be 
developed in order to take this novel method of establishment further. 
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Chapter 9: Future Work 
 
In light of the results obtained in this study, there are many questions that have arisen, 
leading to a multitude of potential routes of investigations that are not only 
interesting, but essential to follow in order to obtain a deeper understanding of the 
mechanisms by which cells operate in maintaining and expressing transgenes on 
plasmid DNA introduced into host cells. These routes would include an array of 
multidisciplinary techniques such as chromatin immunoprecipitaion (ChIP) assays, 
inverse PCR (IPCR), quantitative PCR (Q-PCR), the testing of tissue-specific promoters, 
the use of therapeutic transgenes, long term in vivo studies in animal models such as 
the mdx mouse, and the assessment of the therapeutic index/amelioration of 
dystrophic symptoms as a result. 
ChIP is a technique used to advance our understanding of genome stability, gene 
expression, and how it is regulated by reversible and dynamic protein-chromatin 
interactions (Wong and Wei, 2009). This technique has been used in order to 
investigate transcription factor binding sites (Iyer et al., 2001), the binding of histones 
and other nuclear structural proteins to chromatin (Glynn et al., 2004), and the 
identification of chromatin-bound histone modifications that can occur within cells 
(Barski et al., 2007).  
ChIP is carried out by cross-linking the DNA to the proteins bound, and also covalently 
linking proteins bound to other proteins by the use of UV light or formaldehyde (Wong 
and Wei, 2009). The chromatin is then sonicated in order to break it up into smaller 
fragments and then immunoprecipitated by the use of antibodies specific for the 
target nuclear proteins. The cross-linking can then be reversed, and the DNA and 
protein purified separately. The DNA sequence can then be identified by several 
methods including cloning followed by sequencing (Grandori et al., 1996), or by 
hybridisation methods such as Southern blotting (Orlando et al., 1997) or the use of 
microarrays that represent the entire genome (Iyer et al., 2001). 
The application of this technique was used in the study by Riu et al in order to 
determine whether plasmid DNA transfected into cells was subject to chromatinisation 
and successfully identified both euchromatin- and heterochromatin-associated histone 
markings (Riu et al., 2004). It would be interesting to investigate the presence of such 
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markers at different time points for all the vectors tested in this thesis. It would be also 
be interesting to compare the differences between the markings of the S/MAR plasmid 
from the HepG2 cell samples and those of the HeLa and C2C12 samples. Furthermore, 
this method could identify the epigenetic changes that may have occurred to the 
S/MAR plasmid when being held in G0/G1 or in quiescence in reserve cells, and the 
differences that may exist between them and the control plasmid. It would also be 
worth investigating whether epigenetic marking does, in fact, take place at all if 
selection is not initially imposed upon cells, and whether this is, in part, the reason 
behind why the S/MAR plasmid did not appear to be established when selection was 
not used. 
It would also be worth using other methods in order to screen for integrants in a 
multiclonal population of transfected cells. One such technique that is extremely 
sensitive is inverse PCR (IPCR). This allows the identification of integrated sequences 
within a genome, and can even be coupled with sequencing if the site of integration is 
required to be identified. By being able to totally exclude the possibility of the 
integration of the S/MAR plasmid, the safety profile of this vector would lead it to be a 
highly desirable tool in gene therapeutics. Furthermore, if it does integrate at low 
levels, it would be interesting to investigate whether the sites of integration are quite 
specific or if they occur in more random locations. Also, the successful application of 
IPCR using a sample from a multiclonal population, as opposed to a clonal population, 
means that a greater number of events are simultaneously being screened, leading to 
a more solid conclusion about the nature of the vector’s possible integration patterns, 
or lack of. 
It is also imperative to test other promoters. In this study two ubiquitous promoters 
were tested, however both resulted in declined expression. Argyros et al found that 
when using an S/MAR vector and having the transgene expression driven by a tissue-
specific promoter (liver-specific AAT in their case), that the expression levels remained 
higher than the other ubiquitous promoter tested, and that the S/MAR element 
actually conferred protection for the promoter from being methylated as it was seen 
that the control plasmid’s promoter had, in fact, been methylated (Argyros et al., 
2009).  
Another important experiment that would be useful to conduct is quantitative PCR (Q-
PCR) in order to determine the amount of S/MAR plasmid present as an episome 
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within cells at several different time points. This would be useful to undertake after 
more conclusive evidence is gathered against integration of the vector into the 
genome, that way it would be clear that it is the number of episomes being calculated 
and not integrants. The information derived from such an experiment could show 
whether the episome numbers decline with time, and if so, the rate at which they may 
do so.  
Another interesting experiment would be to attempt to reduce or eliminate the CpG 
sequences present on the S/MAR plasmid prior to assessment of expression. This may 
lead to longer term expression and avoid silencing. 
Otherwise, the S/MAR element could be inserted into a minicircle vector devoid of a 
bacterial backbone, which may further enhance expression and its duration. This 
construct could also potentially be used in actively replicating cells due to the presence 
of the S/MAR element. 
In gathering more information about the way in which cells epigenetically mark S/MAR 
vectors, and how these vectors are retained and passed onto progeny cells, further 
advances in the improvement of this vector’s expression and safety profiles can be 
achieved, thus leading to a clinically viable vector that can be used to deliver 
therapeutic genes in order to correct, or at least ameliorate, pathologies of genetic 
diseases such as Muscular Dystrophy. 
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